Difference between revisions of "LncRNAWiki:Featured"
| (23 intermediate revisions by one other user not shown) | |||
| Line 10: | Line 10: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289501 HSALNT0289501] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289501 HSALNT0289501] | ||
| − | |HPVC1 | + | |[[HPVC1]] |
|PE5L,HPV18E5L | |PE5L,HPV18E5L | ||
|NA | |NA | ||
| Line 18: | Line 18: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289605 HSALNT0289605] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289605 HSALNT0289605] | ||
| − | | | + | |[[NONHSAT104559]] |
| − | | | + | |lnc-C9orf53-2:1 |
|NA | |NA | ||
|NA | |NA | ||
| Line 26: | Line 26: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0199632 HSALNT0199632] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0199632 HSALNT0199632] | ||
| − | |N4BP2L2-IT2 | + | |[[N4BP2L2-IT2]] |
|CG030 | |CG030 | ||
|NA | |NA | ||
| Line 34: | Line 34: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0171094 HSALNT0171094] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0171094 HSALNT0171094] | ||
| − | |LINC01150 | + | |[[LINC01150]] |
|2G7,TCONS_00019134 | |2G7,TCONS_00019134 | ||
|NA | |NA | ||
| Line 42: | Line 42: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289115 HSALNT0289115] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289115 HSALNT0289115] | ||
| − | |LINC01587 | + | |[[LINC01587]] |
|C4orf6,aC1 | |C4orf6,aC1 | ||
|NA | |NA | ||
| Line 50: | Line 50: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290105 HSALNT0290105] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290105 HSALNT0290105] | ||
| − | | | + | |[[NONHSAT115106]] |
|NONHSAT115106 | |NONHSAT115106 | ||
|NA | |NA | ||
| Line 58: | Line 58: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289234 HSALNT0289234] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289234 HSALNT0289234] | ||
| − | |RNF217-AS1 | + | |[[RNF217-AS1]] |
|STL | |STL | ||
|NA | |NA | ||
| Line 66: | Line 66: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0280481 HSALNT0280481] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0280481 HSALNT0280481] | ||
| − | |INE2 | + | |[[INE2]] |
|NCRNA00011 | |NCRNA00011 | ||
|NA | |NA | ||
| Line 74: | Line 74: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289485 HSALNT0289485] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289485 HSALNT0289485] | ||
| − | |INE1 | + | |[[INE1]] |
|NCRNA00010 | |NCRNA00010 | ||
|NA | |NA | ||
| Line 82: | Line 82: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289511 HSALNT0289511] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289511 HSALNT0289511] | ||
| − | |LINC01565 | + | |[[LINC01565]] |
|C3orf27,GR6 | |C3orf27,GR6 | ||
|NA | |NA | ||
| Line 90: | Line 90: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289068 HSALNT0289068] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289068 HSALNT0289068] | ||
| − | |LINC00869 | + | |[[LINC00869]] |
|KIAA0493 | |KIAA0493 | ||
|NA | |NA | ||
| Line 98: | Line 98: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289430 HSALNT0289430] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289430 HSALNT0289430] | ||
| − | |ERC2-IT1 | + | |[[ERC2-IT1]] |
|C1orf1,C3orf51,Po42 | |C1orf1,C3orf51,Po42 | ||
|NA | |NA | ||
| Line 106: | Line 106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290394 HSALNT0290394] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290394 HSALNT0290394] | ||
| − | | | + | |[[Lnc-PDIA4-1:1]] |
|lnc-PDIA4-1:1 | |lnc-PDIA4-1:1 | ||
|NA | |NA | ||
| Line 114: | Line 114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289195 HSALNT0289195] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289195 HSALNT0289195] | ||
| − | |NOP14-AS1 | + | |[[NOP14-AS1]] |
|C4orf10,RES4-24 | |C4orf10,RES4-24 | ||
|NA | |NA | ||
| Line 122: | Line 122: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290309 HSALNT0290309] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290309 HSALNT0290309] | ||
| − | | | + | |[[NONHSAT022116]] |
|NONHSAT022116,AF080092,TSU | |NONHSAT022116,AF080092,TSU | ||
|NA | |NA | ||
| Line 130: | Line 130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289243 HSALNT0289243] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289243 HSALNT0289243] | ||
| − | |SMAD5-AS1 | + | |[[SMAD5-AS1]] |
|SMAD5O,DAMS | |SMAD5O,DAMS | ||
|NA | |NA | ||
| Line 138: | Line 138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289025 HSALNT0289025] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289025 HSALNT0289025] | ||
| − | |LINC00244 | + | |[[LINC00244]] |
|C7orf4,NCRNA00244 | |C7orf4,NCRNA00244 | ||
|NA | |NA | ||
| Line 146: | Line 146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289017 HSALNT0289017] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289017 HSALNT0289017] | ||
| − | |KIF25-AS1 | + | |[[KIF25-AS1]] |
|C6orf54,NCRNA00300,HGC6.1.1 | |C6orf54,NCRNA00300,HGC6.1.1 | ||
|NA | |NA | ||
| Line 154: | Line 154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289332 HSALNT0289332] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289332 HSALNT0289332] | ||
| − | |LINC01558 | + | |[[LINC01558]] |
|C6orf123,LINC01557,HGC6.2,dJ431P23.4 | |C6orf123,LINC01557,HGC6.2,dJ431P23.4 | ||
|NA | |NA | ||
| Line 162: | Line 162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289438 HSALNT0289438] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289438 HSALNT0289438] | ||
| − | |AFDN-AS1 | + | |[[AFDN-AS1]] |
|C6orf124,MLLT4-AS1,HGC6.4,dJ431P23.3 | |C6orf124,MLLT4-AS1,HGC6.4,dJ431P23.3 | ||
|NA | |NA | ||
| Line 170: | Line 170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289232 HSALNT0289232] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289232 HSALNT0289232] | ||
| − | |RFPL3S | + | |[[RFPL3S]] |
|RFPL3-AS1,RFPL3-A, NCRNA00005 | |RFPL3-AS1,RFPL3-A, NCRNA00005 | ||
|NA | |NA | ||
| Line 178: | Line 178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289393 HSALNT0289393] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289393 HSALNT0289393] | ||
| − | |RFPL1S | + | |[[RFPL1S]] |
|RFPL1-AS1,RFPL1-A, NCRNA00006 | |RFPL1-AS1,RFPL1-A, NCRNA00006 | ||
|NA | |NA | ||
| Line 186: | Line 186: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289500 HSALNT0289500] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289500 HSALNT0289500] | ||
| − | |HCG4B | + | |[[HCG4B]] |
|HCG4P6,HCGIV-6,HCGIV.5,HCGIV-06,bCX67J3.3,Em:AB023056.16,bPG309N1.1,bQB90C11.3 | |HCG4P6,HCGIV-6,HCGIV.5,HCGIV-06,bCX67J3.3,Em:AB023056.16,bPG309N1.1,bQB90C11.3 | ||
|NA | |NA | ||
| Line 194: | Line 194: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289894 HSALNT0289894] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289894 HSALNT0289894] | ||
| − | |LINC00294 | + | |[[LINC00294]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 202: | Line 202: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289345 HSALNT0289345] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289345 HSALNT0289345] | ||
| − | |LINC00893 | + | |[[LINC00893]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 210: | Line 210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290133 HSALNT0290133] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290133 HSALNT0290133] | ||
| − | |PCBP3-OT1 | + | |[[PCBP3-OT1]] |
|PCBP3-OT1,FLJ44028 | |PCBP3-OT1,FLJ44028 | ||
|NA | |NA | ||
| Line 218: | Line 218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289488 HSALNT0289488] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289488 HSALNT0289488] | ||
| − | | | + | |[[ENST00000418282.1]] |
|NCRNA00187 | |NCRNA00187 | ||
|NA | |NA | ||
| Line 226: | Line 226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289712 HSALNT0289712] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289712 HSALNT0289712] | ||
| − | |COPG2IT1 | + | |[[COPG2IT1]] |
|CIT1,NCRNA00170,COPG2AS | |CIT1,NCRNA00170,COPG2AS | ||
|NA | |NA | ||
| Line 234: | Line 234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0265040 HSALNT0265040] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0265040 HSALNT0265040] | ||
| − | |LINC00652 | + | |[[LINC00652]] |
|HSPC072 | |HSPC072 | ||
|NA | |NA | ||
| Line 242: | Line 242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289282 HSALNT0289282] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289282 HSALNT0289282] | ||
| − | |WASIR2 | + | |[[WASIR2]] |
|NCRNA00286A | |NCRNA00286A | ||
|NA | |NA | ||
| Line 250: | Line 250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0246856 HSALNT0246856] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0246856 HSALNT0246856] | ||
| − | |LINC00470 | + | |[[LINC00470]] |
|C18orf2 | |C18orf2 | ||
|NA | |NA | ||
| Line 258: | Line 258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289507 HSALNT0289507] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289507 HSALNT0289507] | ||
| − | |LINC00588 | + | |[[LINC00588]] |
|C8orf71,DKFZP434F122 | |C8orf71,DKFZP434F122 | ||
|NA | |NA | ||
| Line 266: | Line 266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0276604 HSALNT0276604] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0276604 HSALNT0276604] | ||
| − | |TTC28-AS1 | + | |[[TTC28-AS1]] |
|TTC28AS,TTC28-AS,KIAA1648 | |TTC28AS,TTC28-AS,KIAA1648 | ||
|NA | |NA | ||
| Line 274: | Line 274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0237577 HSALNT0237577] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0237577 HSALNT0237577] | ||
| − | |CDRT7 | + | |[[CDRT7]] |
|NCRNA00025,LINC00025 | |NCRNA00025,LINC00025 | ||
|NA | |NA | ||
| Line 282: | Line 282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288912 HSALNT0288912] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288912 HSALNT0288912] | ||
| − | |CDRT8 | + | |[[CDRT8]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 290: | Line 290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0275048 HSALNT0275048] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0275048 HSALNT0275048] | ||
| − | |CECR3 | + | |[[CECR3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 298: | Line 298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288915 HSALNT0288915] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288915 HSALNT0288915] | ||
| − | |CECR9 | + | |[[CECR9]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 306: | Line 306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288998 HSALNT0288998] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288998 HSALNT0288998] | ||
| − | |HDHD5-AS1 | + | |[[HDHD5-AS1]] |
|CECR4,CECR5-AS1,NCRNA00017 | |CECR4,CECR5-AS1,NCRNA00017 | ||
|NA | |NA | ||
| Line 314: | Line 314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288914 HSALNT0288914] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288914 HSALNT0288914] | ||
| − | |CECR5-AS1 | + | |[[CECR5-AS1]] |
|NCRNA00017 | |NCRNA00017 | ||
|NA | |NA | ||
| Line 322: | Line 322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288919 HSALNT0288919] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288919 HSALNT0288919] | ||
| − | |CLRN1-AS1 | + | |[[CLRN1-AS1]] |
|CLRN1O,UCRP | |CLRN1O,UCRP | ||
|NA | |NA | ||
| Line 330: | Line 330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289271 HSALNT0289271] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289271 HSALNT0289271] | ||
| − | |TMEM9B-AS1 | + | |[[TMEM9B-AS1]] |
|C11orf18 | |C11orf18 | ||
|NA | |NA | ||
| Line 338: | Line 338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289324 HSALNT0289324] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289324 HSALNT0289324] | ||
| − | |LINC01547 | + | |[[LINC01547]] |
|C21orf69,C21orf67 | |C21orf69,C21orf67 | ||
|NA | |NA | ||
| Line 346: | Line 346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0270409 HSALNT0270409] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0270409 HSALNT0270409] | ||
| − | |LINC00029 | + | |[[LINC00029]] |
|C20orf51,NCRNA00029,bA305P22.4 | |C20orf51,NCRNA00029,bA305P22.4 | ||
|NA | |NA | ||
| Line 354: | Line 354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289336 HSALNT0289336] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289336 HSALNT0289336] | ||
| − | |LINC00529 | + | |[[LINC00529]] |
|C8orf8 | |C8orf8 | ||
|NA | |NA | ||
| Line 362: | Line 362: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288978 HSALNT0288978] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288978 HSALNT0288978] | ||
| − | |FLVCR1-AS1 | + | |[[FLVCR1-AS1]] |
|FLVCR1-DT,LQK1 | |FLVCR1-DT,LQK1 | ||
|NA | |NA | ||
| Line 370: | Line 370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0238050 HSALNT0238050] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0238050 HSALNT0238050] | ||
| − | |SMCR2 | + | |[[SMCR2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 378: | Line 378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289401 HSALNT0289401] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289401 HSALNT0289401] | ||
| − | |SMCR5 | + | |[[SMCR5]] |
|NCRNA00034 | |NCRNA00034 | ||
|NA | |NA | ||
| Line 386: | Line 386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290246 HSALNT0290246] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290246 HSALNT0290246] | ||
| − | |SMCR6 | + | |[[SMCR6]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 394: | Line 394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0274626 HSALNT0274626] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0274626 HSALNT0274626] | ||
| − | |LINC00205 | + | |[[LINC00205]] |
|C21orf86,NCRNA00205, | |C21orf86,NCRNA00205, | ||
|NA | |NA | ||
| Line 402: | Line 402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0271512 HSALNT0271512] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0271512 HSALNT0271512] | ||
| − | |C21orf91-OT1 | + | |[[C21orf91-OT1]] |
|NCRNA00285,D21S2089E | |NCRNA00285,D21S2089E | ||
|NA | |NA | ||
| Line 410: | Line 410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0272596 HSALNT0272596] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0272596 HSALNT0272596] | ||
| − | |LINC00307 | + | |[[LINC00307]] |
|NCRNA00307,D21S2091E | |NCRNA00307,D21S2091E | ||
|NA | |NA | ||
| Line 418: | Line 418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0274502 HSALNT0274502] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0274502 HSALNT0274502] | ||
| − | |TSPEAR-AS2 | + | |[[TSPEAR-AS2]] |
|C21orf90 | |C21orf90 | ||
|NA | |NA | ||
| Line 426: | Line 426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0274807 HSALNT0274807] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0274807 HSALNT0274807] | ||
| − | |MCM3AP-AS1 | + | |[[MCM3AP-AS1]] |
|C21orf85,MCM3APAS,MCM3AP-AS,FLJ10508,NCRNA00031 | |C21orf85,MCM3APAS,MCM3AP-AS,FLJ10508,NCRNA00031 | ||
|NA | |NA | ||
| Line 434: | Line 434: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288888 HSALNT0288888] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288888 HSALNT0288888] | ||
| − | |B3GALT5-AS1 | + | |[[B3GALT5-AS1]] |
|C21orf88 | |C21orf88 | ||
|NA | |NA | ||
| Line 442: | Line 442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288898 HSALNT0288898] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288898 HSALNT0288898] | ||
| − | |BRWD1-AS2 | + | |[[BRWD1-AS2]] |
|C21orf87,NCRNA00257,BRWD1-IT2 | |C21orf87,NCRNA00257,BRWD1-IT2 | ||
|NA | |NA | ||
| Line 450: | Line 450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289031 HSALNT0289031] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289031 HSALNT0289031] | ||
| − | |LINC00315 | + | |[[LINC00315]] |
|C21orf93,NCRNA00315 | |C21orf93,NCRNA00315 | ||
|NA | |NA | ||
| Line 458: | Line 458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289033 HSALNT0289033] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289033 HSALNT0289033] | ||
| − | |LINC00334 | + | |[[LINC00334]] |
|C21orf89,NCRNA00334 | |C21orf89,NCRNA00334 | ||
|NA | |NA | ||
| Line 466: | Line 466: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289322 HSALNT0289322] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289322 HSALNT0289322] | ||
| − | |LINC00314 | + | |[[LINC00314]] |
|C21orf94,NCRNA00314 | |C21orf94,NCRNA00314 | ||
|NA | |NA | ||
| Line 474: | Line 474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0271821 HSALNT0271821] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0271821 HSALNT0271821] | ||
| − | |LINC00308 | + | |[[LINC00308]] |
|C21orf74,NCRNA00308,PRED16 | |C21orf74,NCRNA00308,PRED16 | ||
|NA | |NA | ||
| Line 482: | Line 482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289023 HSALNT0289023] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289023 HSALNT0289023] | ||
| − | |LINC00189 | + | |[[LINC00189]] |
|C21orf109,NCRNA00189 | |C21orf109,NCRNA00189 | ||
|NA | |NA | ||
| Line 490: | Line 490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289375 HSALNT0289375] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289375 HSALNT0289375] | ||
| − | |NCRUPAR | + | |[[NCRUPAR]] |
|ncR-uPAR,ncRuPAR,NCRNA00193 | |ncR-uPAR,ncRuPAR,NCRNA00193 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 498: | Line 498: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0273467 HSALNT0273467] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0273467 HSALNT0273467] | ||
| − | |DSCR10 | + | |[[DSCR10]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 506: | Line 506: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289480 HSALNT0289480] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289480 HSALNT0289480] | ||
| − | |DSCR9 | + | |[[DSCR9]] |
|NCRNA00038 | |NCRNA00038 | ||
|NA | |NA | ||
| Line 514: | Line 514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290051 HSALNT0290051] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290051 HSALNT0290051] | ||
| − | |MDS2 | + | |[[MDS2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 522: | Line 522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0127810 HSALNT0127810] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0127810 HSALNT0127810] | ||
| − | |ST7-AS2 | + | |[[ST7-AS2]] |
|ST7OT2,ST7AS2 | |ST7OT2,ST7AS2 | ||
|NA | |NA | ||
| Line 530: | Line 530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0127813 HSALNT0127813] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0127813 HSALNT0127813] | ||
| − | |ST7-OT3 | + | |[[ST7-OT3]] |
|ST7OT3,NCRNA00026 | |ST7OT3,NCRNA00026 | ||
|NA | |NA | ||
| Line 538: | Line 538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290258 HSALNT0290258] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290258 HSALNT0290258] | ||
| − | |ST7-OT4 | + | |[[ST7-OT4]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 546: | Line 546: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290257 HSALNT0290257] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290257 HSALNT0290257] | ||
| − | | | + | |[[NONHSAT122926]] |
|NONHSAT122926 | |NONHSAT122926 | ||
|NA | |NA | ||
| Line 554: | Line 554: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289372 HSALNT0289372] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289372 HSALNT0289372] | ||
| − | |MIR600HG | + | |[[MIR600HG]] |
|C9orf45,NCRNA00287,GL012,FLJ22161 | |C9orf45,NCRNA00287,GL012,FLJ22161 | ||
|NA | |NA | ||
| Line 562: | Line 562: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0013239 HSALNT0013239] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0013239 HSALNT0013239] | ||
| − | |ATP1A1-AS1 | + | |[[ATP1A1-AS1]] |
|C1orf203,ATP1A1OS,MGC16179 | |C1orf203,ATP1A1OS,MGC16179 | ||
|NA | |NA | ||
| Line 570: | Line 570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0048563 HSALNT0048563] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0048563 HSALNT0048563] | ||
| − | |SPATA3-AS1 | + | |[[SPATA3-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 578: | Line 578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0050859 HSALNT0050859] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0050859 HSALNT0050859] | ||
| − | |LINC00852 | + | |[[LINC00852]] |
|C3orf42,GHRLOS2,NAG73,GHRL-AS2 | |C3orf42,GHRLOS2,NAG73,GHRL-AS2 | ||
|NA | |NA | ||
| Line 586: | Line 586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0069395 HSALNT0069395] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0069395 HSALNT0069395] | ||
| − | |LINC01096 | + | |[[LINC01096]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 594: | Line 594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0072367 HSALNT0072367] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0072367 HSALNT0072367] | ||
| − | |LINC02260 | + | |[[LINC02260]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 602: | Line 602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0077259 HSALNT0077259] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0077259 HSALNT0077259] | ||
| − | |LINC01091 | + | |[[LINC01091]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 610: | Line 610: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0096480 HSALNT0096480] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0096480 HSALNT0096480] | ||
| − | |SAP30L-AS1 | + | |[[SAP30L-AS1]] |
|FLJ38109,GALNT10-AS1 | |FLJ38109,GALNT10-AS1 | ||
|NA | |NA | ||
| Line 618: | Line 618: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0098558 HSALNT0098558] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0098558 HSALNT0098558] | ||
| − | |PRR7-AS1 | + | |[[PRR7-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 626: | Line 626: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0099356 HSALNT0099356] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0099356 HSALNT0099356] | ||
| − | |LINC01622 | + | |[[LINC01622]] |
|TCONS_00011202 | |TCONS_00011202 | ||
|NA | |NA | ||
| Line 634: | Line 634: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0113415 HSALNT0113415] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0113415 HSALNT0113415] | ||
| − | |LINC01312 | + | |[[LINC01312]] |
|MGC34034 | |MGC34034 | ||
|NA | |NA | ||
| Line 642: | Line 642: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0134652 HSALNT0134652] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0134652 HSALNT0134652] | ||
| − | |EXTL3-AS1 | + | |[[EXTL3-AS1]] |
|C8orf50 | |C8orf50 | ||
|NA | |NA | ||
| Line 650: | Line 650: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0138253 HSALNT0138253] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0138253 HSALNT0138253] | ||
| − | |C8orf34-AS1 | + | |[[C8orf34-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 658: | Line 658: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0154876 HSALNT0154876] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0154876 HSALNT0154876] | ||
| − | |PSMD5-AS1 | + | |[[PSMD5-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 666: | Line 666: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0163228 HSALNT0163228] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0163228 HSALNT0163228] | ||
| − | |LINC01553 | + | |[[LINC01553]] |
|C10orf40,AC023904.2 | |C10orf40,AC023904.2 | ||
|NA | |NA | ||
| Line 674: | Line 674: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0175689 HSALNT0175689] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0175689 HSALNT0175689] | ||
| − | |LINC00301 | + | |[[LINC00301]] |
|C11orf64,NCRNA00301,MGC39681 | |C11orf64,NCRNA00301,MGC39681 | ||
|NA | |NA | ||
| Line 682: | Line 682: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0247235 HSALNT0247235] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0247235 HSALNT0247235] | ||
| − | |DLGAP1-AS3 | + | |[[DLGAP1-AS3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 690: | Line 690: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0254200 HSALNT0254200] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0254200 HSALNT0254200] | ||
| − | |CIRBP-AS1 | + | |[[CIRBP-AS1]] |
|C19orf23,MGC39338 | |C19orf23,MGC39338 | ||
|NA | |NA | ||
| Line 698: | Line 698: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0257335 HSALNT0257335] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0257335 HSALNT0257335] | ||
| − | |LINC01785 | + | |[[LINC01785]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 706: | Line 706: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0261582 HSALNT0261582] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0261582 HSALNT0261582] | ||
| − | |LINC01869 | + | |[[LINC01869]] |
|MGC45922 | |MGC45922 | ||
|NA | |NA | ||
| Line 714: | Line 714: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0269743 HSALNT0269743] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0269743 HSALNT0269743] | ||
| − | |LINC01711 | + | |[[LINC01711]] |
|MGC4294 | |MGC4294 | ||
|NA | |NA | ||
| Line 722: | Line 722: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288468 HSALNT0288468] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288468 HSALNT0288468] | ||
| − | |FAM41AY1 | + | |[[FAM41AY1]] |
|FAM41AY | |FAM41AY | ||
|NA | |NA | ||
| Line 730: | Line 730: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288899 HSALNT0288899] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288899 HSALNT0288899] | ||
| − | |C5orf66-AS2 | + | |[[C5orf66-AS2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 738: | Line 738: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288922 HSALNT0288922] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288922 HSALNT0288922] | ||
| − | |CSTF3-AS1 | + | |[[CSTF3-AS1]] |
|CSTF3-DT | |CSTF3-DT | ||
|NA | |NA | ||
| Line 746: | Line 746: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288923 HSALNT0288923] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288923 HSALNT0288923] | ||
| − | |CYP1B1-AS1 | + | |[[CYP1B1-AS1]] |
|C2orf58,MGC34824 | |C2orf58,MGC34824 | ||
|NA | |NA | ||
| Line 754: | Line 754: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288957 HSALNT0288957] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288957 HSALNT0288957] | ||
| − | |ENTPD3-AS1 | + | |[[ENTPD3-AS1]] |
|FLJ36665 | |FLJ36665 | ||
|NA | |NA | ||
| Line 762: | Line 762: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288970 HSALNT0288970] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288970 HSALNT0288970] | ||
| − | |FAM27E3 | + | |[[FAM27E3]] |
|MGC42630 | |MGC42630 | ||
|NA | |NA | ||
| Line 770: | Line 770: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288972 HSALNT0288972] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288972 HSALNT0288972] | ||
| − | |FAM41C | + | |[[FAM41C]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 778: | Line 778: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288977 HSALNT0288977] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288977 HSALNT0288977] | ||
| − | |FLG-AS1 | + | |[[FLG-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 786: | Line 786: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288983 HSALNT0288983] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288983 HSALNT0288983] | ||
| − | |GABPB1-IT1 | + | |[[GABPB1-IT1]] |
|FLJ10038 | |FLJ10038 | ||
|NA | |NA | ||
| Line 794: | Line 794: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289010 HSALNT0289010] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289010 HSALNT0289010] | ||
| − | |ILF3-AS1 | + | |[[ILF3-AS1]] |
|ILF3-DT | |ILF3-DT | ||
|NA | |NA | ||
| Line 802: | Line 802: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289034 HSALNT0289034] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289034 HSALNT0289034] | ||
| − | |LINC00347 | + | |[[LINC00347]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 810: | Line 810: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289039 HSALNT0289039] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289039 HSALNT0289039] | ||
| − | |LINC00466 | + | |[[LINC00466]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 818: | Line 818: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289040 HSALNT0289040] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289040 HSALNT0289040] | ||
| − | |LINC00471 | + | |[[LINC00471]] |
|C2orf52,MGC43122 | |C2orf52,MGC43122 | ||
|NA | |NA | ||
| Line 826: | Line 826: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289044 HSALNT0289044] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289044 HSALNT0289044] | ||
| − | |LINC00526 | + | |[[LINC00526]] |
|C18orf18,MGC17515,HsT959 | |C18orf18,MGC17515,HsT959 | ||
|NA | |NA | ||
| Line 834: | Line 834: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289048 HSALNT0289048] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289048 HSALNT0289048] | ||
| − | |LINC00593 | + | |[[LINC00593]] |
|C15orf50,MGC42951 | |C15orf50,MGC42951 | ||
|NA | |NA | ||
| Line 842: | Line 842: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289050 HSALNT0289050] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289050 HSALNT0289050] | ||
| − | |LINC00608 | + | |[[LINC00608]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 850: | Line 850: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289054 HSALNT0289054] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289054 HSALNT0289054] | ||
| − | |LINC00638 | + | |[[LINC00638]] |
|MGC23270 | |MGC23270 | ||
|NA | |NA | ||
| Line 858: | Line 858: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289056 HSALNT0289056] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289056 HSALNT0289056] | ||
| − | |LINC00661 | + | |[[LINC00661]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 866: | Line 866: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289057 HSALNT0289057] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289057 HSALNT0289057] | ||
| − | |LINC00662 | + | |[[LINC00662]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 874: | Line 874: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289062 HSALNT0289062] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289062 HSALNT0289062] | ||
| − | |LINC00692 | + | |[[LINC00692]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 882: | Line 882: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289064 HSALNT0289064] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289064 HSALNT0289064] | ||
| − | |LINC00705 | + | |[[LINC00705]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 890: | Line 890: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289067 HSALNT0289067] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289067 HSALNT0289067] | ||
| − | |LINC00868 | + | |[[LINC00868]] |
|C17orf52 | |C17orf52 | ||
|NA | |NA | ||
| Line 898: | Line 898: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0130693 HSALNT0130693] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0130693 HSALNT0130693] | ||
| − | |LINC00996 | + | |[[LINC00996]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 906: | Line 906: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289101 HSALNT0289101] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289101 HSALNT0289101] | ||
| − | |LINC01252 | + | |[[LINC01252]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 914: | Line 914: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289131 HSALNT0289131] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289131 HSALNT0289131] | ||
| − | |LINC02135 | + | |[[LINC02135]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 922: | Line 922: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289193 HSALNT0289193] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289193 HSALNT0289193] | ||
| − | |NIFK-AS1 | + | |[[NIFK-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 930: | Line 930: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289244 HSALNT0289244] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289244 HSALNT0289244] | ||
| − | |SMG7-AS1 | + | |[[SMG7-AS1]] |
|DKFZP564C196 | |DKFZP564C196 | ||
|NA | |NA | ||
| Line 938: | Line 938: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0235326 HSALNT0235326] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0235326 HSALNT0235326] | ||
| − | |SNAI3-AS1 | + | |[[SNAI3-AS1]] |
|MGC23284 | |MGC23284 | ||
|NA | |NA | ||
| Line 946: | Line 946: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0215205 HSALNT0215205] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0215205 HSALNT0215205] | ||
| − | |SNHG10 | + | |[[SNHG10]] |
|C14orf62,FLJ40557,NCRNA00063,LINC00063 | |C14orf62,FLJ40557,NCRNA00063,LINC00063 | ||
|NA | |NA | ||
| Line 954: | Line 954: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289290 HSALNT0289290] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289290 HSALNT0289290] | ||
| − | |ZNF205-AS1 | + | |[[ZNF205-AS1]] |
|MGC3771 | |MGC3771 | ||
|NA | |NA | ||
| Line 962: | Line 962: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289294 HSALNT0289294] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289294 HSALNT0289294] | ||
| − | |LINC00260 | + | |[[LINC00260]] |
|C1orf217,NCRNA00260,MGC5457 | |C1orf217,NCRNA00260,MGC5457 | ||
|NA | |NA | ||
| Line 970: | Line 970: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289295 HSALNT0289295] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289295 HSALNT0289295] | ||
| − | |LINC00337 | + | |[[LINC00337]] |
|C1orf211,NCRNA00337,MGC40168 | |C1orf211,NCRNA00337,MGC40168 | ||
|NA | |NA | ||
| Line 978: | Line 978: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289298 HSALNT0289298] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289298 HSALNT0289298] | ||
| − | |WAC-AS1 | + | |[[WAC-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 986: | Line 986: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289299 HSALNT0289299] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289299 HSALNT0289299] | ||
| − | |LINC00839 | + | |[[LINC00839]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 994: | Line 994: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289303 HSALNT0289303] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289303 HSALNT0289303] | ||
| − | |LINC00612 | + | |[[LINC00612]] |
|C12orf33,MGC40170,FLJ41814 | |C12orf33,MGC40170,FLJ41814 | ||
|NA | |NA | ||
| Line 1,002: | Line 1,002: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289312 HSALNT0289312] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289312 HSALNT0289312] | ||
| − | |LINC00663 | + | |[[LINC00663]] |
|MGC39821 | |MGC39821 | ||
|NA | |NA | ||
| Line 1,010: | Line 1,010: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289320 HSALNT0289320] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289320 HSALNT0289320] | ||
| − | |LINC00494 | + | |[[LINC00494]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,018: | Line 1,018: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289330 HSALNT0289330] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289330 HSALNT0289330] | ||
| − | |LINC01019 | + | |[[LINC01019]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,026: | Line 1,026: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289333 HSALNT0289333] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289333 HSALNT0289333] | ||
| − | |LINC00265 | + | |[[LINC00265]] |
|NCRNA00265,NCRNA00265-1 | |NCRNA00265,NCRNA00265-1 | ||
|NA | |NA | ||
| Line 1,034: | Line 1,034: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289334 HSALNT0289334] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289334 HSALNT0289334] | ||
| − | |LINC00689 | + | |[[LINC00689]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,042: | Line 1,042: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289337 HSALNT0289337] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289337 HSALNT0289337] | ||
| − | |LINC01591 | + | |[[LINC01591]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,050: | Line 1,050: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289340 HSALNT0289340] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289340 HSALNT0289340] | ||
| − | |LINC01501 | + | |[[LINC01501]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,058: | Line 1,058: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289346 HSALNT0289346] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289346 HSALNT0289346] | ||
| − | |LINC01560 | + | |[[LINC01560]] |
|CXorf24 | |CXorf24 | ||
|NA | |NA | ||
| Line 1,066: | Line 1,066: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289352 HSALNT0289352] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289352 HSALNT0289352] | ||
| − | |LINC01959 | + | |[[LINC01959]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,074: | Line 1,074: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289353 HSALNT0289353] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289353 HSALNT0289353] | ||
| − | |LINC02175 | + | |[[LINC02175]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,082: | Line 1,082: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289354 HSALNT0289354] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289354 HSALNT0289354] | ||
| − | |LINC02209 | + | |[[LINC02209]] |
|FAM183CP | |FAM183CP | ||
|NA | |NA | ||
| Line 1,090: | Line 1,090: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289359 HSALNT0289359] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289359 HSALNT0289359] | ||
| − | |LINGO1-AS1 | + | |[[LINGO1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,098: | Line 1,098: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289362 HSALNT0289362] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289362 HSALNT0289362] | ||
| − | |MAFG-AS1 | + | |[[MAFG-AS1]] |
|MAFG-DT | |MAFG-DT | ||
|NA | |NA | ||
| Line 1,106: | Line 1,106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289373 HSALNT0289373] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289373 HSALNT0289373] | ||
| − | |MORF4L2-AS1 | + | |[[MORF4L2-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,114: | Line 1,114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289381 HSALNT0289381] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289381 HSALNT0289381] | ||
| − | |NPHP3-AS1 | + | |[[NPHP3-AS1]] |
|NCRNA00119 | |NCRNA00119 | ||
|NA | |NA | ||
| Line 1,122: | Line 1,122: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289385 HSALNT0289385] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289385 HSALNT0289385] | ||
| − | |PAXIP1-AS1 | + | |[[PAXIP1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,130: | Line 1,130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289413 HSALNT0289413] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289413 HSALNT0289413] | ||
| − | |TOLLIP-AS1 | + | |[[TOLLIP-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,138: | Line 1,138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289416 HSALNT0289416] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289416 HSALNT0289416] | ||
| − | |LINC00311 | + | |[[LINC00311]] |
|TMEM148,NCRNA00311,MGC22001 | |TMEM148,NCRNA00311,MGC22001 | ||
|NA | |NA | ||
| Line 1,146: | Line 1,146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289422 HSALNT0289422] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289422 HSALNT0289422] | ||
| − | |ZNF252P-AS1 | + | |[[ZNF252P-AS1]] |
|C8orf77 | |C8orf77 | ||
|NA | |NA | ||
| Line 1,154: | Line 1,154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289423 HSALNT0289423] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289423 HSALNT0289423] | ||
| − | |ZNF436-AS1 | + | |[[ZNF436-AS1]] |
|C1orf213,FLJ90508 | |C1orf213,FLJ90508 | ||
|NA | |NA | ||
| Line 1,162: | Line 1,162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289429 HSALNT0289429] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289429 HSALNT0289429] | ||
| − | |BFSP2-AS1 | + | |[[BFSP2-AS1]] |
|MGC2848 | |MGC2848 | ||
|NA | |NA | ||
| Line 1,170: | Line 1,170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289432 HSALNT0289432] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289432 HSALNT0289432] | ||
| − | |CTBP1- | + | |[[CTBP1-DT]] |
| − | |C4orf42,CTBP1- | + | |C4orf42,CTBP1-AS1,CTBP1-DT,MGC21675 |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,178: | Line 1,178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289436 HSALNT0289436] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289436 HSALNT0289436] | ||
| − | |EXOC3-AS1 | + | |[[EXOC3-AS1]] |
|C5orf55 | |C5orf55 | ||
|NA | |NA | ||
| Line 1,186: | Line 1,186: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289441 HSALNT0289441] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289441 HSALNT0289441] | ||
| − | |HCG27 | + | |[[HCG27]] |
|bPG299F13.9,bCX101P6.9,bQB115I13.2,FLJ40123 | |bPG299F13.9,bCX101P6.9,bQB115I13.2,FLJ40123 | ||
|NA | |NA | ||
| Line 1,194: | Line 1,194: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289450 HSALNT0289450] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289450 HSALNT0289450] | ||
| − | |BAALC-AS2 | + | |[[BAALC-AS2]] |
|C8orf56,BAALCOS,MGC39526 | |C8orf56,BAALCOS,MGC39526 | ||
|NA | |NA | ||
| Line 1,202: | Line 1,202: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289453 HSALNT0289453] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289453 HSALNT0289453] | ||
| − | |FAM87A | + | |[[FAM87A]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,210: | Line 1,210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289459 HSALNT0289459] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289459 HSALNT0289459] | ||
| − | |JMJD1C-AS1 | + | |[[JMJD1C-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,218: | Line 1,218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289465 HSALNT0289465] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289465 HSALNT0289465] | ||
| − | |ATP2B1-AS1 | + | |[[ATP2B1-AS1]] |
|LINC00936 | |LINC00936 | ||
|NA | |NA | ||
| Line 1,226: | Line 1,226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289466 HSALNT0289466] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289466 HSALNT0289466] | ||
| − | |CEP83-AS1 | + | |[[CEP83-AS1]] |
|CEP83-DT | |CEP83-DT | ||
|NA | |NA | ||
| Line 1,234: | Line 1,234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289470 HSALNT0289470] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289470 HSALNT0289470] | ||
| − | |HEXA-AS1 | + | |[[HEXA-AS1]] |
|C15orf34,FLJ13315 | |C15orf34,FLJ13315 | ||
|NA | |NA | ||
| Line 1,242: | Line 1,242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289487 HSALNT0289487] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289487 HSALNT0289487] | ||
| − | |BIN3-IT1 | + | |[[BIN3-IT1]] |
|FLJ14107 | |FLJ14107 | ||
|NA | |NA | ||
| Line 1,250: | Line 1,250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289490 HSALNT0289490] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289490 HSALNT0289490] | ||
| − | |CSNK1G2-AS1 | + | |[[CSNK1G2-AS1]] |
|C19orf34,MGC39696 | |C19orf34,MGC39696 | ||
|NA | |NA | ||
| Line 1,258: | Line 1,258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289508 HSALNT0289508] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289508 HSALNT0289508] | ||
| − | |LINC00634 | + | |[[LINC00634]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,266: | Line 1,266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289510 HSALNT0289510] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289510 HSALNT0289510] | ||
| − | |LINC00685 | + | |[[LINC00685]] |
|CXYorf10,NCRNA00107,PPP2R3B-AS1,OTTHUMT00000055574 | |CXYorf10,NCRNA00107,PPP2R3B-AS1,OTTHUMT00000055574 | ||
|NA | |NA | ||
| Line 1,274: | Line 1,274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289515 HSALNT0289515] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289515 HSALNT0289515] | ||
| − | |SHANK2-AS3 | + | |[[SHANK2-AS3]] |
|C11orf76 | |C11orf76 | ||
|NA | |NA | ||
| Line 1,282: | Line 1,282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290073 HSALNT0290073] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290073 HSALNT0290073] | ||
| − | |NCBP2-AS2 | + | |[[NCBP2-AS2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,290: | Line 1,290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289502 HSALNT0289502] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289502 HSALNT0289502] | ||
| − | | | + | |[[NONHSAT095745]] |
|NCRNA00099,UM9-5 | |NCRNA00099,UM9-5 | ||
|NA | |NA | ||
| Line 1,298: | Line 1,298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289856 HSALNT0289856] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289856 HSALNT0289856] | ||
| − | |GTSCR1 | + | |[[GTSCR1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,306: | Line 1,306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289325 HSALNT0289325] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289325 HSALNT0289325] | ||
| − | |LINC00272 | + | |[[LINC00272]] |
|C1orf120,NCRNA00272,RP1-223H12.3 | |C1orf120,NCRNA00272,RP1-223H12.3 | ||
|NA | |NA | ||
| Line 1,314: | Line 1,314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288512 HSALNT0288512] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288512 HSALNT0288512] | ||
| − | |TTTY9B | + | |[[TTTY9B]] |
|NCRNA00132 | |NCRNA00132 | ||
|NA | |NA | ||
| Line 1,322: | Line 1,322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290155 HSALNT0290155] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290155 HSALNT0290155] | ||
| − | |Prion-associated RNAs | + | |[[Prion-associated RNAs]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,330: | Line 1,330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289444 HSALNT0289444] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289444 HSALNT0289444] | ||
| − | |BLACE | + | |[[BLACE]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,338: | Line 1,338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0060411 HSALNT0060411] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0060411 HSALNT0060411] | ||
| − | |H1FX-AS1 | + | |[[H1FX-AS1]] |
|C3orf47,FLJ34151 | |C3orf47,FLJ34151 | ||
|NA | |NA | ||
| Line 1,346: | Line 1,346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0186668 HSALNT0186668] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0186668 HSALNT0186668] | ||
| − | |LINC00477 | + | |[[LINC00477]] |
|C12orf67,FLJ32894,FAM191B | |C12orf67,FLJ32894,FAM191B | ||
|NA | |NA | ||
| Line 1,354: | Line 1,354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0275096 HSALNT0275096] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0275096 HSALNT0275096] | ||
| − | |LINC00528 | + | |[[LINC00528]] |
|C22orf37,FLJ40542 | |C22orf37,FLJ40542 | ||
|NA | |NA | ||
| Line 1,362: | Line 1,362: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0287824 HSALNT0287824] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0287824 HSALNT0287824] | ||
| − | |ASMTL-AS1 | + | |[[ASMTL-AS1]] |
|CXYorf2,NCRNA00105,ASMTLAS,ASMTL-AS,FLJ13330 | |CXYorf2,NCRNA00105,ASMTLAS,ASMTL-AS,FLJ13330 | ||
|NA | |NA | ||
| Line 1,370: | Line 1,370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288887 HSALNT0288887] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288887 HSALNT0288887] | ||
| − | |ANP32A-IT1 | + | |[[ANP32A-IT1]] |
|C15orf28,NCRNA00321,FLJ11722,HsT18971 | |C15orf28,NCRNA00321,FLJ11722,HsT18971 | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|NA | |NA | ||
|NA | |NA | ||
| Line 1,386: | Line 1,378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289396 HSALNT0289396] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289396 HSALNT0289396] | ||
| − | |RUSC1-AS1 | + | |[[RUSC1-AS1]] |
|C1orf104,FLJ35976 | |C1orf104,FLJ35976 | ||
|NA | |NA | ||
| Line 1,394: | Line 1,386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0084628 HSALNT0084628] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0084628 HSALNT0084628] | ||
| − | |LINC01194 | + | |[[LINC01194]] |
|CT49,TAG | |CT49,TAG | ||
|NA | |NA | ||
| Line 1,402: | Line 1,394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289468 HSALNT0289468] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289468 HSALNT0289468] | ||
| − | | | + | |[[NONHSAT040032]] |
|C14orf134,NCRNA00041,DIO3-AS1,NONHSAT040032,NONHSAT040039,BC111049 | |C14orf134,NCRNA00041,DIO3-AS1,NONHSAT040032,NONHSAT040039,BC111049 | ||
|NA | |NA | ||
| Line 1,410: | Line 1,402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0121060 HSALNT0121060] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0121060 HSALNT0121060] | ||
| − | |NPSR1-AS1 | + | |[[NPSR1-AS1]] |
|AAA1,IMAGE:4827585 | |AAA1,IMAGE:4827585 | ||
|NA | |NA | ||
| Line 1,418: | Line 1,410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0074370 HSALNT0074370] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0074370 HSALNT0074370] | ||
| − | |LINC00575 | + | |[[LINC00575]] |
|C4orf11 | |C4orf11 | ||
|NA | |NA | ||
| Line 1,426: | Line 1,418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0137345 HSALNT0137345] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0137345 HSALNT0137345] | ||
| − | |LINC01602 | + | |[[LINC01602]] |
|T1560 | |T1560 | ||
|NA | |NA | ||
| Line 1,434: | Line 1,426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289433 HSALNT0289433] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289433 HSALNT0289433] | ||
| − | |FAM13A-AS1 | + | |[[FAM13A-AS1]] |
|FAM13A1OS,FAM13AOS,NCRNA00039 | |FAM13A1OS,FAM13AOS,NCRNA00039 | ||
|NA | |NA | ||
| Line 1,442: | Line 1,434: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289186 HSALNT0289186] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289186 HSALNT0289186] | ||
| − | |MIRLET7DHG | + | |[[MIRLET7DHG]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,450: | Line 1,442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0155254 HSALNT0155254] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0155254 HSALNT0155254] | ||
| − | |MIR181A2HG | + | |[[MIR181A2HG]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,458: | Line 1,450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289283 HSALNT0289283] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289283 HSALNT0289283] | ||
| − | |WDFY3-AS2 | + | |[[WDFY3-AS2]] |
|C4orf12,NCRNA00247,FBI4 | |C4orf12,NCRNA00247,FBI4 | ||
|NA | |NA | ||
| Line 1,466: | Line 1,458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0154555 HSALNT0154555] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0154555 HSALNT0154555] | ||
| − | |PAPPA-AS1 | + | |[[PAPPA-AS1]] |
|PAPPAS,PAPPA-AS,DIPAS,TAF4B,TAF2C2,TAFII105,NCRNA00156 | |PAPPAS,PAPPA-AS,DIPAS,TAF4B,TAF2C2,TAFII105,NCRNA00156 | ||
|NA | |NA | ||
| Line 1,474: | Line 1,466: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0136307 HSALNT0136307] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0136307 HSALNT0136307] | ||
| − | |LINC00293 | + | |[[LINC00293]] |
|BEYLA | |BEYLA | ||
|NA | |NA | ||
| Line 1,482: | Line 1,474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0030983 HSALNT0030983] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0030983 HSALNT0030983] | ||
| − | |SIX3-AS1 | + | |[[SIX3-AS1]] |
|SIX3OS | |SIX3OS | ||
|NA | |NA | ||
| Line 1,490: | Line 1,482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0211503 HSALNT0211503] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0211503 HSALNT0211503] | ||
| − | | | + | |[[Lnc-C14orf101-5:1]] |
|OTX2OS1 | |OTX2OS1 | ||
|NA | |NA | ||
| Line 1,498: | Line 1,490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0063422 HSALNT0063422] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0063422 HSALNT0063422] | ||
| − | |LINC01192 | + | |[[LINC01192]] |
|CT64 | |CT64 | ||
|NA | |NA | ||
| Line 1,506: | Line 1,498: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0217123 HSALNT0217123] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0217123 HSALNT0217123] | ||
| − | |LINC01193 | + | |[[LINC01193]] |
|CT60,LOC348120 | |CT60,LOC348120 | ||
|NA | |NA | ||
| Line 1,514: | Line 1,506: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289664 HSALNT0289664] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289664 HSALNT0289664] | ||
| − | |C1QTNF9B-AS1 | + | |[[C1QTNF9B-AS1]] |
|PCOTH | |PCOTH | ||
|NA | |NA | ||
| Line 1,522: | Line 1,514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289623 HSALNT0289623] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289623 HSALNT0289623] | ||
| − | |ATP6V1G2-DDX39B | + | |[[ATP6V1G2-DDX39B]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,530: | Line 1,522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289498 HSALNT0289498] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289498 HSALNT0289498] | ||
| − | |FAM226B | + | |[[FAM226B]] |
|CXorf50B,NCRNA00246B,LINC00246B | |CXorf50B,NCRNA00246B,LINC00246B | ||
|NA | |NA | ||
| Line 1,538: | Line 1,530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289321 HSALNT0289321] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289321 HSALNT0289321] | ||
| − | |LINC00163 | + | |[[LINC00163]] |
|C21orf134,NCRNA00163,NLC1-A,NLC1A | |C21orf134,NCRNA00163,NLC1-A,NLC1A | ||
|NA | |NA | ||
| Line 1,546: | Line 1,538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289505 HSALNT0289505] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289505 HSALNT0289505] | ||
| − | |LINC00165 | + | |[[LINC00165]] |
|C21orf135,NCRNA00165,NLC1-B | |C21orf135,NCRNA00165,NLC1-B | ||
|NA | |NA | ||
| Line 1,554: | Line 1,546: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290297 HSALNT0290297] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290297 HSALNT0290297] | ||
| − | | | + | |[[NONHSAT035776]] |
|ENSG00000251002 | |ENSG00000251002 | ||
|NA | |NA | ||
| Line 1,562: | Line 1,554: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0274212 HSALNT0274212] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0274212 HSALNT0274212] | ||
| − | |LINC00322 | + | |[[LINC00322]] |
|C21orf136,NCRNA00322,FLJ16545 | |C21orf136,NCRNA00322,FLJ16545 | ||
|NA | |NA | ||
| Line 1,570: | Line 1,562: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289741 HSALNT0289741] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289741 HSALNT0289741] | ||
| − | | | + | |[[NONHSAT102417]] |
|DHFR minor transcript 5'-UTR,ENSG00000228716,NONHSAT102417 | |DHFR minor transcript 5'-UTR,ENSG00000228716,NONHSAT102417 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 1,578: | Line 1,570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289527 HSALNT0289527] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289527 HSALNT0289527] | ||
| − | | | + | |[[NONHSAT128494]] |
|ncRNA 21A,NONHSAT128494 | |ncRNA 21A,NONHSAT128494 | ||
|NA | |NA | ||
| Line 1,586: | Line 1,578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289409 HSALNT0289409] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289409 HSALNT0289409] | ||
| − | |TLX1NB | + | |[[TLX1NB]] |
|TD1,TDI,APT-B7 | |TD1,TDI,APT-B7 | ||
|NA | |NA | ||
| Line 1,594: | Line 1,586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289662 HSALNT0289662] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289662 HSALNT0289662] | ||
| − | |C15orf2 | + | |[[C15orf2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,602: | Line 1,594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290097 HSALNT0290097] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290097 HSALNT0290097] | ||
| − | |NPAP1 | + | |[[NPAP1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,610: | Line 1,602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0217406 HSALNT0217406] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0217406 HSALNT0217406] | ||
| − | | | + | |[[NONHSAT040875]] |
|NCRNA00199 | |NCRNA00199 | ||
|NA | |NA | ||
| Line 1,618: | Line 1,610: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289227 HSALNT0289227] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289227 HSALNT0289227] | ||
| − | | | + | |[[NONHSAT040920]] |
|NCRNA00198 | |NCRNA00198 | ||
|NA | |NA | ||
| Line 1,626: | Line 1,618: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0262816 HSALNT0262816] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0262816 HSALNT0262816] | ||
| − | |MIMT1 | + | |[[MIMT1]] |
|MIM1,NCRNA00067,LINC00067 | |MIM1,NCRNA00067,LINC00067 | ||
|NA | |NA | ||
| Line 1,634: | Line 1,626: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289180 HSALNT0289180] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289180 HSALNT0289180] | ||
| − | |MIR34AHG | + | |[[MIR34AHG]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,642: | Line 1,634: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289357 HSALNT0289357] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289357 HSALNT0289357] | ||
| − | |LINC02570 | + | |[[LINC02570]] |
|XXbac-BPG27H4.8 | |XXbac-BPG27H4.8 | ||
|NA | |NA | ||
| Line 1,650: | Line 1,642: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290177 HSALNT0290177] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290177 HSALNT0290177] | ||
| − | |RNY1 | + | |[[RNY1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,658: | Line 1,650: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289378 HSALNT0289378] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289378 HSALNT0289378] | ||
| − | |NKX2-2-AS1 | + | |[[NKX2-2-AS1]] |
|NKX2-2AS | |NKX2-2AS | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 1,666: | Line 1,658: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290151 HSALNT0290151] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290151 HSALNT0290151] | ||
| − | | | + | |[[NONHSAT023851]] |
|FJ515872.1,NONHSAT023851 | |FJ515872.1,NONHSAT023851 | ||
|transcriptional regulation | |transcriptional regulation | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|NA | |NA | ||
|NA | |NA | ||
| Line 1,682: | Line 1,666: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289607 HSALNT0289607] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289607 HSALNT0289607] | ||
| − | | | + | |[[Anti-NOS2A]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,690: | Line 1,674: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289687 HSALNT0289687] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289687 HSALNT0289687] | ||
| − | |CDKN1A-AS1 | + | |[[CDKN1A-AS1]] |
|p21NAT | |p21NAT | ||
|transcriptional regulation | |transcriptional regulation | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|NA | |NA | ||
|NA | |NA | ||
| Line 1,706: | Line 1,682: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0116668 HSALNT0116668] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0116668 HSALNT0116668] | ||
| − | |RPS6KA2-AS1 | + | |[[RPS6KA2-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,714: | Line 1,690: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289384 HSALNT0289384] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289384 HSALNT0289384] | ||
| − | |PAPPA-AS2 | + | |[[PAPPA-AS2]] |
|AGU1 | |AGU1 | ||
|NA | |NA | ||
| Line 1,722: | Line 1,698: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0262802 HSALNT0262802] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0262802 HSALNT0262802] | ||
| − | |ZIM2-AS1 | + | |[[ZIM2-AS1]] |
|ZIM2as | |ZIM2as | ||
|NA | |NA | ||
| Line 1,730: | Line 1,706: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289824 HSALNT0289824] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289824 HSALNT0289824] | ||
| − | | | + | |[[Lnc-DLX5-3:1]] |
|Evf-2,Dlx6as1,Dlx6os1,ENSG00000231764, ENST00000430027.2,lnc-DLX5-3:1 | |Evf-2,Dlx6as1,Dlx6os1,ENSG00000231764, ENST00000430027.2,lnc-DLX5-3:1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 1,738: | Line 1,714: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289481 HSALNT0289481] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289481 HSALNT0289481] | ||
| − | |ADORA2A-AS1 | + | |[[ADORA2A-AS1]] |
|C22orf45,FLJ34651 | |C22orf45,FLJ34651 | ||
|NA | |NA | ||
| Line 1,746: | Line 1,722: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290146 HSALNT0290146] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290146 HSALNT0290146] | ||
| − | |POU5F1P4 | + | |[[POU5F1P4]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,754: | Line 1,730: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290033 HSALNT0290033] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290033 HSALNT0290033] | ||
| − | |LSINCT1 | + | |[[LSINCT1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,762: | Line 1,738: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290034 HSALNT0290034] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290034 HSALNT0290034] | ||
| − | |LSINCT10 | + | |[[LSINCT10]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,770: | Line 1,746: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290035 HSALNT0290035] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290035 HSALNT0290035] | ||
| − | |LSINCT11 | + | |[[LSINCT11]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,778: | Line 1,754: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290036 HSALNT0290036] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290036 HSALNT0290036] | ||
| − | |LSINCT12 | + | |[[LSINCT12]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,786: | Line 1,762: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290037 HSALNT0290037] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290037 HSALNT0290037] | ||
| − | |LSINCT2 | + | |[[LSINCT2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,794: | Line 1,770: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290038 HSALNT0290038] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290038 HSALNT0290038] | ||
| − | |LSINCT3 | + | |[[LSINCT3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,802: | Line 1,778: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290039 HSALNT0290039] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290039 HSALNT0290039] | ||
| − | |LSINCT4 | + | |[[LSINCT4]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,810: | Line 1,786: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290041 HSALNT0290041] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290041 HSALNT0290041] | ||
| − | |LSINCT6 | + | |[[LSINCT6]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,818: | Line 1,794: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290042 HSALNT0290042] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290042 HSALNT0290042] | ||
| − | |LSINCT7 | + | |[[LSINCT7]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,826: | Line 1,802: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290043 HSALNT0290043] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290043 HSALNT0290043] | ||
| − | |LSINCT8 | + | |[[LSINCT8]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,834: | Line 1,810: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290044 HSALNT0290044] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290044 HSALNT0290044] | ||
| − | |LSINCT9 | + | |[[LSINCT9]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,842: | Line 1,818: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289676 HSALNT0289676] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289676 HSALNT0289676] | ||
| − | | | + | |[[NONHSAT016928]] |
|FLJ31066,NONHSAT016928,lnc-FANK1-3:1 | |FLJ31066,NONHSAT016928,lnc-FANK1-3:1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 1,850: | Line 1,826: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290032 HSALNT0290032] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290032 HSALNT0290032] | ||
| − | |LRRC3DN | + | |[[LRRC3DN]] |
|C21orf30,DKFZP434C128 | |C21orf30,DKFZP434C128 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 1,858: | Line 1,834: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0266984 HSALNT0266984] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0266984 HSALNT0266984] | ||
| − | |SNHG11 | + | |[[SNHG11]] |
|C20orf198,LINC00101,NCRNA00101 | |C20orf198,LINC00101,NCRNA00101 | ||
|NA | |NA | ||
| Line 1,866: | Line 1,842: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289880 HSALNT0289880] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289880 HSALNT0289880] | ||
| − | | | + | |[[NONHSAT113225]] |
|NONHSAT113225,ENSG00000220635 | |NONHSAT113225,ENSG00000220635 | ||
|ceRNA | |ceRNA | ||
| Line 1,874: | Line 1,850: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0006368 HSALNT0006368] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0006368 HSALNT0006368] | ||
| − | | | + | |[[ENST00000444042.2]] |
|ncRNA-a3 | |ncRNA-a3 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 1,882: | Line 1,858: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0027470 HSALNT0027470] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0027470 HSALNT0027470] | ||
| − | | | + | |[[ENST00000417473.2]] |
|ncRNA-a5 | |ncRNA-a5 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 1,890: | Line 1,866: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289066 HSALNT0289066] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289066 HSALNT0289066] | ||
| − | | | + | |[[ENST00000429328.2]] |
|PDZK1IP1-AS1,ncRNA-a4 | |PDZK1IP1-AS1,ncRNA-a4 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 1,898: | Line 1,874: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289936 HSALNT0289936] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289936 HSALNT0289936] | ||
| − | | | + | |[[NONHSAT059436]] |
|ROR,lincRNA-ST8SIA3,ENSG00000258609,NONHSAT059436 | |ROR,lincRNA-ST8SIA3,ENSG00000258609,NONHSAT059436 | ||
|NA | |NA | ||
| Line 1,906: | Line 1,882: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289705 HSALNT0289705] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289705 HSALNT0289705] | ||
| − | |CHL1-AS2 | + | |[[CHL1-AS2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,914: | Line 1,890: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0076084 HSALNT0076084] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0076084 HSALNT0076084] | ||
| − | |SEC24B-AS1 | + | |[[SEC24B-AS1]] |
|1/2-SBSRNA4 | |1/2-SBSRNA4 | ||
|siRNA | |siRNA | ||
| Line 1,922: | Line 1,898: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290137 HSALNT0290137] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290137 HSALNT0290137] | ||
| − | |PDZRN3-AS1 | + | |[[PDZRN3-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,930: | Line 1,906: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290237 HSALNT0290237] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290237 HSALNT0290237] | ||
| − | |SCAANT1 | + | |[[SCAANT1]] |
|ATXN7-AS1 | |ATXN7-AS1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 1,938: | Line 1,914: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289594 HSALNT0289594] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289594 HSALNT0289594] | ||
| − | |AK123790 | + | |[[AK123790]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,946: | Line 1,922: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289911 HSALNT0289911] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289911 HSALNT0289911] | ||
| − | |LINC01451 | + | |[[LINC01451]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,954: | Line 1,930: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290401 HSALNT0290401] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290401 HSALNT0290401] | ||
| − | |ZNF350-AS1 | + | |[[ZNF350-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,962: | Line 1,938: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289845 HSALNT0289845] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289845 HSALNT0289845] | ||
| − | |GADD45G | + | |[[GADD45G]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,970: | Line 1,946: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289410 HSALNT0289410] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289410 HSALNT0289410] | ||
| − | | | + | |[[Lnc-RASA1-3:23]] |
|AK082072,linc-POLR3G-8,ENSG00000247828 | |AK082072,linc-POLR3G-8,ENSG00000247828 | ||
|NA | |NA | ||
| Line 1,978: | Line 1,954: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289736 HSALNT0289736] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289736 HSALNT0289736] | ||
| − | |DAPK1 | + | |[[DAPK1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 1,986: | Line 1,962: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290048 HSALNT0290048] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290048 HSALNT0290048] | ||
| − | |MAP3K14 | + | |[[MAP3K14]] |
|MAP3K14 | |MAP3K14 | ||
|NA | |NA | ||
| Line 1,994: | Line 1,970: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290150 HSALNT0290150] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290150 HSALNT0290150] | ||
| − | |PPP3CB | + | |[[PPP3CB]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,002: | Line 1,978: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0151531 HSALNT0151531] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0151531 HSALNT0151531] | ||
| − | |DAPK1-IT1 | + | |[[DAPK1-IT1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,010: | Line 1,986: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288990 HSALNT0288990] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288990 HSALNT0288990] | ||
| − | |GDNF-AS1 | + | |[[GDNF-AS1]] |
|GDNFOS | |GDNFOS | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 2,018: | Line 1,994: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0029702 HSALNT0029702] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0029702 HSALNT0029702] | ||
| − | |BIRC6-AS2 | + | |[[BIRC6-AS2]] |
|megamind | |megamind | ||
|NA | |NA | ||
| Line 2,026: | Line 2,002: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0029692 HSALNT0029692] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0029692 HSALNT0029692] | ||
| − | |BIRC6-AS1 | + | |[[BIRC6-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,034: | Line 2,010: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289310 HSALNT0289310] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289310 HSALNT0289310] | ||
| − | |LINC00854 | + | |[[LINC00854]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,042: | Line 2,018: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290332 HSALNT0290332] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290332 HSALNT0290332] | ||
| − | | | + | |[[Uc.73]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,050: | Line 2,026: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289841 HSALNT0289841] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289841 HSALNT0289841] | ||
| − | |FR0257520 | + | |[[FR0257520]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,058: | Line 2,034: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290104 HSALNT0290104] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290104 HSALNT0290104] | ||
| − | |NRG1 | + | |[[NRG1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,066: | Line 2,042: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289689 HSALNT0289689] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289689 HSALNT0289689] | ||
| − | |CDKN2B-AS11 | + | |[[CDKN2B-AS11]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,074: | Line 2,050: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289690 HSALNT0289690] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289690 HSALNT0289690] | ||
| − | |CDKN2B-AS12 | + | |[[CDKN2B-AS12]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,082: | Line 2,058: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289691 HSALNT0289691] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289691 HSALNT0289691] | ||
| − | |CDKN2B-AS13 | + | |[[CDKN2B-AS13]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,090: | Line 2,066: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289697 HSALNT0289697] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289697 HSALNT0289697] | ||
| − | |CDKN2B-AS7 | + | |[[CDKN2B-AS7]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,098: | Line 2,074: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289826 HSALNT0289826] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289826 HSALNT0289826] | ||
| − | |FADS1 | + | |[[FADS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,106: | Line 2,082: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289698 HSALNT0289698] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289698 HSALNT0289698] | ||
| − | |CDKN2B-AS8 | + | |[[CDKN2B-AS8]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,114: | Line 2,090: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289696 HSALNT0289696] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289696 HSALNT0289696] | ||
| − | |CDKN2B-AS6 | + | |[[CDKN2B-AS6]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,122: | Line 2,098: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289699 HSALNT0289699] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289699 HSALNT0289699] | ||
| − | |CDKN2B-AS9 | + | |[[CDKN2B-AS9]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,130: | Line 2,106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289688 HSALNT0289688] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289688 HSALNT0289688] | ||
| − | |CDKN2B-AS10 | + | |[[CDKN2B-AS10]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,138: | Line 2,114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288950 HSALNT0288950] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288950 HSALNT0288950] | ||
| − | |ENST00000456816 | + | |[[ENST00000456816]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,146: | Line 2,122: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290021 HSALNT0290021] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290021 HSALNT0290021] | ||
| − | |LOC389332 | + | |[[LOC389332]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,154: | Line 2,130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290306 HSALNT0290306] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290306 HSALNT0290306] | ||
| − | |TMEM72 | + | |[[TMEM72]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,162: | Line 2,138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289641 HSALNT0289641] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289641 HSALNT0289641] | ||
| − | |BC029135 | + | |[[BC029135]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,170: | Line 2,146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290374 HSALNT0290374] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290374 HSALNT0290374] | ||
| − | |X91348 | + | |[[X91348]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,178: | Line 2,154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289694 HSALNT0289694] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289694 HSALNT0289694] | ||
| − | |CDKN2B-AS4 | + | |[[CDKN2B-AS4]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,186: | Line 2,162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289692 HSALNT0289692] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289692 HSALNT0289692] | ||
| − | |CDKN2B-AS2 | + | |[[CDKN2B-AS2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,194: | Line 2,170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289693 HSALNT0289693] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289693 HSALNT0289693] | ||
| − | |CDKN2B-AS3 | + | |[[CDKN2B-AS3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,202: | Line 2,178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289695 HSALNT0289695] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289695 HSALNT0289695] | ||
| − | |CDKN2B-AS5 | + | |[[CDKN2B-AS5]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,210: | Line 2,186: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290319 HSALNT0290319] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290319 HSALNT0290319] | ||
| − | |T-UCRs | + | |[[T-UCRs]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,218: | Line 2,194: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289530 HSALNT0289530] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289530 HSALNT0289530] | ||
| − | |51A | + | |[[51A]] |
|NA | |NA | ||
|splicing regulation | |splicing regulation | ||
| Line 2,226: | Line 2,202: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290163 HSALNT0290163] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290163 HSALNT0290163] | ||
| − | |RAB4B-EGLN2 | + | |[[RAB4B-EGLN2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,234: | Line 2,210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290167 HSALNT0290167] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290167 HSALNT0290167] | ||
| − | |RERT | + | |[[RERT]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,242: | Line 2,218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0265263 HSALNT0265263] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0265263 HSALNT0265263] | ||
| − | |LINC00237 | + | |[[LINC00237]] |
|NCRNA00237 | |NCRNA00237 | ||
|NA | |NA | ||
| Line 2,250: | Line 2,226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0267186 HSALNT0267186] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0267186 HSALNT0267186] | ||
| − | |LINC01370 | + | |[[LINC01370]] |
|HI-LNC25,HILNC25 | |HI-LNC25,HILNC25 | ||
|NA | |NA | ||
| Line 2,258: | Line 2,234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289114 HSALNT0289114] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289114 HSALNT0289114] | ||
| − | |LINC01574 | + | |[[LINC01574]] |
|HI-LNC12,TCONS_00009551 | |HI-LNC12,TCONS_00009551 | ||
|NA | |NA | ||
| Line 2,266: | Line 2,242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290159 HSALNT0290159] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290159 HSALNT0290159] | ||
| − | |PTHLH | + | |[[PTHLH]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,274: | Line 2,250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0189394 HSALNT0189394] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0189394 HSALNT0189394] | ||
| − | | | + | |[[NONHSAT028496]] |
|CISTR-ACT,CISTRACT,re52431 | |CISTR-ACT,CISTRACT,re52431 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 2,282: | Line 2,258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289862 HSALNT0289862] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289862 HSALNT0289862] | ||
| − | |HELLPAR | + | |[[HELLPAR]] |
|LINC-HELLP | |LINC-HELLP | ||
|NA | |NA | ||
| Line 2,290: | Line 2,266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289904 HSALNT0289904] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289904 HSALNT0289904] | ||
| − | |LINC01125 | + | |[[LINC01125]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,298: | Line 2,274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289544 HSALNT0289544] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289544 HSALNT0289544] | ||
| − | |AC002511.1 | + | |[[AC002511.1]] |
|LINC01531 | |LINC01531 | ||
|NA | |NA | ||
| Line 2,306: | Line 2,282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289609 HSALNT0289609] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289609 HSALNT0289609] | ||
| − | |AP000688.29 | + | |[[AP000688.29]] |
|AP000688.2 | |AP000688.2 | ||
|NA | |NA | ||
| Line 2,314: | Line 2,290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289832 HSALNT0289832] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289832 HSALNT0289832] | ||
| − | |FFAR2 | + | |[[FFAR2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,322: | Line 2,298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290222 HSALNT0290222] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290222 HSALNT0290222] | ||
| − | |RP4-620F22.3 | + | |[[RP4-620F22.3]] |
|AC099063.2 | |AC099063.2 | ||
|NA | |NA | ||
| Line 2,330: | Line 2,306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290227 HSALNT0290227] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290227 HSALNT0290227] | ||
| − | |RP5-843L14.1 | + | |[[RP5-843L14.1]] |
|LINC01716 | |LINC01716 | ||
|NA | |NA | ||
| Line 2,338: | Line 2,314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0287285 HSALNT0287285] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0287285 HSALNT0287285] | ||
| − | |MAGEA8-AS1 | + | |[[MAGEA8-AS1]] |
|RP5-869M20.2 | |RP5-869M20.2 | ||
|NA | |NA | ||
| Line 2,346: | Line 2,322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289019 HSALNT0289019] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289019 HSALNT0289019] | ||
| − | |LHX5-AS1 | + | |[[LHX5-AS1]] |
|locus4010 | |locus4010 | ||
|NA | |NA | ||
| Line 2,354: | Line 2,330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288902 HSALNT0288902] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288902 HSALNT0288902] | ||
| − | |CAPN10-AS1 | + | |[[CAPN10-AS1]] |
|CAPN10-DT,locus959 | |CAPN10-DT,locus959 | ||
|NA | |NA | ||
| Line 2,362: | Line 2,338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289404 HSALNT0289404] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289404 HSALNT0289404] | ||
| − | |STAM-AS1 | + | |[[STAM-AS1]] |
|locus3182 | |locus3182 | ||
|NA | |NA | ||
| Line 2,370: | Line 2,346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0148276 HSALNT0148276] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0148276 HSALNT0148276] | ||
| − | |PTENP1-AS | + | |[[PTENP1-AS]] |
|PTENpg1-asRNA | |PTENpg1-asRNA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 2,378: | Line 2,354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289562 HSALNT0289562] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289562 HSALNT0289562] | ||
| − | |AF116616 | + | |[[AF116616]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,386: | Line 2,362: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289589 HSALNT0289589] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289589 HSALNT0289589] | ||
| − | |AK094838 | + | |[[AK094838]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,394: | Line 2,370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289620 HSALNT0289620] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289620 HSALNT0289620] | ||
| − | |ASLNC00339 | + | |[[ASLNC00339]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,402: | Line 2,378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289629 HSALNT0289629] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289629 HSALNT0289629] | ||
| − | |BC002350 | + | |[[BC002350]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,410: | Line 2,386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289651 HSALNT0289651] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289651 HSALNT0289651] | ||
| − | |BC091525 | + | |[[BC091525]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,418: | Line 2,394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289652 HSALNT0289652] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289652 HSALNT0289652] | ||
| − | |BE503655 | + | |[[BE503655]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,426: | Line 2,402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289753 HSALNT0289753] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289753 HSALNT0289753] | ||
| − | |ENO1 | + | |[[ENO1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,434: | Line 2,410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289835 HSALNT0289835] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289835 HSALNT0289835] | ||
| − | |FKBP10 | + | |[[FKBP10]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,442: | Line 2,418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290064 HSALNT0290064] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290064 HSALNT0290064] | ||
| − | |MYHAS | + | |[[MYHAS]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,450: | Line 2,426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289985 HSALNT0289985] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289985 HSALNT0289985] | ||
| − | |LncRNA-LALR1 | + | |[[LncRNA-LALR1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 2,456: | Line 2,432: | ||
|liver cancer | |liver cancer | ||
|Neoplasms;Digestive System Diseases | |Neoplasms;Digestive System Diseases | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0091577 HSALNT0091577] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0091577 HSALNT0091577] | ||
| − | |NR2F1-AS1 | + | |[[NR2F1-AS1]] |
|FLJ42709 | |FLJ42709 | ||
|NA | |NA | ||
| Line 2,474: | Line 2,442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289709 HSALNT0289709] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289709 HSALNT0289709] | ||
| − | |CK19 | + | |[[CK19]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,482: | Line 2,450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289943 HSALNT0289943] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289943 HSALNT0289943] | ||
| − | |Llme23 | + | |[[Llme23]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,490: | Line 2,458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289553 HSALNT0289553] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289553 HSALNT0289553] | ||
| − | |AC096655.1 | + | |[[AC096655.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,498: | Line 2,466: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289178 HSALNT0289178] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289178 HSALNT0289178] | ||
| − | | | + | |[[ENST00000602507.1]] |
|Lnc-Ang362 | |Lnc-Ang362 | ||
|NA | |NA | ||
| Line 2,506: | Line 2,474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289261 HSALNT0289261] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289261 HSALNT0289261] | ||
| − | |STX18-AS1 | + | |[[STX18-AS1]] |
|LOC100507266 | |LOC100507266 | ||
|NA | |NA | ||
| Line 2,514: | Line 2,482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289849 HSALNT0289849] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289849 HSALNT0289849] | ||
| − | |GHSR | + | |[[GHSR]] |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|NA | |NA | ||
|NA | |NA | ||
| Line 2,530: | Line 2,490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289210 HSALNT0289210] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289210 HSALNT0289210] | ||
| − | | | + | |[[ENST00000452148.2]] |
|PCAN-R2 | |PCAN-R2 | ||
|NA | |NA | ||
| Line 2,538: | Line 2,498: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289702 HSALNT0289702] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289702 HSALNT0289702] | ||
| − | |CES1P1 | + | |[[CES1P1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,546: | Line 2,506: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289892 HSALNT0289892] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289892 HSALNT0289892] | ||
| − | |LINC00210 | + | |[[LINC00210]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,554: | Line 2,514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290006 HSALNT0290006] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290006 HSALNT0290006] | ||
| − | |LOC100506974 | + | |[[LOC100506974]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,562: | Line 2,522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290219 HSALNT0290219] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290219 HSALNT0290219] | ||
| − | |RP3-508I15.14 | + | |[[RP3-508I15.14]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,570: | Line 2,530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290243 HSALNT0290243] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290243 HSALNT0290243] | ||
| − | |SLC6A6 | + | |[[SLC6A6]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,578: | Line 2,538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290342 HSALNT0290342] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290342 HSALNT0290342] | ||
| − | | | + | |[[Uc003bgl.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,586: | Line 2,546: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289075 HSALNT0289075] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289075 HSALNT0289075] | ||
| − | |LINC00970 | + | |[[LINC00970]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,594: | Line 2,554: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0211868 HSALNT0211868] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0211868 HSALNT0211868] | ||
| − | |SALRNA1 | + | |[[SALRNA1]] |
|SAL-RNA1,XLOC_023166 | |SAL-RNA1,XLOC_023166 | ||
|NA | |NA | ||
| Line 2,602: | Line 2,562: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0222267 HSALNT0222267] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0222267 HSALNT0222267] | ||
| − | |SALRNA3 | + | |[[SALRNA3]] |
|SAL-RNA3,XLOC_025918 | |SAL-RNA3,XLOC_025918 | ||
|NA | |NA | ||
| Line 2,610: | Line 2,570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0222274 HSALNT0222274] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0222274 HSALNT0222274] | ||
| − | |SALRNA2 | + | |[[SALRNA2]] |
|SAL-RNA2,XLOC_025931 | |SAL-RNA2,XLOC_025931 | ||
|NA | |NA | ||
| Line 2,618: | Line 2,578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289428 HSALNT0289428] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289428 HSALNT0289428] | ||
| − | | | + | |[[NONHSAT076558]] |
|GPR1-AS1,GPR1AS | |GPR1-AS1,GPR1AS | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 2,626: | Line 2,586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0226207 HSALNT0226207] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0226207 HSALNT0226207] | ||
| − | |LINC00235 | + | |[[LINC00235]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,634: | Line 2,594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289526 HSALNT0289526] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289526 HSALNT0289526] | ||
| − | |1B FGF-antisense transcripts | + | |[[1B FGF-antisense transcripts]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,642: | Line 2,602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290171 HSALNT0290171] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290171 HSALNT0290171] | ||
| − | |RNA polymerase III-dependent lncRNAs | + | |[[RNA polymerase III-dependent lncRNAs]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,650: | Line 2,610: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290168 HSALNT0290168] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290168 HSALNT0290168] | ||
| − | |REST/CoREST-regulated lncRNAs | + | |[[REST/CoREST-regulated lncRNAs]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,658: | Line 2,618: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289606 HSALNT0289606] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289606 HSALNT0289606] | ||
| − | |Alu lncRNAs | + | |[[Alu lncRNAs]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,666: | Line 2,626: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290358 HSALNT0290358] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290358 HSALNT0290358] | ||
| − | |UCH1LAS | + | |[[UCH1LAS]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,674: | Line 2,634: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290244 HSALNT0290244] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290244 HSALNT0290244] | ||
| − | |SLC7A2-IT1A/B | + | |[[SLC7A2-IT1A/B]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,682: | Line 2,642: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289877 HSALNT0289877] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289877 HSALNT0289877] | ||
| − | |Kcna2-AS | + | |[[Kcna2-AS]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,690: | Line 2,650: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289191 HSALNT0289191] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289191 HSALNT0289191] | ||
| − | |NCOA7-AS1 | + | |[[NCOA7-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,698: | Line 2,658: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290020 HSALNT0290020] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290020 HSALNT0290020] | ||
| − | |LOC389023 | + | |[[LOC389023]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 2,706: | Line 2,666: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0175124 HSALNT0175124] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0175124 HSALNT0175124] | ||
| − | |PTPRJ-AS1 | + | |[[PTPRJ-AS1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 2,714: | Line 2,674: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289654 HSALNT0289654] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289654 HSALNT0289654] | ||
| − | |BM742401 | + | |[[BM742401]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,722: | Line 2,682: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289331 HSALNT0289331] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289331 HSALNT0289331] | ||
| − | |LINC00951 | + | |[[LINC00951]] |
|lincRNA-uc003opf.1,FLJ41649 | |lincRNA-uc003opf.1,FLJ41649 | ||
|NA | |NA | ||
| Line 2,730: | Line 2,690: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290130 HSALNT0290130] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290130 HSALNT0290130] | ||
| − | |PAWR | + | |[[PAWR]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,738: | Line 2,698: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290264 HSALNT0290264] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290264 HSALNT0290264] | ||
| − | |T-ALL-R-LncR1 | + | |[[T-ALL-R-LncR1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,746: | Line 2,706: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289599 HSALNT0289599] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289599 HSALNT0289599] | ||
| − | |AK130977 | + | |[[AK130977]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,754: | Line 2,714: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289625 HSALNT0289625] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289625 HSALNT0289625] | ||
| − | |AX746718 | + | |[[AX746718]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,762: | Line 2,722: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289738 HSALNT0289738] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289738 HSALNT0289738] | ||
| − | |DDR2 | + | |[[DDR2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,770: | Line 2,730: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290003 HSALNT0290003] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290003 HSALNT0290003] | ||
| − | |LOC100131831 | + | |[[LOC100131831]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,778: | Line 2,738: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290144 HSALNT0290144] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290144 HSALNT0290144] | ||
| − | |POT1-AS1 | + | |[[POT1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,786: | Line 2,746: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290253 HSALNT0290253] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290253 HSALNT0290253] | ||
| − | |SNORA17B | + | |[[SNORA17B]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,794: | Line 2,754: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0207421 HSALNT0207421] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0207421 HSALNT0207421] | ||
| − | |GAS6-AS1 | + | |[[GAS6-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,802: | Line 2,762: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289838 HSALNT0289838] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289838 HSALNT0289838] | ||
| − | |FMR5 | + | |[[FMR5]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,810: | Line 2,770: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0208907 HSALNT0208907] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0208907 HSALNT0208907] | ||
| − | |FOXG1-AS1 | + | |[[FOXG1-AS1]] |
|FOXG1-AS | |FOXG1-AS | ||
|NA | |NA | ||
| Line 2,818: | Line 2,778: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290263 HSALNT0290263] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290263 HSALNT0290263] | ||
| − | |SYNGAP1-AS1 | + | |[[SYNGAP1-AS1]] |
|SYNGAP1-AS | |SYNGAP1-AS | ||
|NA | |NA | ||
| Line 2,826: | Line 2,786: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290176 HSALNT0290176] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290176 HSALNT0290176] | ||
| − | |RNase MRP | + | |[[RNase MRP]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,834: | Line 2,794: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289469 HSALNT0289469] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289469 HSALNT0289469] | ||
| − | |GABPB1-AS1 | + | |[[GABPB1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,842: | Line 2,802: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289009 HSALNT0289009] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289009 HSALNT0289009] | ||
| − | |IDI2-AS1 | + | |[[IDI2-AS1]] |
|C10orf110,IDI2-A,HT009,Em:AC022536.4 | |C10orf110,IDI2-A,HT009,Em:AC022536.4 | ||
|NA | |NA | ||
| Line 2,850: | Line 2,810: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289093 HSALNT0289093] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289093 HSALNT0289093] | ||
| − | |LINC01184 | + | |[[LINC01184]] |
|FLJ33630 | |FLJ33630 | ||
|NA | |NA | ||
| Line 2,858: | Line 2,818: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290108 HSALNT0290108] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290108 HSALNT0290108] | ||
| − | |OGT | + | |[[OGT]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,866: | Line 2,826: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290077 HSALNT0290077] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290077 HSALNT0290077] | ||
| − | | | + | |[[NcNRFR]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 2,874: | Line 2,834: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290337 HSALNT0290337] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290337 HSALNT0290337] | ||
| − | | | + | |[[Uc001lsz]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,882: | Line 2,842: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289087 HSALNT0289087] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289087 HSALNT0289087] | ||
| − | |LINC01090 | + | |[[LINC01090]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,888: | Line 2,848: | ||
|post-traumatic stress disorder | |post-traumatic stress disorder | ||
|Mental Disorders | |Mental Disorders | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289981 HSALNT0289981] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289981 HSALNT0289981] | ||
| − | | | + | |[[LncRNA-DQ786227]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,906: | Line 2,858: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289876 HSALNT0289876] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289876 HSALNT0289876] | ||
| − | |JADRR | + | |[[JADRR]] |
|LINC00915,lncRNA-JADE | |LINC00915,lncRNA-JADE | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 2,914: | Line 2,866: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290254 HSALNT0290254] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290254 HSALNT0290254] | ||
| − | |SOX2OT-S1 | + | |[[SOX2OT-S1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,920: | Line 2,872: | ||
|esophageal squamous cell cancer | |esophageal squamous cell cancer | ||
|Neoplasms | |Neoplasms | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289870 HSALNT0289870] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289870 HSALNT0289870] | ||
| − | |HOXA13 | + | |[[HOXA13]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,938: | Line 2,882: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0078946 HSALNT0078946] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0078946 HSALNT0078946] | ||
| − | |SMAD1-AS1 | + | |[[SMAD1-AS1]] |
|ENST00000513542 | |ENST00000513542 | ||
|NA | |NA | ||
| Line 2,946: | Line 2,890: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0087329 HSALNT0087329] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0087329 HSALNT0087329] | ||
| − | |FGF10-AS1 | + | |[[FGF10-AS1]] |
|RP11-473L15.2 | |RP11-473L15.2 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 2,954: | Line 2,898: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290318 HSALNT0290318] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290318 HSALNT0290318] | ||
| − | |TUC339 | + | |[[TUC339]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,962: | Line 2,906: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289819 HSALNT0289819] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289819 HSALNT0289819] | ||
| − | | | + | |[[Lnc-CHRAC1-2:1]] |
|LINC01130,TCONS_00014875,ERIC | |LINC01130,TCONS_00014875,ERIC | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 2,970: | Line 2,914: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289615 HSALNT0289615] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289615 HSALNT0289615] | ||
| − | |ARA | + | |[[ARA]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,978: | Line 2,922: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289822 HSALNT0289822] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289822 HSALNT0289822] | ||
| − | |ESCCAL-5 | + | |[[ESCCAL-5]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,986: | Line 2,930: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290074 HSALNT0290074] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290074 HSALNT0290074] | ||
| − | | | + | |[[NcC11orf49]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 2,994: | Line 2,938: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290076 HSALNT0290076] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290076 HSALNT0290076] | ||
| − | | | + | |[[NcHDAC5]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,002: | Line 2,946: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290078 HSALNT0290078] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290078 HSALNT0290078] | ||
| − | | | + | |[[NcRAB31]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,010: | Line 2,954: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290080 HSALNT0290080] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290080 HSALNT0290080] | ||
| − | | | + | |[[NcSRPK1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,018: | Line 2,962: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0018253 HSALNT0018253] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0018253 HSALNT0018253] | ||
| − | | | + | |[[ENST00000442621.1]] |
|LINC01131,OVAL | |LINC01131,OVAL | ||
|NA | |NA | ||
| Line 3,026: | Line 2,970: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289884 HSALNT0289884] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289884 HSALNT0289884] | ||
| − | |LALR | + | |[[LALR]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 3,034: | Line 2,978: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289701 HSALNT0289701] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289701 HSALNT0289701] | ||
| − | |CEACAMP8 | + | |[[CEACAMP8]] |
|CEACAMP8 | |CEACAMP8 | ||
|NA | |NA | ||
| Line 3,042: | Line 2,986: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290018 HSALNT0290018] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290018 HSALNT0290018] | ||
| − | |LOC284100 | + | |[[LOC284100]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,050: | Line 2,994: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290023 HSALNT0290023] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290023 HSALNT0290023] | ||
| − | |LOC391533 | + | |[[LOC391533]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,058: | Line 3,002: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0189558 HSALNT0189558] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0189558 HSALNT0189558] | ||
| − | |LINC01154 | + | |[[LINC01154]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,066: | Line 3,010: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0196616 HSALNT0196616] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0196616 HSALNT0196616] | ||
| − | | | + | |[[Lnc-DHX37-1:1]] |
|BRI3BP-AS1,BRI3BPAS1,Linc1992,TCONS_00020260 | |BRI3BP-AS1,BRI3BPAS1,Linc1992,TCONS_00020260 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 3,074: | Line 3,018: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289235 HSALNT0289235] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289235 HSALNT0289235] | ||
| − | |RNF219-AS1 | + | |[[RNF219-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,082: | Line 3,026: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289561 HSALNT0289561] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289561 HSALNT0289561] | ||
| − | |AF086415 | + | |[[AF086415]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,090: | Line 3,034: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289583 HSALNT0289583] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289583 HSALNT0289583] | ||
| − | |AK056098 | + | |[[AK056098]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,098: | Line 3,042: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289590 HSALNT0289590] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289590 HSALNT0289590] | ||
| − | |AK095147 | + | |[[AK095147]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,106: | Line 3,050: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289600 HSALNT0289600] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289600 HSALNT0289600] | ||
| − | |AK294004 | + | |[[AK294004]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 3,114: | Line 3,058: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289612 HSALNT0289612] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289612 HSALNT0289612] | ||
| − | |AP5M1 | + | |[[AP5M1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,122: | Line 3,066: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290110 HSALNT0290110] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290110 HSALNT0290110] | ||
| − | |ORAOV1 | + | |[[ORAOV1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,130: | Line 3,074: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290210 HSALNT0290210] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290210 HSALNT0290210] | ||
| − | |RP1-179N16.3 | + | |[[RP1-179N16.3]] |
|Z95152.1 | |Z95152.1 | ||
|NA | |NA | ||
| Line 3,138: | Line 3,082: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0037026 HSALNT0037026] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0037026 HSALNT0037026] | ||
| − | |LINC01159 | + | |[[LINC01159]] |
|linc-Brn1b | |linc-Brn1b | ||
|NA | |NA | ||
| Line 3,146: | Line 3,090: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289014 HSALNT0289014] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289014 HSALNT0289014] | ||
| − | | | + | |[[ENST00000604849.1]] |
|KDM5C adjacent non-coding transcript | |KDM5C adjacent non-coding transcript | ||
|NA | |NA | ||
| Line 3,154: | Line 3,098: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289905 HSALNT0289905] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289905 HSALNT0289905] | ||
| − | |LINC01157 | + | |[[LINC01157]] |
|TCONS_00010378,linc-Enc1 | |TCONS_00010378,linc-Enc1 | ||
|NA | |NA | ||
| Line 3,162: | Line 3,106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289460 HSALNT0289460] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289460 HSALNT0289460] | ||
| − | | | + | |[[ENST00000444200.1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 3,170: | Line 3,114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290400 HSALNT0290400] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290400 HSALNT0290400] | ||
| − | |ZNF300P1 | + | |[[ZNF300P1]] |
|ZNF300P1 | |ZNF300P1 | ||
|NA | |NA | ||
| Line 3,178: | Line 3,122: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289750 HSALNT0289750] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289750 HSALNT0289750] | ||
| − | |EEF1A1P9 | + | |[[EEF1A1P9]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,186: | Line 3,130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289796 HSALNT0289796] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289796 HSALNT0289796] | ||
| − | |ENST00000318333 | + | |[[ENST00000318333]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,194: | Line 3,138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289797 HSALNT0289797] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289797 HSALNT0289797] | ||
| − | |ENST00000374520 | + | |[[ENST00000374520]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,202: | Line 3,146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289800 HSALNT0289800] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289800 HSALNT0289800] | ||
| − | |ENST00000422362 | + | |[[ENST00000422362]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,210: | Line 3,154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289808 HSALNT0289808] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289808 HSALNT0289808] | ||
| − | |ENST00000455912 | + | |[[ENST00000455912]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,218: | Line 3,162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289809 HSALNT0289809] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289809 HSALNT0289809] | ||
| − | |ENST00000456007 | + | |[[ENST00000456007]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,226: | Line 3,170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289810 HSALNT0289810] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289810 HSALNT0289810] | ||
| − | |ENST00000456185 | + | |[[ENST00000456185]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,234: | Line 3,178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289817 HSALNT0289817] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289817 HSALNT0289817] | ||
| − | |EPOR | + | |[[EPOR]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,242: | Line 3,186: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289913 HSALNT0289913] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289913 HSALNT0289913] | ||
| − | |LINC01550 | + | |[[LINC01550]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,250: | Line 3,194: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290142 HSALNT0290142] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290142 HSALNT0290142] | ||
| − | |PMS2P5 | + | |[[PMS2P5]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,258: | Line 3,202: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290269 HSALNT0290269] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290269 HSALNT0290269] | ||
| − | |TCF7 | + | |[[TCF7]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,266: | Line 3,210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290345 HSALNT0290345] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290345 HSALNT0290345] | ||
| − | | | + | |[[Uc003jfz.2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,274: | Line 3,218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289095 HSALNT0289095] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289095 HSALNT0289095] | ||
| − | | | + | |[[ENST00000412690.1]] |
|VIN,lnc-ACTR3 | |VIN,lnc-ACTR3 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 3,282: | Line 3,226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288976 HSALNT0288976] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288976 HSALNT0288976] | ||
| − | | | + | |[[ENST00000427391.1]] |
|LINC01200 | |LINC01200 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 3,290: | Line 3,234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289097 HSALNT0289097] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289097 HSALNT0289097] | ||
| − | |LINC01202 | + | |[[LINC01202]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,298: | Line 3,242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290271 HSALNT0290271] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290271 HSALNT0290271] | ||
| − | |TCONS_00014512 | + | |[[TCONS_00014512]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,306: | Line 3,250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290272 HSALNT0290272] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290272 HSALNT0290272] | ||
| − | |TCONS_00014978 | + | |[[TCONS_00014978]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,314: | Line 3,258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290274 HSALNT0290274] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290274 HSALNT0290274] | ||
| − | |TCONS_00024647 | + | |[[TCONS_00024647]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,322: | Line 3,266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290279 HSALNT0290279] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290279 HSALNT0290279] | ||
| − | |TCONS_00090092_MEG3 | + | |[[TCONS_00090092_MEG3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,330: | Line 3,274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290280 HSALNT0290280] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290280 HSALNT0290280] | ||
| − | |TCONS_l2_00000179 | + | |[[TCONS_l2_00000179]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,338: | Line 3,282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290283 HSALNT0290283] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290283 HSALNT0290283] | ||
| − | |TCONS_l2_00004424 | + | |[[TCONS_l2_00004424]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,346: | Line 3,290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290284 HSALNT0290284] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290284 HSALNT0290284] | ||
| − | |TCONS_l2_00006843 | + | |[[TCONS_l2_00006843]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,354: | Line 3,298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290289 HSALNT0290289] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290289 HSALNT0290289] | ||
| − | |TCONS_l2_00014091 | + | |[[TCONS_l2_00014091]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,362: | Line 3,306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290291 HSALNT0290291] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290291 HSALNT0290291] | ||
| − | |TCONS_l2_00018070 | + | |[[TCONS_l2_00018070]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,370: | Line 3,314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290292 HSALNT0290292] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290292 HSALNT0290292] | ||
| − | |TCONS_l2_00020565 | + | |[[TCONS_l2_00020565]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,378: | Line 3,322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290293 HSALNT0290293] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290293 HSALNT0290293] | ||
| − | |TCONS_l2_00021262 | + | |[[TCONS_l2_00021262]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,386: | Line 3,330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290296 HSALNT0290296] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290296 HSALNT0290296] | ||
| − | |TCONS_l2_00030560 | + | |[[TCONS_l2_00030560]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,394: | Line 3,338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289927 HSALNT0289927] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289927 HSALNT0289927] | ||
| − | | | + | |[[LincRNA1611]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,402: | Line 3,346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290149 HSALNT0290149] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290149 HSALNT0290149] | ||
| − | |Ppp3ca | + | |[[Ppp3ca]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,410: | Line 3,354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290265 HSALNT0290265] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290265 HSALNT0290265] | ||
| − | |TC0100223 | + | |[[TC0100223]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,418: | Line 3,362: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290267 HSALNT0290267] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290267 HSALNT0290267] | ||
| − | |TC0101686 | + | |[[TC0101686]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,426: | Line 3,370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290268 HSALNT0290268] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290268 HSALNT0290268] | ||
| − | |TC1500845 | + | |[[TC1500845]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,434: | Line 3,378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289318 HSALNT0289318] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289318 HSALNT0289318] | ||
| − | |LAMP5-AS1 | + | |[[LAMP5-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,442: | Line 3,386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0234022 HSALNT0234022] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0234022 HSALNT0234022] | ||
| − | |LINC01228 | + | |[[LINC01228]] |
|lincRNA-DYNLRB2-2 | |lincRNA-DYNLRB2-2 | ||
|NA | |NA | ||
| Line 3,450: | Line 3,394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0162654 HSALNT0162654] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0162654 HSALNT0162654] | ||
| − | |SGMS1-AS1 | + | |[[SGMS1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,458: | Line 3,402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289206 HSALNT0289206] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289206 HSALNT0289206] | ||
| − | |PCAT19 | + | |[[PCAT19]] |
|LOC100505495,LINC01190 | |LOC100505495,LINC01190 | ||
|NA | |NA | ||
| Line 3,466: | Line 3,410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289521 HSALNT0289521] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289521 HSALNT0289521] | ||
| − | |ABHD15-AS1 | + | |[[ABHD15-AS1]] |
|linc-TP53I13,lnc-TP53I13 | |linc-TP53I13,lnc-TP53I13 | ||
|NA | |NA | ||
| Line 3,474: | Line 3,418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289100 HSALNT0289100] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289100 HSALNT0289100] | ||
| − | |LINC01230 | + | |[[LINC01230]] |
|linc-DMRT2,lnc-DRMT2,TCONS_00015639 | |linc-DMRT2,lnc-DRMT2,TCONS_00015639 | ||
|NA | |NA | ||
| Line 3,482: | Line 3,426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0249183 HSALNT0249183] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0249183 HSALNT0249183] | ||
| − | |PCAT18 | + | |[[PCAT18]] |
|LINC01092 | |LINC01092 | ||
|NA | |NA | ||
| Line 3,490: | Line 3,434: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290029 HSALNT0290029] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290029 HSALNT0290029] | ||
| − | |LOC728606 | + | |[[LOC728606]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,498: | Line 3,442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288956 HSALNT0288956] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288956 HSALNT0288956] | ||
| − | |ENST00000547963.1 | + | |[[ENST00000547963.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,506: | Line 3,450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289802 HSALNT0289802] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289802 HSALNT0289802] | ||
| − | |ENST00000435885 | + | |[[ENST00000435885]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,514: | Line 3,458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0205898 HSALNT0205898] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0205898 HSALNT0205898] | ||
| − | |LINC01232 | + | |[[LINC01232]] |
|FLJ41590,TCONS_00021520 | |FLJ41590,TCONS_00021520 | ||
|NA | |NA | ||
| Line 3,522: | Line 3,466: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0257311 HSALNT0257311] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0257311 HSALNT0257311] | ||
| − | |LINC01233 | + | |[[LINC01233]] |
|XLOC_013014 | |XLOC_013014 | ||
|NA | |NA | ||
| Line 3,530: | Line 3,474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0183247 HSALNT0183247] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0183247 HSALNT0183247] | ||
| − | | | + | |[[ENST00000526269.2]] |
|FLI1-AS1 | |FLI1-AS1 | ||
|NA | |NA | ||
| Line 3,538: | Line 3,482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289296 HSALNT0289296] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289296 HSALNT0289296] | ||
| − | |LINC00467 | + | |[[LINC00467]] |
|C1orf97,MGC14801 | |C1orf97,MGC14801 | ||
|NA | |NA | ||
| Line 3,546: | Line 3,490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0143586 HSALNT0143586] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0143586 HSALNT0143586] | ||
| − | |CASC21 | + | |[[CASC21]] |
|LINC01244,CARLo-2 | |LINC01244,CARLo-2 | ||
|NA | |NA | ||
| Line 3,554: | Line 3,498: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288906 HSALNT0288906] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288906 HSALNT0288906] | ||
| − | |CASC19 | + | |[[CASC19]] |
|LINC01245,CARLo-6 | |LINC01245,CARLo-6 | ||
|NA | |NA | ||
| Line 3,562: | Line 3,506: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289754 HSALNT0289754] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289754 HSALNT0289754] | ||
| − | |ENSG00000135253.9 | + | |[[ENSG00000135253.9]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,570: | Line 3,514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289755 HSALNT0289755] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289755 HSALNT0289755] | ||
| − | |ENSG00000147753.5 | + | |[[ENSG00000147753.5]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,578: | Line 3,522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289756 HSALNT0289756] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289756 HSALNT0289756] | ||
| − | |ENSG00000196096 | + | |[[ENSG00000196096]] |
|AC079610.1 | |AC079610.1 | ||
|NA | |NA | ||
| Line 3,586: | Line 3,530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289757 HSALNT0289757] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289757 HSALNT0289757] | ||
| − | |ENSG00000197251.3 | + | |[[ENSG00000197251.3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,594: | Line 3,538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289758 HSALNT0289758] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289758 HSALNT0289758] | ||
| − | |ENSG00000203325 | + | |[[ENSG00000203325]] |
|AL445248.1 | |AL445248.1 | ||
|NA | |NA | ||
| Line 3,602: | Line 3,546: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289759 HSALNT0289759] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289759 HSALNT0289759] | ||
| − | |ENSG00000206129 | + | |[[ENSG00000206129]] |
|AC006305.1 | |AC006305.1 | ||
|NA | |NA | ||
| Line 3,610: | Line 3,554: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289760 HSALNT0289760] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289760 HSALNT0289760] | ||
| − | |ENSG00000215231.3 | + | |[[ENSG00000215231.3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,618: | Line 3,562: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289761 HSALNT0289761] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289761 HSALNT0289761] | ||
| − | |ENSG00000215374.4 | + | |[[ENSG00000215374.4]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,626: | Line 3,570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289762 HSALNT0289762] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289762 HSALNT0289762] | ||
| − | |ENSG00000215808.2 | + | |[[ENSG00000215808.2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,634: | Line 3,578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289763 HSALNT0289763] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289763 HSALNT0289763] | ||
| − | |ENSG00000226496.1 | + | |[[ENSG00000226496.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,642: | Line 3,586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289764 HSALNT0289764] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289764 HSALNT0289764] | ||
| − | |ENSG00000229563.1 | + | |[[ENSG00000229563.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,650: | Line 3,594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289765 HSALNT0289765] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289765 HSALNT0289765] | ||
| − | |ENSG00000230133.1 | + | |[[ENSG00000230133.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,658: | Line 3,602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289766 HSALNT0289766] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289766 HSALNT0289766] | ||
| − | |ENSG00000230544.1 | + | |[[ENSG00000230544.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,666: | Line 3,610: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289767 HSALNT0289767] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289767 HSALNT0289767] | ||
| − | |ENSG00000231133.1 | + | |[[ENSG00000231133.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,674: | Line 3,618: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289768 HSALNT0289768] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289768 HSALNT0289768] | ||
| − | |ENSG00000231185 | + | |[[ENSG00000231185]] |
|AC010317.1 | |AC010317.1 | ||
|NA | |NA | ||
| Line 3,682: | Line 3,626: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289769 HSALNT0289769] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289769 HSALNT0289769] | ||
| − | |ENSG00000232021.2 | + | |[[ENSG00000232021.2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,690: | Line 3,634: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289770 HSALNT0289770] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289770 HSALNT0289770] | ||
| − | |ENSG00000232046.1 | + | |[[ENSG00000232046.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,698: | Line 3,642: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289771 HSALNT0289771] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289771 HSALNT0289771] | ||
| − | |ENSG00000232956.3 | + | |[[ENSG00000232956.3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,706: | Line 3,650: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289772 HSALNT0289772] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289772 HSALNT0289772] | ||
| − | |ENSG00000233154.1 | + | |[[ENSG00000233154.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,714: | Line 3,658: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289773 HSALNT0289773] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289773 HSALNT0289773] | ||
| − | |ENSG00000233251 | + | |[[ENSG00000233251]] |
|AC007743.1 | |AC007743.1 | ||
|NA | |NA | ||
| Line 3,722: | Line 3,666: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289774 HSALNT0289774] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289774 HSALNT0289774] | ||
| − | |ENSG00000235285.1 | + | |[[ENSG00000235285.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,730: | Line 3,674: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289775 HSALNT0289775] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289775 HSALNT0289775] | ||
| − | |ENSG00000237036.3 | + | |[[ENSG00000237036.3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,738: | Line 3,682: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289776 HSALNT0289776] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289776 HSALNT0289776] | ||
| − | |ENSG00000237548.1 | + | |[[ENSG00000237548.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,746: | Line 3,690: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289777 HSALNT0289777] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289777 HSALNT0289777] | ||
| − | |ENSG00000240453.1 | + | |[[ENSG00000240453.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,754: | Line 3,698: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289778 HSALNT0289778] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289778 HSALNT0289778] | ||
| − | |ENSG00000241269.1 | + | |[[ENSG00000241269.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,762: | Line 3,706: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289779 HSALNT0289779] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289779 HSALNT0289779] | ||
| − | |ENSG00000245910.3 | + | |[[ENSG00000245910.3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,770: | Line 3,714: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289780 HSALNT0289780] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289780 HSALNT0289780] | ||
| − | |ENSG00000248176 | + | |[[ENSG00000248176]] |
|AC109349.1 | |AC109349.1 | ||
|NA | |NA | ||
| Line 3,778: | Line 3,722: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289781 HSALNT0289781] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289781 HSALNT0289781] | ||
| − | |ENSG00000249364 | + | |[[ENSG00000249364]] |
|AC112206.2 | |AC112206.2 | ||
|NA | |NA | ||
| Line 3,786: | Line 3,730: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289782 HSALNT0289782] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289782 HSALNT0289782] | ||
| − | |ENSG00000249772 | + | |[[ENSG00000249772]] |
|AC026427.1 | |AC026427.1 | ||
|NA | |NA | ||
| Line 3,794: | Line 3,738: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289783 HSALNT0289783] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289783 HSALNT0289783] | ||
| − | |ENSG00000250195 | + | |[[ENSG00000250195]] |
|AC109927.1 | |AC109927.1 | ||
|NA | |NA | ||
| Line 3,802: | Line 3,746: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289784 HSALNT0289784] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289784 HSALNT0289784] | ||
| − | |ENSG00000250608 | + | |[[ENSG00000250608]] |
|AC010210.1 | |AC010210.1 | ||
|NA | |NA | ||
| Line 3,810: | Line 3,754: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289785 HSALNT0289785] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289785 HSALNT0289785] | ||
| − | |ENSG00000254154 | + | |[[ENSG00000254154]] |
|AL359075.2 | |AL359075.2 | ||
|NA | |NA | ||
| Line 3,818: | Line 3,762: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289786 HSALNT0289786] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289786 HSALNT0289786] | ||
| − | |ENSG00000255471 | + | |[[ENSG00000255471]] |
|AP001528.2 | |AP001528.2 | ||
|NA | |NA | ||
| Line 3,826: | Line 3,770: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289787 HSALNT0289787] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289787 HSALNT0289787] | ||
| − | |ENSG00000256218 | + | |[[ENSG00000256218]] |
|AC007848.2 | |AC007848.2 | ||
|NA | |NA | ||
| Line 3,834: | Line 3,778: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289788 HSALNT0289788] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289788 HSALNT0289788] | ||
| − | |ENSG00000259150.1 | + | |[[ENSG00000259150.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,842: | Line 3,786: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289789 HSALNT0289789] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289789 HSALNT0289789] | ||
| − | |ENSG00000259334.1 | + | |[[ENSG00000259334.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,850: | Line 3,794: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289790 HSALNT0289790] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289790 HSALNT0289790] | ||
| − | |ENSG00000259484.1 | + | |[[ENSG00000259484.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,858: | Line 3,802: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289791 HSALNT0289791] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289791 HSALNT0289791] | ||
| − | |ENSG00000259758.1 | + | |[[ENSG00000259758.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,866: | Line 3,810: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289793 HSALNT0289793] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289793 HSALNT0289793] | ||
| − | |ENSG00000263753.1 | + | |[[ENSG00000263753.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,874: | Line 3,818: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289794 HSALNT0289794] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289794 HSALNT0289794] | ||
| − | |ENSG00000264772 | + | |[[ENSG00000264772]] |
|AC016876.2 | |AC016876.2 | ||
|NA | |NA | ||
| Line 3,882: | Line 3,826: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289795 HSALNT0289795] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289795 HSALNT0289795] | ||
| − | |ENSG00000266952.1 | + | |[[ENSG00000266952.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,890: | Line 3,834: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289828 HSALNT0289828] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289828 HSALNT0289828] | ||
| − | |FAM66B | + | |[[FAM66B]] |
|FAM66E | |FAM66E | ||
|NA | |NA | ||
| Line 3,898: | Line 3,842: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289895 HSALNT0289895] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289895 HSALNT0289895] | ||
| − | |LINC00336 | + | |[[LINC00336]] |
|C6orf227,NCRNA00336 | |C6orf227,NCRNA00336 | ||
|NA | |NA | ||
| Line 3,906: | Line 3,850: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289899 HSALNT0289899] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289899 HSALNT0289899] | ||
| − | |LINC00929 | + | |[[LINC00929]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,914: | Line 3,858: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289906 HSALNT0289906] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289906 HSALNT0289906] | ||
| − | |LINC01204 | + | |[[LINC01204]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,922: | Line 3,866: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289912 HSALNT0289912] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289912 HSALNT0289912] | ||
| − | |LINC01538 | + | |[[LINC01538]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,930: | Line 3,874: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289915 HSALNT0289915] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289915 HSALNT0289915] | ||
| − | |LINC01721 | + | |[[LINC01721]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,938: | Line 3,882: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289916 HSALNT0289916] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289916 HSALNT0289916] | ||
| − | |LINC01762 | + | |[[LINC01762]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,946: | Line 3,890: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289917 HSALNT0289917] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289917 HSALNT0289917] | ||
| − | |LINC01798 | + | |[[LINC01798]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 3,954: | Line 3,898: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290247 HSALNT0290247] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290247 HSALNT0290247] | ||
| − | |SMIM2-IT1 | + | |[[SMIM2-IT1]] |
|C13orf44-IT1 | |C13orf44-IT1 | ||
|NA | |NA | ||
| Line 3,962: | Line 3,906: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290316 HSALNT0290316] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290316 HSALNT0290316] | ||
| − | |TTTY7 | + | |[[TTTY7]] |
|CLONE795723,LINC00129,NCRNA00129A,TTTY7B,TTY7,TTTY7 | |CLONE795723,LINC00129,NCRNA00129A,TTTY7B,TTY7,TTTY7 | ||
|NA | |NA | ||
| Line 3,968: | Line 3,912: | ||
|hereditary haemorrhagic telangiectasia | |hereditary haemorrhagic telangiectasia | ||
|Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases | |Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290175 HSALNT0290175] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290175 HSALNT0290175] | ||
| − | |RNA-a | + | |[[RNA-a]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 3,986: | Line 3,922: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289525 HSALNT0289525] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289525 HSALNT0289525] | ||
| − | |116HG | + | |[[116HG]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 3,994: | Line 3,930: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290320 HSALNT0290320] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290320 HSALNT0290320] | ||
| − | |U1 spliceosomal lncRNA | + | |[[U1 spliceosomal lncRNA]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,002: | Line 3,938: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289102 HSALNT0289102] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289102 HSALNT0289102] | ||
| − | |LINC01262 | + | |[[LINC01262]] |
|TCONS_l2_00021807,RP11-462G22.1 | |TCONS_l2_00021807,RP11-462G22.1 | ||
|ceRNA | |ceRNA | ||
| Line 4,010: | Line 3,946: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289681 HSALNT0289681] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289681 HSALNT0289681] | ||
| − | |CCAT1-L | + | |[[CCAT1-L]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 4,018: | Line 3,954: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290062 HSALNT0290062] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290062 HSALNT0290062] | ||
| − | |MT-LIPCAR | + | |[[MT-LIPCAR]] |
|uc022bqs.1,LIPCAR | |uc022bqs.1,LIPCAR | ||
|NA | |NA | ||
| Line 4,026: | Line 3,962: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289941 HSALNT0289941] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289941 HSALNT0289941] | ||
| − | |LIPCAR | + | |[[LIPCAR]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,034: | Line 3,970: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0200965 HSALNT0200965] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0200965 HSALNT0200965] | ||
| − | |TUSC8 | + | |[[TUSC8]] |
|LINC01071,XLOC_010588 | |LINC01071,XLOC_010588 | ||
|NA | |NA | ||
| Line 4,042: | Line 3,978: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0161787 HSALNT0161787] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0161787 HSALNT0161787] | ||
| − | |LINC01264 | + | |[[LINC01264]] |
|RP11-124O11.2 | |RP11-124O11.2 | ||
|NA | |NA | ||
| Line 4,050: | Line 3,986: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289733 HSALNT0289733] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289733 HSALNT0289733] | ||
| − | |D4Z4 | + | |[[D4Z4]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,058: | Line 3,994: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289678 HSALNT0289678] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289678 HSALNT0289678] | ||
| − | |CARL | + | |[[CARL]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 4,066: | Line 4,002: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289923 HSALNT0289923] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289923 HSALNT0289923] | ||
| − | | | + | |[[Linc-CBR1-2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,074: | Line 4,010: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0243354 HSALNT0243354] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0243354 HSALNT0243354] | ||
| − | | | + | |[[Lnc-HEATR6-1:4]] |
|WAP four-disulfide core domain 21,pseudogene | |WAP four-disulfide core domain 21,pseudogene | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 4,082: | Line 4,018: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290232 HSALNT0290232] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290232 HSALNT0290232] | ||
| − | |RUNX1 | + | |[[RUNX1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,090: | Line 4,026: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290234 HSALNT0290234] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290234 HSALNT0290234] | ||
| − | |RUNXOR | + | |[[RUNXOR]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,098: | Line 4,034: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289979 HSALNT0289979] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289979 HSALNT0289979] | ||
| − | | | + | |[[LncRNA-CIR]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,106: | Line 4,042: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290368 HSALNT0290368] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290368 HSALNT0290368] | ||
| − | |VIM2P | + | |[[VIM2P]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,114: | Line 4,050: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289879 HSALNT0289879] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289879 HSALNT0289879] | ||
| − | |KRAS1P | + | |[[KRAS1P]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,122: | Line 4,058: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290054 HSALNT0290054] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290054 HSALNT0290054] | ||
| − | |MINA | + | |[[MINA]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,130: | Line 4,066: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289270 HSALNT0289270] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289270 HSALNT0289270] | ||
| − | |TMEM92-AS1 | + | |[[TMEM92-AS1]] |
|RP11-893F2.9,lncRNA-508851,TCONS_00025237 | |RP11-893F2.9,lncRNA-508851,TCONS_00025237 | ||
|NA | |NA | ||
| Line 4,138: | Line 4,074: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288900 HSALNT0288900] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288900 HSALNT0288900] | ||
| − | | | + | |[[ENST00000604200.1]] |
|LINC00468 | |LINC00468 | ||
|NA | |NA | ||
| Line 4,146: | Line 4,082: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289593 HSALNT0289593] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289593 HSALNT0289593] | ||
| − | |AK123657 | + | |[[AK123657]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,154: | Line 4,090: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289659 HSALNT0289659] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289659 HSALNT0289659] | ||
| − | |BX648207 | + | |[[BX648207]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,162: | Line 4,098: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289660 HSALNT0289660] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289660 HSALNT0289660] | ||
| − | |BX649059 | + | |[[BX649059]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,170: | Line 4,106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289846 HSALNT0289846] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289846 HSALNT0289846] | ||
| − | |GAS2L3 | + | |[[GAS2L3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,178: | Line 4,114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289633 HSALNT0289633] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289633 HSALNT0289633] | ||
| − | |BC011663 | + | |[[BC011663]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,186: | Line 4,122: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289867 HSALNT0289867] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289867 HSALNT0289867] | ||
| − | |HIV1230 | + | |[[HIV1230]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,194: | Line 4,130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290045 HSALNT0290045] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290045 HSALNT0290045] | ||
| − | |M14574 | + | |[[M14574]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,202: | Line 4,138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290245 HSALNT0290245] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290245 HSALNT0290245] | ||
| − | |SLCO5A1 | + | |[[SLCO5A1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,210: | Line 4,146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290326 HSALNT0290326] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290326 HSALNT0290326] | ||
| − | | | + | |[[Uc.341]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,218: | Line 4,154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290344 HSALNT0290344] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290344 HSALNT0290344] | ||
| − | | | + | |[[Uc003iqu]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,226: | Line 4,162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290346 HSALNT0290346] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290346 HSALNT0290346] | ||
| − | | | + | |[[Uc003tfx]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,234: | Line 4,170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289950 HSALNT0289950] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289950 HSALNT0289950] | ||
| − | | | + | |[[Lnc-AL355149.1-1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,242: | Line 4,178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290001 HSALNT0290001] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290001 HSALNT0290001] | ||
| − | | | + | |[[Lnc-ZNF674-1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,250: | Line 4,186: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0286909 HSALNT0286909] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0286909 HSALNT0286909] | ||
| − | |LINC00632 | + | |[[LINC00632]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,258: | Line 4,194: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289105 HSALNT0289105] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289105 HSALNT0289105] | ||
| − | |LINC01317 | + | |[[LINC01317]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,266: | Line 4,202: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0234804 HSALNT0234804] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0234804 HSALNT0234804] | ||
| − | |LINC01081 | + | |[[LINC01081]] |
|TCONS_00024764 | |TCONS_00024764 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 4,274: | Line 4,210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289840 HSALNT0289840] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289840 HSALNT0289840] | ||
| − | |FOSB | + | |[[FOSB]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,282: | Line 4,218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289587 HSALNT0289587] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289587 HSALNT0289587] | ||
| − | |AK093543 | + | |[[AK093543]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,290: | Line 4,226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289732 HSALNT0289732] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289732 HSALNT0289732] | ||
| − | |D16366 | + | |[[D16366]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,298: | Line 4,234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289814 HSALNT0289814] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289814 HSALNT0289814] | ||
| − | |ENST00000501583 | + | |[[ENST00000501583]] |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|NA | |NA | ||
|NA | |NA | ||
| Line 4,314: | Line 4,242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289907 HSALNT0289907] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289907 HSALNT0289907] | ||
| − | |LINC01374 | + | |[[LINC01374]] |
|TCONS_00018278 | |TCONS_00018278 | ||
|NA | |NA | ||
| Line 4,322: | Line 4,250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0231106 HSALNT0231106] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0231106 HSALNT0231106] | ||
| − | |CASC22 | + | |[[CASC22]] |
|LINC01373,TCONS_00024290,LincRNA-ENST00000515084 | |LINC01373,TCONS_00024290,LincRNA-ENST00000515084 | ||
|NA | |NA | ||
| Line 4,330: | Line 4,258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0058246 HSALNT0058246] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0058246 HSALNT0058246] | ||
| − | |LINC00882 | + | |[[LINC00882]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 4,338: | Line 4,266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0018288 HSALNT0018288] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0018288 HSALNT0018288] | ||
| − | |KIAA1614-AS1 | + | |[[KIAA1614-AS1]] |
|RP11-46A10.4 | |RP11-46A10.4 | ||
|ceRNA | |ceRNA | ||
| Line 4,346: | Line 4,274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0142310 HSALNT0142310] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0142310 HSALNT0142310] | ||
| − | |LINC00536 | + | |[[LINC00536]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,354: | Line 4,282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0034200 HSALNT0034200] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0034200 HSALNT0034200] | ||
| − | |LBX2-AS1 | + | |[[LBX2-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,362: | Line 4,290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0149799 HSALNT0149799] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0149799 HSALNT0149799] | ||
| − | |ENST00000414223 | + | |[[ENST00000414223]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,370: | Line 4,298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290012 HSALNT0290012] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290012 HSALNT0290012] | ||
| − | |LOC105374631 | + | |[[LOC105374631]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,378: | Line 4,306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290305 HSALNT0290305] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290305 HSALNT0290305] | ||
| − | |TMEM179 | + | |[[TMEM179]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,386: | Line 4,314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290315 HSALNT0290315] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290315 HSALNT0290315] | ||
| − | |TSPAN8 | + | |[[TSPAN8]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,394: | Line 4,322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290334 HSALNT0290334] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290334 HSALNT0290334] | ||
| − | | | + | |[[Uc001aka.2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,402: | Line 4,330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290339 HSALNT0290339] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290339 HSALNT0290339] | ||
| − | | | + | |[[Uc001vjj.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,410: | Line 4,338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290343 HSALNT0290343] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290343 HSALNT0290343] | ||
| − | | | + | |[[Uc003erl.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,418: | Line 4,346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290354 HSALNT0290354] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290354 HSALNT0290354] | ||
| − | | | + | |[[Uc009wkz.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,426: | Line 4,354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0027893 HSALNT0027893] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0027893 HSALNT0027893] | ||
| − | | | + | |[[ENST00000433810.1]] |
|MYCNUN,lncUSMycN | |MYCNUN,lncUSMycN | ||
|NA | |NA | ||
| Line 4,434: | Line 4,362: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0273205 HSALNT0273205] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0273205 HSALNT0273205] | ||
| − | |LINC01436 | + | |[[LINC01436]] |
|AP000688.8 | |AP000688.8 | ||
|NA | |NA | ||
| Line 4,442: | Line 4,370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0266116 HSALNT0266116] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0266116 HSALNT0266116] | ||
| − | |MIR663AHG | + | |[[MIR663AHG]] |
|RP3-410C9.1 | |RP3-410C9.1 | ||
|NA | |NA | ||
| Line 4,450: | Line 4,378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289108 HSALNT0289108] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289108 HSALNT0289108] | ||
| − | |LINC01435 | + | |[[LINC01435]] |
|RP11-215N21.1,TCONS_00018040 | |RP11-215N21.1,TCONS_00018040 | ||
|NA | |NA | ||
| Line 4,458: | Line 4,386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289674 HSALNT0289674] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289674 HSALNT0289674] | ||
| − | |CADM3-AS1 | + | |[[CADM3-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,466: | Line 4,394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289882 HSALNT0289882] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289882 HSALNT0289882] | ||
| − | |KRT19P3 | + | |[[KRT19P3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,474: | Line 4,402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290310 HSALNT0290310] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290310 HSALNT0290310] | ||
| − | |TNXA | + | |[[TNXA]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,482: | Line 4,410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0008750 HSALNT0008750] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0008750 HSALNT0008750] | ||
| − | |ZRANB2-AS2 | + | |[[ZRANB2-AS2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,490: | Line 4,418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289745 HSALNT0289745] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289745 HSALNT0289745] | ||
| − | |DMTF1 | + | |[[DMTF1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,498: | Line 4,426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290059 HSALNT0290059] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290059 HSALNT0290059] | ||
| − | |MRUL | + | |[[MRUL]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 4,506: | Line 4,434: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0185163 HSALNT0185163] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0185163 HSALNT0185163] | ||
| − | |FAM66C | + | |[[FAM66C]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,514: | Line 4,442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289476 HSALNT0289476] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289476 HSALNT0289476] | ||
| − | | | + | |[[ENST00000357401.3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,522: | Line 4,450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289535 HSALNT0289535] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289535 HSALNT0289535] | ||
| − | |AA174084 | + | |[[AA174084]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,530: | Line 4,458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0266298 HSALNT0266298] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0266298 HSALNT0266298] | ||
| − | |ABALON | + | |[[ABALON]] |
|INXS | |INXS | ||
|splicing regulation | |splicing regulation | ||
| Line 4,538: | Line 4,466: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290370 HSALNT0290370] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290370 HSALNT0290370] | ||
| − | |VTRNA2-1 | + | |[[VTRNA2-1]] |
|CBL-3,CBL3,MIR886,MIRN886,VTRNA2,hsa-mir-886,hvg-5,nc886,svtRNA2-1a | |CBL-3,CBL3,MIR886,MIRN886,VTRNA2,hsa-mir-886,hvg-5,nc886,svtRNA2-1a | ||
|NA | |NA | ||
| Line 4,546: | Line 4,474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289619 HSALNT0289619] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289619 HSALNT0289619] | ||
| − | |ASK00420 | + | |[[ASK00420]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,554: | Line 4,482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289749 HSALNT0289749] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289749 HSALNT0289749] | ||
| − | |EBIC | + | |[[EBIC]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 4,562: | Line 4,490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290299 HSALNT0290299] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290299 HSALNT0290299] | ||
| − | |TI09485 | + | |[[TI09485]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,570: | Line 4,498: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290300 HSALNT0290300] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290300 HSALNT0290300] | ||
| − | |TI10124 | + | |[[TI10124]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,578: | Line 4,506: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290301 HSALNT0290301] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290301 HSALNT0290301] | ||
| − | |TI13831 | + | |[[TI13831]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,586: | Line 4,514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290302 HSALNT0290302] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290302 HSALNT0290302] | ||
| − | |TI18318 | + | |[[TI18318]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,594: | Line 4,522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290303 HSALNT0290303] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290303 HSALNT0290303] | ||
| − | |TI21327 | + | |[[TI21327]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,602: | Line 4,530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290304 HSALNT0290304] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290304 HSALNT0290304] | ||
| − | |TI22687 | + | |[[TI22687]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,610: | Line 4,538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290307 HSALNT0290307] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290307 HSALNT0290307] | ||
| − | |TMPOP2 | + | |[[TMPOP2]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 4,618: | Line 4,546: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289570 HSALNT0289570] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289570 HSALNT0289570] | ||
| − | |AK021444 | + | |[[AK021444]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,626: | Line 4,554: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289601 HSALNT0289601] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289601 HSALNT0289601] | ||
| − | |AK307796 | + | |[[AK307796]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,634: | Line 4,562: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289801 HSALNT0289801] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289801 HSALNT0289801] | ||
| − | |ENST00000425785 | + | |[[ENST00000425785]] |
|SEC63P1 | |SEC63P1 | ||
|NA | |NA | ||
| Line 4,642: | Line 4,570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289871 HSALNT0289871] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289871 HSALNT0289871] | ||
| − | |HOXB-AS3 | + | |[[HOXB-AS3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,650: | Line 4,578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290367 HSALNT0290367] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290367 HSALNT0290367] | ||
| − | |URHC | + | |[[URHC]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,658: | Line 4,586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289085 HSALNT0289085] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289085 HSALNT0289085] | ||
| − | |LINC01080 | + | |[[LINC01080]] |
|TCONS_00021856 | |TCONS_00021856 | ||
|NA | |NA | ||
| Line 4,666: | Line 4,594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289751 HSALNT0289751] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289751 HSALNT0289751] | ||
| − | |EFNA3 | + | |[[EFNA3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,674: | Line 4,602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289798 HSALNT0289798] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289798 HSALNT0289798] | ||
| − | |ENST00000395084 | + | |[[ENST00000395084]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,682: | Line 4,610: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289829 HSALNT0289829] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289829 HSALNT0289829] | ||
| − | |FAM83A-AS1 | + | |[[FAM83A-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,690: | Line 4,618: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290164 HSALNT0290164] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290164 HSALNT0290164] | ||
| − | |RAD1 | + | |[[RAD1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,698: | Line 4,626: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289585 HSALNT0289585] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289585 HSALNT0289585] | ||
| − | |AK056988 | + | |[[AK056988]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,706: | Line 4,634: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289638 HSALNT0289638] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289638 HSALNT0289638] | ||
| − | |BC017743 | + | |[[BC017743]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,714: | Line 4,642: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290156 HSALNT0290156] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290156 HSALNT0290156] | ||
| − | |PRR26 | + | |[[PRR26]] |
|C10orf108 | |C10orf108 | ||
|NA | |NA | ||
| Line 4,722: | Line 4,650: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290349 HSALNT0290349] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290349 HSALNT0290349] | ||
| − | | | + | |[[Uc003yqb.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,730: | Line 4,658: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289675 HSALNT0289675] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289675 HSALNT0289675] | ||
| − | |CAI2 | + | |[[CAI2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,736: | Line 4,664: | ||
|neuroblastoma | |neuroblastoma | ||
|Neoplasms | |Neoplasms | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290313 HSALNT0290313] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290313 HSALNT0290313] | ||
| − | |TSLC1-AS1 | + | |[[TSLC1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,754: | Line 4,674: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0013359 HSALNT0013359] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0013359 HSALNT0013359] | ||
| − | |LINC01525 | + | |[[LINC01525]] |
|lnc-MAN1A2-1 | |lnc-MAN1A2-1 | ||
|NA | |NA | ||
| Line 4,762: | Line 4,682: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0109106 HSALNT0109106] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0109106 HSALNT0109106] | ||
| − | |LINC01526 | + | |[[LINC01526]] |
|Lnc-FAM46A-1 | |Lnc-FAM46A-1 | ||
|NA | |NA | ||
| Line 4,770: | Line 4,690: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0162774 HSALNT0162774] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0162774 HSALNT0162774] | ||
| − | |LINC01468 | + | |[[LINC01468]] |
|lnc-MBL2-4 | |lnc-MBL2-4 | ||
|NA | |NA | ||
| Line 4,778: | Line 4,698: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289110 HSALNT0289110] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289110 HSALNT0289110] | ||
| − | |LINC01503 | + | |[[LINC01503]] |
|lnc-PPP2R4-5 | |lnc-PPP2R4-5 | ||
|NA | |NA | ||
| Line 4,786: | Line 4,706: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289968 HSALNT0289968] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289968 HSALNT0289968] | ||
| − | | | + | |[[Lnc-MBL2-4:3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,794: | Line 4,714: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289993 HSALNT0289993] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289993 HSALNT0289993] | ||
| − | | | + | |[[Lnc-STXBP5-1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,802: | Line 4,722: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289563 HSALNT0289563] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289563 HSALNT0289563] | ||
| − | |AF118081 | + | |[[AF118081]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,810: | Line 4,730: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289597 HSALNT0289597] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289597 HSALNT0289597] | ||
| − | |AK124939 | + | |[[AK124939]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,818: | Line 4,738: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290153 HSALNT0290153] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290153 HSALNT0290153] | ||
| − | |PRAS | + | |[[PRAS]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,826: | Line 4,746: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290249 HSALNT0290249] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290249 HSALNT0290249] | ||
| − | |SNAR-A1 | + | |[[SNAR-A1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,834: | Line 4,754: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289929 HSALNT0289929] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289929 HSALNT0289929] | ||
| − | | | + | |[[LincRNA-BC2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,842: | Line 4,762: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289930 HSALNT0289930] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289930 HSALNT0289930] | ||
| − | | | + | |[[LincRNA-BC4]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,850: | Line 4,770: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289931 HSALNT0289931] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289931 HSALNT0289931] | ||
| − | | | + | |[[LincRNA-BC5]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,858: | Line 4,778: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289932 HSALNT0289932] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289932 HSALNT0289932] | ||
| − | | | + | |[[LincRNA-BC8]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,866: | Line 4,786: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0083190 HSALNT0083190] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0083190 HSALNT0083190] | ||
| − | |LINC01511 | + | |[[LINC01511]] |
|RP11-325I22.2 | |RP11-325I22.2 | ||
|NA | |NA | ||
| Line 4,874: | Line 4,794: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290026 HSALNT0290026] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290026 HSALNT0290026] | ||
| − | |LOC440905 | + | |[[LOC440905]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,880: | Line 4,800: | ||
|lung adenocarcinoma | |lung adenocarcinoma | ||
|Respiratory Tract Diseases;Neoplasms | |Respiratory Tract Diseases;Neoplasms | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289552 HSALNT0289552] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289552 HSALNT0289552] | ||
| − | |AC079776.2 | + | |[[AC079776.2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,898: | Line 4,810: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289720 HSALNT0289720] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289720 HSALNT0289720] | ||
| − | |CTA-363E6.2 | + | |[[CTA-363E6.2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,906: | Line 4,818: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289901 HSALNT0289901] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289901 HSALNT0289901] | ||
| − | |LINC00987 | + | |[[LINC00987]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,914: | Line 4,826: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290185 HSALNT0290185] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290185 HSALNT0290185] | ||
| − | |RP11-1C1.7 | + | |[[RP11-1C1.7]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,922: | Line 4,834: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290197 HSALNT0290197] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290197 HSALNT0290197] | ||
| − | |RP11-445K13.2 | + | |[[RP11-445K13.2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,930: | Line 4,842: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290199 HSALNT0290199] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290199 HSALNT0290199] | ||
| − | |RP11-473M20.11 | + | |[[RP11-473M20.11]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,938: | Line 4,850: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290213 HSALNT0290213] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290213 HSALNT0290213] | ||
| − | |RP11-893F2.6 | + | |[[RP11-893F2.6]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,946: | Line 4,858: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290217 HSALNT0290217] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290217 HSALNT0290217] | ||
| − | |RP13-514E23.1 | + | |[[RP13-514E23.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,954: | Line 4,866: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290218 HSALNT0290218] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290218 HSALNT0290218] | ||
| − | |RP1-90D4.3 | + | |[[RP1-90D4.3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,962: | Line 4,874: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290220 HSALNT0290220] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290220 HSALNT0290220] | ||
| − | |RP4-575N6.5 | + | |[[RP4-575N6.5]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,970: | Line 4,882: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290226 HSALNT0290226] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290226 HSALNT0290226] | ||
| − | |RP5-826L7.1 | + | |[[RP5-826L7.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,978: | Line 4,890: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290378 HSALNT0290378] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290378 HSALNT0290378] | ||
| − | |XLOC_003286 | + | |[[XLOC_003286]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,986: | Line 4,898: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290379 HSALNT0290379] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290379 HSALNT0290379] | ||
| − | |XLOC_003405 | + | |[[XLOC_003405]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 4,994: | Line 4,906: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290389 HSALNT0290389] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290389 HSALNT0290389] | ||
| − | |XLOC_012255 | + | |[[XLOC_012255]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,002: | Line 4,914: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290056 HSALNT0290056] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290056 HSALNT0290056] | ||
| − | |MIR21 | + | |[[MIR21]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,010: | Line 4,922: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289621 HSALNT0289621] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289621 HSALNT0289621] | ||
| − | |ASncmtRNAs | + | |[[ASncmtRNAs]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 5,018: | Line 4,930: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289316 HSALNT0289316] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289316 HSALNT0289316] | ||
| − | |LINC01614 | + | |[[LINC01614]] |
|LCAL4,TCONS_00003105 | |LCAL4,TCONS_00003105 | ||
|NA | |NA | ||
| Line 5,026: | Line 4,938: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289982 HSALNT0289982] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289982 HSALNT0289982] | ||
| − | | | + | |[[LncRNA-FER1L4]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 5,034: | Line 4,946: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290016 HSALNT0290016] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290016 HSALNT0290016] | ||
| − | |LOC283177 | + | |[[LOC283177]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,042: | Line 4,954: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289003 HSALNT0289003] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289003 HSALNT0289003] | ||
| − | |HORMAD2-AS1 | + | |[[HORMAD2-AS1]] |
|MTMR3-AS1,NONHSAG033653 | |MTMR3-AS1,NONHSAG033653 | ||
|NA | |NA | ||
| Line 5,050: | Line 4,962: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290372 HSALNT0290372] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290372 HSALNT0290372] | ||
| − | |WNT4 | + | |[[WNT4]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,058: | Line 4,970: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289540 HSALNT0289540] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289540 HSALNT0289540] | ||
| − | |AB074278 | + | |[[AB074278]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,066: | Line 4,978: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290166 HSALNT0290166] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290166 HSALNT0290166] | ||
| − | |RCCRT1 | + | |[[RCCRT1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,074: | Line 4,986: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289043 HSALNT0289043] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289043 HSALNT0289043] | ||
| − | |LINC00491 | + | |[[LINC00491]] |
|BC008363 | |BC008363 | ||
|NA | |NA | ||
|pathogenic process | |pathogenic process | ||
|pancreatic ductal adenocarcinoma | |pancreatic ductal adenocarcinoma | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|Neoplasms | |Neoplasms | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289858 HSALNT0289858] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289858 HSALNT0289858] | ||
| − | |H1.3 | + | |[[H1.3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,098: | Line 5,002: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289896 HSALNT0289896] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289896 HSALNT0289896] | ||
| − | |LINC00582 | + | |[[LINC00582]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,106: | Line 5,010: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289301 HSALNT0289301] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289301 HSALNT0289301] | ||
| − | |LINC01537 | + | |[[LINC01537]] |
|RP11-169D4.1-001 | |RP11-169D4.1-001 | ||
|NA | |NA | ||
| Line 5,114: | Line 5,018: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289551 HSALNT0289551] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289551 HSALNT0289551] | ||
| − | |AC026166.2 | + | |[[AC026166.2]] |
|MTCO1P5 | |MTCO1P5 | ||
|NA | |NA | ||
| Line 5,122: | Line 5,026: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290184 HSALNT0290184] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290184 HSALNT0290184] | ||
| − | |RP11-169D4.1-001 | + | |[[RP11-169D4.1-001]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,130: | Line 5,034: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289545 HSALNT0289545] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289545 HSALNT0289545] | ||
| − | |AC006050.3 | + | |[[AC006050.3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,138: | Line 5,042: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289556 HSALNT0289556] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289556 HSALNT0289556] | ||
| − | |AC138128.1 | + | |[[AC138128.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,146: | Line 5,050: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289818 HSALNT0289818] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289818 HSALNT0289818] | ||
| − | |ERCC1 | + | |[[ERCC1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,154: | Line 5,058: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290061 HSALNT0290061] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290061 HSALNT0290061] | ||
| − | |MT1DP | + | |[[MT1DP]] |
|MT1DP | |MT1DP | ||
|NA | |NA | ||
| Line 5,162: | Line 5,066: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289578 HSALNT0289578] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289578 HSALNT0289578] | ||
| − | |AK023096 | + | |[[AK023096]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,170: | Line 5,074: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289112 HSALNT0289112] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289112 HSALNT0289112] | ||
| − | |LINC01562 | + | |[[LINC01562]] |
|RP11-296A18.3 | |RP11-296A18.3 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 5,178: | Line 5,082: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289567 HSALNT0289567] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289567 HSALNT0289567] | ||
| − | |AK000974 | + | |[[AK000974]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,186: | Line 5,090: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289579 HSALNT0289579] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289579 HSALNT0289579] | ||
| − | |AK024118 | + | |[[AK024118]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,194: | Line 5,098: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289645 HSALNT0289645] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289645 HSALNT0289645] | ||
| − | |BC040204 | + | |[[BC040204]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,202: | Line 5,106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290321 HSALNT0290321] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290321 HSALNT0290321] | ||
| − | |U79277 | + | |[[U79277]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,210: | Line 5,114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289869 HSALNT0289869] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289869 HSALNT0289869] | ||
| − | |HOST2 | + | |[[HOST2]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 5,218: | Line 5,122: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289368 HSALNT0289368] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289368 HSALNT0289368] | ||
| − | |MGAT3-AS1 | + | |[[MGAT3-AS1]] |
|TapSAKI | |TapSAKI | ||
|NA | |NA | ||
| Line 5,226: | Line 5,130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289624 HSALNT0289624] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289624 HSALNT0289624] | ||
| − | |ATXN7L3B | + | |[[ATXN7L3B]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,234: | Line 5,138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289990 HSALNT0289990] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289990 HSALNT0289990] | ||
| − | | | + | |[[Lnc-SCA7]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 5,242: | Line 5,146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290004 HSALNT0290004] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290004 HSALNT0290004] | ||
| − | |LOC100287482 | + | |[[LOC100287482]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,250: | Line 5,154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290383 HSALNT0290383] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290383 HSALNT0290383] | ||
| − | |XLOC_007697 | + | |[[XLOC_007697]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,258: | Line 5,162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290384 HSALNT0290384] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290384 HSALNT0290384] | ||
| − | |XLOC_008559 | + | |[[XLOC_008559]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,266: | Line 5,170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290385 HSALNT0290385] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290385 HSALNT0290385] | ||
| − | |XLOC_009911 | + | |[[XLOC_009911]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,274: | Line 5,178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289813 HSALNT0289813] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289813 HSALNT0289813] | ||
| − | |ENST00000480739 | + | |[[ENST00000480739]] |
|RPL13AP23 | |RPL13AP23 | ||
|NA | |NA | ||
| Line 5,282: | Line 5,186: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290111 HSALNT0290111] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290111 HSALNT0290111] | ||
| − | |OS9 | + | |[[OS9]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,290: | Line 5,194: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290324 HSALNT0290324] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290324 HSALNT0290324] | ||
| − | | | + | |[[Uc.283-plus]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,298: | Line 5,202: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289117 HSALNT0289117] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289117 HSALNT0289117] | ||
| − | |LINC01611 | + | |[[LINC01611]] |
|RP1-90L14.1,TCONS_l2_00025430 | |RP1-90L14.1,TCONS_l2_00025430 | ||
|NA | |NA | ||
| Line 5,306: | Line 5,210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289529 HSALNT0289529] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289529 HSALNT0289529] | ||
| − | |2900055J20Rik | + | |[[2900055J20Rik]] |
|2900055J20Rik | |2900055J20Rik | ||
|NA | |NA | ||
| Line 5,314: | Line 5,218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289792 HSALNT0289792] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289792 HSALNT0289792] | ||
| − | |ENSG00000261777 | + | |[[ENSG00000261777]] |
|AC012184.3 | |AC012184.3 | ||
|NA | |NA | ||
| Line 5,322: | Line 5,226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289618 HSALNT0289618] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289618 HSALNT0289618] | ||
| − | |Asb3 | + | |[[Asb3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,330: | Line 5,234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289703 HSALNT0289703] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289703 HSALNT0289703] | ||
| − | |Chac2 | + | |[[Chac2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,338: | Line 5,242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290139 HSALNT0290139] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290139 HSALNT0290139] | ||
| − | |Pex11b | + | |[[Pex11b]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,346: | Line 5,250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290255 HSALNT0290255] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290255 HSALNT0290255] | ||
| − | |Sp5 | + | |[[Sp5]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,354: | Line 5,258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0211639 HSALNT0211639] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0211639 HSALNT0211639] | ||
| − | |PSMA3-AS1 | + | |[[PSMA3-AS1]] |
|FLJ31306 | |FLJ31306 | ||
|NA | |NA | ||
| Line 5,362: | Line 5,266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289319 HSALNT0289319] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289319 HSALNT0289319] | ||
| − | |LINC00493 | + | |[[LINC00493]] |
|LOC388789 | |LOC388789 | ||
|NA | |NA | ||
| Line 5,370: | Line 5,274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288903 HSALNT0288903] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288903 HSALNT0288903] | ||
| − | |CARD8-AS1 | + | |[[CARD8-AS1]] |
|LOC100505812 | |LOC100505812 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 5,378: | Line 5,282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0064729 HSALNT0064729] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0064729 HSALNT0064729] | ||
| − | |KCNMB2-AS1 | + | |[[KCNMB2-AS1]] |
|RP11-385J1.2 | |RP11-385J1.2 | ||
|NA | |NA | ||
| Line 5,386: | Line 5,290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289548 HSALNT0289548] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289548 HSALNT0289548] | ||
| − | |AC013264.2 | + | |[[AC013264.2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,394: | Line 5,298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289857 HSALNT0289857] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289857 HSALNT0289857] | ||
| − | |GUCY1B2 | + | |[[GUCY1B2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,402: | Line 5,306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290190 HSALNT0290190] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290190 HSALNT0290190] | ||
| − | |RP11-385J1.2 | + | |[[RP11-385J1.2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,410: | Line 5,314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290216 HSALNT0290216] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290216 HSALNT0290216] | ||
| − | |RP1-317E23.3 | + | |[[RP1-317E23.3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,418: | Line 5,322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290317 HSALNT0290317] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290317 HSALNT0290317] | ||
| − | |TUBA4B | + | |[[TUBA4B]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,426: | Line 5,330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290375 HSALNT0290375] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290375 HSALNT0290375] | ||
| − | |XLOC_000371 | + | |[[XLOC_000371]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,434: | Line 5,338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290397 HSALNT0290397] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290397 HSALNT0290397] | ||
| − | |Z82214.3 | + | |[[Z82214.3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,442: | Line 5,346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289735 HSALNT0289735] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289735 HSALNT0289735] | ||
| − | |DALIR | + | |[[DALIR]] |
|DALI | |DALI | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 5,450: | Line 5,354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290376 HSALNT0290376] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290376 HSALNT0290376] | ||
| − | |XLOC_000620 | + | |[[XLOC_000620]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,458: | Line 5,362: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290380 HSALNT0290380] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290380 HSALNT0290380] | ||
| − | |XLOC_004122 | + | |[[XLOC_004122]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,466: | Line 5,370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290381 HSALNT0290381] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290381 HSALNT0290381] | ||
| − | |XLOC_004562 | + | |[[XLOC_004562]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,474: | Line 5,378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290382 HSALNT0290382] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290382 HSALNT0290382] | ||
| − | |XLOC_005912 | + | |[[XLOC_005912]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,482: | Line 5,386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290391 HSALNT0290391] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290391 HSALNT0290391] | ||
| − | |XLOC_014388 | + | |[[XLOC_014388]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,490: | Line 5,394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290028 HSALNT0290028] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290028 HSALNT0290028] | ||
| − | |LOC652276 | + | |[[LOC652276]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,498: | Line 5,402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290162 HSALNT0290162] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290162 HSALNT0290162] | ||
| − | |R05532 | + | |[[R05532]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,506: | Line 5,410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0098175 HSALNT0098175] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0098175 HSALNT0098175] | ||
| − | |LINC01411 | + | |[[LINC01411]] |
|RP11-267A15.1 | |RP11-267A15.1 | ||
|NA | |NA | ||
| Line 5,514: | Line 5,418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290025 HSALNT0290025] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290025 HSALNT0290025] | ||
| − | |LOC401317 | + | |[[LOC401317]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,522: | Line 5,426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289726 HSALNT0289726] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289726 HSALNT0289726] | ||
| − | |CTD-2574D22.4 | + | |[[CTD-2574D22.4]] |
|AC120114.2 | |AC120114.2 | ||
|NA | |NA | ||
| Line 5,530: | Line 5,434: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290141 HSALNT0290141] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290141 HSALNT0290141] | ||
| − | |PMS2L2 | + | |[[PMS2L2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,538: | Line 5,442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289974 HSALNT0289974] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289974 HSALNT0289974] | ||
| − | | | + | |[[LncRNA-422]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,546: | Line 5,450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289520 HSALNT0289520] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289520 HSALNT0289520] | ||
| − | |AATBC | + | |[[AATBC]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,554: | Line 5,458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289311 HSALNT0289311] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289311 HSALNT0289311] | ||
| − | |LINC00974 | + | |[[LINC00974]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 5,562: | Line 5,466: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0089943 HSALNT0089943] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0089943 HSALNT0089943] | ||
| − | |ZBED3-AS1 | + | |[[ZBED3-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,570: | Line 5,474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289116 HSALNT0289116] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289116 HSALNT0289116] | ||
| − | |LINC01589 | + | |[[LINC01589]] |
|CTA-941F9.9,TCONS_00029353 | |CTA-941F9.9,TCONS_00029353 | ||
|NA | |NA | ||
| Line 5,578: | Line 5,482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289910 HSALNT0289910] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289910 HSALNT0289910] | ||
| − | |LINC01426 | + | |[[LINC01426]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,586: | Line 5,490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290341 HSALNT0290341] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290341 HSALNT0290341] | ||
| − | | | + | |[[Uc002yug.2]] |
|NA | |NA | ||
|splicing regulation | |splicing regulation | ||
| Line 5,594: | Line 5,498: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290250 HSALNT0290250] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290250 HSALNT0290250] | ||
| − | |SNCG | + | |[[SNCG]] |
|NA | |NA | ||
|NA | |NA | ||
|pathogenic process | |pathogenic process | ||
|gastric cancer | |gastric cancer | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|Neoplasms;Digestive System Diseases | |Neoplasms;Digestive System Diseases | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289996 HSALNT0289996] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289996 HSALNT0289996] | ||
| − | | | + | |[[Lnc-uc003wbd]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,618: | Line 5,514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289559 HSALNT0289559] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289559 HSALNT0289559] | ||
| − | |AF085935 | + | |[[AF085935]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,626: | Line 5,522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290347 HSALNT0290347] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290347 HSALNT0290347] | ||
| − | | | + | |[[Uc003wbd]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,634: | Line 5,530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290098 HSALNT0290098] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290098 HSALNT0290098] | ||
| − | |NR_001284 | + | |[[NR_001284]] |
|TNXA | |TNXA | ||
|NA | |NA | ||
| Line 5,642: | Line 5,538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290327 HSALNT0290327] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290327 HSALNT0290327] | ||
| − | | | + | |[[Uc.343]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,650: | Line 5,546: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289196 HSALNT0289196] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289196 HSALNT0289196] | ||
| − | |NRAV | + | |[[NRAV]] |
|DYNLL1-AS1 | |DYNLL1-AS1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 5,658: | Line 5,554: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290140 HSALNT0290140] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290140 HSALNT0290140] | ||
| − | |PLEC | + | |[[PLEC]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,666: | Line 5,562: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290172 HSALNT0290172] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290172 HSALNT0290172] | ||
| − | |RNA44121 | + | |[[RNA44121]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,674: | Line 5,570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290173 HSALNT0290173] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290173 HSALNT0290173] | ||
| − | |RNA50010 | + | |[[RNA50010]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,682: | Line 5,578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290174 HSALNT0290174] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290174 HSALNT0290174] | ||
| − | |RNA58351 | + | |[[RNA58351]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,690: | Line 5,586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289714 HSALNT0289714] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289714 HSALNT0289714] | ||
| − | |CR613944 | + | |[[CR613944]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,698: | Line 5,594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289933 HSALNT0289933] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289933 HSALNT0289933] | ||
| − | | | + | |[[LincRNA-CALCA]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,706: | Line 5,602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290200 HSALNT0290200] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290200 HSALNT0290200] | ||
| − | |RP11-501G6.1 | + | |[[RP11-501G6.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,714: | Line 5,610: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290208 HSALNT0290208] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290208 HSALNT0290208] | ||
| − | |RP11-672F9.1 | + | |[[RP11-672F9.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,722: | Line 5,618: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290405 HSALNT0290405] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290405 HSALNT0290405] | ||
| − | |C14orf132 | + | |[[C14orf132]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,730: | Line 5,626: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289937 HSALNT0289937] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289937 HSALNT0289937] | ||
| − | | | + | |[[LincRNA-TSPAN8]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,738: | Line 5,634: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290225 HSALNT0290225] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290225 HSALNT0290225] | ||
| − | |RP5-1014O16.1 | + | |[[RP5-1014O16.1]] |
|AC244098.1 | |AC244098.1 | ||
|NA | |NA | ||
| Line 5,746: | Line 5,642: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290275 HSALNT0290275] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290275 HSALNT0290275] | ||
| − | |TCONS_00026102 | + | |[[TCONS_00026102]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,754: | Line 5,650: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290277 HSALNT0290277] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290277 HSALNT0290277] | ||
| − | |TCONS_00032546 | + | |[[TCONS_00032546]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,762: | Line 5,658: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289037 HSALNT0289037] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289037 HSALNT0289037] | ||
| − | |LINC00441 | + | |[[LINC00441]] |
|RB1-DT,ncRNA-RB1 | |RB1-DT,ncRNA-RB1 | ||
|NA | |NA | ||
| Line 5,770: | Line 5,666: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289661 HSALNT0289661] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289661 HSALNT0289661] | ||
| − | |C1401f132 | + | |[[C1401f132]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,778: | Line 5,674: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289141 HSALNT0289141] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289141 HSALNT0289141] | ||
| − | |LINC02365 | + | |[[LINC02365]] |
|LVCAT8 | |LVCAT8 | ||
|NA | |NA | ||
| Line 5,786: | Line 5,682: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288885 HSALNT0288885] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288885 HSALNT0288885] | ||
| − | |ADGRD1-AS1 | + | |[[ADGRD1-AS1]] |
|LACAT8 | |LACAT8 | ||
|NA | |NA | ||
| Line 5,794: | Line 5,690: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289142 HSALNT0289142] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289142 HSALNT0289142] | ||
| − | |LINC02475 | + | |[[LINC02475]] |
|LVCAT1 | |LVCAT1 | ||
|NA | |NA | ||
| Line 5,802: | Line 5,698: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289542 HSALNT0289542] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289542 HSALNT0289542] | ||
| − | |Abhd11os | + | |[[Abhd11os]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,810: | Line 5,706: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288895 HSALNT0288895] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288895 HSALNT0288895] | ||
| − | |BISPR | + | |[[BISPR]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,818: | Line 5,714: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0233975 HSALNT0233975] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0233975 HSALNT0233975] | ||
| − | |MAFTRR | + | |[[MAFTRR]] |
|linc-MAF-4 | |linc-MAF-4 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 5,826: | Line 5,722: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290058 HSALNT0290058] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290058 HSALNT0290058] | ||
| − | |MRAK052686 | + | |[[MRAK052686]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,834: | Line 5,730: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290221 HSALNT0290221] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290221 HSALNT0290221] | ||
| − | |RP4-583P15.10 | + | |[[RP4-583P15.10]] |
|AL121845.1 | |AL121845.1 | ||
|NA | |NA | ||
| Line 5,842: | Line 5,738: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0211341 HSALNT0211341] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0211341 HSALNT0211341] | ||
| − | |KTN1-AS1 | + | |[[KTN1-AS1]] |
|C14orf33,MYCLo-3 | |C14orf33,MYCLo-3 | ||
|NA | |NA | ||
| Line 5,850: | Line 5,746: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0266752 HSALNT0266752] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0266752 HSALNT0266752] | ||
| − | |DLGAP4-AS1 | + | |[[DLGAP4-AS1]] |
|CCAT7 | |CCAT7 | ||
|NA | |NA | ||
| Line 5,858: | Line 5,754: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289682 HSALNT0289682] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289682 HSALNT0289682] | ||
| − | |CCAT3 | + | |[[CCAT3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,866: | Line 5,762: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289684 HSALNT0289684] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289684 HSALNT0289684] | ||
| − | |CCAT8 | + | |[[CCAT8]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,874: | Line 5,770: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289898 HSALNT0289898] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289898 HSALNT0289898] | ||
| − | |LINC00659 | + | |[[LINC00659]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,880: | Line 5,776: | ||
|colorectal cancer | |colorectal cancer | ||
|Neoplasms;Digestive System Diseases | |Neoplasms;Digestive System Diseases | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289627 HSALNT0289627] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289627 HSALNT0289627] | ||
| − | |BALR-2 | + | |[[BALR-2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,898: | Line 5,786: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289948 HSALNT0289948] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289948 HSALNT0289948] | ||
| − | | | + | |[[Lnc-ACACA-1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,906: | Line 5,794: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289953 HSALNT0289953] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289953 HSALNT0289953] | ||
| − | | | + | |[[Lnc-BMP2-2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,914: | Line 5,802: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289955 HSALNT0289955] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289955 HSALNT0289955] | ||
| − | | | + | |[[Lnc-CPN2-1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,922: | Line 5,810: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289958 HSALNT0289958] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289958 HSALNT0289958] | ||
| − | | | + | |[[Lnc-FOXG1-2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,930: | Line 5,818: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289960 HSALNT0289960] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289960 HSALNT0289960] | ||
| − | | | + | |[[Lnc-FZD1-2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,938: | Line 5,826: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289962 HSALNT0289962] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289962 HSALNT0289962] | ||
| − | | | + | |[[Lnc-ITPR2-3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,946: | Line 5,834: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289965 HSALNT0289965] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289965 HSALNT0289965] | ||
| − | | | + | |[[Lnc-LCP2-2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,954: | Line 5,842: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289988 HSALNT0289988] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289988 HSALNT0289988] | ||
| − | | | + | |[[Lnc-RP3-368B9]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,962: | Line 5,850: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289991 HSALNT0289991] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289991 HSALNT0289991] | ||
| − | | | + | |[[Lnc-SLC30A4-1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,970: | Line 5,858: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289992 HSALNT0289992] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289992 HSALNT0289992] | ||
| − | | | + | |[[Lnc-SPAM1-6]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,978: | Line 5,866: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289995 HSALNT0289995] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289995 HSALNT0289995] | ||
| − | | | + | |[[Lnc-TTC34-3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,986: | Line 5,874: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0222064 HSALNT0222064] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0222064 HSALNT0222064] | ||
| − | |DRAIC | + | |[[DRAIC]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 5,992: | Line 5,880: | ||
|prostate cancer;glioma;cancer;bladder cancer;renal clear cell cancer;skin melanoma;hepatocellular cancer;lung adenocarcinoma;stomach adenocarcinoma | |prostate cancer;glioma;cancer;bladder cancer;renal clear cell cancer;skin melanoma;hepatocellular cancer;lung adenocarcinoma;stomach adenocarcinoma | ||
|Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases | |Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290390 HSALNT0290390] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290390 HSALNT0290390] | ||
| − | |XLOC_014172 | + | |[[XLOC_014172]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,010: | Line 5,890: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290014 HSALNT0290014] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290014 HSALNT0290014] | ||
| − | |LOC149086 | + | |[[LOC149086]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,018: | Line 5,898: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290183 HSALNT0290183] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290183 HSALNT0290183] | ||
| − | |RP11-160H22.5 | + | |[[RP11-160H22.5]] |
|AL121983.2 | |AL121983.2 | ||
|NA | |NA | ||
| Line 6,026: | Line 5,906: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289945 HSALNT0289945] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289945 HSALNT0289945] | ||
| − | |LNC00964-3 | + | |[[LNC00964-3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,034: | Line 5,914: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289616 HSALNT0289616] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289616 HSALNT0289616] | ||
| − | |Arid2-IR | + | |[[Arid2-IR]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,042: | Line 5,922: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289716 HSALNT0289716] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289716 HSALNT0289716] | ||
| − | |CR619813 | + | |[[CR619813]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,050: | Line 5,930: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289739 HSALNT0289739] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289739 HSALNT0289739] | ||
| − | |DDX6P1 | + | |[[DDX6P1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,058: | Line 5,938: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289938 HSALNT0289938] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289938 HSALNT0289938] | ||
| − | | | + | |[[LincRNA-ZNF532]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,066: | Line 5,946: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290011 HSALNT0290011] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290011 HSALNT0290011] | ||
| − | |LOC105372753 | + | |[[LOC105372753]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,074: | Line 5,954: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290013 HSALNT0290013] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290013 HSALNT0290013] | ||
| − | |LOC105377769 | + | |[[LOC105377769]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,082: | Line 5,962: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290205 HSALNT0290205] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290205 HSALNT0290205] | ||
| − | |RP11-58D2.1 | + | |[[RP11-58D2.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,090: | Line 5,970: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288946 HSALNT0288946] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288946 HSALNT0288946] | ||
| − | |ENST00000434223 | + | |[[ENST00000434223]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,098: | Line 5,978: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288947 HSALNT0288947] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288947 HSALNT0288947] | ||
| − | |ENST00000442037 | + | |[[ENST00000442037]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,106: | Line 5,986: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288953 HSALNT0288953] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288953 HSALNT0288953] | ||
| − | |ENST00000540136 | + | |[[ENST00000540136]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,114: | Line 5,994: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290103 HSALNT0290103] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290103 HSALNT0290103] | ||
| − | |NR_038125 | + | |[[NR_038125]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,122: | Line 6,002: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290136 HSALNT0290136] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290136 HSALNT0290136] | ||
| − | |PDLIM3 | + | |[[PDLIM3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,130: | Line 6,010: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290335 HSALNT0290335] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290335 HSALNT0290335] | ||
| − | | | + | |[[Uc001gch.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,138: | Line 6,018: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290336 HSALNT0290336] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290336 HSALNT0290336] | ||
| − | | | + | |[[Uc001gzl.3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,146: | Line 6,026: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290351 HSALNT0290351] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290351 HSALNT0290351] | ||
| − | | | + | |[[Uc004bbl.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,154: | Line 6,034: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290369 HSALNT0290369] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290369 HSALNT0290369] | ||
| − | |VNN2 | + | |[[VNN2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,162: | Line 6,042: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289577 HSALNT0289577] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289577 HSALNT0289577] | ||
| − | |AK022798 | + | |[[AK022798]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,170: | Line 6,050: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289663 HSALNT0289663] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289663 HSALNT0289663] | ||
| − | |C1orf74 | + | |[[C1orf74]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,178: | Line 6,058: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289602 HSALNT0289602] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289602 HSALNT0289602] | ||
| − | |AKR7L | + | |[[AKR7L]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,186: | Line 6,066: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289711 HSALNT0289711] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289711 HSALNT0289711] | ||
| − | |COL3A1 | + | |[[COL3A1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,194: | Line 6,074: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289878 HSALNT0289878] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289878 HSALNT0289878] | ||
| − | |KCNE2 | + | |[[KCNE2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,202: | Line 6,082: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289636 HSALNT0289636] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289636 HSALNT0289636] | ||
| − | |BC015134 | + | |[[BC015134]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,210: | Line 6,090: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289713 HSALNT0289713] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289713 HSALNT0289713] | ||
| − | |CR594506 | + | |[[CR594506]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,218: | Line 6,098: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289928 HSALNT0289928] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289928 HSALNT0289928] | ||
| − | | | + | |[[LincRNA-BBOX1-2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,226: | Line 6,106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0271719 HSALNT0271719] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0271719 HSALNT0271719] | ||
| − | |LINC00320 | + | |[[LINC00320]] |
|PRED14,FLJ37539 | |PRED14,FLJ37539 | ||
|NA | |NA | ||
| Line 6,234: | Line 6,114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289823 HSALNT0289823] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289823 HSALNT0289823] | ||
| − | |EVADR | + | |[[EVADR]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,240: | Line 6,120: | ||
|pancreatic cancer;lung cancer;colorectal cancer;rectal cancer | |pancreatic cancer;lung cancer;colorectal cancer;rectal cancer | ||
|Respiratory Tract Diseases;Endocrine System Diseases;Neoplasms;Digestive System Diseases | |Respiratory Tract Diseases;Endocrine System Diseases;Neoplasms;Digestive System Diseases | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289952 HSALNT0289952] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289952 HSALNT0289952] | ||
| − | | | + | |[[Lnc-bc060912]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,258: | Line 6,130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289613 HSALNT0289613] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289613 HSALNT0289613] | ||
| − | |APF | + | |[[APF]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 6,266: | Line 6,138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289617 HSALNT0289617] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289617 HSALNT0289617] | ||
| − | |AS Uchl1 | + | |[[AS Uchl1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,274: | Line 6,146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289104 HSALNT0289104] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289104 HSALNT0289104] | ||
| − | |LINC01296 | + | |[[LINC01296]] |
|FLJ39632 | |FLJ39632 | ||
|NA | |NA | ||
| Line 6,282: | Line 6,154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290403 HSALNT0290403] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290403 HSALNT0290403] | ||
| − | |ZXF2 | + | |[[ZXF2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,290: | Line 6,162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290113 HSALNT0290113] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290113 HSALNT0290113] | ||
| − | |P14695 | + | |[[P14695]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,298: | Line 6,170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290114 HSALNT0290114] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290114 HSALNT0290114] | ||
| − | |P16984 | + | |[[P16984]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,306: | Line 6,178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290115 HSALNT0290115] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290115 HSALNT0290115] | ||
| − | |P19780 | + | |[[P19780]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,314: | Line 6,186: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290116 HSALNT0290116] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290116 HSALNT0290116] | ||
| − | |P23099 | + | |[[P23099]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,322: | Line 6,194: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290117 HSALNT0290117] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290117 HSALNT0290117] | ||
| − | |P24363 | + | |[[P24363]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,330: | Line 6,202: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290118 HSALNT0290118] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290118 HSALNT0290118] | ||
| − | |P28210 | + | |[[P28210]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,338: | Line 6,210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290120 HSALNT0290120] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290120 HSALNT0290120] | ||
| − | |P33863 | + | |[[P33863]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,346: | Line 6,218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290121 HSALNT0290121] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290121 HSALNT0290121] | ||
| − | |P4091 | + | |[[P4091]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,354: | Line 6,226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290122 HSALNT0290122] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290122 HSALNT0290122] | ||
| − | |P6391 | + | |[[P6391]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,362: | Line 6,234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290123 HSALNT0290123] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290123 HSALNT0290123] | ||
| − | |P6488 | + | |[[P6488]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,370: | Line 6,242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290124 HSALNT0290124] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290124 HSALNT0290124] | ||
| − | |P700 | + | |[[P700]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,378: | Line 6,250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290125 HSALNT0290125] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290125 HSALNT0290125] | ||
| − | |P8611 | + | |[[P8611]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,386: | Line 6,258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290126 HSALNT0290126] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290126 HSALNT0290126] | ||
| − | |P8725 | + | |[[P8725]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,394: | Line 6,266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290127 HSALNT0290127] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290127 HSALNT0290127] | ||
| − | |P8860 | + | |[[P8860]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,402: | Line 6,274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290128 HSALNT0290128] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290128 HSALNT0290128] | ||
| − | |P9745 | + | |[[P9745]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,410: | Line 6,282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289269 HSALNT0289269] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289269 HSALNT0289269] | ||
| − | |TH2LCRR | + | |[[TH2LCRR]] |
|TH2-LCR | |TH2-LCR | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 6,418: | Line 6,290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289964 HSALNT0289964] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289964 HSALNT0289964] | ||
| − | | | + | |[[Lnc-LCE5A-1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,426: | Line 6,298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0055198 HSALNT0055198] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0055198 HSALNT0055198] | ||
| − | |FAM3D-AS1 | + | |[[FAM3D-AS1]] |
|lnc-KCTD6-3 | |lnc-KCTD6-3 | ||
|NA | |NA | ||
| Line 6,434: | Line 6,306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289843 HSALNT0289843] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289843 HSALNT0289843] | ||
| − | |FRLnc1 | + | |[[FRLnc1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,442: | Line 6,314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0242005 HSALNT0242005] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0242005 HSALNT0242005] | ||
| − | |ENST00000575202 | + | |[[ENST00000575202]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,450: | Line 6,322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288952 HSALNT0288952] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288952 HSALNT0288952] | ||
| − | |ENST00000539009 | + | |[[ENST00000539009]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,458: | Line 6,330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288954 HSALNT0288954] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288954 HSALNT0288954] | ||
| − | |ENST00000544591 | + | |[[ENST00000544591]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,466: | Line 6,338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289752 HSALNT0289752] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289752 HSALNT0289752] | ||
| − | |EHHADH-AS1 | + | |[[EHHADH-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,474: | Line 6,346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289812 HSALNT0289812] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289812 HSALNT0289812] | ||
| − | |ENST00000468960 | + | |[[ENST00000468960]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,482: | Line 6,354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290276 HSALNT0290276] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290276 HSALNT0290276] | ||
| − | |TCONS_00026506 | + | |[[TCONS_00026506]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,490: | Line 6,362: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0189952 HSALNT0189952] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0189952 HSALNT0189952] | ||
| − | |LRP1-AS | + | |[[LRP1-AS]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 6,498: | Line 6,370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0032045 HSALNT0032045] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0032045 HSALNT0032045] | ||
| − | |LINC01122 | + | |[[LINC01122]] |
|FLJ30838,AC007092.1 | |FLJ30838,AC007092.1 | ||
|NA | |NA | ||
| Line 6,506: | Line 6,378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289565 HSALNT0289565] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289565 HSALNT0289565] | ||
| − | |AI364715 | + | |[[AI364715]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,514: | Line 6,386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289921 HSALNT0289921] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289921 HSALNT0289921] | ||
| − | |LINC0949 | + | |[[LINC0949]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,522: | Line 6,394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289680 HSALNT0289680] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289680 HSALNT0289680] | ||
| − | |CCAL | + | |[[CCAL]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,530: | Line 6,402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289079 HSALNT0289079] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289079 HSALNT0289079] | ||
| − | |LINC00993 | + | |[[LINC00993]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,538: | Line 6,410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289811 HSALNT0289811] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289811 HSALNT0289811] | ||
| − | |ENST00000460164 | + | |[[ENST00000460164]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,546: | Line 6,418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290282 HSALNT0290282] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290282 HSALNT0290282] | ||
| − | |TCONS_l2_00003938 | + | |[[TCONS_l2_00003938]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,554: | Line 6,426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289888 HSALNT0289888] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289888 HSALNT0289888] | ||
| − | |LGALS3 | + | |[[LGALS3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,562: | Line 6,434: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289963 HSALNT0289963] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289963 HSALNT0289963] | ||
| − | | | + | |[[Lnc-KCMF1-2:1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,570: | Line 6,442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289967 HSALNT0289967] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289967 HSALNT0289967] | ||
| − | | | + | |[[Lnc-LLPH-2:1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,578: | Line 6,450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289971 HSALNT0289971] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289971 HSALNT0289971] | ||
| − | | | + | |[[Lnc-PLA2R1-1:1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,586: | Line 6,458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289972 HSALNT0289972] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289972 HSALNT0289972] | ||
| − | | | + | |[[Lnc-PSD4-1:14]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,594: | Line 6,466: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290066 HSALNT0290066] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290066 HSALNT0290066] | ||
| − | | | + | |[[N335550]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,602: | Line 6,474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290070 HSALNT0290070] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290070 HSALNT0290070] | ||
| − | | | + | |[[N340790]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,610: | Line 6,482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290072 HSALNT0290072] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290072 HSALNT0290072] | ||
| − | | | + | |[[N386477]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,618: | Line 6,490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290286 HSALNT0290286] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290286 HSALNT0290286] | ||
| − | |TCONS_l2_00010365 | + | |[[TCONS_l2_00010365]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,624: | Line 6,496: | ||
|papillary thyroid cancer | |papillary thyroid cancer | ||
|Endocrine System Diseases;Neoplasms | |Endocrine System Diseases;Neoplasms | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289118 HSALNT0289118] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289118 HSALNT0289118] | ||
| − | |LINC01612 | + | |[[LINC01612]] |
|RP11-789C1.1,TCONS_00008319 | |RP11-789C1.1,TCONS_00008319 | ||
|NA | |NA | ||
| Line 6,642: | Line 6,506: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289610 HSALNT0289610] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289610 HSALNT0289610] | ||
| − | |AP001439.2 | + | |[[AP001439.2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,650: | Line 6,514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289671 HSALNT0289671] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289671 HSALNT0289671] | ||
| − | |CACNAICAS3 | + | |[[CACNAICAS3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,658: | Line 6,522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289853 HSALNT0289853] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289853 HSALNT0289853] | ||
| − | |GS1-5L10.1 | + | |[[GS1-5L10.1]] |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|NA | |NA | ||
|NA | |NA | ||
| Line 6,674: | Line 6,530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290065 HSALNT0290065] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290065 HSALNT0290065] | ||
| − | |MYLK-AS1 | + | |[[MYLK-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,682: | Line 6,538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290157 HSALNT0290157] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290157 HSALNT0290157] | ||
| − | |PRSS21 | + | |[[PRSS21]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,690: | Line 6,546: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290202 HSALNT0290202] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290202 HSALNT0290202] | ||
| − | |RP11-528G1.2 | + | |[[RP11-528G1.2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,698: | Line 6,554: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290207 HSALNT0290207] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290207 HSALNT0290207] | ||
| − | |RP11-643M14.1 | + | |[[RP11-643M14.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,706: | Line 6,562: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290209 HSALNT0290209] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290209 HSALNT0290209] | ||
| − | |RP11-789C1.1 | + | |[[RP11-789C1.1]] |
|LINC01612 | |LINC01612 | ||
|NA | |NA | ||
| Line 6,714: | Line 6,570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290314 HSALNT0290314] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290314 HSALNT0290314] | ||
| − | |TSNAX-DISC1 | + | |[[TSNAX-DISC1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,722: | Line 6,578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290386 HSALNT0290386] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290386 HSALNT0290386] | ||
| − | |XLOC_010235 | + | |[[XLOC_010235]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,730: | Line 6,586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289558 HSALNT0289558] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289558 HSALNT0289558] | ||
| − | |AF075041 | + | |[[AF075041]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,738: | Line 6,594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289564 HSALNT0289564] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289564 HSALNT0289564] | ||
| − | |AF339813 | + | |[[AF339813]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,746: | Line 6,602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289575 HSALNT0289575] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289575 HSALNT0289575] | ||
| − | |AK022029 | + | |[[AK022029]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,754: | Line 6,610: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289576 HSALNT0289576] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289576 HSALNT0289576] | ||
| − | |AK022159 | + | |[[AK022159]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,762: | Line 6,618: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289604 HSALNT0289604] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289604 HSALNT0289604] | ||
| − | |AL389956 | + | |[[AL389956]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,770: | Line 6,626: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289640 HSALNT0289640] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289640 HSALNT0289640] | ||
| − | |BC023629 | + | |[[BC023629]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,778: | Line 6,634: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290096 HSALNT0290096] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290096 HSALNT0290096] | ||
| − | |NONHSAT125629 | + | |[[NONHSAT125629]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,786: | Line 6,642: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290393 HSALNT0290393] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290393 HSALNT0290393] | ||
| − | |XR_250621.1 | + | |[[XR_250621.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,794: | Line 6,650: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288951 HSALNT0288951] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288951 HSALNT0288951] | ||
| − | |ENST00000503938 | + | |[[ENST00000503938]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,802: | Line 6,658: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290085 HSALNT0290085] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290085 HSALNT0290085] | ||
| − | |NONHSAT012762 | + | |[[NONHSAT012762]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,810: | Line 6,666: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289151 HSALNT0289151] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289151 HSALNT0289151] | ||
| − | |LMCD1-AS1 | + | |[[LMCD1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,818: | Line 6,674: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289926 HSALNT0289926] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289926 HSALNT0289926] | ||
| − | | | + | |[[Linc-PXN-1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,826: | Line 6,682: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290281 HSALNT0290281] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290281 HSALNT0290281] | ||
| − | |TCONS_l2_00001418 | + | |[[TCONS_l2_00001418]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,834: | Line 6,690: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290285 HSALNT0290285] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290285 HSALNT0290285] | ||
| − | |TCONS_l2_00008237 | + | |[[TCONS_l2_00008237]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,842: | Line 6,698: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290287 HSALNT0290287] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290287 HSALNT0290287] | ||
| − | |TCONS_l2_00011130 | + | |[[TCONS_l2_00011130]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,850: | Line 6,706: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290288 HSALNT0290288] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290288 HSALNT0290288] | ||
| − | |TCONS_l2_00013175 | + | |[[TCONS_l2_00013175]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,858: | Line 6,714: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290294 HSALNT0290294] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290294 HSALNT0290294] | ||
| − | |TCONS_l2_00022611 | + | |[[TCONS_l2_00022611]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,866: | Line 6,722: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290295 HSALNT0290295] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290295 HSALNT0290295] | ||
| − | |TCONS_l2_00022670 | + | |[[TCONS_l2_00022670]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,874: | Line 6,730: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290352 HSALNT0290352] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290352 HSALNT0290352] | ||
| − | | | + | |[[Uc004bdv.3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,882: | Line 6,738: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290363 HSALNT0290363] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290363 HSALNT0290363] | ||
| − | |ULK4P2 | + | |[[ULK4P2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,890: | Line 6,746: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289942 HSALNT0289942] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289942 HSALNT0289942] | ||
| − | |LK4P2 | + | |[[LK4P2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,898: | Line 6,754: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289538 HSALNT0289538] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289538 HSALNT0289538] | ||
| − | |AB019562 | + | |[[AB019562]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,906: | Line 6,762: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0091661 HSALNT0091661] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0091661 HSALNT0091661] | ||
| − | |ENST00000503710 | + | |[[ENST00000503710]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,914: | Line 6,770: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289806 HSALNT0289806] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289806 HSALNT0289806] | ||
| − | |ENST00000445734 | + | |[[ENST00000445734]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,922: | Line 6,778: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289807 HSALNT0289807] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289807 HSALNT0289807] | ||
| − | |ENST00000448093 | + | |[[ENST00000448093]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,930: | Line 6,786: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289815 HSALNT0289815] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289815 HSALNT0289815] | ||
| − | |ENST00000502941 | + | |[[ENST00000502941]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,938: | Line 6,794: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290340 HSALNT0290340] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290340 HSALNT0290340] | ||
| − | | | + | |[[Uc002nbr.3]] |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|NA | |NA | ||
|NA | |NA | ||
| Line 6,954: | Line 6,802: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290356 HSALNT0290356] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290356 HSALNT0290356] | ||
| − | | | + | |[[Uc021re1.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,962: | Line 6,810: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289549 HSALNT0289549] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289549 HSALNT0289549] | ||
| − | |AC016745.3 | + | |[[AC016745.3]] |
|AC016745.1 | |AC016745.1 | ||
|NA | |NA | ||
| Line 6,970: | Line 6,818: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290180 HSALNT0290180] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290180 HSALNT0290180] | ||
| − | |RP11-128A17.1 | + | |[[RP11-128A17.1]] |
|AC078909.1 | |AC078909.1 | ||
|NA | |NA | ||
| Line 6,978: | Line 6,826: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290377 HSALNT0290377] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290377 HSALNT0290377] | ||
| − | |XLOC_001711 | + | |[[XLOC_001711]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,986: | Line 6,834: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289975 HSALNT0289975] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289975 HSALNT0289975] | ||
| − | | | + | |[[LncRNA-AK058003]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 6,994: | Line 6,842: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289061 HSALNT0289061] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289061 HSALNT0289061] | ||
| − | |LINC00682 | + | |[[LINC00682]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,002: | Line 6,850: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289305 HSALNT0289305] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289305 HSALNT0289305] | ||
| − | |LINC01559 | + | |[[LINC01559]] |
|FLJ33810 | |FLJ33810 | ||
|NA | |NA | ||
| Line 7,010: | Line 6,858: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289854 HSALNT0289854] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289854 HSALNT0289854] | ||
| − | |GSTT1-AS1 | + | |[[GSTT1-AS1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 7,018: | Line 6,866: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289978 HSALNT0289978] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289978 HSALNT0289978] | ||
| − | | | + | |[[LncRNA-CD244]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 7,026: | Line 6,874: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289237 HSALNT0289237] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289237 HSALNT0289237] | ||
| − | |SAMD12-AS1 | + | |[[SAMD12-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,034: | Line 6,882: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290179 HSALNT0290179] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290179 HSALNT0290179] | ||
| − | |RP11-119F7.4 | + | |[[RP11-119F7.4]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,042: | Line 6,890: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290278 HSALNT0290278] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290278 HSALNT0290278] | ||
| − | |TCONS_00068220 | + | |[[TCONS_00068220]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,050: | Line 6,898: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0285573 HSALNT0285573] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0285573 HSALNT0285573] | ||
| − | |DANT1 | + | |[[DANT1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 7,058: | Line 6,906: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288926 HSALNT0288926] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288926 HSALNT0288926] | ||
| − | |DANT2 | + | |[[DANT2]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 7,066: | Line 6,914: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290399 HSALNT0290399] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290399 HSALNT0290399] | ||
| − | |ZMAT1 | + | |[[ZMAT1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,074: | Line 6,922: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289554 HSALNT0289554] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289554 HSALNT0289554] | ||
| − | |AC100865.1 | + | |[[AC100865.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,082: | Line 6,930: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289228 HSALNT0289228] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289228 HSALNT0289228] | ||
| − | |RAD51-AS1 | + | |[[RAD51-AS1]] |
|TODRA | |TODRA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 7,090: | Line 6,938: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289743 HSALNT0289743] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289743 HSALNT0289743] | ||
| − | |DKFZP434K028 | + | |[[DKFZP434K028]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,098: | Line 6,946: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289630 HSALNT0289630] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289630 HSALNT0289630] | ||
| − | |BC002811 | + | |[[BC002811]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,106: | Line 6,954: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290387 HSALNT0290387] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290387 HSALNT0290387] | ||
| − | |XLOC_010967 | + | |[[XLOC_010967]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,114: | Line 6,962: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288955 HSALNT0288955] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288955 HSALNT0288955] | ||
| − | |ENST00000545440 | + | |[[ENST00000545440]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,122: | Line 6,970: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288981 HSALNT0288981] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288981 HSALNT0288981] | ||
| − | |FRGCA | + | |[[FRGCA]] |
|LncRNA-AP001631.9 | |LncRNA-AP001631.9 | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|NA | |NA | ||
|pathogenic process | |pathogenic process | ||
| Line 7,138: | Line 6,978: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289976 HSALNT0289976] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289976 HSALNT0289976] | ||
| − | |LncRNA-AP001631.9 | + | |[[LncRNA-AP001631.9]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,146: | Line 6,986: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289686 HSALNT0289686] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289686 HSALNT0289686] | ||
| − | |CD99P1 | + | |[[CD99P1]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 7,154: | Line 6,994: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289119 HSALNT0289119] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289119 HSALNT0289119] | ||
| − | |LINC01613 | + | |[[LINC01613]] |
|n341773 | |n341773 | ||
|NA | |NA | ||
| Line 7,162: | Line 7,002: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289844 HSALNT0289844] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289844 HSALNT0289844] | ||
| − | |FTH1P3 | + | |[[FTH1P3]] |
|FTH1P3 | |FTH1P3 | ||
|NA | |NA | ||
| Line 7,170: | Line 7,010: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289855 HSALNT0289855] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289855 HSALNT0289855] | ||
| − | |GTF2IRD2P1 | + | |[[GTF2IRD2P1]] |
|GTF2IRD2P1 | |GTF2IRD2P1 | ||
|NA | |NA | ||
| Line 7,178: | Line 7,018: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290135 HSALNT0290135] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290135 HSALNT0290135] | ||
| − | |PDIA3F | + | |[[PDIA3F]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,186: | Line 7,026: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289329 HSALNT0289329] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289329 HSALNT0289329] | ||
| − | |LINC00994 | + | |[[LINC00994]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,194: | Line 7,034: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289208 HSALNT0289208] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289208 HSALNT0289208] | ||
| − | |PCAT5 | + | |[[PCAT5]] |
|LINC01452,TPCAT-10-36067 | |LINC01452,TPCAT-10-36067 | ||
|NA | |NA | ||
| Line 7,202: | Line 7,042: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0114870 HSALNT0114870] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0114870 HSALNT0114870] | ||
| − | |LUADT1 | + | |[[LUADT1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 7,210: | Line 7,050: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289154 HSALNT0289154] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289154 HSALNT0289154] | ||
| − | |LOXL1-AS1 | + | |[[LOXL1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,218: | Line 7,058: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289734 HSALNT0289734] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289734 HSALNT0289734] | ||
| − | |DACOR1 | + | |[[DACOR1]] |
|TCONS_00023265 | |TCONS_00023265 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 7,226: | Line 7,066: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289060 HSALNT0289060] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289060 HSALNT0289060] | ||
| − | |LINC00675 | + | |[[LINC00675]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,234: | Line 7,074: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288889 HSALNT0288889] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288889 HSALNT0288889] | ||
| − | |B4GALT1-AS1 | + | |[[B4GALT1-AS1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 7,242: | Line 7,082: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289348 HSALNT0289348] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289348 HSALNT0289348] | ||
| − | |LINC01616 | + | |[[LINC01616]] |
|n341006 | |n341006 | ||
|NA | |NA | ||
| Line 7,250: | Line 7,090: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290068 HSALNT0290068] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290068 HSALNT0290068] | ||
| − | | | + | |[[N336934]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,258: | Line 7,098: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290240 HSALNT0290240] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290240 HSALNT0290240] | ||
| − | |SIRT1-AS | + | |[[SIRT1-AS]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,266: | Line 7,106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290198 HSALNT0290198] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290198 HSALNT0290198] | ||
| − | |RP11-457M11.2 | + | |[[RP11-457M11.2]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 7,274: | Line 7,114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0150768 HSALNT0150768] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0150768 HSALNT0150768] | ||
| − | |LINC01507 | + | |[[LINC01507]] |
|XLOC_000303 | |XLOC_000303 | ||
|NA | |NA | ||
| Line 7,282: | Line 7,122: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289903 HSALNT0289903] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289903 HSALNT0289903] | ||
| − | |LINC01057 | + | |[[LINC01057]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,290: | Line 7,130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289914 HSALNT0289914] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289914 HSALNT0289914] | ||
| − | |LINC01617 | + | |[[LINC01617]] |
|C8orf23,NCRNA00249,XLOC_006844 | |C8orf23,NCRNA00249,XLOC_006844 | ||
|NA | |NA | ||
| Line 7,298: | Line 7,138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290015 HSALNT0290015] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290015 HSALNT0290015] | ||
| − | |LOC152578 | + | |[[LOC152578]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,306: | Line 7,146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0072252 HSALNT0072252] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0072252 HSALNT0072252] | ||
| − | |LINC01618 | + | |[[LINC01618]] |
|LOC152578 | |LOC152578 | ||
|NA | |NA | ||
| Line 7,314: | Line 7,154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0156870 HSALNT0156870] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0156870 HSALNT0156870] | ||
| − | |NALT1 | + | |[[NALT1]] |
|MIR4674HG,LINC01573,TCONS_l2_00029132 | |MIR4674HG,LINC01573,TCONS_l2_00029132 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 7,322: | Line 7,162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289083 HSALNT0289083] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289083 HSALNT0289083] | ||
| − | |MALINC1 | + | |[[MALINC1]] |
|LINC01024,MA-linc1 | |LINC01024,MA-linc1 | ||
|NA | |NA | ||
| Line 7,330: | Line 7,170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289902 HSALNT0289902] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289902 HSALNT0289902] | ||
| − | |LINC01024 | + | |[[LINC01024]] |
|MA-linc1 | |MA-linc1 | ||
|NA | |NA | ||
| Line 7,338: | Line 7,178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289120 HSALNT0289120] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289120 HSALNT0289120] | ||
| − | |LINC01627 | + | |[[LINC01627]] |
|RP11-397D12.4 | |RP11-397D12.4 | ||
|NA | |NA | ||
| Line 7,346: | Line 7,186: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289121 HSALNT0289121] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289121 HSALNT0289121] | ||
| − | |LINC01628 | + | |[[LINC01628]] |
|AC007403.1 | |AC007403.1 | ||
|NA | |NA | ||
| Line 7,354: | Line 7,194: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289820 HSALNT0289820] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289820 HSALNT0289820] | ||
| − | |ERICH1-AS1 | + | |[[ERICH1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,362: | Line 7,202: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290193 HSALNT0290193] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290193 HSALNT0290193] | ||
| − | |RP11-397D12.4 | + | |[[RP11-397D12.4]] |
|LINC01627 | |LINC01627 | ||
|NA | |NA | ||
| Line 7,370: | Line 7,210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289122 HSALNT0289122] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289122 HSALNT0289122] | ||
| − | |LINC01629 | + | |[[LINC01629]] |
|linc-KIAA1737-2 | |linc-KIAA1737-2 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 7,378: | Line 7,218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290161 HSALNT0290161] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290161 HSALNT0290161] | ||
| − | |PTPRG-AS1 | + | |[[PTPRG-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,386: | Line 7,226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289980 HSALNT0289980] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289980 HSALNT0289980] | ||
| − | | | + | |[[LncRNA-DLEU1]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 7,394: | Line 7,234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289983 HSALNT0289983] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289983 HSALNT0289983] | ||
| − | | | + | |[[LncRNA-Hh]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,402: | Line 7,242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288986 HSALNT0288986] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288986 HSALNT0288986] | ||
| − | |GAS1RR | + | |[[GAS1RR]] |
|LncRNA-Hh | |LncRNA-Hh | ||
|NA | |NA | ||
| Line 7,410: | Line 7,250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288908 HSALNT0288908] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288908 HSALNT0288908] | ||
| − | |CCDC18-AS1 | + | |[[CCDC18-AS1]] |
|ENST00000440778.1 | |ENST00000440778.1 | ||
|NA | |NA | ||
| Line 7,418: | Line 7,258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289055 HSALNT0289055] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289055 HSALNT0289055] | ||
| − | |LINC00649 | + | |[[LINC00649]] |
|TCONS_00028768 | |TCONS_00028768 | ||
|NA | |NA | ||
| Line 7,426: | Line 7,266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289219 HSALNT0289219] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289219 HSALNT0289219] | ||
| − | |PRKCQ-AS1 | + | |[[PRKCQ-AS1]] |
|ENST00000414894.1 | |ENST00000414894.1 | ||
|NA | |NA | ||
| Line 7,434: | Line 7,274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290203 HSALNT0290203] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290203 HSALNT0290203] | ||
| − | |RP11-567G11.1 | + | |[[RP11-567G11.1]] |
|LINC02041 | |LINC02041 | ||
|NA | |NA | ||
| Line 7,442: | Line 7,282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289805 HSALNT0289805] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289805 HSALNT0289805] | ||
| − | |ENST00000438550 | + | |[[ENST00000438550]] |
|RPS24P1 | |RPS24P1 | ||
|NA | |NA | ||
| Line 7,450: | Line 7,290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290083 HSALNT0290083] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290083 HSALNT0290083] | ||
| − | |NONHSAG011351 | + | |[[NONHSAG011351]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,458: | Line 7,298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290049 HSALNT0290049] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290049 HSALNT0290049] | ||
| − | |MCHR2-AS1 | + | |[[MCHR2-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,466: | Line 7,306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289799 HSALNT0289799] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289799 HSALNT0289799] | ||
| − | |ENST00000414355 | + | |[[ENST00000414355]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,474: | Line 7,314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290241 HSALNT0290241] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290241 HSALNT0290241] | ||
| − | |SKP2 | + | |[[SKP2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,482: | Line 7,322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289837 HSALNT0289837] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289837 HSALNT0289837] | ||
| − | |FLJ90757 | + | |[[FLJ90757]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 7,490: | Line 7,330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290017 HSALNT0290017] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290017 HSALNT0290017] | ||
| − | |LOC283663 | + | |[[LOC283663]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 7,498: | Line 7,338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290019 HSALNT0290019] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290019 HSALNT0290019] | ||
| − | |LOC338651 | + | |[[LOC338651]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 7,506: | Line 7,346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290132 HSALNT0290132] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290132 HSALNT0290132] | ||
| − | |PCATs | + | |[[PCATs]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,514: | Line 7,354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0086786 HSALNT0086786] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0086786 HSALNT0086786] | ||
| − | |EGFLAM-AS1 | + | |[[EGFLAM-AS1]] |
|lncRNA-LOWEG | |lncRNA-LOWEG | ||
|NA | |NA | ||
| Line 7,522: | Line 7,362: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290031 HSALNT0290031] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290031 HSALNT0290031] | ||
| − | |LOWEG | + | |[[LOWEG]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,530: | Line 7,370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289635 HSALNT0289635] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289635 HSALNT0289635] | ||
| − | |BC014579 | + | |[[BC014579]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,538: | Line 7,378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289721 HSALNT0289721] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289721 HSALNT0289721] | ||
| − | |CTB-167B5.2 | + | |[[CTB-167B5.2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,546: | Line 7,386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289863 HSALNT0289863] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289863 HSALNT0289863] | ||
| − | |HELLS | + | |[[HELLS]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,554: | Line 7,394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290195 HSALNT0290195] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290195 HSALNT0290195] | ||
| − | |RP11-401P9.4 | + | |[[RP11-401P9.4]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,562: | Line 7,402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290252 HSALNT0290252] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290252 HSALNT0290252] | ||
| − | |SNHG19 | + | |[[SNHG19]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,570: | Line 7,410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289557 HSALNT0289557] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289557 HSALNT0289557] | ||
| − | |AF070632 | + | |[[AF070632]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,578: | Line 7,418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289569 HSALNT0289569] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289569 HSALNT0289569] | ||
| − | |AK021443 | + | |[[AK021443]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,586: | Line 7,426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289728 HSALNT0289728] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289728 HSALNT0289728] | ||
| − | |CTD-3080P12.3 | + | |[[CTD-3080P12.3]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 7,594: | Line 7,434: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289987 HSALNT0289987] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289987 HSALNT0289987] | ||
| − | | | + | |[[LncRNA-n336928]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,602: | Line 7,442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289723 HSALNT0289723] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289723 HSALNT0289723] | ||
| − | |CTC-523E23.5 | + | |[[CTC-523E23.5]] |
|AC008555.2 | |AC008555.2 | ||
|NA | |NA | ||
| Line 7,610: | Line 7,450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289724 HSALNT0289724] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289724 HSALNT0289724] | ||
| − | |CTD-2246P4.1 | + | |[[CTD-2246P4.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,618: | Line 7,458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290055 HSALNT0290055] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290055 HSALNT0290055] | ||
| − | |MIR132 | + | |[[MIR132]] |
|MIRN132,miRNA132,mir-132 | |MIRN132,miRNA132,mir-132 | ||
|NA | |NA | ||
| Line 7,626: | Line 7,466: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290189 HSALNT0290189] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290189 HSALNT0290189] | ||
| − | |RP11-363G2.4 | + | |[[RP11-363G2.4]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,634: | Line 7,474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290191 HSALNT0290191] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290191 HSALNT0290191] | ||
| − | |RP11-38F22.1 | + | |[[RP11-38F22.1]] |
|LINC02424 | |LINC02424 | ||
|NA | |NA | ||
| Line 7,642: | Line 7,482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290223 HSALNT0290223] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290223 HSALNT0290223] | ||
| − | |RP4-639J15.1 | + | |[[RP4-639J15.1]] |
|AC006967.2 | |AC006967.2 | ||
|NA | |NA | ||
| Line 7,650: | Line 7,490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290233 HSALNT0290233] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290233 HSALNT0290233] | ||
| − | |RUNX1-IT1 | + | |[[RUNX1-IT1]] |
|C21orf96 | |C21orf96 | ||
|NA | |NA | ||
| Line 7,658: | Line 7,498: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288943 HSALNT0288943] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288943 HSALNT0288943] | ||
| − | |ENST00000415964 | + | |[[ENST00000415964]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,666: | Line 7,506: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290009 HSALNT0290009] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290009 HSALNT0290009] | ||
| − | |LOC101927497 | + | |[[LOC101927497]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,674: | Line 7,514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289956 HSALNT0289956] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289956 HSALNT0289956] | ||
| − | | | + | |[[Lnc-CYP4A22-2/3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,682: | Line 7,522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289999 HSALNT0289999] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289999 HSALNT0289999] | ||
| − | | | + | |[[Lnc-ZNF180-2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,690: | Line 7,530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290086 HSALNT0290086] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290086 HSALNT0290086] | ||
| − | |NONHSAT037832 | + | |[[NONHSAT037832]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,698: | Line 7,538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289658 HSALNT0289658] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289658 HSALNT0289658] | ||
| − | |BX647187 | + | |[[BX647187]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,705: | Line 7,545: | ||
|Male Urogenital Diseases;Neoplasms | |Male Urogenital Diseases;Neoplasms | ||
|- | |- | ||
| − | |[https://bigd.big.ac.cn/lncbook/transcript?transid= | + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289584 HSALNT0289584] |
| − | | | + | |[[AK056155]] |
| − | |||
|NA | |NA | ||
|NA | |NA | ||
| − | + | |pathogenic process | |
| − | + | |Loeys-Dietz syndrome | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |pathogenic process | ||
| − | |Loeys-Dietz syndrome | ||
|Musculoskeletal Diseases | |Musculoskeletal Diseases | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290057 HSALNT0290057] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290057 HSALNT0290057] | ||
| − | |MR1 | + | |[[MR1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,730: | Line 7,562: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289543 HSALNT0289543] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289543 HSALNT0289543] | ||
| − | |AC002454.1 | + | |[[AC002454.1]] |
|AC002454.1 | |AC002454.1 | ||
|NA | |NA | ||
| Line 7,738: | Line 7,570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289909 HSALNT0289909] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289909 HSALNT0289909] | ||
| − | |LINC01420 | + | |[[LINC01420]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,746: | Line 7,578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289531 HSALNT0289531] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289531 HSALNT0289531] | ||
| − | |53BP1 | + | |[[53BP1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,754: | Line 7,586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290101 HSALNT0290101] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290101 HSALNT0290101] | ||
| − | |NR_024118 | + | |[[NR_024118]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,762: | Line 7,594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290239 HSALNT0290239] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290239 HSALNT0290239] | ||
| − | |SGO1-AS1 | + | |[[SGO1-AS1]] |
|SGOL1-AS1 | |SGOL1-AS1 | ||
|NA | |NA | ||
| Line 7,770: | Line 7,602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289293 HSALNT0289293] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289293 HSALNT0289293] | ||
| − | |ZNF667-AS1 | + | |[[ZNF667-AS1]] |
|MORT | |MORT | ||
|NA | |NA | ||
| Line 7,778: | Line 7,610: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289984 HSALNT0289984] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289984 HSALNT0289984] | ||
| − | | | + | |[[LncRNA-HIF2PUT]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,786: | Line 7,618: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288945 HSALNT0288945] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288945 HSALNT0288945] | ||
| − | |ENST00000433673 | + | |[[ENST00000433673]] |
|AC068282.1 | |AC068282.1 | ||
|NA | |NA | ||
| Line 7,794: | Line 7,626: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288948 HSALNT0288948] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288948 HSALNT0288948] | ||
| − | |ENST00000454271 | + | |[[ENST00000454271]] |
|AL021940.1 | |AL021940.1 | ||
|NA | |NA | ||
| Line 7,802: | Line 7,634: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289495 HSALNT0289495] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289495 HSALNT0289495] | ||
| − | |ENST00000432431 | + | |[[ENST00000432431]] |
|AC023128.1 | |AC023128.1 | ||
|NA | |NA | ||
| Line 7,810: | Line 7,642: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289918 HSALNT0289918] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289918 HSALNT0289918] | ||
| − | |LINC01828 | + | |[[LINC01828]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,818: | Line 7,650: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290388 HSALNT0290388] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290388 HSALNT0290388] | ||
| − | |XLOC_011402 | + | |[[XLOC_011402]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,826: | Line 7,658: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289873 HSALNT0289873] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289873 HSALNT0289873] | ||
| − | |ICAM-1 | + | |[[ICAM-1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,832: | Line 7,664: | ||
|hepatocellular cancer | |hepatocellular cancer | ||
|Neoplasms;Digestive System Diseases | |Neoplasms;Digestive System Diseases | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289666 HSALNT0289666] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289666 HSALNT0289666] | ||
| − | |C5-OT1 | + | |[[C5-OT1]] |
|C5T1lncRNA | |C5T1lncRNA | ||
|NA | |NA | ||
| Line 7,858: | Line 7,674: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289626 HSALNT0289626] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289626 HSALNT0289626] | ||
| − | |AX800134 | + | |[[AX800134]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,866: | Line 7,682: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290338 HSALNT0290338] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290338 HSALNT0290338] | ||
| − | | | + | |[[Uc001ncr]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,874: | Line 7,690: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290330 HSALNT0290330] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290330 HSALNT0290330] | ||
| − | | | + | |[[Uc.48+]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,882: | Line 7,698: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289098 HSALNT0289098] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289098 HSALNT0289098] | ||
| − | |LINC01207 | + | |[[LINC01207]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 7,890: | Line 7,706: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289628 HSALNT0289628] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289628 HSALNT0289628] | ||
| − | |BALR-6 | + | |[[BALR-6]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 7,898: | Line 7,714: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290022 HSALNT0290022] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290022 HSALNT0290022] | ||
| − | |LOC389641 | + | |[[LOC389641]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,906: | Line 7,722: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289725 HSALNT0289725] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289725 HSALNT0289725] | ||
| − | |CTD-2541M15 | + | |[[CTD-2541M15]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,914: | Line 7,730: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289940 HSALNT0289940] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289940 HSALNT0289940] | ||
| − | |LINK-A | + | |[[LINK-A]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,922: | Line 7,738: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290107 HSALNT0290107] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290107 HSALNT0290107] | ||
| − | |NUTF2P3 | + | |[[NUTF2P3]] |
|NUTF2P3 | |NUTF2P3 | ||
|NA | |NA | ||
| Line 7,930: | Line 7,746: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290095 HSALNT0290095] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290095 HSALNT0290095] | ||
| − | |NONHSAT123350 | + | |[[NONHSAT123350]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,938: | Line 7,754: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290362 HSALNT0290362] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290362 HSALNT0290362] | ||
| − | |UHRF1 | + | |[[UHRF1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,946: | Line 7,762: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290366 HSALNT0290366] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290366 HSALNT0290366] | ||
| − | |UPAT | + | |[[UPAT]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,954: | Line 7,770: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289307 HSALNT0289307] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289307 HSALNT0289307] | ||
| − | |LINC00324 | + | |[[LINC00324]] |
|FLJ34790,MGC104931 | |FLJ34790,MGC104931 | ||
|NA | |NA | ||
| Line 7,962: | Line 7,778: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289969 HSALNT0289969] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289969 HSALNT0289969] | ||
| − | | | + | |[[Lnc-MX1-1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,970: | Line 7,786: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290024 HSALNT0290024] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290024 HSALNT0290024] | ||
| − | |LOC400891 | + | |[[LOC400891]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 7,978: | Line 7,794: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289883 HSALNT0289883] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289883 HSALNT0289883] | ||
| − | |LA16c-313D11.11 | + | |[[LA16c-313D11.11]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 7,986: | Line 7,802: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290192 HSALNT0290192] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290192 HSALNT0290192] | ||
| − | |RP11-395G23.3 | + | |[[RP11-395G23.3]] |
|AC027031.2 | |AC027031.2 | ||
|NA | |NA | ||
| Line 7,992: | Line 7,808: | ||
|endometrial cancer | |endometrial cancer | ||
|Female Urogenital Diseases and Pregnancy Complications;Neoplasms | |Female Urogenital Diseases and Pregnancy Complications;Neoplasms | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289581 HSALNT0289581] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289581 HSALNT0289581] | ||
| − | |AK027294 | + | |[[AK027294]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,018: | Line 7,818: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290371 HSALNT0290371] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290371 HSALNT0290371] | ||
| − | |WISP1 | + | |[[WISP1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,026: | Line 7,826: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0206117 HSALNT0206117] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0206117 HSALNT0206117] | ||
| − | |FGF14-AS2 | + | |[[FGF14-AS2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,034: | Line 7,834: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290131 HSALNT0290131] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290131 HSALNT0290131] | ||
| − | |PCAT2 | + | |[[PCAT2]] |
|CARLo-4,PCA2,TCONS_00015167 | |CARLo-4,PCA2,TCONS_00015167 | ||
|NA | |NA | ||
| Line 8,042: | Line 7,842: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289528 HSALNT0289528] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289528 HSALNT0289528] | ||
| − | |2700086A05Rik | + | |[[2700086A05Rik]] |
|2700086A05Rik | |2700086A05Rik | ||
|NA | |NA | ||
| Line 8,050: | Line 7,850: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290251 HSALNT0290251] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290251 HSALNT0290251] | ||
| − | |SNED1 | + | |[[SNED1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,058: | Line 7,858: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290333 HSALNT0290333] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290333 HSALNT0290333] | ||
| − | | | + | |[[Uc.77]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,066: | Line 7,866: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289816 HSALNT0289816] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289816 HSALNT0289816] | ||
| − | |ENST00000537266 | + | |[[ENST00000537266]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,074: | Line 7,874: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289860 HSALNT0289860] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289860 HSALNT0289860] | ||
| − | |HAGLROS | + | |[[HAGLROS]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,082: | Line 7,882: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289881 HSALNT0289881] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289881 HSALNT0289881] | ||
| − | |KRT18P55 | + | |[[KRT18P55]] |
|KRT18P55 | |KRT18P55 | ||
|NA | |NA | ||
| Line 8,090: | Line 7,890: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0229266 HSALNT0229266] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0229266 HSALNT0229266] | ||
| − | |IL21R-AS1 | + | |[[IL21R-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,098: | Line 7,898: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290112 HSALNT0290112] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290112 HSALNT0290112] | ||
| − | |OTTHUMT00000387022 | + | |[[OTTHUMT00000387022]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,106: | Line 7,906: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0000551 HSALNT0000551] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0000551 HSALNT0000551] | ||
| − | |PRKCZ-AS1 | + | |[[PRKCZ-AS1]] |
|RP11-181G12.2 | |RP11-181G12.2 | ||
|NA | |NA | ||
| Line 8,114: | Line 7,914: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0030981 HSALNT0030981] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0030981 HSALNT0030981] | ||
| − | |LINC01833 | + | |[[LINC01833]] |
|RP11-89,K21.1 | |RP11-89,K21.1 | ||
|NA | |NA | ||
| Line 8,122: | Line 7,922: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290214 HSALNT0290214] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290214 HSALNT0290214] | ||
| − | |RP11-89K21 | + | |[[RP11-89K21]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,130: | Line 7,930: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0165271 HSALNT0165271] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0165271 HSALNT0165271] | ||
| − | |LINC00857 | + | |[[LINC00857]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,138: | Line 7,938: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290109 HSALNT0290109] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290109 HSALNT0290109] | ||
| − | |OR3A4 | + | |[[OR3A4]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,146: | Line 7,946: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290046 HSALNT0290046] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290046 HSALNT0290046] | ||
| − | |MAGI1-IT1 | + | |[[MAGI1-IT1]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 8,154: | Line 7,954: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290242 HSALNT0290242] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290242 HSALNT0290242] | ||
| − | |SLC26A4-AS1 | + | |[[SLC26A4-AS1]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 8,162: | Line 7,962: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289302 HSALNT0289302] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289302 HSALNT0289302] | ||
| − | |KRT7-AS | + | |[[KRT7-AS]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,170: | Line 7,970: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0218672 HSALNT0218672] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0218672 HSALNT0218672] | ||
| − | |LINC01852 | + | |[[LINC01852]] |
|ENST00000434223 | |ENST00000434223 | ||
|NA | |NA | ||
| Line 8,178: | Line 7,978: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290178 HSALNT0290178] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290178 HSALNT0290178] | ||
| − | |RP11-1008C21.2 | + | |[[RP11-1008C21.2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,186: | Line 7,986: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289592 HSALNT0289592] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289592 HSALNT0289592] | ||
| − | |AK123072 | + | |[[AK123072]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,194: | Line 7,994: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289573 HSALNT0289573] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289573 HSALNT0289573] | ||
| − | |AK021954 | + | |[[AK021954]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,202: | Line 8,002: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288916 HSALNT0288916] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288916 HSALNT0288916] | ||
| − | |CERNA1 | + | |[[CERNA1]] |
|LOC100129973 | |LOC100129973 | ||
|ceRNA | |ceRNA | ||
| Line 8,210: | Line 8,010: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0018525 HSALNT0018525] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0018525 HSALNT0018525] | ||
| − | |LAMC1-AS1 | + | |[[LAMC1-AS1]] |
|lnc-LAMC2-1:1 | |lnc-LAMC2-1:1 | ||
|NA | |NA | ||
| Line 8,218: | Line 8,018: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290087 HSALNT0290087] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290087 HSALNT0290087] | ||
| − | |NONHSAT040387 | + | |[[NONHSAT040387]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,226: | Line 8,026: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290092 HSALNT0290092] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290092 HSALNT0290092] | ||
| − | |NONHSAT098586 | + | |[[NONHSAT098586]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,234: | Line 8,034: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289213 HSALNT0289213] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289213 HSALNT0289213] | ||
| − | |PCSK6-AS1 | + | |[[PCSK6-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,242: | Line 8,042: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289637 HSALNT0289637] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289637 HSALNT0289637] | ||
| − | |BC016831 | + | |[[BC016831]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,250: | Line 8,050: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289874 HSALNT0289874] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289874 HSALNT0289874] | ||
| − | |IGKV | + | |[[IGKV]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,258: | Line 8,058: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290196 HSALNT0290196] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290196 HSALNT0290196] | ||
| − | |RP11-434D9.1 | + | |[[RP11-434D9.1]] |
|AC112206.2 | |AC112206.2 | ||
|NA | |NA | ||
| Line 8,266: | Line 8,066: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289885 HSALNT0289885] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289885 HSALNT0289885] | ||
| − | |LCAL6 | + | |[[LCAL6]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,274: | Line 8,074: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289650 HSALNT0289650] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289650 HSALNT0289650] | ||
| − | |BC088254 | + | |[[BC088254]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,282: | Line 8,082: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289596 HSALNT0289596] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289596 HSALNT0289596] | ||
| − | |AK124454 | + | |[[AK124454]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,290: | Line 8,090: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289731 HSALNT0289731] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289731 HSALNT0289731] | ||
| − | |CYP4B1-PS1 | + | |[[CYP4B1-PS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,298: | Line 8,098: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289106 HSALNT0289106] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289106 HSALNT0289106] | ||
| − | |LINC01405 | + | |[[LINC01405]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,306: | Line 8,106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290259 HSALNT0290259] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290259 HSALNT0290259] | ||
| − | |ST8SIA6-AS1 | + | |[[ST8SIA6-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,314: | Line 8,114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289278 HSALNT0289278] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289278 HSALNT0289278] | ||
| − | |TRIM52-AS1 | + | |[[TRIM52-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,322: | Line 8,122: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289634 HSALNT0289634] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289634 HSALNT0289634] | ||
| − | |BC012900 | + | |[[BC012900]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,330: | Line 8,130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0274011 HSALNT0274011] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0274011 HSALNT0274011] | ||
| − | |UMODL1-AS1 | + | |[[UMODL1-AS1]] |
|FLJ33471 | |FLJ33471 | ||
|NA | |NA | ||
| Line 8,338: | Line 8,138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289454 HSALNT0289454] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289454 HSALNT0289454] | ||
| − | |ARRDC1-AS1 | + | |[[ARRDC1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,346: | Line 8,146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289456 HSALNT0289456] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289456 HSALNT0289456] | ||
| − | |FAM74A3 | + | |[[FAM74A3]] |
|OTTHUMG00000067149 | |OTTHUMG00000067149 | ||
|NA | |NA | ||
| Line 8,354: | Line 8,154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289834 HSALNT0289834] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289834 HSALNT0289834] | ||
| − | |FH | + | |[[FH]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,362: | Line 8,162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289961 HSALNT0289961] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289961 HSALNT0289961] | ||
| − | | | + | |[[Lnc-HOXC4-3:1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,370: | Line 8,170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289994 HSALNT0289994] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289994 HSALNT0289994] | ||
| − | | | + | |[[Lnc-TEAD4-1:1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,378: | Line 8,178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290270 HSALNT0290270] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290270 HSALNT0290270] | ||
| − | |TCONS_00003876 | + | |[[TCONS_00003876]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,384: | Line 8,184: | ||
|breast cancer | |breast cancer | ||
|Skin and Connective Tissue Diseases;Neoplasms | |Skin and Connective Tissue Diseases;Neoplasms | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290235 HSALNT0290235] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290235 HSALNT0290235] | ||
| − | |SARCC | + | |[[SARCC]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,402: | Line 8,194: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290360 HSALNT0290360] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290360 HSALNT0290360] | ||
| − | | | + | |[[Ucoo2kmd.1]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 8,410: | Line 8,202: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289015 HSALNT0289015] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289015 HSALNT0289015] | ||
| − | |KAZN-AS1 | + | |[[KAZN-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,418: | Line 8,210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289722 HSALNT0289722] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289722 HSALNT0289722] | ||
| − | |CTB-89H12.4 | + | |[[CTB-89H12.4]] |
|AC021078.1 | |AC021078.1 | ||
|ceRNA | |ceRNA | ||
| Line 8,426: | Line 8,218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289496 HSALNT0289496] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289496 HSALNT0289496] | ||
| − | |EPB41L4A-AS2 | + | |[[EPB41L4A-AS2]] |
|FLJ11235 | |FLJ11235 | ||
|NA | |NA | ||
| Line 8,434: | Line 8,226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289146 HSALNT0289146] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289146 HSALNT0289146] | ||
| − | |LINC02567 | + | |[[LINC02567]] |
|ENST00000427806 | |ENST00000427806 | ||
|NA | |NA | ||
| Line 8,442: | Line 8,234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289833 HSALNT0289833] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289833 HSALNT0289833] | ||
| − | |FGFR3-AS1 | + | |[[FGFR3-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,450: | Line 8,242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289707 HSALNT0289707] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289707 HSALNT0289707] | ||
| − | |CILinc01 | + | |[[CILinc01]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,458: | Line 8,250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289708 HSALNT0289708] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289708 HSALNT0289708] | ||
| − | |CILinc02 | + | |[[CILinc02]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,466: | Line 8,258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0286597 HSALNT0286597] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0286597 HSALNT0286597] | ||
| − | |LINC00629 | + | |[[LINC00629]] |
|LINC00629AB,LINC00629C,LINC00629D,LINC00629 | |LINC00629AB,LINC00629C,LINC00629D,LINC00629 | ||
|NA | |NA | ||
| Line 8,474: | Line 8,266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289665 HSALNT0289665] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289665 HSALNT0289665] | ||
| − | |C2dat1 | + | |[[C2dat1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,482: | Line 8,274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289217 HSALNT0289217] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289217 HSALNT0289217] | ||
| − | |POU6F2-AS2 | + | |[[POU6F2-AS2]] |
|FLJ12971 | |FLJ12971 | ||
|protein localization | |protein localization | ||
| Line 8,490: | Line 8,282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289946 HSALNT0289946] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289946 HSALNT0289946] | ||
| − | | | + | |[[Lnc13]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,498: | Line 8,290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289729 HSALNT0289729] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289729 HSALNT0289729] | ||
| − | |CTD903 | + | |[[CTD903]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,506: | Line 8,298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290093 HSALNT0290093] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290093 HSALNT0290093] | ||
| − | |NONHSAT104436 | + | |[[NONHSAT104436]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,514: | Line 8,306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289550 HSALNT0289550] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289550 HSALNT0289550] | ||
| − | |AC024560.2 | + | |[[AC024560.2]] |
|AC024560.1 | |AC024560.1 | ||
|NA | |NA | ||
| Line 8,522: | Line 8,314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289483 HSALNT0289483] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289483 HSALNT0289483] | ||
| − | |ENST00000436681 | + | |[[ENST00000436681]] |
|AP000552.1 | |AP000552.1 | ||
|NA | |NA | ||
| Line 8,530: | Line 8,322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289536 HSALNT0289536] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289536 HSALNT0289536] | ||
| − | |AA584040 | + | |[[AA584040]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,538: | Line 8,330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289537 HSALNT0289537] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289537 HSALNT0289537] | ||
| − | |AA709223 | + | |[[AA709223]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,546: | Line 8,338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289657 HSALNT0289657] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289657 HSALNT0289657] | ||
| − | |BX478947 | + | |[[BX478947]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,554: | Line 8,346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0247515 HSALNT0247515] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0247515 HSALNT0247515] | ||
| − | |LINC00668 | + | |[[LINC00668]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,562: | Line 8,354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289719 HSALNT0289719] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289719 HSALNT0289719] | ||
| − | |CRNDE-h | + | |[[CRNDE-h]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,570: | Line 8,362: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0142879 HSALNT0142879] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0142879 HSALNT0142879] | ||
| − | |SMILR | + | |[[SMILR]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,578: | Line 8,370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290396 HSALNT0290396] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290396 HSALNT0290396] | ||
| − | |Z38 | + | |[[Z38]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,586: | Line 8,378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0197213 HSALNT0197213] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0197213 HSALNT0197213] | ||
| − | |LINC00507 | + | |[[LINC00507]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,594: | Line 8,386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289086 HSALNT0289086] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289086 HSALNT0289086] | ||
| − | |LINC01082 | + | |[[LINC01082]] |
|TCONSNA00024492 | |TCONSNA00024492 | ||
|NA | |NA | ||
| Line 8,602: | Line 8,394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289094 HSALNT0289094] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289094 HSALNT0289094] | ||
| − | |LINC01185 | + | |[[LINC01185]] |
|FLJ16341 | |FLJ16341 | ||
|NA | |NA | ||
| Line 8,610: | Line 8,402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290160 HSALNT0290160] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290160 HSALNT0290160] | ||
| − | |PTPRD-AS1 | + | |[[PTPRD-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,618: | Line 8,410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290186 HSALNT0290186] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290186 HSALNT0290186] | ||
| − | |RP11-254I22.1 | + | |[[RP11-254I22.1]] |
|MIR583HG | |MIR583HG | ||
|NA | |NA | ||
| Line 8,626: | Line 8,418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290204 HSALNT0290204] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290204 HSALNT0290204] | ||
| − | |RP11-57P19.1 | + | |[[RP11-57P19.1]] |
|AC009432.1 | |AC009432.1 | ||
|NA | |NA | ||
| Line 8,634: | Line 8,426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290211 HSALNT0290211] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290211 HSALNT0290211] | ||
| − | |RP11-80H5.7 | + | |[[RP11-80H5.7]] |
|AL157400.4 | |AL157400.4 | ||
|NA | |NA | ||
| Line 8,642: | Line 8,434: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290215 HSALNT0290215] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290215 HSALNT0290215] | ||
| − | |RP1-223E5.4 | + | |[[RP1-223E5.4]] |
|AL441883.1 | |AL441883.1 | ||
|NA | |NA | ||
| Line 8,650: | Line 8,442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290224 HSALNT0290224] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290224 HSALNT0290224] | ||
| − | |RP4-799P18.3 | + | |[[RP4-799P18.3]] |
|AL122008.4 | |AL122008.4 | ||
|NA | |NA | ||
| Line 8,658: | Line 8,450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289126 HSALNT0289126] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289126 HSALNT0289126] | ||
| − | |LINC01844 | + | |[[LINC01844]] |
|LOC101926975 | |LOC101926975 | ||
|NA | |NA | ||
| Line 8,666: | Line 8,458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289947 HSALNT0289947] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289947 HSALNT0289947] | ||
| − | |Lnc34a | + | |[[Lnc34a]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 8,674: | Line 8,466: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289150 HSALNT0289150] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289150 HSALNT0289150] | ||
| − | |LINP1 | + | |[[LINP1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,682: | Line 8,474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289951 HSALNT0289951] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289951 HSALNT0289951] | ||
| − | | | + | |[[LncARSR]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 8,690: | Line 8,482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289392 HSALNT0289392] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289392 HSALNT0289392] | ||
| − | |RBM15-AS1 | + | |[[RBM15-AS1]] |
|AS-RBM15 | |AS-RBM15 | ||
|translational control | |translational control | ||
| Line 8,698: | Line 8,490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290089 HSALNT0290089] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290089 HSALNT0290089] | ||
| − | |NONHSAT073641 | + | |[[NONHSAT073641]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,706: | Line 8,498: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290027 HSALNT0290027] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290027 HSALNT0290027] | ||
| − | |LOC572558 | + | |[[LOC572558]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,714: | Line 8,506: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289582 HSALNT0289582] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289582 HSALNT0289582] | ||
| − | |AK033210 | + | |[[AK033210]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,722: | Line 8,514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289848 HSALNT0289848] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289848 HSALNT0289848] | ||
| − | |GClnc1 | + | |[[GClnc1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 8,730: | Line 8,522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289572 HSALNT0289572] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289572 HSALNT0289572] | ||
| − | |AK021630 | + | |[[AK021630]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,738: | Line 8,530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289603 HSALNT0289603] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289603 HSALNT0289603] | ||
| − | |AL049437 | + | |[[AL049437]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,746: | Line 8,538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290007 HSALNT0290007] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290007 HSALNT0290007] | ||
| − | |LOC100507661 | + | |[[LOC100507661]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,754: | Line 8,546: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289084 HSALNT0289084] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289084 HSALNT0289084] | ||
| − | |LINC01029 | + | |[[LINC01029]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,762: | Line 8,554: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290169 HSALNT0290169] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290169 HSALNT0290169] | ||
| − | |RMEL3 | + | |[[RMEL3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,770: | Line 8,562: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289959 HSALNT0289959] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289959 HSALNT0289959] | ||
| − | | | + | |[[Lnc-FRG2C-3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,778: | Line 8,570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289966 HSALNT0289966] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289966 HSALNT0289966] | ||
| − | | | + | |[[Lnc-LIN54-1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,786: | Line 8,578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289997 HSALNT0289997] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289997 HSALNT0289997] | ||
| − | | | + | |[[Lnc-USP50-2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,794: | Line 8,586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290000 HSALNT0290000] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290000 HSALNT0290000] | ||
| − | | | + | |[[Lnc-ZNF354A-1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,802: | Line 8,594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288949 HSALNT0288949] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288949 HSALNT0288949] | ||
| − | |ENST00000455309 | + | |[[ENST00000455309]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,810: | Line 8,602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289920 HSALNT0289920] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289920 HSALNT0289920] | ||
| − | |LINC02384 | + | |[[LINC02384]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,818: | Line 8,610: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289998 HSALNT0289998] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289998 HSALNT0289998] | ||
| − | |Lnc-UTS2D-1:1 | + | |[[Lnc-UTS2D-1:1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,826: | Line 8,618: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290067 HSALNT0290067] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290067 HSALNT0290067] | ||
| − | | | + | |[[N336161]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,834: | Line 8,626: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290069 HSALNT0290069] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290069 HSALNT0290069] | ||
| − | | | + | |[[N340599]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,842: | Line 8,634: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290099 HSALNT0290099] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290099 HSALNT0290099] | ||
| − | |NR_002712 | + | |[[NR_002712]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,850: | Line 8,642: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290290 HSALNT0290290] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290290 HSALNT0290290] | ||
| − | |TCONS_l2_00014794 | + | |[[TCONS_l2_00014794]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,858: | Line 8,650: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290170 HSALNT0290170] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290170 HSALNT0290170] | ||
| − | |RMRP | + | |[[RMRP]] |
|CHH,NME1R,RRP2,RMRP | |CHH,NME1R,RRP2,RMRP | ||
|ceRNA | |ceRNA | ||
| Line 8,866: | Line 8,658: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289900 HSALNT0289900] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289900 HSALNT0289900] | ||
| − | |LINC00961 | + | |[[LINC00961]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,874: | Line 8,666: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289077 HSALNT0289077] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289077 HSALNT0289077] | ||
| − | |LINC00977 | + | |[[LINC00977]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,882: | Line 8,674: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289560 HSALNT0289560] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289560 HSALNT0289560] | ||
| − | |AF085995 | + | |[[AF085995]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,890: | Line 8,682: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289566 HSALNT0289566] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289566 HSALNT0289566] | ||
| − | |AK000053 | + | |[[AK000053]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,898: | Line 8,690: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289571 HSALNT0289571] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289571 HSALNT0289571] | ||
| − | |AK021595 | + | |[[AK021595]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,906: | Line 8,698: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289574 HSALNT0289574] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289574 HSALNT0289574] | ||
| − | |AK022024 | + | |[[AK022024]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,914: | Line 8,706: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289595 HSALNT0289595] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289595 HSALNT0289595] | ||
| − | |AK124307 | + | |[[AK124307]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,922: | Line 8,714: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289639 HSALNT0289639] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289639 HSALNT0289639] | ||
| − | |BC020384 | + | |[[BC020384]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,930: | Line 8,722: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289642 HSALNT0289642] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289642 HSALNT0289642] | ||
| − | |BC030759 | + | |[[BC030759]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,938: | Line 8,730: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289715 HSALNT0289715] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289715 HSALNT0289715] | ||
| − | |CR615992 | + | |[[CR615992]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,946: | Line 8,738: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289954 HSALNT0289954] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289954 HSALNT0289954] | ||
| − | | | + | |[[Lnc-CC3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,954: | Line 8,746: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289614 HSALNT0289614] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289614 HSALNT0289614] | ||
| − | |APOC1P1-3 | + | |[[APOC1P1-3]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 8,962: | Line 8,754: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290365 HSALNT0290365] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290365 HSALNT0290365] | ||
| − | |UNMIBC | + | |[[UNMIBC]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 8,970: | Line 8,762: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290323 HSALNT0290323] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290323 HSALNT0290323] | ||
| − | | | + | |[[Uc.167]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,978: | Line 8,770: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290212 HSALNT0290212] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290212 HSALNT0290212] | ||
| − | |RP11-838N2.4 | + | |[[RP11-838N2.4]] |
|GAPLINC | |GAPLINC | ||
|ceRNA | |ceRNA | ||
| Line 8,986: | Line 8,778: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289109 HSALNT0289109] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289109 HSALNT0289109] | ||
| − | |LINC01478 | + | |[[LINC01478]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 8,994: | Line 8,786: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289313 HSALNT0289313] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289313 HSALNT0289313] | ||
| − | |LINC00342 | + | |[[LINC00342]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,002: | Line 8,794: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289677 HSALNT0289677] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289677 HSALNT0289677] | ||
| − | |CAR10 | + | |[[CAR10]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,010: | Line 8,802: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289365 HSALNT0289365] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289365 HSALNT0289365] | ||
| − | |MAPT-AS1 | + | |[[MAPT-AS1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,018: | Line 8,810: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289679 HSALNT0289679] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289679 HSALNT0289679] | ||
| − | |CAT104 | + | |[[CAT104]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 9,026: | Line 8,818: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290260 HSALNT0290260] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290260 HSALNT0290260] | ||
| − | |STXBP5-AS1 | + | |[[STXBP5-AS1]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 9,034: | Line 8,826: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289861 HSALNT0289861] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289861 HSALNT0289861] | ||
| − | |HAR1 | + | |[[HAR1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,042: | Line 8,834: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290359 HSALNT0290359] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290359 HSALNT0290359] | ||
| − | |UCHL1-AS1 | + | |[[UCHL1-AS1]] |
|NA | |NA | ||
|translational control | |translational control | ||
| Line 9,050: | Line 8,842: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290238 HSALNT0290238] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290238 HSALNT0290238] | ||
| − | |SCAANT1-AS | + | |[[SCAANT1-AS]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,058: | Line 8,850: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289648 HSALNT0289648] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289648 HSALNT0289648] | ||
| − | |BC041488 | + | |[[BC041488]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,066: | Line 8,858: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290188 HSALNT0290188] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290188 HSALNT0290188] | ||
| − | |RP11-359E19.2 | + | |[[RP11-359E19.2]] |
|AC022733.1 | |AC022733.1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,072: | Line 8,864: | ||
|bladder cancer | |bladder cancer | ||
|Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms | |Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289851 HSALNT0289851] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289851 HSALNT0289851] | ||
| − | |GIHCG | + | |[[GIHCG]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,098: | Line 8,874: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289649 HSALNT0289649] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289649 HSALNT0289649] | ||
| − | |BC087858 | + | |[[BC087858]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,106: | Line 8,882: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290353 HSALNT0290353] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290353 HSALNT0290353] | ||
| − | | | + | |[[Uc004cov.4]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,114: | Line 8,890: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290357 HSALNT0290357] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290357 HSALNT0290357] | ||
| − | | | + | |[[Uc022bqu.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,122: | Line 8,898: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0127837 HSALNT0127837] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0127837 HSALNT0127837] | ||
| − | |CFTR-AS1 | + | |[[CFTR-AS1]] |
|BGas | |BGas | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,130: | Line 8,906: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0046367 HSALNT0046367] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0046367 HSALNT0046367] | ||
| − | |MYOSLID | + | |[[MYOSLID]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,138: | Line 8,914: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290331 HSALNT0290331] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290331 HSALNT0290331] | ||
| − | | | + | |[[Uc.63]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,146: | Line 8,922: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290106 HSALNT0290106] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290106 HSALNT0290106] | ||
| − | | | + | |[[Numb]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,154: | Line 8,930: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289847 HSALNT0289847] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289847 HSALNT0289847] | ||
| − | |GCASPC | + | |[[GCASPC]] |
|TCONS_00011605,RP1-56L9.7-001,lnc-SOD2-1 | |TCONS_00011605,RP1-56L9.7-001,lnc-SOD2-1 | ||
|NA | |NA | ||
| Line 9,162: | Line 8,938: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289568 HSALNT0289568] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289568 HSALNT0289568] | ||
| − | |AK001094 | + | |[[AK001094]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,170: | Line 8,946: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289588 HSALNT0289588] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289588 HSALNT0289588] | ||
| − | |AK093735 | + | |[[AK093735]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,178: | Line 8,954: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289631 HSALNT0289631] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289631 HSALNT0289631] | ||
| − | |BC003519 | + | |[[BC003519]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,186: | Line 8,962: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290100 HSALNT0290100] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290100 HSALNT0290100] | ||
| − | |NR_003573 | + | |[[NR_003573]] |
|ANXA2P2 | |ANXA2P2 | ||
|NA | |NA | ||
| Line 9,194: | Line 8,970: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290119 HSALNT0290119] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290119 HSALNT0290119] | ||
| − | |P2RX7-V3 | + | |[[P2RX7-V3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,202: | Line 8,978: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290308 HSALNT0290308] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290308 HSALNT0290308] | ||
| − | |TMSB4 | + | |[[TMSB4]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 9,210: | Line 8,986: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288928 HSALNT0288928] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288928 HSALNT0288928] | ||
| − | |DDX11-AS1 | + | |[[DDX11-AS1]] |
|CONCR | |CONCR | ||
|NA | |NA | ||
| Line 9,218: | Line 8,994: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290052 HSALNT0290052] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290052 HSALNT0290052] | ||
| − | |MELOE | + | |[[MELOE]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,226: | Line 9,002: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290231 HSALNT0290231] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290231 HSALNT0290231] | ||
| − | |RSU1P2 | + | |[[RSU1P2]] |
|RSU1P2 | |RSU1P2 | ||
|ceRNA | |ceRNA | ||
| Line 9,234: | Line 9,010: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290165 HSALNT0290165] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290165 HSALNT0290165] | ||
| − | |RBMY2FP | + | |[[RBMY2FP]] |
|RBMY2FP | |RBMY2FP | ||
|NA | |NA | ||
| Line 9,242: | Line 9,018: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290071 HSALNT0290071] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290071 HSALNT0290071] | ||
| − | | | + | |[[N375709]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,250: | Line 9,026: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289748 HSALNT0289748] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289748 HSALNT0289748] | ||
| − | |DUXAP8 | + | |[[DUXAP8]] |
|DUXAP8 | |DUXAP8 | ||
|NA | |NA | ||
| Line 9,258: | Line 9,034: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290030 HSALNT0290030] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290030 HSALNT0290030] | ||
| − | |LOC729966 | + | |[[LOC729966]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,266: | Line 9,042: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290143 HSALNT0290143] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290143 HSALNT0290143] | ||
| − | |POIR | + | |[[POIR]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 9,274: | Line 9,050: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0067481 HSALNT0067481] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0067481 HSALNT0067481] | ||
| − | |MELTF-AS1 | + | |[[MELTF-AS1]] |
|MFI2-AS1,AC068302.3 | |MFI2-AS1,AC068302.3 | ||
|NA | |NA | ||
| Line 9,282: | Line 9,058: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290053 HSALNT0290053] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290053 HSALNT0290053] | ||
| − | |MFI2 | + | |[[MFI2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,290: | Line 9,066: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289922 HSALNT0289922] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289922 HSALNT0289922] | ||
| − | | | + | |[[Linc-223]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 9,298: | Line 9,074: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0014603 HSALNT0014603] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0014603 HSALNT0014603] | ||
| − | |LINC01138 | + | |[[LINC01138]] |
|LINC00875,FLJ39739 | |LINC00875,FLJ39739 | ||
|NA | |NA | ||
| Line 9,306: | Line 9,082: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290262 HSALNT0290262] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290262 HSALNT0290262] | ||
| − | |SUZ12P1 | + | |[[SUZ12P1]] |
|SUZ12P1 | |SUZ12P1 | ||
|NA | |NA | ||
| Line 9,314: | Line 9,090: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290005 HSALNT0290005] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290005 HSALNT0290005] | ||
| − | |LOC100505976 | + | |[[LOC100505976]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,322: | Line 9,098: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290392 HSALNT0290392] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290392 HSALNT0290392] | ||
| − | |XLOC_l2_010636 | + | |[[XLOC_l2_010636]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,330: | Line 9,106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0090295 HSALNT0090295] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0090295 HSALNT0090295] | ||
| − | |RASGRF2-AS1 | + | |[[RASGRF2-AS1]] |
|CTC-459I6.1 | |CTC-459I6.1 | ||
|NA | |NA | ||
| Line 9,338: | Line 9,114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289852 HSALNT0289852] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289852 HSALNT0289852] | ||
| − | |GPC3-AS1 | + | |[[GPC3-AS1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,346: | Line 9,122: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0189472 HSALNT0189472] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0189472 HSALNT0189472] | ||
| − | |HOXC-AS1 | + | |[[HOXC-AS1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,354: | Line 9,130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289157 HSALNT0289157] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289157 HSALNT0289157] | ||
| − | |LUARIS | + | |[[LUARIS]] |
|lncRNA#32 | |lncRNA#32 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,362: | Line 9,138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289371 HSALNT0289371] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289371 HSALNT0289371] | ||
| − | |MIR3936HG | + | |[[MIR3936HG]] |
|LOC553103,SLC22A5-AS1 | |LOC553103,SLC22A5-AS1 | ||
|NA | |NA | ||
| Line 9,370: | Line 9,146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290148 HSALNT0290148] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290148 HSALNT0290148] | ||
| − | |Ppp1r1b | + | |[[Ppp1r1b]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,378: | Line 9,154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289038 HSALNT0289038] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289038 HSALNT0289038] | ||
| − | |LINC00460 | + | |[[LINC00460]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,386: | Line 9,162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290194 HSALNT0290194] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290194 HSALNT0290194] | ||
| − | |RP1-13P20.6 | + | |[[RP1-13P20.6]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,394: | Line 9,170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290364 HSALNT0290364] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290364 HSALNT0290364] | ||
| − | |Unigene56159 | + | |[[Unigene56159]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 9,402: | Line 9,178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290355 HSALNT0290355] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290355 HSALNT0290355] | ||
| − | | | + | |[[Uc009yby.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,410: | Line 9,186: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289406 HSALNT0289406] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289406 HSALNT0289406] | ||
| − | |TFAP2A-AS2 | + | |[[TFAP2A-AS2]] |
|HIPSTR | |HIPSTR | ||
|NA | |NA | ||
| Line 9,418: | Line 9,194: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289704 HSALNT0289704] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289704 HSALNT0289704] | ||
| − | |Chaer | + | |[[Chaer]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,424: | Line 9,200: | ||
|cardiac hypertrophy | |cardiac hypertrophy | ||
|Cardiovascular Diseases | |Cardiovascular Diseases | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0211378 HSALNT0211378] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0211378 HSALNT0211378] | ||
| − | |LINC00520 | + | |[[LINC00520]] |
|C14orf34 | |C14orf34 | ||
|NA | |NA | ||
| Line 9,442: | Line 9,210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0087374 HSALNT0087374] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0087374 HSALNT0087374] | ||
| − | |MRPS30-DT | + | |[[MRPS30-DT]] |
|BRCAT54 | |BRCAT54 | ||
|NA | |NA | ||
| Line 9,450: | Line 9,218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289388 HSALNT0289388] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289388 HSALNT0289388] | ||
| − | |PPP1R12A-AS1 | + | |[[PPP1R12A-AS1]] |
|R12A-AS1 | |R12A-AS1 | ||
|translational control | |translational control | ||
| Line 9,458: | Line 9,226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289013 HSALNT0289013] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289013 HSALNT0289013] | ||
| − | |ITFG2-AS1 | + | |[[ITFG2-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,466: | Line 9,234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290088 HSALNT0290088] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290088 HSALNT0290088] | ||
| − | |NONHSAT041499 | + | |[[NONHSAT041499]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,474: | Line 9,242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290091 HSALNT0290091] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290091 HSALNT0290091] | ||
| − | |NONHSAT089447 | + | |[[NONHSAT089447]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,482: | Line 9,250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289970 HSALNT0289970] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289970 HSALNT0289970] | ||
| − | | | + | |[[Lnc-NKX2-3-1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,490: | Line 9,258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289989 HSALNT0289989] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289989 HSALNT0289989] | ||
| − | | | + | |[[Lnc-RTN4R-1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,498: | Line 9,266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289821 HSALNT0289821] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289821 HSALNT0289821] | ||
| − | |ERL | + | |[[ERL]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,506: | Line 9,274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0192459 HSALNT0192459] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0192459 HSALNT0192459] | ||
| − | |LINC02258 | + | |[[LINC02258]] |
|RP11-248E9.5 | |RP11-248E9.5 | ||
|NA | |NA | ||
| Line 9,514: | Line 9,282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0241871 HSALNT0241871] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0241871 HSALNT0241871] | ||
| − | |SKAP1-AS1 | + | |[[SKAP1-AS1]] |
|RP11-456D7.1 | |RP11-456D7.1 | ||
|NA | |NA | ||
| Line 9,522: | Line 9,290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289439 HSALNT0289439] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289439 HSALNT0289439] | ||
| − | |DINOL | + | |[[DINOL]] |
|DINO | |DINO | ||
|NA | |NA | ||
| Line 9,530: | Line 9,298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288901 HSALNT0288901] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288901 HSALNT0288901] | ||
| − | |CAMTA1-DT | + | |[[CAMTA1-DT]] |
|lncCAMTA1 | |lncCAMTA1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,538: | Line 9,306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290328 HSALNT0290328] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290328 HSALNT0290328] | ||
| − | | | + | |[[Uc.345]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,546: | Line 9,314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290060 HSALNT0290060] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290060 HSALNT0290060] | ||
| − | |MSNP1AS | + | |[[MSNP1AS]] |
|NA | |NA | ||
|translational control | |translational control | ||
| Line 9,554: | Line 9,322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289376 HSALNT0289376] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289376 HSALNT0289376] | ||
| − | |NEXN-AS1 | + | |[[NEXN-AS1]] |
|C1orf118,FLJ90637 | |C1orf118,FLJ90637 | ||
|NA | |NA | ||
| Line 9,562: | Line 9,330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0183194 HSALNT0183194] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0183194 HSALNT0183194] | ||
| − | |LINC02098 | + | |[[LINC02098]] |
|RP11-702B10.1 | |RP11-702B10.1 | ||
|NA | |NA | ||
| Line 9,570: | Line 9,338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0198055 HSALNT0198055] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0198055 HSALNT0198055] | ||
| − | |PSPC1-AS2 | + | |[[PSPC1-AS2]] |
|RP11-523H24.3 | |RP11-523H24.3 | ||
|NA | |NA | ||
| Line 9,578: | Line 9,346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289155 HSALNT0289155] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289155 HSALNT0289155] | ||
| − | |LRRC75A-AS1 | + | |[[LRRC75A-AS1]] |
|C17orf45,NCRNA00188,C17orf76-AS1,FAM211A-AS1,MGC40157 | |C17orf45,NCRNA00188,C17orf76-AS1,FAM211A-AS1,MGC40157 | ||
|NA | |NA | ||
| Line 9,586: | Line 9,354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289220 HSALNT0289220] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289220 HSALNT0289220] | ||
| − | |PRKG1-AS1 | + | |[[PRKG1-AS1]] |
|RP11-573I11.2 | |RP11-573I11.2 | ||
|NA | |NA | ||
| Line 9,594: | Line 9,362: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289262 HSALNT0289262] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289262 HSALNT0289262] | ||
| − | |SVIL-AS1 | + | |[[SVIL-AS1]] |
|RP11-534G20.3 | |RP11-534G20.3 | ||
|NA | |NA | ||
| Line 9,602: | Line 9,370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289281 HSALNT0289281] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289281 HSALNT0289281] | ||
| − | |VPS33B-DT | + | |[[VPS33B-DT]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,610: | Line 9,378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289804 HSALNT0289804] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289804 HSALNT0289804] | ||
| − | |ENST00000438399 | + | |[[ENST00000438399]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,618: | Line 9,386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290228 HSALNT0290228] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290228 HSALNT0290228] | ||
| − | |RPKG1-AS1 | + | |[[RPKG1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,626: | Line 9,394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290350 HSALNT0290350] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290350 HSALNT0290350] | ||
| − | | | + | |[[Uc004afb.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,634: | Line 9,402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289398 HSALNT0289398] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289398 HSALNT0289398] | ||
| − | |SLC5A4-AS1 | + | |[[SLC5A4-AS1]] |
|RP1-90G24.10 | |RP1-90G24.10 | ||
|NA | |NA | ||
| Line 9,642: | Line 9,410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289411 HSALNT0289411] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289411 HSALNT0289411] | ||
| − | |TNFRSF10A-AS1 | + | |[[TNFRSF10A-AS1]] |
|RP11-1149O23.2 | |RP11-1149O23.2 | ||
|NA | |NA | ||
| Line 9,650: | Line 9,418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289727 HSALNT0289727] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289727 HSALNT0289727] | ||
| − | |CTD-2616J11.14 | + | |[[CTD-2616J11.14]] |
|AC008750.7 | |AC008750.7 | ||
|NA | |NA | ||
| Line 9,658: | Line 9,426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290182 HSALNT0290182] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290182 HSALNT0290182] | ||
| − | |RP11-150O12.3 | + | |[[RP11-150O12.3]] |
|AC124067.4 | |AC124067.4 | ||
|NA | |NA | ||
| Line 9,666: | Line 9,434: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289730 HSALNT0289730] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289730 HSALNT0289730] | ||
| − | |CXCL1P1 | + | |[[CXCL1P1]] |
|CXCL1P1 | |CXCL1P1 | ||
|NA | |NA | ||
| Line 9,674: | Line 9,442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289803 HSALNT0289803] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289803 HSALNT0289803] | ||
| − | |ENST00000438347 | + | |[[ENST00000438347]] |
|CCND3P1 | |CCND3P1 | ||
|NA | |NA | ||
| Line 9,682: | Line 9,450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289897 HSALNT0289897] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289897 HSALNT0289897] | ||
| − | |LINC00601 | + | |[[LINC00601]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,690: | Line 9,458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289503 HSALNT0289503] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289503 HSALNT0289503] | ||
| − | |KIAA0087 | + | |[[KIAA0087]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,698: | Line 9,466: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289827 HSALNT0289827] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289827 HSALNT0289827] | ||
| − | |FAM212B-AS1 | + | |[[FAM212B-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,706: | Line 9,474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290010 HSALNT0290010] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290010 HSALNT0290010] | ||
| − | |LOC102723552 | + | |[[LOC102723552]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,714: | Line 9,482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290181 HSALNT0290181] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290181 HSALNT0290181] | ||
| − | |RP11-140I24 | + | |[[RP11-140I24]] |
|LINC01568 | |LINC01568 | ||
|NA | |NA | ||
| Line 9,722: | Line 9,490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290201 HSALNT0290201] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290201 HSALNT0290201] | ||
| − | |RP11-501O2 | + | |[[RP11-501O2]] |
|LINC02046 | |LINC02046 | ||
|NA | |NA | ||
| Line 9,730: | Line 9,498: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290206 HSALNT0290206] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290206 HSALNT0290206] | ||
| − | |RP11-600K151 | + | |[[RP11-600K151]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,738: | Line 9,506: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290084 HSALNT0290084] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290084 HSALNT0290084] | ||
| − | |NONHSAG051968 | + | |[[NONHSAG051968]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,746: | Line 9,514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290090 HSALNT0290090] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290090 HSALNT0290090] | ||
| − | |NONHSAT076747 | + | |[[NONHSAT076747]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,754: | Line 9,522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290094 HSALNT0290094] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290094 HSALNT0290094] | ||
| − | |NONHSAT122730 | + | |[[NONHSAT122730]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,762: | Line 9,530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0138768 HSALNT0138768] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0138768 HSALNT0138768] | ||
| − | |MIR2052HG | + | |[[MIR2052HG]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,770: | Line 9,538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289096 HSALNT0289096] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289096 HSALNT0289096] | ||
| − | |LINC01198 | + | |[[LINC01198]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,778: | Line 9,546: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289274 HSALNT0289274] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289274 HSALNT0289274] | ||
| − | |TPT1-AS1 | + | |[[TPT1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,786: | Line 9,554: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289924 HSALNT0289924] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289924 HSALNT0289924] | ||
| − | | | + | |[[Linc-cdh4-2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,794: | Line 9,562: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0144641 HSALNT0144641] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0144641 HSALNT0144641] | ||
| − | |LINC02055 | + | |[[LINC02055]] |
|RP1130-1 | |RP1130-1 | ||
|NA | |NA | ||
| Line 9,802: | Line 9,570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289737 HSALNT0289737] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289737 HSALNT0289737] | ||
| − | |DBCCR1 | + | |[[DBCCR1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 9,810: | Line 9,578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289547 HSALNT0289547] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289547 HSALNT0289547] | ||
| − | |AC012065.7 | + | |[[AC012065.7]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,818: | Line 9,586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289229 HSALNT0289229] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289229 HSALNT0289229] | ||
| − | |RAMP2-AS1 | + | |[[RAMP2-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,826: | Line 9,594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289591 HSALNT0289591] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289591 HSALNT0289591] | ||
| − | |AK098081 | + | |[[AK098081]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,834: | Line 9,602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289644 HSALNT0289644] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289644 HSALNT0289644] | ||
| − | |BC037331 | + | |[[BC037331]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,842: | Line 9,610: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289646 HSALNT0289646] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289646 HSALNT0289646] | ||
| − | |BC040303 | + | |[[BC040303]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,850: | Line 9,618: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289717 HSALNT0289717] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289717 HSALNT0289717] | ||
| − | |CR749831 | + | |[[CR749831]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,858: | Line 9,626: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289250 HSALNT0289250] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289250 HSALNT0289250] | ||
| − | |SNHG18 | + | |[[SNHG18]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,866: | Line 9,634: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0106140 HSALNT0106140] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0106140 HSALNT0106140] | ||
| − | |FOXP4-AS1 | + | |[[FOXP4-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,874: | Line 9,642: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0026202 HSALNT0026202] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0026202 HSALNT0026202] | ||
| − | |RNASEH1-AS1 | + | |[[RNASEH1-AS1]] |
|LOC100506054 | |LOC100506054 | ||
|NA | |NA | ||
| Line 9,882: | Line 9,650: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288993 HSALNT0288993] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288993 HSALNT0288993] | ||
| − | |GSEC | + | |[[GSEC]] |
|ST3GAL4-AS1,DCPS-AS1,FLJ39051 | |ST3GAL4-AS1,DCPS-AS1,FLJ39051 | ||
|NA | |NA | ||
| Line 9,890: | Line 9,658: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0060264 HSALNT0060264] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0060264 HSALNT0060264] | ||
| − | |DNAJB8-AS1 | + | |[[DNAJB8-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,898: | Line 9,666: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0248137 HSALNT0248137] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0248137 HSALNT0248137] | ||
| − | |CHMP1B-AS1 | + | |[[CHMP1B-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,906: | Line 9,674: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0021970 HSALNT0021970] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0021970 HSALNT0021970] | ||
| − | |TGFB2-AS1 | + | |[[TGFB2-AS1]] |
|NR_046268 | |NR_046268 | ||
|NA | |NA | ||
| Line 9,914: | Line 9,682: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0078323 HSALNT0078323] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0078323 HSALNT0078323] | ||
| − | |SLC7A11-AS1 | + | |[[SLC7A11-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,922: | Line 9,690: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0134663 HSALNT0134663] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0134663 HSALNT0134663] | ||
| − | |INTS9-AS1 | + | |[[INTS9-AS1]] |
|ENST00000520055 | |ENST00000520055 | ||
|NA | |NA | ||
| Line 9,930: | Line 9,698: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0231572 HSALNT0231572] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0231572 HSALNT0231572] | ||
| − | |MMP2-AS1 | + | |[[MMP2-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,938: | Line 9,706: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0267869 HSALNT0267869] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0267869 HSALNT0267869] | ||
| − | |SLC12A5-AS1 | + | |[[SLC12A5-AS1]] |
|RP11-465L10.10 | |RP11-465L10.10 | ||
|NA | |NA | ||
| Line 9,946: | Line 9,714: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288921 HSALNT0288921] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288921 HSALNT0288921] | ||
| − | |CSMD2-AS1 | + | |[[CSMD2-AS1]] |
|ENST00000434181 | |ENST00000434181 | ||
|NA | |NA | ||
| Line 9,954: | Line 9,722: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288997 HSALNT0288997] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288997 HSALNT0288997] | ||
| − | |HDAC2-AS2 | + | |[[HDAC2-AS2]] |
|ENST00000421891 | |ENST00000421891 | ||
|NA | |NA | ||
| Line 9,962: | Line 9,730: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289012 HSALNT0289012] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289012 HSALNT0289012] | ||
| − | |INO80-AS1 | + | |[[INO80-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,970: | Line 9,738: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289140 HSALNT0289140] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289140 HSALNT0289140] | ||
| − | |LINC02247 | + | |[[LINC02247]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,978: | Line 9,746: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289161 HSALNT0289161] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289161 HSALNT0289161] | ||
| − | |MAGI2-AS3 | + | |[[MAGI2-AS3]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,986: | Line 9,754: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289188 HSALNT0289188] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289188 HSALNT0289188] | ||
| − | |MNX1-AS2 | + | |[[MNX1-AS2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 9,994: | Line 9,762: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289245 HSALNT0289245] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289245 HSALNT0289245] | ||
| − | |SMIM10L2B-AS1 | + | |[[SMIM10L2B-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,002: | Line 9,770: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289407 HSALNT0289407] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289407 HSALNT0289407] | ||
| − | |TGFB3-AS1 | + | |[[TGFB3-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,010: | Line 9,778: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289457 HSALNT0289457] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289457 HSALNT0289457] | ||
| − | |HSD17B3-AS1 | + | |[[HSD17B3-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,018: | Line 9,786: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289919 HSALNT0289919] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289919 HSALNT0289919] | ||
| − | |LINC02246 | + | |[[LINC02246]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,026: | Line 9,794: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289288 HSALNT0289288] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289288 HSALNT0289288] | ||
| − | |ZNF710-AS1 | + | |[[ZNF710-AS1]] |
|ENST00000558334 | |ENST00000558334 | ||
|NA | |NA | ||
| Line 10,034: | Line 9,802: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289266 HSALNT0289266] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289266 HSALNT0289266] | ||
| − | |TDRKH-AS1 | + | |[[TDRKH-AS1]] |
|RP11-98D18.9 | |RP11-98D18.9 | ||
|NA | |NA | ||
| Line 10,042: | Line 9,810: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289128 HSALNT0289128] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289128 HSALNT0289128] | ||
| − | |LINC01952 | + | |[[LINC01952]] |
|AC004854.4 | |AC004854.4 | ||
|NA | |NA | ||
| Line 10,050: | Line 9,818: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290075 HSALNT0290075] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290075 HSALNT0290075] | ||
| − | |NCF4-AS1 | + | |[[NCF4-AS1]] |
|CTA-833B7.2 | |CTA-833B7.2 | ||
|NA | |NA | ||
| Line 10,058: | Line 9,826: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289360 HSALNT0289360] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289360 HSALNT0289360] | ||
| − | |LNCSRLR | + | |[[LNCSRLR]] |
|lncRNA-SRLR | |lncRNA-SRLR | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 10,066: | Line 9,834: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288918 HSALNT0288918] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288918 HSALNT0288918] | ||
| − | |CFLAR-AS1 | + | |[[CFLAR-AS1]] |
|ALS2CR10 | |ALS2CR10 | ||
|NA | |NA | ||
| Line 10,074: | Line 9,842: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289710 HSALNT0289710] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289710 HSALNT0289710] | ||
| − | |COL1A2-AS1 | + | |[[COL1A2-AS1]] |
|TCONS_00013888,lncRNA8975-1 | |TCONS_00013888,lncRNA8975-1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 10,082: | Line 9,850: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0075075 HSALNT0075075] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0075075 HSALNT0075075] | ||
| − | |LNCPRESS2 | + | |[[LNCPRESS2]] |
|lncPRESS2 | |lncPRESS2 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 10,090: | Line 9,858: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0011289 HSALNT0011289] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0011289 HSALNT0011289] | ||
| − | |LINC01930 | + | |[[LINC01930]] |
|EU358092 | |EU358092 | ||
|NA | |NA | ||
| Line 10,098: | Line 9,866: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0097120 HSALNT0097120] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0097120 HSALNT0097120] | ||
| − | |HMMR-AS1 | + | |[[HMMR-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,106: | Line 9,874: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0184498 HSALNT0184498] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0184498 HSALNT0184498] | ||
| − | |CCND2-AS1 | + | |[[CCND2-AS1]] |
|CCND2-AS2 | |CCND2-AS2 | ||
|NA | |NA | ||
| Line 10,114: | Line 9,882: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289045 HSALNT0289045] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289045 HSALNT0289045] | ||
| − | |LINC00578 | + | |[[LINC00578]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,122: | Line 9,890: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288884 HSALNT0288884] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288884 HSALNT0288884] | ||
| − | |ADAMTS9-AS1 | + | |[[ADAMTS9-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,130: | Line 9,898: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0080041 HSALNT0080041] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0080041 HSALNT0080041] | ||
| − | |FAM198B-AS1 | + | |[[FAM198B-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,138: | Line 9,906: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0103007 HSALNT0103007] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0103007 HSALNT0103007] | ||
| − | |LINC00240 | + | |[[LINC00240]] |
|C6orf41,NCRNA00240,bA373D17.1 | |C6orf41,NCRNA00240,bA373D17.1 | ||
|ceRNA | |ceRNA | ||
| Line 10,146: | Line 9,914: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289071 HSALNT0289071] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289071 HSALNT0289071] | ||
| − | |LINC00909 | + | |[[LINC00909]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,154: | Line 9,922: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289509 HSALNT0289509] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289509 HSALNT0289509] | ||
| − | |LINC00680 | + | |[[LINC00680]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,162: | Line 9,930: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0129070 HSALNT0129070] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0129070 HSALNT0129070] | ||
| − | |LINC00513 | + | |[[LINC00513]] |
|AC016831.7 | |AC016831.7 | ||
|NA | |NA | ||
| Line 10,170: | Line 9,938: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289129 HSALNT0289129] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289129 HSALNT0289129] | ||
| − | |LINC02001 | + | |[[LINC02001]] |
|RP11-1094M14.11 | |RP11-1094M14.11 | ||
|NA | |NA | ||
| Line 10,178: | Line 9,946: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289215 HSALNT0289215] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289215 HSALNT0289215] | ||
| − | |POC1B-AS1 | + | |[[POC1B-AS1]] |
|RP11-734K2.4 | |RP11-734K2.4 | ||
|NA | |NA | ||
| Line 10,186: | Line 9,954: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289241 HSALNT0289241] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289241 HSALNT0289241] | ||
| − | |SLC12A9-AS1 | + | |[[SLC12A9-AS1]] |
|RP11-126L15.4 | |RP11-126L15.4 | ||
|NA | |NA | ||
| Line 10,194: | Line 9,962: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289275 HSALNT0289275] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289275 HSALNT0289275] | ||
| − | |TRAM2-AS1 | + | |[[TRAM2-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,202: | Line 9,970: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0002243 HSALNT0002243] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0002243 HSALNT0002243] | ||
| − | | | + | |[[ENST00000457898.1]] |
|ENSG00000226029 | |ENSG00000226029 | ||
|ceRNA | |ceRNA | ||
| Line 10,210: | Line 9,978: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288941 HSALNT0288941] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288941 HSALNT0288941] | ||
| − | |ELF3-AS1 | + | |[[ELF3-AS1]] |
|ENST00000415582 | |ENST00000415582 | ||
|NA | |NA | ||
| Line 10,218: | Line 9,986: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289134 HSALNT0289134] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289134 HSALNT0289134] | ||
| − | |LINC02158 | + | |[[LINC02158]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,226: | Line 9,994: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289350 HSALNT0289350] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289350 HSALNT0289350] | ||
| − | |LINC01671 | + | |[[LINC01671]] |
|BC041455 | |BC041455 | ||
|NA | |NA | ||
| Line 10,234: | Line 10,002: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289124 HSALNT0289124] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289124 HSALNT0289124] | ||
| − | |LINC01684 | + | |[[LINC01684]] |
|lnc-JAM2-6 | |lnc-JAM2-6 | ||
|NA | |NA | ||
| Line 10,242: | Line 10,010: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289036 HSALNT0289036] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289036 HSALNT0289036] | ||
| − | |LINC00365 | + | |[[LINC00365]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,250: | Line 10,018: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289111 HSALNT0289111] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289111 HSALNT0289111] | ||
| − | |LINC01554 | + | |[[LINC01554]] |
|C5orf27,FLJ38821,FIS | |C5orf27,FLJ38821,FIS | ||
|NA | |NA | ||
| Line 10,258: | Line 10,026: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289132 HSALNT0289132] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289132 HSALNT0289132] | ||
| − | |LINC02154 | + | |[[LINC02154]] |
|GS1-600G8.5 | |GS1-600G8.5 | ||
|NA | |NA | ||
| Line 10,266: | Line 10,034: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0137721 HSALNT0137721] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0137721 HSALNT0137721] | ||
| − | |LINC02155 | + | |[[LINC02155]] |
|RP11-705O24.1 | |RP11-705O24.1 | ||
|NA | |NA | ||
| Line 10,274: | Line 10,042: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0225363 HSALNT0225363] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0225363 HSALNT0225363] | ||
| − | |LINC02157 | + | |[[LINC02157]] |
|RP11-327J17.1 | |RP11-327J17.1 | ||
|NA | |NA | ||
| Line 10,282: | Line 10,050: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289133 HSALNT0289133] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289133 HSALNT0289133] | ||
| − | |LINC02156 | + | |[[LINC02156]] |
|RP1-90J4.1 | |RP1-90J4.1 | ||
|NA | |NA | ||
| Line 10,290: | Line 10,058: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0133924 HSALNT0133924] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0133924 HSALNT0133924] | ||
| − | |LINC02153 | + | |[[LINC02153]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,298: | Line 10,066: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0181656 HSALNT0181656] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0181656 HSALNT0181656] | ||
| − | |LINC02151 | + | |[[LINC02151]] |
|TCONS_00019174 | |TCONS_00019174 | ||
|NA | |NA | ||
| Line 10,306: | Line 10,074: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0227367 HSALNT0227367] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0227367 HSALNT0227367] | ||
| − | |LINC02152 | + | |[[LINC02152]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,314: | Line 10,082: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0029246 HSALNT0029246] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0029246 HSALNT0029246] | ||
| − | |BRE-AS1 | + | |[[BRE-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,322: | Line 10,090: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289251 HSALNT0289251] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289251 HSALNT0289251] | ||
| − | |SNHG26 | + | |[[SNHG26]] |
|AC005682.5 | |AC005682.5 | ||
|NA | |NA | ||
| Line 10,330: | Line 10,098: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0252719 HSALNT0252719] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0252719 HSALNT0252719] | ||
| − | |LIVAR | + | |[[LIVAR]] |
|lnc18q22.2 | |lnc18q22.2 | ||
|NA | |NA | ||
| Line 10,338: | Line 10,106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289074 HSALNT0289074] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289074 HSALNT0289074] | ||
| − | |LINC00969 | + | |[[LINC00969]] |
|ENST00000453324 | |ENST00000453324 | ||
|NA | |NA | ||
| Line 10,346: | Line 10,114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289138 HSALNT0289138] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289138 HSALNT0289138] | ||
| − | |LINC02243 | + | |[[LINC02243]] |
|ENST00000441841 | |ENST00000441841 | ||
|NA | |NA | ||
| Line 10,354: | Line 10,122: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289399 HSALNT0289399] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289399 HSALNT0289399] | ||
| − | |SLC9A3-AS1 | + | |[[SLC9A3-AS1]] |
|UC011CLY.2 | |UC011CLY.2 | ||
|NA | |NA | ||
| Line 10,362: | Line 10,130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288934 HSALNT0288934] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288934 HSALNT0288934] | ||
| − | |DM1-AS | + | |[[DM1-AS]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,370: | Line 10,138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0009014 HSALNT0009014] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0009014 HSALNT0009014] | ||
| − | |LINC02238 | + | |[[LINC02238]] |
|RP4-788P17.1 | |RP4-788P17.1 | ||
|NA | |NA | ||
| Line 10,378: | Line 10,146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289163 HSALNT0289163] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289163 HSALNT0289163] | ||
| − | |MEF2C-AS2 | + | |[[MEF2C-AS2]] |
|CTC-467M3.1 | |CTC-467M3.1 | ||
|NA | |NA | ||
| Line 10,386: | Line 10,154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289181 HSALNT0289181] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289181 HSALNT0289181] | ||
| − | |MIR4422HG | + | |[[MIR4422HG]] |
|RP11-101C11.1 | |RP11-101C11.1 | ||
|NA | |NA | ||
| Line 10,394: | Line 10,162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289403 HSALNT0289403] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289403 HSALNT0289403] | ||
| − | |SPON1-AS1 | + | |[[SPON1-AS1]] |
|RP11-21,L19.1 | |RP11-21,L19.1 | ||
|NA | |NA | ||
| Line 10,402: | Line 10,170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289461 HSALNT0289461] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289461 HSALNT0289461] | ||
| − | |CD44-AS1 | + | |[[CD44-AS1]] |
|RP1-68D18.4 | |RP1-68D18.4 | ||
|NA | |NA | ||
| Line 10,410: | Line 10,178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0262277 HSALNT0262277] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0262277 HSALNT0262277] | ||
| − | |LILRB1-AS1 | + | |[[LILRB1-AS1]] |
|AC009892.10 | |AC009892.10 | ||
|NA | |NA | ||
| Line 10,417: | Line 10,185: | ||
|NA | |NA | ||
|- | |- | ||
| − | |[https://bigd.big.ac.cn/lncbook/transcript?transid= | + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0282241 HSALNT0282241] |
| − | | | + | |[[LINC01186]] |
| − | |||
|NA | |NA | ||
|NA | |NA | ||
| − | + | |pathogenic process | |
| − | + | |lung cancer | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |pathogenic process | ||
| − | |lung cancer | ||
|Respiratory Tract Diseases;Neoplasms | |Respiratory Tract Diseases;Neoplasms | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289168 HSALNT0289168] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289168 HSALNT0289168] | ||
| − | |MHENCR | + | |[[MHENCR]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 10,442: | Line 10,202: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0072994 HSALNT0072994] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0072994 HSALNT0072994] | ||
| − | |LINC02232 | + | |[[LINC02232]] |
|RP11-707A18.1 | |RP11-707A18.1 | ||
|NA | |NA | ||
| Line 10,450: | Line 10,210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0080161 HSALNT0080161] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0080161 HSALNT0080161] | ||
| − | |LINC02233 | + | |[[LINC02233]] |
|RP11-6C14.1 | |RP11-6C14.1 | ||
|NA | |NA | ||
| Line 10,458: | Line 10,218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0084027 HSALNT0084027] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0084027 HSALNT0084027] | ||
| − | |LINC02236 | + | |[[LINC02236]] |
|RP11-332J15.1 | |RP11-332J15.1 | ||
|NA | |NA | ||
| Line 10,466: | Line 10,226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0091870 HSALNT0091870] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0091870 HSALNT0091870] | ||
| − | |LINC02234 | + | |[[LINC02234]] |
|RP11-455B3.1 | |RP11-455B3.1 | ||
|NA | |NA | ||
| Line 10,474: | Line 10,234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0139521 HSALNT0139521] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0139521 HSALNT0139521] | ||
| − | |LINC02235 | + | |[[LINC02235]] |
|RP11-354A14.1 | |RP11-354A14.1 | ||
|NA | |NA | ||
| Line 10,482: | Line 10,242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0142040 HSALNT0142040] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0142040 HSALNT0142040] | ||
| − | |LINC02237 | + | |[[LINC02237]] |
|RP11-1101K5.1 | |RP11-1101K5.1 | ||
|NA | |NA | ||
| Line 10,490: | Line 10,250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289135 HSALNT0289135] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289135 HSALNT0289135] | ||
| − | |LINC02179 | + | |[[LINC02179]] |
|RP11-189E14.4 | |RP11-189E14.4 | ||
|NA | |NA | ||
| Line 10,498: | Line 10,258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289351 HSALNT0289351] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289351 HSALNT0289351] | ||
| − | |LINC01689 | + | |[[LINC01689]] |
|AP000469.2 | |AP000469.2 | ||
|NA | |NA | ||
| Line 10,506: | Line 10,266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289137 HSALNT0289137] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289137 HSALNT0289137] | ||
| − | |LINC02231 | + | |[[LINC02231]] |
|RP11-766N7.4 | |RP11-766N7.4 | ||
|NA | |NA | ||
| Line 10,514: | Line 10,274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0220239 HSALNT0220239] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0220239 HSALNT0220239] | ||
| − | |MIR4713HG | + | |[[MIR4713HG]] |
|RP11-108K3.1 | |RP11-108K3.1 | ||
|NA | |NA | ||
| Line 10,522: | Line 10,282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288967 HSALNT0288967] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288967 HSALNT0288967] | ||
| − | |FAM160A1-DT | + | |[[FAM160A1-DT]] |
|RP11-610P16.1 | |RP11-610P16.1 | ||
|NA | |NA | ||
| Line 10,530: | Line 10,290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289239 HSALNT0289239] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289239 HSALNT0289239] | ||
| − | |SATB2-AS1 | + | |[[SATB2-AS1]] |
|NA | |NA | ||
|translational control | |translational control | ||
| Line 10,538: | Line 10,298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289512 HSALNT0289512] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289512 HSALNT0289512] | ||
| − | |LINC01826 | + | |[[LINC01826]] |
|lnc-MKI67IP-3 | |lnc-MKI67IP-3 | ||
|ceRNA | |ceRNA | ||
| Line 10,546: | Line 10,306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289024 HSALNT0289024] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289024 HSALNT0289024] | ||
| − | |LINC00226 | + | |[[LINC00226]] |
|C14orf97,NCRNA00226 | |C14orf97,NCRNA00226 | ||
|NA | |NA | ||
| Line 10,554: | Line 10,314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0082192 HSALNT0082192] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0082192 HSALNT0082192] | ||
| − | |F11-AS1 | + | |[[F11-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,562: | Line 10,322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0219108 HSALNT0219108] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0219108 HSALNT0219108] | ||
| − | |SPINT1-AS1 | + | |[[SPINT1-AS1]] |
|RP11-532F12.5 | |RP11-532F12.5 | ||
|NA | |NA | ||
| Line 10,570: | Line 10,330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289177 HSALNT0289177] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289177 HSALNT0289177] | ||
| − | |MIR200CHG | + | |[[MIR200CHG]] |
|U47924.27 | |U47924.27 | ||
|NA | |NA | ||
| Line 10,578: | Line 10,338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289328 HSALNT0289328] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289328 HSALNT0289328] | ||
| − | |LINC00888 | + | |[[LINC00888]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,586: | Line 10,346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289309 HSALNT0289309] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289309 HSALNT0289309] | ||
| − | |LINC00672 | + | |[[LINC00672]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 10,594: | Line 10,354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289198 HSALNT0289198] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289198 HSALNT0289198] | ||
| − | |P4HA3-AS1 | + | |[[P4HA3-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,602: | Line 10,362: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0197312 HSALNT0197312] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0197312 HSALNT0197312] | ||
| − | |TMEM132D-AS1 | + | |[[TMEM132D-AS1]] |
|LOC283352 | |LOC283352 | ||
|NA | |NA | ||
| Line 10,610: | Line 10,370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289472 HSALNT0289472] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289472 HSALNT0289472] | ||
| − | |ATP2C2-AS1 | + | |[[ATP2C2-AS1]] |
|RP11-517C16.2-001 | |RP11-517C16.2-001 | ||
|NA | |NA | ||
| Line 10,618: | Line 10,378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0233849 HSALNT0233849] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0233849 HSALNT0233849] | ||
| − | |WWOX-AS1 | + | |[[WWOX-AS1]] |
|RP11-190D6.2 | |RP11-190D6.2 | ||
|NA | |NA | ||
| Line 10,626: | Line 10,386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0128829 HSALNT0128829] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0128829 HSALNT0128829] | ||
| − | |FLNC-AS1 | + | |[[FLNC-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,634: | Line 10,394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289889 HSALNT0289889] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289889 HSALNT0289889] | ||
| − | |LIF-AS1 | + | |[[LIF-AS1]] |
|Lnc-LIF-AS | |Lnc-LIF-AS | ||
|NA | |NA | ||
| Line 10,642: | Line 10,402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0011283 HSALNT0011283] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0011283 HSALNT0011283] | ||
| − | |DPYD-AS2 | + | |[[DPYD-AS2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,650: | Line 10,410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289836 HSALNT0289836] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289836 HSALNT0289836] | ||
| − | |FLICR | + | |[[FLICR]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 10,658: | Line 10,418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289356 HSALNT0289356] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289356 HSALNT0289356] | ||
| − | |LINC02402 | + | |[[LINC02402]] |
|ENST00000550337.1 | |ENST00000550337.1 | ||
|NA | |NA | ||
| Line 10,666: | Line 10,426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0137118 HSALNT0137118] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0137118 HSALNT0137118] | ||
| − | |CERNA3 | + | |[[CERNA3]] |
|CTA | |CTA | ||
|ceRNA | |ceRNA | ||
| Line 10,674: | Line 10,434: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0090838 HSALNT0090838] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0090838 HSALNT0090838] | ||
| − | |LINC02488 | + | |[[LINC02488]] |
|CTD-2316B1 | |CTD-2316B1 | ||
|NA | |NA | ||
| Line 10,682: | Line 10,442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0174947 HSALNT0174947] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0174947 HSALNT0174947] | ||
| − | |LINC02489 | + | |[[LINC02489]] |
|CTD-2589M5 | |CTD-2589M5 | ||
|NA | |NA | ||
| Line 10,690: | Line 10,450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0220441 HSALNT0220441] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0220441 HSALNT0220441] | ||
| − | |LINC02490 | + | |[[LINC02490]] |
|RP11-209E8 | |RP11-209E8 | ||
|NA | |NA | ||
| Line 10,698: | Line 10,458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289260 HSALNT0289260] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289260 HSALNT0289260] | ||
| − | |STK32A-AS1 | + | |[[STK32A-AS1]] |
|CTC-255N20 | |CTC-255N20 | ||
|NA | |NA | ||
| Line 10,706: | Line 10,466: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289143 HSALNT0289143] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289143 HSALNT0289143] | ||
| − | |LINC02487 | + | |[[LINC02487]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,714: | Line 10,474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0095585 HSALNT0095585] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0095585 HSALNT0095585] | ||
| − | |SPRY4-AS1 | + | |[[SPRY4-AS1]] |
|THCAT68 | |THCAT68 | ||
|NA | |NA | ||
| Line 10,722: | Line 10,482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288927 HSALNT0288927] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288927 HSALNT0288927] | ||
| − | |DDN-AS1 | + | |[[DDN-AS1]] |
|CAT1507 | |CAT1507 | ||
|NA | |NA | ||
| Line 10,730: | Line 10,490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0012862 HSALNT0012862] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0012862 HSALNT0012862] | ||
| − | |SLC16A1-AS1 | + | |[[SLC16A1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,738: | Line 10,498: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289412 HSALNT0289412] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289412 HSALNT0289412] | ||
| − | |TNFRSF14-AS1 | + | |[[TNFRSF14-AS1]] |
|ENST00000416860.2 | |ENST00000416860.2 | ||
|NA | |NA | ||
| Line 10,746: | Line 10,506: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0259139 HSALNT0259139] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0259139 HSALNT0259139] | ||
| − | |LINC00665 | + | |[[LINC00665]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,754: | Line 10,514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0040268 HSALNT0040268] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0040268 HSALNT0040268] | ||
| − | |DARS-AS1 | + | |[[DARS-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,762: | Line 10,522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288913 HSALNT0288913] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288913 HSALNT0288913] | ||
| − | |CEBPA-AS1 | + | |[[CEBPA-AS1]] |
|CEBPA-DT | |CEBPA-DT | ||
|NA | |NA | ||
| Line 10,770: | Line 10,530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289011 HSALNT0289011] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289011 HSALNT0289011] | ||
| − | |INHBA-AS1 | + | |[[INHBA-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,778: | Line 10,538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288988 HSALNT0288988] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288988 HSALNT0288988] | ||
| − | |GASAL1 | + | |[[GASAL1]] |
|GASL1 | |GASL1 | ||
|NA | |NA | ||
| Line 10,786: | Line 10,546: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289127 HSALNT0289127] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289127 HSALNT0289127] | ||
| − | |LINC01857 | + | |[[LINC01857]] |
|AC079767.4 | |AC079767.4 | ||
|NA | |NA | ||
| Line 10,794: | Line 10,554: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289091 HSALNT0289091] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289091 HSALNT0289091] | ||
| − | |LINC01140 | + | |[[LINC01140]] |
|FLJ41676 | |FLJ41676 | ||
|NA | |NA | ||
| Line 10,802: | Line 10,562: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0281957 HSALNT0281957] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0281957 HSALNT0281957] | ||
| − | |PINCR | + | |[[PINCR]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 10,810: | Line 10,570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289344 HSALNT0289344] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289344 HSALNT0289344] | ||
| − | |LINC00890 | + | |[[LINC00890]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,818: | Line 10,578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0019828 HSALNT0019828] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0019828 HSALNT0019828] | ||
| − | |LINC00862 | + | |[[LINC00862]] |
|C1orf98,SMIM16 | |C1orf98,SMIM16 | ||
|NA | |NA | ||
| Line 10,826: | Line 10,586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0073790 HSALNT0073790] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0073790 HSALNT0073790] | ||
| − | |LINC02562 | + | |[[LINC02562]] |
|RP11-44F21.5 | |RP11-44F21.5 | ||
|NA | |NA | ||
| Line 10,834: | Line 10,594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0263101 HSALNT0263101] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0263101 HSALNT0263101] | ||
| − | |LINC02560 | + | |[[LINC02560]] |
|CTD-2619J13.13 | |CTD-2619J13.13 | ||
|NA | |NA | ||
| Line 10,842: | Line 10,602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289144 HSALNT0289144] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289144 HSALNT0289144] | ||
| − | |LINC02551 | + | |[[LINC02551]] |
|RP11-890B15.2 | |RP11-890B15.2 | ||
|NA | |NA | ||
| Line 10,850: | Line 10,610: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289458 HSALNT0289458] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289458 HSALNT0289458] | ||
| − | |DDIT4-AS1 | + | |[[DDIT4-AS1]] |
|RP11-442H21.2 | |RP11-442H21.2 | ||
|NA | |NA | ||
| Line 10,858: | Line 10,618: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288992 HSALNT0288992] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288992 HSALNT0288992] | ||
| − | |GPRC5D-AS1 | + | |[[GPRC5D-AS1]] |
|RP11-392P7.6 | |RP11-392P7.6 | ||
|NA | |NA | ||
| Line 10,866: | Line 10,626: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289386 HSALNT0289386] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289386 HSALNT0289386] | ||
| − | |PCBP1-AS1 | + | |[[PCBP1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,874: | Line 10,634: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289405 HSALNT0289405] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289405 HSALNT0289405] | ||
| − | |STARD4-AS1 | + | |[[STARD4-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,882: | Line 10,642: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0201547 HSALNT0201547] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0201547 HSALNT0201547] | ||
| − | |LINC00462 | + | |[[LINC00462]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,890: | Line 10,650: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0207103 HSALNT0207103] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0207103 HSALNT0207103] | ||
| − | |SOX1-OT | + | |[[SOX1-OT]] |
|LINC00403 | |LINC00403 | ||
|NA | |NA | ||
| Line 10,898: | Line 10,658: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0002131 HSALNT0002131] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0002131 HSALNT0002131] | ||
| − | |SLC25A34-AS1 | + | |[[SLC25A34-AS1]] |
|RP11-169K16.4 | |RP11-169K16.4 | ||
|NA | |NA | ||
| Line 10,906: | Line 10,666: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289218 HSALNT0289218] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289218 HSALNT0289218] | ||
| − | |PPP1R26-AS1 | + | |[[PPP1R26-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,914: | Line 10,674: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289047 HSALNT0289047] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289047 HSALNT0289047] | ||
| − | |LINC00589 | + | |[[LINC00589]] |
|C8orf75,TSLNC8 | |C8orf75,TSLNC8 | ||
|NA | |NA | ||
| Line 10,922: | Line 10,682: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289516 HSALNT0289516] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289516 HSALNT0289516] | ||
| − | |TPM1-AS | + | |[[TPM1-AS]] |
|TPM1-AS1 | |TPM1-AS1 | ||
|splicing regulation | |splicing regulation | ||
| Line 10,930: | Line 10,690: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289314 HSALNT0289314] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289314 HSALNT0289314] | ||
| − | |LINC01101 | + | |[[LINC01101]] |
|FLJ14816 | |FLJ14816 | ||
|NA | |NA | ||
| Line 10,938: | Line 10,698: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289147 HSALNT0289147] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289147 HSALNT0289147] | ||
| − | |LINC02572 | + | |[[LINC02572]] |
|AC079776.2 | |AC079776.2 | ||
|NA | |NA | ||
| Line 10,946: | Line 10,706: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0096804 HSALNT0096804] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0096804 HSALNT0096804] | ||
| − | |LINC02202 | + | |[[LINC02202]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,954: | Line 10,714: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289076 HSALNT0289076] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289076 HSALNT0289076] | ||
| − | |LINC00973 | + | |[[LINC00973]] |
|CTD-2021J15.2 | |CTD-2021J15.2 | ||
|NA | |NA | ||
| Line 10,962: | Line 10,722: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288625 HSALNT0288625] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288625 HSALNT0288625] | ||
| − | |TTTY10 | + | |[[TTTY10]] |
|NCRNA00133 | |NCRNA00133 | ||
|NA | |NA | ||
| Line 10,970: | Line 10,730: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289323 HSALNT0289323] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289323 HSALNT0289323] | ||
| − | |LINC00319 | + | |[[LINC00319]] |
|C21orf125,NCRNA00319,PRED49,FLJ38036 | |C21orf125,NCRNA00319,PRED49,FLJ38036 | ||
|ceRNA | |ceRNA | ||
| Line 10,978: | Line 10,738: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0015533 HSALNT0015533] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0015533 HSALNT0015533] | ||
| − | |IL6R-AS1 | + | |[[IL6R-AS1]] |
|RP11-350G8.5 | |RP11-350G8.5 | ||
|NA | |NA | ||
| Line 10,986: | Line 10,746: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0090330 HSALNT0090330] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0090330 HSALNT0090330] | ||
| − | |CKMT2-AS1 | + | |[[CKMT2-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 10,994: | Line 10,754: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0012995 HSALNT0012995] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0012995 HSALNT0012995] | ||
| − | |HIPK1-AS1 | + | |[[HIPK1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,002: | Line 10,762: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289216 HSALNT0289216] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289216 HSALNT0289216] | ||
| − | |POLH-AS1 | + | |[[POLH-AS1]] |
|RP3-337H4.8 | |RP3-337H4.8 | ||
|NA | |NA | ||
| Line 11,010: | Line 10,770: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289276 HSALNT0289276] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289276 HSALNT0289276] | ||
| − | |TRDN-AS1 | + | |[[TRDN-AS1]] |
|HRAT13 | |HRAT13 | ||
|NA | |NA | ||
| Line 11,018: | Line 10,778: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289159 HSALNT0289159] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289159 HSALNT0289159] | ||
| − | |LY6E-DT | + | |[[LY6E-DT]] |
|LOC100133669 | |LOC100133669 | ||
|NA | |NA | ||
| Line 11,024: | Line 10,784: | ||
|ovarian cancer | |ovarian cancer | ||
|Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms | |Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288991 HSALNT0288991] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288991 HSALNT0288991] | ||
| − | |GLIS3-AS1 | + | |[[GLIS3-AS1]] |
|C9orf70,MGC16153 | |C9orf70,MGC16153 | ||
|NA | |NA | ||
| Line 11,042: | Line 10,794: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288896 HSALNT0288896] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288896 HSALNT0288896] | ||
| − | |BNC2-AS1 | + | |[[BNC2-AS1]] |
|RP11-62F24.2 | |RP11-62F24.2 | ||
|NA | |NA | ||
| Line 11,050: | Line 10,802: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289292 HSALNT0289292] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289292 HSALNT0289292] | ||
| − | |ZNF503-AS1 | + | |[[ZNF503-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,058: | Line 10,810: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0159506 HSALNT0159506] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0159506 HSALNT0159506] | ||
| − | |VIM-AS1 | + | |[[VIM-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,066: | Line 10,818: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288882 HSALNT0288882] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288882 HSALNT0288882] | ||
| − | |ACBD3-AS1 | + | |[[ACBD3-AS1]] |
|RP11-275I14.4 | |RP11-275I14.4 | ||
|NA | |NA | ||
| Line 11,074: | Line 10,826: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289156 HSALNT0289156] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289156 HSALNT0289156] | ||
| − | |LRRC8C-DT | + | |[[LRRC8C-DT]] |
|FLJ27354 | |FLJ27354 | ||
|NA | |NA | ||
| Line 11,082: | Line 10,834: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289447 HSALNT0289447] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289447 HSALNT0289447] | ||
| − | |ELN-AS1 | + | |[[ELN-AS1]] |
|CTB-51J22.1 | |CTB-51J22.1 | ||
|NA | |NA | ||
| Line 11,090: | Line 10,842: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0076712 HSALNT0076712] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0076712 HSALNT0076712] | ||
| − | |LINC02264 | + | |[[LINC02264]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,098: | Line 10,850: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0093666 HSALNT0093666] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0093666 HSALNT0093666] | ||
| − | |LINC02201 | + | |[[LINC02201]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,106: | Line 10,858: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0271685 HSALNT0271685] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0271685 HSALNT0271685] | ||
| − | |LINC02573 | + | |[[LINC02573]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,114: | Line 10,866: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289125 HSALNT0289125] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289125 HSALNT0289125] | ||
| − | |LINC01816 | + | |[[LINC01816]] |
|LOC100133985 | |LOC100133985 | ||
|NA | |NA | ||
| Line 11,122: | Line 10,874: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289355 HSALNT0289355] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289355 HSALNT0289355] | ||
| − | |LINC02381 | + | |[[LINC02381]] |
|LOC400043 | |LOC400043 | ||
|NA | |NA | ||
| Line 11,130: | Line 10,882: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289366 HSALNT0289366] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289366 HSALNT0289366] | ||
| − | |MBNL1-AS1 | + | |[[MBNL1-AS1]] |
|LOC401093 | |LOC401093 | ||
|NA | |NA | ||
| Line 11,138: | Line 10,890: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289513 HSALNT0289513] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289513 HSALNT0289513] | ||
| − | |MIR4697HG | + | |[[MIR4697HG]] |
|LINC00947,LOC283174 | |LINC00947,LOC283174 | ||
|NA | |NA | ||
| Line 11,146: | Line 10,898: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289073 HSALNT0289073] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289073 HSALNT0289073] | ||
| − | |LINC00968 | + | |[[LINC00968]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,154: | Line 10,906: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0114453 HSALNT0114453] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0114453 HSALNT0114453] | ||
| − | |NMBR-AS1 | + | |[[NMBR-AS1]] |
|RP11-137J7.2 | |RP11-137J7.2 | ||
|NA | |NA | ||
| Line 11,162: | Line 10,914: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289300 HSALNT0289300] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289300 HSALNT0289300] | ||
| − | |LINC01518 | + | |[[LINC01518]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,170: | Line 10,922: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0003783 HSALNT0003783] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0003783 HSALNT0003783] | ||
| − | |LINC02574 | + | |[[LINC02574]] |
|RP11-288L9.1 | |RP11-288L9.1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,176: | Line 10,928: | ||
|UVB-irradiated KC & non-melanoma skin cancer | |UVB-irradiated KC & non-melanoma skin cancer | ||
|Skin and Connective Tissue Diseases;Neoplasms | |Skin and Connective Tissue Diseases;Neoplasms | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0030828 HSALNT0030828] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0030828 HSALNT0030828] | ||
| − | |LINC02580 | + | |[[LINC02580]] |
|AC093609.1 | |AC093609.1 | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|NA | |NA | ||
|pathogenic process | |pathogenic process | ||
| Line 11,202: | Line 10,938: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0127022 HSALNT0127022] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0127022 HSALNT0127022] | ||
| − | |LINC02577 | + | |[[LINC02577]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,210: | Line 10,946: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0154722 HSALNT0154722] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0154722 HSALNT0154722] | ||
| − | |LINC02578 | + | |[[LINC02578]] |
|RP11-127L21.1 | |RP11-127L21.1 | ||
|NA | |NA | ||
| Line 11,218: | Line 10,954: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288962 HSALNT0288962] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288962 HSALNT0288962] | ||
| − | |FAM111A-DT | + | |[[FAM111A-DT]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,226: | Line 10,962: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289148 HSALNT0289148] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289148 HSALNT0289148] | ||
| − | |LINC02575 | + | |[[LINC02575]] |
|AP001065.15 | |AP001065.15 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,232: | Line 10,968: | ||
|UVB-irradiated KC & non-melanoma skin cancer | |UVB-irradiated KC & non-melanoma skin cancer | ||
|Skin and Connective Tissue Diseases;Neoplasms | |Skin and Connective Tissue Diseases;Neoplasms | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0177212 HSALNT0177212] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0177212 HSALNT0177212] | ||
| − | |RPS6KB2-AS1 | + | |[[RPS6KB2-AS1]] |
|AP003419.16 | |AP003419.16 | ||
|NA | |NA | ||
| Line 11,250: | Line 10,978: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289072 HSALNT0289072] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289072 HSALNT0289072] | ||
| − | |LINC00941 | + | |[[LINC00941]] |
|lncRNA-MUF | |lncRNA-MUF | ||
|ceRNA | |ceRNA | ||
| Line 11,258: | Line 10,986: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289338 HSALNT0289338] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289338 HSALNT0289338] | ||
| − | |LINC00094 | + | |[[LINC00094]] |
|FLJ35348,bA374P20.3 | |FLJ35348,bA374P20.3 | ||
|NA | |NA | ||
| Line 11,266: | Line 10,994: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0114192 HSALNT0114192] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0114192 HSALNT0114192] | ||
| − | |FILNC1 | + | |[[FILNC1]] |
|NA | |NA | ||
|translational control | |translational control | ||
| Line 11,274: | Line 11,002: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289199 HSALNT0289199] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289199 HSALNT0289199] | ||
| − | |PARAL1 | + | |[[PARAL1]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 11,280: | Line 11,008: | ||
|obesity | |obesity | ||
|Pathological Conditions, Signs and Symptoms;Nutritional and Metabolic Diseases;Physiological Phenomena | |Pathological Conditions, Signs and Symptoms;Nutritional and Metabolic Diseases;Physiological Phenomena | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0056667 HSALNT0056667] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0056667 HSALNT0056667] | ||
| − | |LINC02027 | + | |[[LINC02027]] |
|LOC728290 | |LOC728290 | ||
|NA | |NA | ||
| Line 11,304: | Line 11,016: | ||
|hepatocellular cancer | |hepatocellular cancer | ||
|Neoplasms;Digestive System Diseases | |Neoplasms;Digestive System Diseases | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289069 HSALNT0289069] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289069 HSALNT0289069] | ||
| − | |LINC00880 | + | |[[LINC00880]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,322: | Line 11,026: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0252974 HSALNT0252974] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0252974 HSALNT0252974] | ||
| − | |LINC02582 | + | |[[LINC02582]] |
|CTD-2354A18.1 | |CTD-2354A18.1 | ||
|NA | |NA | ||
| Line 11,330: | Line 11,034: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289035 HSALNT0289035] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289035 HSALNT0289035] | ||
| − | |LINC00364 | + | |[[LINC00364]] |
|LncRNA00364 | |LncRNA00364 | ||
|NA | |NA | ||
| Line 11,338: | Line 11,042: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0060981 HSALNT0060981] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0060981 HSALNT0060981] | ||
| − | |NCK1-DT | + | |[[NCK1-DT]] |
|NCK1-AS1,SLC35G2-AS1 | |NCK1-AS1,SLC35G2-AS1 | ||
|ceRNA | |ceRNA | ||
| Line 11,346: | Line 11,050: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288890 HSALNT0288890] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288890 HSALNT0288890] | ||
| − | |BAALC-AS1 | + | |[[BAALC-AS1]] |
|lncFZD6,FZD6-DT | |lncFZD6,FZD6-DT | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,354: | Line 11,058: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0046602 HSALNT0046602] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0046602 HSALNT0046602] | ||
| − | |CPS1-IT1 | + | |[[CPS1-IT1]] |
|CPS1-IT,CPS1IT,CPS1IT1,PRO0132 | |CPS1-IT,CPS1IT,CPS1IT1,PRO0132 | ||
|NA | |NA | ||
| Line 11,362: | Line 11,066: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289445 HSALNT0289445] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289445 HSALNT0289445] | ||
| − | |DLX6-AS1 | + | |[[DLX6-AS1]] |
|DLX6-A, DLX6A, Evf-2,NCRNA00212,NCRNA00212,FLJ34048 | |DLX6-A, DLX6A, Evf-2,NCRNA00212,NCRNA00212,FLJ34048 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,370: | Line 11,074: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289891 HSALNT0289891] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289891 HSALNT0289891] | ||
| − | |LINC00114 | + | |[[LINC00114]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,378: | Line 11,082: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289415 HSALNT0289415] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289415 HSALNT0289415] | ||
| − | |TSIX | + | |[[TSIX]] |
|LINC00013,NCRNA00013,XIST-A, XIST-AS1,XISTAS | |LINC00013,NCRNA00013,XIST-A, XIST-AS1,XISTAS | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,386: | Line 11,090: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0217334 HSALNT0217334] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0217334 HSALNT0217334] | ||
| − | |MKRN3-AS1 | + | |[[MKRN3-AS1]] |
|ZNF127A, MKRN3A, MKRN3-A,FNZ127,NCRNA00009,ZNF127-AS | |ZNF127A, MKRN3A, MKRN3-A,FNZ127,NCRNA00009,ZNF127-AS | ||
|NA | |NA | ||
| Line 11,394: | Line 11,098: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290256 HSALNT0290256] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290256 HSALNT0290256] | ||
| − | | | + | |[[Lnc-SRA1-1:1]] |
|lnc-SRA1-1:1,SRA1,ENSG00000213523 | |lnc-SRA1-1:1,SRA1,ENSG00000213523 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,402: | Line 11,106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289442 HSALNT0289442] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289442 HSALNT0289442] | ||
| − | |HCP5 | + | |[[HCP5]] |
|6S2650E,D6S2650E,P5-1 | |6S2650E,D6S2650E,P5-1 | ||
|NA | |NA | ||
| Line 11,410: | Line 11,114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289284 HSALNT0289284] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289284 HSALNT0289284] | ||
| − | | | + | |[[Lnc-EIF3M-1:1]] |
|WIT1,WIT-1,WT1A, WT1-AS1 | |WIT1,WIT-1,WT1A, WT1-AS1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,418: | Line 11,122: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289421 HSALNT0289421] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289421 HSALNT0289421] | ||
| − | | | + | |[[NONHSAT017524]] |
|KCNQ1-AS2,KCNQ10T1,Kncq1,KvDMR1,KvLQT1-A, LIT1,NCRNA00012 | |KCNQ1-AS2,KCNQ10T1,Kncq1,KvDMR1,KvLQT1-A, LIT1,NCRNA00012 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,426: | Line 11,130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0263784 HSALNT0263784] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0263784 HSALNT0263784] | ||
| − | |PCNA-AS1 | + | |[[PCNA-AS1]] |
|PCNAA, PCNA-AS | |PCNAA, PCNA-AS | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,434: | Line 11,138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289524 HSALNT0289524] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289524 HSALNT0289524] | ||
| − | |HCG9 | + | |[[HCG9]] |
|PERB11,HCGIX,HCGIX4,HCGIX-4 | |PERB11,HCGIX,HCGIX4,HCGIX-4 | ||
|NA | |NA | ||
| Line 11,442: | Line 11,146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289264 HSALNT0289264] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289264 HSALNT0289264] | ||
| − | |TCL6 | + | |[[TCL6]] |
|TCL6e1,TNG2,TNG1 | |TCL6e1,TNG2,TNG1 | ||
|NA | |NA | ||
| Line 11,450: | Line 11,154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289203 HSALNT0289203] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289203 HSALNT0289203] | ||
| − | | | + | |[[ENST00000412654.1]] |
|DD3,NCRNA00019,PCAT3 | |DD3,NCRNA00019,PCAT3 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 11,458: | Line 11,162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289462 HSALNT0289462] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289462 HSALNT0289462] | ||
| − | | | + | |[[NONHSAT017465]] |
|ASM,ASM1,BW, D11S813E,LINC00008,NCRNA00008,WT2 | |ASM,ASM1,BW, D11S813E,LINC00008,NCRNA00008,WT2 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 11,466: | Line 11,170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288932 HSALNT0288932] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288932 HSALNT0288932] | ||
| − | | | + | |[[NONHSAT033797]] |
|BCM, BCMS1,DLB1,LEU1,LEU2,LINC00021,NCRNA00021,XTP6 | |BCM, BCMS1,DLB1,LEU1,LEU2,LINC00021,NCRNA00021,XTP6 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 11,474: | Line 11,178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289493 HSALNT0289493] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289493 HSALNT0289493] | ||
| − | |DBH-AS1 | + | |[[DBH-AS1]] |
|NCRNA00118,BPR | |NCRNA00118,BPR | ||
|NA | |NA | ||
| Line 11,482: | Line 11,186: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0088415 HSALNT0088415] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0088415 HSALNT0088415] | ||
| − | | | + | |[[ENST00000506884.1]] |
|DKFZP586D0823,NCRNA00206 | |DKFZP586D0823,NCRNA00206 | ||
|NA | |NA | ||
| Line 11,490: | Line 11,194: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289463 HSALNT0289463] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289463 HSALNT0289463] | ||
| − | |IGF2-AS | + | |[[IGF2-AS]] |
|IGF2A,PEG8,IGF2-AS1 | |IGF2A,PEG8,IGF2-AS1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,498: | Line 11,202: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0269786 HSALNT0269786] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0269786 HSALNT0269786] | ||
| − | | | + | |[[Lnc-CTSZ-5:1]] |
|GNASA, GNAS-A,SANG,NESP-A, NESPA, GNAS1A, NCRNA00075 | |GNASA, GNAS-A,SANG,NESP-A, NESPA, GNAS1A, NCRNA00075 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,506: | Line 11,210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289252 HSALNT0289252] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289252 HSALNT0289252] | ||
| − | | | + | |[[NONHSAT054526]] |
|C6orf160,MGC16362,bA33E24.2,U50HG,NCRNA00044,LINC00044 | |C6orf160,MGC16362,bA33E24.2,U50HG,NCRNA00044,LINC00044 | ||
|NA | |NA | ||
| Line 11,514: | Line 11,218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0023827 HSALNT0023827] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0023827 HSALNT0023827] | ||
| − | | | + | |[[NONHSAT010191]] |
|DISC1-AS1,DISC1O, NCRNA00015 | |DISC1-AS1,DISC1O, NCRNA00015 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,522: | Line 11,226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0203415 HSALNT0203415] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0203415 HSALNT0203415] | ||
| − | | | + | |[[NONHSAT034251]] |
|SCA8,KLHL1A,NCRNA00003 | |SCA8,KLHL1A,NCRNA00003 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,530: | Line 11,234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290312 HSALNT0290312] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290312 HSALNT0290312] | ||
| − | |TRAF3IP2-AS1 | + | |[[TRAF3IP2-AS1]] |
|C6UA, C6orf3,NCRNA00248,TRAF3IP2-AS2 | |C6UA, C6orf3,NCRNA00248,TRAF3IP2-AS2 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,538: | Line 11,242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289008 HSALNT0289008] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289008 HSALNT0289008] | ||
| − | |HYMAI | + | |[[HYMAI]] |
|NCRNA00020 | |NCRNA00020 | ||
|NA | |NA | ||
| Line 11,546: | Line 11,250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288968 HSALNT0288968] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288968 HSALNT0288968] | ||
| − | |FAM201A | + | |[[FAM201A]] |
|C9orf122 | |C9orf122 | ||
|NA | |NA | ||
| Line 11,554: | Line 11,258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288969 HSALNT0288969] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288969 HSALNT0288969] | ||
| − | |FAM222A-AS1 | + | |[[FAM222A-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,562: | Line 11,266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289484 HSALNT0289484] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289484 HSALNT0289484] | ||
| − | |FAM226A | + | |[[FAM226A]] |
|CXorf50,NCRNA00246,NCRNA00246A,LINC00246A,MGC34827 | |CXorf50,NCRNA00246,NCRNA00246A,LINC00246A,MGC34827 | ||
|NA | |NA | ||
| Line 11,570: | Line 11,274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289497 HSALNT0289497] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289497 HSALNT0289497] | ||
| − | |FAM215A | + | |[[FAM215A]] |
|C17orf88,APR-2,LINC00530 | |C17orf88,APR-2,LINC00530 | ||
|NA | |NA | ||
| Line 11,578: | Line 11,282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289230 HSALNT0289230] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289230 HSALNT0289230] | ||
| − | | | + | |[[NONHSAT089783]] |
|LUST | |LUST | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,586: | Line 11,290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0002923 HSALNT0002923] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0002923 HSALNT0002923] | ||
| − | |LINC00339 | + | |[[LINC00339]] |
|NCRNA00339,HSPC157 | |NCRNA00339,HSPC157 | ||
|NA | |NA | ||
| Line 11,594: | Line 11,298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0144027 HSALNT0144027] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0144027 HSALNT0144027] | ||
| − | |ASAP1-IT1 | + | |[[ASAP1-IT1]] |
|ASAP1-IT,ASAP1IT,ASAP1IT1,DDEF1IT1,HSPC054,NCRNA00050 | |ASAP1-IT,ASAP1IT,ASAP1IT1,DDEF1IT1,HSPC054,NCRNA00050 | ||
|NA | |NA | ||
| Line 11,602: | Line 11,306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289212 HSALNT0289212] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289212 HSALNT0289212] | ||
| − | | | + | |[[NONHSAT076153]] |
|NCRNA00071,LINC00071,PCAT9 | |NCRNA00071,LINC00071,PCAT9 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 11,610: | Line 11,314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289016 HSALNT0289016] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289016 HSALNT0289016] | ||
| − | |KCNQ1DN | + | |[[KCNQ1DN]] |
|BWRT,HSA404617 | |BWRT,HSA404617 | ||
|NA | |NA | ||
| Line 11,618: | Line 11,322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288933 HSALNT0288933] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288933 HSALNT0288933] | ||
| − | | | + | |[[NONHSAT033821]] |
|DLB2,BCMSUN,RFP2O,LEU2,TRIM13O, NCRNA00022,LINC00022,MIR15AHG | |DLB2,BCMSUN,RFP2O,LEU2,TRIM13O, NCRNA00022,LINC00022,MIR15AHG | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,626: | Line 11,330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0217624 HSALNT0217624] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0217624 HSALNT0217624] | ||
| − | |PWAR4 | + | |[[PWAR4]] |
|PAR4,PAR-4 | |PAR4,PAR-4 | ||
|NA | |NA | ||
| Line 11,634: | Line 11,338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289165 HSALNT0289165] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289165 HSALNT0289165] | ||
| − | | | + | |[[ENST00000553584.1]] |
|SNHG23,SNHG24,NCRNA00024,Irm,Rian,Bsr,LINC00024,AL132709.8,lnc-MGC | |SNHG23,SNHG24,NCRNA00024,Irm,Rian,Bsr,LINC00024,AL132709.8,lnc-MGC | ||
|NA | |NA | ||
| Line 11,642: | Line 11,346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289482 HSALNT0289482] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289482 HSALNT0289482] | ||
| − | |CECR7 | + | |[[CECR7]] |
|SAHL1 | |SAHL1 | ||
|NA | |NA | ||
| Line 11,650: | Line 11,354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0074223 HSALNT0074223] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0074223 HSALNT0074223] | ||
| − | | | + | |[[ENST00000504263.1]] |
|GDEP,PCAN1,PCA4 | |GDEP,PCAN1,PCA4 | ||
|NA | |NA | ||
| Line 11,658: | Line 11,362: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0061175 HSALNT0061175] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0061175 HSALNT0061175] | ||
| − | |PISRT1 | + | |[[PISRT1]] |
|NCRNA00195 | |NCRNA00195 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,666: | Line 11,370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0190912 HSALNT0190912] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0190912 HSALNT0190912] | ||
| − | | | + | |[[ENST00000538665.1]] |
|Tmevpg1,LincR-Ifng-3'A, NEST | |Tmevpg1,LincR-Ifng-3'A, NEST | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,674: | Line 11,378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0038178 HSALNT0038178] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0038178 HSALNT0038178] | ||
| − | |FAM138B | + | |[[FAM138B]] |
|F379 | |F379 | ||
|NA | |NA | ||
| Line 11,682: | Line 11,386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0145703 HSALNT0145703] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0145703 HSALNT0145703] | ||
| − | |FAM138C | + | |[[FAM138C]] |
|F379 | |F379 | ||
|NA | |NA | ||
| Line 11,690: | Line 11,394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288963 HSALNT0288963] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288963 HSALNT0288963] | ||
| − | |FAM138A | + | |[[FAM138A]] |
|F379 | |F379 | ||
|NA | |NA | ||
| Line 11,698: | Line 11,402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0183947 HSALNT0183947] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0183947 HSALNT0183947] | ||
| − | |FAM138D | + | |[[FAM138D]] |
|F379 | |F379 | ||
|NA | |NA | ||
| Line 11,706: | Line 11,410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0226092 HSALNT0226092] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0226092 HSALNT0226092] | ||
| − | |FAM138E | + | |[[FAM138E]] |
|F379 | |F379 | ||
|NA | |NA | ||
| Line 11,714: | Line 11,418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0253925 HSALNT0253925] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0253925 HSALNT0253925] | ||
| − | |FAM138F | + | |[[FAM138F]] |
|F379 | |F379 | ||
|NA | |NA | ||
| Line 11,722: | Line 11,426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289326 HSALNT0289326] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289326 HSALNT0289326] | ||
| − | | | + | |[[NONHSAT087716]] |
|LOH3CR2A,NCRNA00312,NAG7,NAG-7,ERR10,ERR-10,LMCD1DN | |LOH3CR2A,NCRNA00312,NAG7,NAG-7,ERR10,ERR-10,LMCD1DN | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,730: | Line 11,434: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288886 HSALNT0288886] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288886 HSALNT0288886] | ||
| − | | | + | |[[ENST00000609176.1]] |
|AIR,NCRNA00088,IGF2RA, IGF2R-AS1 | |AIR,NCRNA00088,IGF2RA, IGF2R-AS1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,738: | Line 11,442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0254857 HSALNT0254857] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0254857 HSALNT0254857] | ||
| − | |MIR7-3HG | + | |[[MIR7-3HG]] |
|C19orf30,NCRNA00306,LINC00306,PGSF1,PGSF1a,PGSF1b,Huh7,uc002mbe.2 | |C19orf30,NCRNA00306,LINC00306,PGSF1,PGSF1a,PGSF1b,Huh7,uc002mbe.2 | ||
|NA | |NA | ||
| Line 11,746: | Line 11,450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0185751 HSALNT0185751] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0185751 HSALNT0185751] | ||
| − | |LOH12CR2 | + | |[[LOH12CR2]] |
|LOH2CR12 | |LOH2CR12 | ||
|NA | |NA | ||
| Line 11,754: | Line 11,458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289479 HSALNT0289479] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289479 HSALNT0289479] | ||
| − | |DSCR8 | + | |[[DSCR8]] |
|C21orf65,MTAG2,CT25.1a,CT25.1b,MMA-1a,MMA-1b | |C21orf65,MTAG2,CT25.1a,CT25.1b,MMA-1a,MMA-1b | ||
|NA | |NA | ||
| Line 11,762: | Line 11,466: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289030 HSALNT0289030] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289030 HSALNT0289030] | ||
| − | |LINC00313 | + | |[[LINC00313]] |
|C21orf84,NCRNA00313, | |C21orf84,NCRNA00313, | ||
|NA | |NA | ||
| Line 11,770: | Line 11,474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289029 HSALNT0289029] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289029 HSALNT0289029] | ||
| − | |LINC00310 | + | |[[LINC00310]] |
|C21orf82,NCRNA00310 | |C21orf82,NCRNA00310 | ||
|NA | |NA | ||
| Line 11,778: | Line 11,482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0272435 HSALNT0272435] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0272435 HSALNT0272435] | ||
| − | |LINC00161 | + | |[[LINC00161]] |
|C21orf100,NCRNA00161 | |C21orf100,NCRNA00161 | ||
|ceRNA | |ceRNA | ||
| Line 11,786: | Line 11,490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289184 HSALNT0289184] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289184 HSALNT0289184] | ||
| − | | | + | |[[ENST00000602580.1]] |
|C21orf35,FLJ38295,C21orf34,LINC00478,MONC | |C21orf35,FLJ38295,C21orf34,LINC00478,MONC | ||
|NA | |NA | ||
| Line 11,794: | Line 11,498: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289005 HSALNT0289005] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289005 HSALNT0289005] | ||
| − | |HOXA11-AS | + | |[[HOXA11-AS]] |
|HOXA11A,HOXA11-AS1,HOXA11, HOXA-AS5,NCRNA00076 | |HOXA11A,HOXA11-AS1,HOXA11, HOXA-AS5,NCRNA00076 | ||
|ceRNA | |ceRNA | ||
| Line 11,802: | Line 11,506: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0193654 HSALNT0193654] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0193654 HSALNT0193654] | ||
| − | |RMST | + | |[[RMST]] |
|NCRM, NCRNA00054,LINC00054 | |NCRM, NCRNA00054,LINC00054 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,810: | Line 11,514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290079 HSALNT0290079] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290079 HSALNT0290079] | ||
| − | | | + | |[[NONHSAT102247]] |
|NCRUPAR,ENSG00000225407 | |NCRUPAR,ENSG00000225407 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 11,818: | Line 11,522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289167 HSALNT0289167] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289167 HSALNT0289167] | ||
| − | |MESTIT1 | + | |[[MESTIT1]] |
|MEST-AS1,MEST-IT,MEST-IT1,NCRNA00040,PEG1-AS | |MEST-AS1,MEST-IT,MEST-IT1,NCRNA00040,PEG1-AS | ||
|NA | |NA | ||
| Line 11,826: | Line 11,530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0273791 HSALNT0273791] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0273791 HSALNT0273791] | ||
| − | |DSCAM-AS1 | + | |[[DSCAM-AS1]] |
|M41 | |M41 | ||
|NA | |NA | ||
| Line 11,834: | Line 11,538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289391 HSALNT0289391] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289391 HSALNT0289391] | ||
| − | |PWARSN | + | |[[PWARSN]] |
|PAR-SN,PARSN | |PAR-SN,PARSN | ||
|NA | |NA | ||
| Line 11,842: | Line 11,546: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0127791 HSALNT0127791] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0127791 HSALNT0127791] | ||
| − | |ST7-AS1 | + | |[[ST7-AS1]] |
|ST7OT1,ST7AS1 | |ST7OT1,ST7AS1 | ||
|NA | |NA | ||
| Line 11,850: | Line 11,554: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0206298 HSALNT0206298] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0206298 HSALNT0206298] | ||
| − | |DAOA-AS1 | + | |[[DAOA-AS1]] |
|DAOAA, DAOA-A,G30 | |DAOAA, DAOA-A,G30 | ||
|NA | |NA | ||
| Line 11,858: | Line 11,562: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0167060 HSALNT0167060] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0167060 HSALNT0167060] | ||
| − | |OLMALINC | + | |[[OLMALINC]] |
|C10orf75,NCRNA00263,LINC00263,bA34D15.5,FLJ12974,HI-LNC80 | |C10orf75,NCRNA00263,LINC00263,bA34D15.5,FLJ12974,HI-LNC80 | ||
|NA | |NA | ||
| Line 11,866: | Line 11,570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0026878 HSALNT0026878] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0026878 HSALNT0026878] | ||
| − | |LINC00299 | + | |[[LINC00299]] |
|C2orf46,NCRNA00299,FLJ45673 | |C2orf46,NCRNA00299,FLJ45673 | ||
|NA | |NA | ||
| Line 11,874: | Line 11,578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289081 HSALNT0289081] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289081 HSALNT0289081] | ||
| − | |LINC01020 | + | |[[LINC01020]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,882: | Line 11,586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0101186 HSALNT0101186] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0101186 HSALNT0101186] | ||
| − | |LINC00518 | + | |[[LINC00518]] |
|C6orf218,MGC40222 | |C6orf218,MGC40222 | ||
|NA | |NA | ||
| Line 11,890: | Line 11,594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0083960 HSALNT0083960] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0083960 HSALNT0083960] | ||
| − | |LINC01018 | + | |[[LINC01018]] |
|SRHC | |SRHC | ||
|NA | |NA | ||
| Line 11,898: | Line 11,602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289361 HSALNT0289361] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289361 HSALNT0289361] | ||
| − | |LPP-AS2 | + | |[[LPP-AS2]] |
|MYCLo-5,MYCLo-6 | |MYCLo-5,MYCLo-6 | ||
|NA | |NA | ||
| Line 11,906: | Line 11,610: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0143233 HSALNT0143233] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0143233 HSALNT0143233] | ||
| − | |LINC00964 | + | |[[LINC00964]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,914: | Line 11,618: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289364 HSALNT0289364] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289364 HSALNT0289364] | ||
| − | |MAPKAPK5-AS1 | + | |[[MAPKAPK5-AS1]] |
|C12orf47,FLJ39616 | |C12orf47,FLJ39616 | ||
|NA | |NA | ||
| Line 11,922: | Line 11,626: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289053 HSALNT0289053] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289053 HSALNT0289053] | ||
| − | |LINC00635 | + | |[[LINC00635]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,930: | Line 11,634: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289327 HSALNT0289327] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289327 HSALNT0289327] | ||
| − | |LINC00636 | + | |[[LINC00636]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,938: | Line 11,642: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0262657 HSALNT0262657] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0262657 HSALNT0262657] | ||
| − | |ZNF582-AS1 | + | |[[ZNF582-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 11,946: | Line 11,650: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289020 HSALNT0289020] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289020 HSALNT0289020] | ||
| − | |LINC00115 | + | |[[LINC00115]] |
|NCRNA00115,FLJ22639 | |NCRNA00115,FLJ22639 | ||
|ceRNA | |ceRNA | ||
| Line 11,954: | Line 11,658: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289254 HSALNT0289254] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289254 HSALNT0289254] | ||
| − | |SNHG7 | + | |[[SNHG7]] |
|MGC16037,NCRNA00061 | |MGC16037,NCRNA00061 | ||
|NA | |NA | ||
| Line 11,962: | Line 11,666: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289162 HSALNT0289162] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289162 HSALNT0289162] | ||
| − | |MAP3K20-AS1 | + | |[[MAP3K20-AS1]] |
|MLK7-AS1 | |MLK7-AS1 | ||
|NA | |NA | ||
| Line 11,970: | Line 11,674: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0145357 HSALNT0145357] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0145357 HSALNT0145357] | ||
| − | |RHPN1-AS1 | + | |[[RHPN1-AS1]] |
|C8orf51,MGC3113 | |C8orf51,MGC3113 | ||
|NA | |NA | ||
| Line 11,978: | Line 11,682: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289343 HSALNT0289343] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289343 HSALNT0289343] | ||
| − | | | + | |[[NONHSAT137541]] |
|DXS399E,NCRNA00001,DXS1089,swd66,LINC00001 | |DXS399E,NCRNA00001,DXS1089,swd66,LINC00001 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 11,986: | Line 11,690: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289389 HSALNT0289389] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289389 HSALNT0289389] | ||
| − | |PRNT | + | |[[PRNT]] |
|M8 | |M8 | ||
|NA | |NA | ||
| Line 11,994: | Line 11,698: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288942 HSALNT0288942] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288942 HSALNT0288942] | ||
| − | | | + | |[[Lnc-PDZD8-3:1]] |
|NCRNA00045,EMX2-AS1 | |NCRNA00045,EMX2-AS1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,002: | Line 11,706: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0200443 HSALNT0200443] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0200443 HSALNT0200443] | ||
| − | |LINC00598 | + | |[[LINC00598]] |
|TTL | |TTL | ||
|NA | |NA | ||
| Line 12,010: | Line 11,714: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289517 HSALNT0289517] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289517 HSALNT0289517] | ||
| − | |TTTY17A | + | |[[TTTY17A]] |
|NCRNA00140 | |NCRNA00140 | ||
|NA | |NA | ||
| Line 12,018: | Line 11,722: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0027901 HSALNT0027901] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0027901 HSALNT0027901] | ||
| − | |MYCNOS | + | |[[MYCNOS]] |
|NCYM,N-CYM,MYCN-AS1 | |NCYM,N-CYM,MYCN-AS1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,026: | Line 11,730: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0047175 HSALNT0047175] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0047175 HSALNT0047175] | ||
| − | |DIRC3 | + | |[[DIRC3]] |
|FLJ14199 | |FLJ14199 | ||
|NA | |NA | ||
| Line 12,034: | Line 11,738: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289363 HSALNT0289363] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289363 HSALNT0289363] | ||
| − | | | + | |[[ENST00000534336.1]] |
|PRO1073,MALAT-1,NCRNA00047,HCN,NEAT2,LINC00047,mascRNA | |PRO1073,MALAT-1,NCRNA00047,HCN,NEAT2,LINC00047,mascRNA | ||
|splicing regulation;;translational control;transcriptional regulation;protein localization;ceRNA | |splicing regulation;;translational control;transcriptional regulation;protein localization;ceRNA | ||
| Line 12,042: | Line 11,746: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289744 HSALNT0289744] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289744 HSALNT0289744] | ||
| − | |DLG2-AS1 | + | |[[DLG2-AS1]] |
|DLG2A, DLG2-A,PSZA11q14,SZ-1 | |DLG2A, DLG2-A,PSZA11q14,SZ-1 | ||
|NA | |NA | ||
| Line 12,050: | Line 11,754: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289164 HSALNT0289164] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289164 HSALNT0289164] | ||
| − | | | + | |[[NONHSAT039745]] |
|FP504,GTL2,LINC00023,NCRNA00023,PRO0518,PRO2160,onco-lncRNA-83,prebp1 | |FP504,GTL2,LINC00023,NCRNA00023,PRO0518,PRO2160,onco-lncRNA-83,prebp1 | ||
|translational control;transcriptional regulation;ceRNA | |translational control;transcriptional regulation;ceRNA | ||
| Line 12,058: | Line 11,762: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290298 HSALNT0290298] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290298 HSALNT0290298] | ||
| − | |TERC | + | |[[TERC]] |
|DKCA1,PFBMFT2,SCARNA19,TR,TRC3,hTR | |DKCA1,PFBMFT2,SCARNA19,TR,TRC3,hTR | ||
|NA | |NA | ||
| Line 12,066: | Line 11,770: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288907 HSALNT0288907] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288907 HSALNT0288907] | ||
| − | |CASC2 | + | |[[CASC2]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 12,074: | Line 11,778: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0205332 HSALNT0205332] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0205332 HSALNT0205332] | ||
| − | |MIR17HG | + | |[[MIR17HG]] |
|C13orf25,MIRHG1,FLJ14178,MIRH1,MIHG1,NCRNA00048,miR-17-92,LINC00048 | |C13orf25,MIRHG1,FLJ14178,MIRH1,MIHG1,NCRNA00048,miR-17-92,LINC00048 | ||
|NA | |NA | ||
| Line 12,082: | Line 11,786: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288716 HSALNT0288716] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288716 HSALNT0288716] | ||
| − | |TTTY6 | + | |[[TTTY6]] |
|TTY6,TTTY6A,LINC00127 | |TTY6,TTTY6A,LINC00127 | ||
|NA | |NA | ||
| Line 12,090: | Line 11,794: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288731 HSALNT0288731] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288731 HSALNT0288731] | ||
| − | |TTTY4 | + | |[[TTTY4]] |
|TTY4,TTTY4A,LINC00123 | |TTY4,TTTY4A,LINC00123 | ||
|NA | |NA | ||
| Line 12,098: | Line 11,802: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288815 HSALNT0288815] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288815 HSALNT0288815] | ||
| − | |TTTY3 | + | |[[TTTY3]] |
|TTY3,TTTY3A,LINC00121 | |TTY3,TTTY3A,LINC00121 | ||
|NA | |NA | ||
| Line 12,106: | Line 11,810: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288703 HSALNT0288703] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288703 HSALNT0288703] | ||
| − | |TTTY5 | + | |[[TTTY5]] |
|TTY5,LINC00126 | |TTY5,LINC00126 | ||
|NA | |NA | ||
| Line 12,114: | Line 11,818: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289255 HSALNT0289255] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289255 HSALNT0289255] | ||
| − | |SNHG8 | + | |[[SNHG8]] |
|NCRNA00060,LINC00060 | |NCRNA00060,LINC00060 | ||
|NA | |NA | ||
| Line 12,122: | Line 11,826: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289486 HSALNT0289486] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289486 HSALNT0289486] | ||
| − | | | + | |[[Lnc-EPCAM-1:2]] |
|BC200,BC200a,NCRNA00004,LINC00004 | |BC200,BC200a,NCRNA00004,LINC00004 | ||
|splicing regulation;translational control | |splicing regulation;translational control | ||
| Line 12,130: | Line 11,834: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0144426 HSALNT0144426] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0144426 HSALNT0144426] | ||
| − | |ZFAT-AS1 | + | |[[ZFAT-AS1]] |
|ZFATAS,ZFAT-AS,SAS-ZFAT,NCRNA00070 | |ZFATAS,ZFAT-AS,SAS-ZFAT,NCRNA00070 | ||
|NA | |NA | ||
| Line 12,138: | Line 11,842: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289285 HSALNT0289285] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289285 HSALNT0289285] | ||
| − | |ZEB1-AS1 | + | |[[ZEB1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 12,146: | Line 11,850: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289185 HSALNT0289185] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289185 HSALNT0289185] | ||
| − | |MIRLET7BHG | + | |[[MIRLET7BHG]] |
|linc-Ppara | |linc-Ppara | ||
|NA | |NA | ||
| Line 12,154: | Line 11,858: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289374 HSALNT0289374] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289374 HSALNT0289374] | ||
| − | |NBR2 | + | |[[NBR2]] |
|NCRNA00192 | |NCRNA00192 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,162: | Line 11,866: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289417 HSALNT0289417] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289417 HSALNT0289417] | ||
| − | | | + | |[[NONHSAT084827]] |
|FLJ20618,NCRNA00080,LINC00080 | |FLJ20618,NCRNA00080,LINC00080 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 12,170: | Line 11,874: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288973 HSALNT0288973] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288973 HSALNT0288973] | ||
| − | |FAS-AS1 | + | |[[FAS-AS1]] |
|FASA, FAS-A,SAF | |FASA, FAS-A,SAF | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,178: | Line 11,882: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288996 HSALNT0288996] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288996 HSALNT0288996] | ||
| − | |HAS2-AS1 | + | |[[HAS2-AS1]] |
|HAS2A, HAS2-A,HASNT,NCRNA00077 | |HAS2A, HAS2-A,HASNT,NCRNA00077 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,186: | Line 11,890: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289390 HSALNT0289390] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289390 HSALNT0289390] | ||
| − | |PSORS1C3 | + | |[[PSORS1C3]] |
|NCRNA00196 | |NCRNA00196 | ||
|NA | |NA | ||
| Line 12,194: | Line 11,898: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289868 HSALNT0289868] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289868 HSALNT0289868] | ||
| − | |HLA-AS1 | + | |[[HLA-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 12,202: | Line 11,906: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290154 HSALNT0290154] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290154 HSALNT0290154] | ||
| − | | | + | |[[NONHSAT011777]] |
|NCRNA00074 | |NCRNA00074 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,210: | Line 11,914: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0262809 HSALNT0262809] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0262809 HSALNT0262809] | ||
| − | |PEG3-AS1 | + | |[[PEG3-AS1]] |
|PEG3AS,PEG3-AS,APEG3,NCRNA00155 | |PEG3AS,PEG3-AS,APEG3,NCRNA00155 | ||
|NA | |NA | ||
| Line 12,218: | Line 11,922: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289533 HSALNT0289533] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289533 HSALNT0289533] | ||
| − | | | + | |[[Lnc-LRR1-1:1]] |
|7S RNA,SRP RNA,4.5S SRP RNA,4.5S RNA,RN7SL1 RNA,ENSG00000258486,lnc-LRR1-1:1 | |7S RNA,SRP RNA,4.5S SRP RNA,4.5S RNA,RN7SL1 RNA,ENSG00000258486,lnc-LRR1-1:1 | ||
|protein localization | |protein localization | ||
| Line 12,226: | Line 11,930: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290081 HSALNT0290081] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290081 HSALNT0290081] | ||
| − | | | + | |[[Lnc-C11orf16-1:1]] |
|29A,lnc-C11orf16-1:1 | |29A,lnc-C11orf16-1:1 | ||
|NA | |NA | ||
| Line 12,234: | Line 11,938: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289382 HSALNT0289382] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289382 HSALNT0289382] | ||
| − | | | + | |[[NONHSAT134764]] |
|NCRNA00194 | |NCRNA00194 | ||
|NA | |NA | ||
| Line 12,242: | Line 11,946: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289253 HSALNT0289253] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289253 HSALNT0289253] | ||
| − | | | + | |[[Lnc-TCF24-2:3]] |
|U87HG,HBII-276HG,NCRNA00058 | |U87HG,HBII-276HG,NCRNA00058 | ||
|translational control;ceRNA | |translational control;ceRNA | ||
| Line 12,250: | Line 11,954: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289653 HSALNT0289653] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289653 HSALNT0289653] | ||
| − | | | + | |[[NONHSAT017676]] |
| − | |AY195961.1,NONHSAT017674,AY034469.1,NONHSAT017675,AY034470.1 | + | |AY195961.1,NONHSAT017674,AY034469.1,NONHSAT017675,AY034470.1 |
|NA | |NA | ||
|NA | |NA | ||
| Line 12,258: | Line 11,962: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290398 HSALNT0290398] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290398 HSALNT0290398] | ||
| − | | | + | |[[ENST00000554403.1]] |
|Zfh-5AS,ENSG00000157306,ENST00000554403.1 | |Zfh-5AS,ENSG00000157306,ENST00000554403.1 | ||
|NA | |NA | ||
| Line 12,266: | Line 11,970: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0011306 HSALNT0011306] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0011306 HSALNT0011306] | ||
| − | |MIR137HG | + | |[[MIR137HG]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 12,274: | Line 11,978: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289449 HSALNT0289449] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289449 HSALNT0289449] | ||
| − | | | + | |[[Lnc-EVX1-9:1]] |
|HOXA6as | |HOXA6as | ||
|NA | |NA | ||
| Line 12,282: | Line 11,986: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289451 HSALNT0289451] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289451 HSALNT0289451] | ||
| − | |CCDC26 | + | |[[CCDC26]] |
|MGC27434,RAM | |MGC27434,RAM | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,290: | Line 11,994: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289893 HSALNT0289893] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289893 HSALNT0289893] | ||
| − | |LINC00271 | + | |[[LINC00271]] |
|C6orf217,NCRNA00271 | |C6orf217,NCRNA00271 | ||
|NA | |NA | ||
| Line 12,298: | Line 12,002: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288892 HSALNT0288892] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288892 HSALNT0288892] | ||
| − | |BCAR4 | + | |[[BCAR4]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,306: | Line 12,010: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289890 HSALNT0289890] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289890 HSALNT0289890] | ||
| − | |LINC00032 | + | |[[LINC00032]] |
|C9orf14,NCRNA00032 | |C9orf14,NCRNA00032 | ||
|NA | |NA | ||
| Line 12,314: | Line 12,018: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0274572 HSALNT0274572] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0274572 HSALNT0274572] | ||
| − | |PICSAR | + | |[[PICSAR]] |
|C21orf113,LINC00162,NCRNA00162,NLC1-C,NLC1C,PRED74 | |C21orf113,LINC00162,NCRNA00162,NLC1-C,NLC1C,PRED74 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,322: | Line 12,026: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0256354 HSALNT0256354] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0256354 HSALNT0256354] | ||
| − | | | + | |[[Lnc-OR10H5-1:1]] |
|CUDR,LINC00178,NCRNA00178,UCAT1,onco-lncRNA-36 | |CUDR,LINC00178,NCRNA00178,UCAT1,onco-lncRNA-36 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 12,328: | Line 12,032: | ||
|oral squamous cell cancer;osteosarcoma;prostate cancer;ovarian cancer;non-small cell lung cancer;acute myocardial infarction;pancreaticobiliary maljunction;pancreatic cancer;melanoma;tongue squamous cell cancer;hepatocelluar cancer;bladder cancer;acute myeloid leukemia;esophageal squamous cell cancer;esophageal cancer;liver cancer;colorectal cancer;Pancreatic ductal adenocarcinoma;urinary bladder;gastric cancer;endometrial cancer;breast cancer;hepatocellular cancer;squamous cell cancer;lung cancer;renal cell cancer | |oral squamous cell cancer;osteosarcoma;prostate cancer;ovarian cancer;non-small cell lung cancer;acute myocardial infarction;pancreaticobiliary maljunction;pancreatic cancer;melanoma;tongue squamous cell cancer;hepatocelluar cancer;bladder cancer;acute myeloid leukemia;esophageal squamous cell cancer;esophageal cancer;liver cancer;colorectal cancer;Pancreatic ductal adenocarcinoma;urinary bladder;gastric cancer;endometrial cancer;breast cancer;hepatocellular cancer;squamous cell cancer;lung cancer;renal cell cancer | ||
|Skin and Connective Tissue Diseases;Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Cardiovascular Diseases;Endocrine System Diseases;Digestive System Diseases | |Skin and Connective Tissue Diseases;Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Cardiovascular Diseases;Endocrine System Diseases;Digestive System Diseases | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289475 HSALNT0289475] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289475 HSALNT0289475] | ||
| − | | | + | |[[Lnc-BIRC7-2:1]] |
|HAR1F,NCRNA00064,LINC00064 | |HAR1F,NCRNA00064,LINC00064 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,346: | Line 12,042: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288995 HSALNT0288995] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288995 HSALNT0288995] | ||
| − | | | + | |[[ENST00000447910.2]] |
|HAR1R,NCRNA00065,LINC00065 | |HAR1R,NCRNA00065,LINC00065 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,354: | Line 12,050: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288958 HSALNT0288958] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288958 HSALNT0288958] | ||
| − | |EPB41L4A-AS1 | + | |[[EPB41L4A-AS1]] |
|C5orf26,NCRNA00219,TIGA1 | |C5orf26,NCRNA00219,TIGA1 | ||
|NA | |NA | ||
| Line 12,362: | Line 12,058: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289170 HSALNT0289170] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289170 HSALNT0289170] | ||
| − | | | + | |[[Lnc-CRYBA4-2:1]] |
|C22orf35,FLJ25967,Rncr2,gomafu,NCRNA00066,LINC00066,lncRNA-MIAT | |C22orf35,FLJ25967,Rncr2,gomafu,NCRNA00066,LINC00066,lncRNA-MIAT | ||
|splicing regulation;ceRNA | |splicing regulation;ceRNA | ||
| Line 12,370: | Line 12,066: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289007 HSALNT0289007] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289007 HSALNT0289007] | ||
| − | | | + | |[[NONHSAT107640]] |
|NCRNA00078,LINC00078,HCCAT1 | |NCRNA00078,LINC00078,HCCAT1 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 12,378: | Line 12,074: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288940 HSALNT0288940] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288940 HSALNT0288940] | ||
| − | | | + | |[[NONHSAT087635]] |
|EGO,NCRNA00190 | |EGO,NCRNA00190 | ||
|NA | |NA | ||
| Line 12,386: | Line 12,082: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289387 HSALNT0289387] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289387 HSALNT0289387] | ||
| − | |PINK1-AS | + | |[[PINK1-AS]] |
|PINK1-AS1,FLJ00387,PINK1A, naPINK1 | |PINK1-AS1,FLJ00387,PINK1A, naPINK1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,394: | Line 12,090: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289225 HSALNT0289225] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289225 HSALNT0289225] | ||
| − | | | + | |[[ENST00000513868.2]] |
|NCRNA00079,LINC00079,onco-lncRNA-100,MIR1204HG,PVT | |NCRNA00079,LINC00079,onco-lncRNA-100,MIR1204HG,PVT | ||
|transcriptional regulation;translational control | |transcriptional regulation;translational control | ||
| Line 12,402: | Line 12,098: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289189 HSALNT0289189] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289189 HSALNT0289189] | ||
| − | | | + | |[[ENST00000604258.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 12,410: | Line 12,106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0246525 HSALNT0246525] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0246525 HSALNT0246525] | ||
| − | |NARF-AS1 | + | |[[NARF-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 12,418: | Line 12,114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0147433 HSALNT0147433] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0147433 HSALNT0147433] | ||
| − | | | + | |[[NONHSAT130421]] |
|CDKN2BA,ANRIL,RP11-145E5.4,NCRNA00089,p15A, CDKN2B-A, PCAT12 | |CDKN2BA,ANRIL,RP11-145E5.4,NCRNA00089,p15A, CDKN2B-A, PCAT12 | ||
|siRNA;transcriptional regulation;ceRNA | |siRNA;transcriptional regulation;ceRNA | ||
| Line 12,426: | Line 12,122: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0050854 HSALNT0050854] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0050854 HSALNT0050854] | ||
| − | | | + | |[[NONHSAT087920]] |
|NCRNA00068,GHRL-AS1 | |NCRNA00068,GHRL-AS1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,434: | Line 12,130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288959 HSALNT0288959] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288959 HSALNT0288959] | ||
| − | | | + | |[[ENST00000583516.1]] |
|HESRG | |HESRG | ||
|NA | |NA | ||
| Line 12,442: | Line 12,138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0287173 HSALNT0287173] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0287173 HSALNT0287173] | ||
| − | |FMR1-AS1 | + | |[[FMR1-AS1]] |
|FMR1A, FMR1-A,ASFMR1,FMR4 | |FMR1A, FMR1-A,ASFMR1,FMR4 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,450: | Line 12,146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289499 HSALNT0289499] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289499 HSALNT0289499] | ||
| − | |HCG4 | + | |[[HCG4]] |
|HCGIV-10,HCGIV.9 | |HCGIV-10,HCGIV.9 | ||
|NA | |NA | ||
| Line 12,458: | Line 12,154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288994 HSALNT0288994] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288994 HSALNT0288994] | ||
| − | |HAND2-AS1 | + | |[[HAND2-AS1]] |
|DEIN,NBLA00301,FLJ11539 | |DEIN,NBLA00301,FLJ11539 | ||
|NA | |NA | ||
| Line 12,466: | Line 12,162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289286 HSALNT0289286] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289286 HSALNT0289286] | ||
| − | | | + | |[[NONHSAT074775]] |
|ZEB2A, ZEB2-A,ZEB2NAT | |ZEB2A, ZEB2-A,ZEB2NAT | ||
|splicing regulation | |splicing regulation | ||
| Line 12,474: | Line 12,170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0017702 HSALNT0017702] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0017702 HSALNT0017702] | ||
| − | | | + | |[[NONHSAT007663]] |
|SNHG2,NCRNA00030 | |SNHG2,NCRNA00030 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 12,482: | Line 12,178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288891 HSALNT0288891] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288891 HSALNT0288891] | ||
| − | | | + | |[[NONHSAT024403]] |
|BACE1A,FJ573250,NCRNA00177,BACE1-AS1 | |BACE1A,FJ573250,NCRNA00177,BACE1-AS1 | ||
|translational control;transcriptional regulation | |translational control;transcriptional regulation | ||
| Line 12,490: | Line 12,186: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289414 HSALNT0289414] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289414 HSALNT0289414] | ||
| − | |TRPM2-AS | + | |[[TRPM2-AS]] |
|TRPM2-AS1 | |TRPM2-AS1 | ||
|NA | |NA | ||
| Line 12,498: | Line 12,194: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288935 HSALNT0288935] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288935 HSALNT0288935] | ||
| − | |DNM3OS | + | |[[DNM3OS]] |
|DNM3-AS1,MIR199A2HG | |DNM3-AS1,MIR199A2HG | ||
|NA | |NA | ||
| Line 12,506: | Line 12,202: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288930 HSALNT0288930] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288930 HSALNT0288930] | ||
| − | |DGCR5 | + | |[[DGCR5]] |
|NCRNA00037,LINC00037 | |NCRNA00037,LINC00037 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,514: | Line 12,210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288893 HSALNT0288893] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288893 HSALNT0288893] | ||
| − | | | + | |[[ENST00000499008.3]] |
|BDNFO,BT2A,BT2B,BT2C,BT2D,NCRNA00049,BDNF-AS1,BDNFAS | |BDNFO,BT2A,BT2B,BT2C,BT2D,NCRNA00049,BDNF-AS1,BDNFAS | ||
|siRNA;transcriptional regulation | |siRNA;transcriptional regulation | ||
| Line 12,522: | Line 12,218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0120317 HSALNT0120317] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0120317 HSALNT0120317] | ||
| − | | | + | |[[Lnc-EVX1-12:1]] |
|HOXA-AS1,NCRNA00179,HOXA1-AS1 | |HOXA-AS1,NCRNA00179,HOXA1-AS1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,530: | Line 12,226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290158 HSALNT0290158] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290158 HSALNT0290158] | ||
| − | | | + | |[[NONHSAT129210]] |
|PTCSC,AK023948,NCRNA00197 | |PTCSC,AK023948,NCRNA00197 | ||
|NA | |NA | ||
| Line 12,538: | Line 12,234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289004 HSALNT0289004] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289004 HSALNT0289004] | ||
| − | | | + | |[[NONHSAT028508]] |
|HOXC-AS4,HOXC11-AS1,NCRNA00072 | |HOXC-AS4,HOXC11-AS1,NCRNA00072 | ||
|siRNA;transcriptional regulation;ceRNA | |siRNA;transcriptional regulation;ceRNA | ||
| Line 12,546: | Line 12,242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289192 HSALNT0289192] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289192 HSALNT0289192] | ||
| − | | | + | |[[ENST00000501122.2]] |
|NCRNA00084,TncRNA,MENepsilon/beta,LINC00084,VINC | |NCRNA00084,TncRNA,MENepsilon/beta,LINC00084,VINC | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 12,554: | Line 12,250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0095094 HSALNT0095094] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0095094 HSALNT0095094] | ||
| − | | | + | |[[NONHSAT104072]] |
|U19H,NCRNA00059 | |U19H,NCRNA00059 | ||
|NA | |NA | ||
| Line 12,562: | Line 12,258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0245443 HSALNT0245443] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0245443 HSALNT0245443] | ||
| − | | | + | |[[NONHSAT056039]] |
|ncRAN,Nbla12061,Nbla10727 | |ncRAN,Nbla12061,Nbla10727 | ||
|NA | |NA | ||
| Line 12,570: | Line 12,266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288897 HSALNT0288897] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288897 HSALNT0288897] | ||
| − | |BOK-AS1 | + | |[[BOK-AS1]] |
|BOKA,NCRNA00151,NAToB | |BOKA,NCRNA00151,NAToB | ||
|NA | |NA | ||
| Line 12,578: | Line 12,274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289532 HSALNT0289532] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289532 HSALNT0289532] | ||
| − | | | + | |[[NONHSAT113149]] |
|7-3 RNA,K-RNA,7SK-RNA,7SK snRNA,RN7SK,ENSG00000202198,NONHSAT113149 | |7-3 RNA,K-RNA,7SK-RNA,7SK snRNA,RN7SK,ENSG00000202198,NONHSAT113149 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,586: | Line 12,282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289182 HSALNT0289182] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289182 HSALNT0289182] | ||
| − | |MIR4435-2HG | + | |[[MIR4435-2HG]] |
|MIR4435-1HG,LINC00978,AGD2,AK001796,lncRNA-AWPPH,MORRBID | |MIR4435-1HG,LINC00978,AGD2,AK001796,lncRNA-AWPPH,MORRBID | ||
|NA | |NA | ||
| Line 12,594: | Line 12,290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289200 HSALNT0289200] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289200 HSALNT0289200] | ||
| − | |PARTICL | + | |[[PARTICL]] |
|PARTICLE | |PARTICLE | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,602: | Line 12,298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289172 HSALNT0289172] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289172 HSALNT0289172] | ||
| − | | | + | |[[ENST00000517411.1]] |
|LINC01604,TCONS_00015189 | |LINC01604,TCONS_00015189 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 12,610: | Line 12,306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0001792 HSALNT0001792] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0001792 HSALNT0001792] | ||
| − | |NPPA-AS1 | + | |[[NPPA-AS1]] |
|NPPAA, NPPA-AS | |NPPAA, NPPA-AS | ||
|splicing regulation | |splicing regulation | ||
| Line 12,618: | Line 12,314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290230 HSALNT0290230] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290230 HSALNT0290230] | ||
| − | |RRP1B | + | |[[RRP1B]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,626: | Line 12,322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289467 HSALNT0289467] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289467 HSALNT0289467] | ||
| − | |CLLU1 | + | |[[CLLU1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 12,634: | Line 12,330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289173 HSALNT0289173] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289173 HSALNT0289173] | ||
| − | | | + | |[[ENST00000531381.1]] |
|AGD1,lncRNA-N2,linc-NeD125 | |AGD1,lncRNA-N2,linc-NeD125 | ||
|NA | |NA | ||
| Line 12,642: | Line 12,338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0059175 HSALNT0059175] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0059175 HSALNT0059175] | ||
| − | | | + | |[[NONHSAT091315]] |
|LINC00902,LSAMP-AS1,LSAMP-AS3,LSAMPAS3,NCRNA00295 | |LINC00902,LSAMP-AS1,LSAMP-AS3,LSAMPAS3,NCRNA00295 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 12,650: | Line 12,346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289647 HSALNT0289647] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289647 HSALNT0289647] | ||
| − | |BC040587 | + | |[[BC040587]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 12,658: | Line 12,354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0059186 HSALNT0059186] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0059186 HSALNT0059186] | ||
| − | |LINC00901 | + | |[[LINC00901]] |
|LSAMP-AS4,TCONS_00005428,BC040587 | |LSAMP-AS4,TCONS_00005428,BC040587 | ||
|NA | |NA | ||
| Line 12,666: | Line 12,362: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0233366 HSALNT0233366] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0233366 HSALNT0233366] | ||
| − | |HCCAT5 | + | |[[HCCAT5]] |
|HTA,FJ222407 | |HTA,FJ222407 | ||
|NA | |NA | ||
| Line 12,674: | Line 12,370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290040 HSALNT0290040] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290040 HSALNT0290040] | ||
| − | |LSINCT5 | + | |[[LSINCT5]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 12,682: | Line 12,378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0179611 HSALNT0179611] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0179611 HSALNT0179611] | ||
| − | |DISC1FP1 | + | |[[DISC1FP1]] |
|Boymaw | |Boymaw | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,690: | Line 12,386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0217643 HSALNT0217643] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0217643 HSALNT0217643] | ||
| − | |SNHG14 | + | |[[SNHG14]] |
|115HG,IC-SNURF-SNRPN,LNCAT,NCRNA00214,U-UBE3A-AT, UBE3A-A, UBE3A-AS1,UBE3AATS | |115HG,IC-SNURF-SNRPN,LNCAT,NCRNA00214,U-UBE3A-AT, UBE3A-A, UBE3A-AS1,UBE3AATS | ||
|ceRNA | |ceRNA | ||
| Line 12,698: | Line 12,394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289273 HSALNT0289273] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289273 HSALNT0289273] | ||
| − | |TP73-AS1 | + | |[[TP73-AS1]] |
|KIAA0495,PDAM | |KIAA0495,PDAM | ||
|NA | |NA | ||
| Line 12,706: | Line 12,402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290311 HSALNT0290311] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290311 HSALNT0290311] | ||
| − | |TP53COR1 | + | |[[TP53COR1]] |
|Trp53cor1 | |Trp53cor1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,714: | Line 12,410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289221 HSALNT0289221] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289221 HSALNT0289221] | ||
| − | | | + | |[[NONHSAT129019]] |
|CARLo-3,PCAT8 | |CARLo-3,PCAT8 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,722: | Line 12,418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0020131 HSALNT0020131] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0020131 HSALNT0020131] | ||
| − | |PCAT6 | + | |[[PCAT6]] |
|KDM5B-AS1,ncRNA-a2,PCAN-R1,KDM5BAS1,onco-lncRNA-96 | |KDM5B-AS1,ncRNA-a2,PCAN-R1,KDM5BAS1,onco-lncRNA-96 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,730: | Line 12,426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289277 HSALNT0289277] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289277 HSALNT0289277] | ||
| − | |TRERNA1 | + | |[[TRERNA1]] |
|LINC00651,ncRNA-a7,treRNA | |LINC00651,ncRNA-a7,treRNA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,738: | Line 12,434: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0014972 HSALNT0014972] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0014972 HSALNT0014972] | ||
| − | | | + | |[[ENST00000416894.1]] |
|LINC00568,ncRNA-a1,FAL1 | |LINC00568,ncRNA-a1,FAL1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,746: | Line 12,442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290008 HSALNT0290008] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290008 HSALNT0290008] | ||
| − | | | + | |[[Lnc-SNAI1-1:1]] |
|Noncoding RNA activating7: ncRNA-a7,ENST00000431460.1,ENSG00000231265,TRERNA1 | |Noncoding RNA activating7: ncRNA-a7,ENST00000431460.1,ENSG00000231265,TRERNA1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,754: | Line 12,450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290248 HSALNT0290248] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290248 HSALNT0290248] | ||
| − | | | + | |[[Lnc-BSPH1-1:1]] |
|EU035784.1,lnc-BSPH1-1:1 | |EU035784.1,lnc-BSPH1-1:1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,762: | Line 12,458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289342 HSALNT0289342] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289342 HSALNT0289342] | ||
| − | | | + | |[[Lnc-ZCCHC13-1:1]] |
|NCRNA00183,ENOX,LINC00183,DCBALD06 | |NCRNA00183,ENOX,LINC00183,DCBALD06 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,768: | Line 12,464: | ||
|hepatocellular cancer | |hepatocellular cancer | ||
|Neoplasms;Digestive System Diseases | |Neoplasms;Digestive System Diseases | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289280 HSALNT0289280] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289280 HSALNT0289280] | ||
| − | |VLDLR-AS1 | + | |[[VLDLR-AS1]] |
|lincRNA-VLDLR | |lincRNA-VLDLR | ||
|NA | |NA | ||
| Line 12,786: | Line 12,474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288982 HSALNT0288982] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288982 HSALNT0288982] | ||
| − | | | + | |[[ENST00000602812.1]] |
|NCRNA00182,MIR374AHG,LINC00182,FLJ33139 | |NCRNA00182,MIR374AHG,LINC00182,FLJ33139 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,794: | Line 12,482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0091079 HSALNT0091079] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0091079 HSALNT0091079] | ||
| − | |MEF2C-AS1 | + | |[[MEF2C-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 12,802: | Line 12,490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0189341 HSALNT0189341] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0189341 HSALNT0189341] | ||
| − | |PCBP2-OT1 | + | |[[PCBP2-OT1]] |
|TUC338 | |TUC338 | ||
|NA | |NA | ||
| Line 12,810: | Line 12,498: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290373 HSALNT0290373] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290373 HSALNT0290373] | ||
| − | |WRAP53 | + | |[[WRAP53]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 12,818: | Line 12,506: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289265 HSALNT0289265] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289265 HSALNT0289265] | ||
| − | | | + | |[[NONHSAT112472]] |
|LINC00532,lincRNA-NRNA024015 | |LINC00532,lincRNA-NRNA024015 | ||
|NA | |NA | ||
| Line 12,826: | Line 12,514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289175 HSALNT0289175] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289175 HSALNT0289175] | ||
| − | | | + | |[[NONHSAT081499]] |
|MIRHG2,BIC,NCRNA00172 | |MIRHG2,BIC,NCRNA00172 | ||
|NA | |NA | ||
| Line 12,834: | Line 12,522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289051 HSALNT0289051] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289051 HSALNT0289051] | ||
| − | |LINC00620 | + | |[[LINC00620]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 12,842: | Line 12,530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0120390 HSALNT0120390] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0120390 HSALNT0120390] | ||
| − | | | + | |[[NONHSAT119717]] |
|NCRNA00213,HOXA-AS6,RP1-170O19.3,HOXA13-AS1 | |NCRNA00213,HOXA-AS6,RP1-170O19.3,HOXA13-AS1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,850: | Line 12,538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289287 HSALNT0289287] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289287 HSALNT0289287] | ||
| − | | | + | |[[NONHSAT080206]] |
|C20orf199,NCRNA00275,ZNFX1-AS1,HSUP1,HSUP2 | |C20orf199,NCRNA00275,ZNFX1-AS1,HSUP1,HSUP2 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 12,858: | Line 12,546: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289259 HSALNT0289259] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289259 HSALNT0289259] | ||
| − | | | + | |[[Lnc-NDFIP1-3:1]] |
|SPRIGHTLY | |SPRIGHTLY | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,866: | Line 12,554: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0105595 HSALNT0105595] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0105595 HSALNT0105595] | ||
| − | | | + | |[[Lnc-CDKN1A-1:1]] |
|PANDA | |PANDA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,874: | Line 12,562: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0068185 HSALNT0068185] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0068185 HSALNT0068185] | ||
| − | |HTT-AS | + | |[[HTT-AS]] |
|HTT-AS1,HTTAS | |HTT-AS1,HTTAS | ||
|NA | |NA | ||
| Line 12,882: | Line 12,570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0099036 HSALNT0099036] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0099036 HSALNT0099036] | ||
| − | |HEIH | + | |[[HEIH]] |
|LINC-HEIH,lncRNA-HEIH,LINC00848,HCCAT2 | |LINC-HEIH,lncRNA-HEIH,LINC00848,HCCAT2 | ||
|NA | |NA | ||
| Line 12,890: | Line 12,578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0222533 HSALNT0222533] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0222533 HSALNT0222533] | ||
| − | |NPTN-IT1 | + | |[[NPTN-IT1]] |
|lncRNA-LET | |lncRNA-LET | ||
|NA | |NA | ||
| Line 12,898: | Line 12,586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289747 HSALNT0289747] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289747 HSALNT0289747] | ||
| − | |DQ786243 | + | |[[DQ786243]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,906: | Line 12,594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289204 HSALNT0289204] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289204 HSALNT0289204] | ||
| − | | | + | |[[ENST00000561978.1]] |
|PCAT-1,PCA1 | |PCAT-1,PCA1 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 12,914: | Line 12,602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0275894 HSALNT0275894] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0275894 HSALNT0275894] | ||
| − | |PCAT14 | + | |[[PCAT14]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 12,922: | Line 12,610: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0211999 HSALNT0211999] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0211999 HSALNT0211999] | ||
| − | |HIF1A-AS2 | + | |[[HIF1A-AS2]] |
|3'aHIF-1A,aHIF | |3'aHIF-1A,aHIF | ||
|translational control | |translational control | ||
| Line 12,930: | Line 12,618: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288999 HSALNT0288999] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288999 HSALNT0288999] | ||
| − | |HIF1A-AS1 | + | |[[HIF1A-AS1]] |
|5'aHIF-1A,5'aHIF1alpha | |5'aHIF-1A,5'aHIF1alpha | ||
|NA | |NA | ||
| Line 12,938: | Line 12,626: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289258 HSALNT0289258] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289258 HSALNT0289258] | ||
| − | |SOX2-OT | + | |[[SOX2-OT]] |
|SOX2OT,DKFZp761J1324,NCRNA00043 | |SOX2OT,DKFZp761J1324,NCRNA00043 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,946: | Line 12,634: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289700 HSALNT0289700] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289700 HSALNT0289700] | ||
| − | |CDR1-AS | + | |[[CDR1-AS]] |
|CDR1NAT,ciRS-7,CDR1as | |CDR1NAT,ciRS-7,CDR1as | ||
|ceRNA | |ceRNA | ||
| Line 12,954: | Line 12,642: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289149 HSALNT0289149] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289149 HSALNT0289149] | ||
| − | |LINCMD1 | + | |[[LINCMD1]] |
|MIR133BHG,LINC-MD1 | |MIR133BHG,LINC-MD1 | ||
|ceRNA | |ceRNA | ||
| Line 12,962: | Line 12,650: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288894 HSALNT0288894] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288894 HSALNT0288894] | ||
| − | |BGLT3 | + | |[[BGLT3]] |
|LINC01083,BGL3,lncRNA-BGL3 | |LINC01083,BGL3,lncRNA-BGL3 | ||
|ceRNA | |ceRNA | ||
| Line 12,970: | Line 12,658: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289042 HSALNT0289042] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289042 HSALNT0289042] | ||
| − | |LINC00473 | + | |[[LINC00473]] |
|C6orf176,bA142J11.1 | |C6orf176,bA142J11.1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,978: | Line 12,666: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0101681 HSALNT0101681] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0101681 HSALNT0101681] | ||
| − | |LINC01108 | + | |[[LINC01108]] |
|LncRNA-ES1 | |LncRNA-ES1 | ||
|NA | |NA | ||
| Line 12,986: | Line 12,674: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289418 HSALNT0289418] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289418 HSALNT0289418] | ||
| − | |TUNAR | + | |[[TUNAR]] |
|LINC00617,TUNA,HI-LNC78 | |LINC00617,TUNA,HI-LNC78 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 12,994: | Line 12,682: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289197 HSALNT0289197] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289197 HSALNT0289197] | ||
| − | | | + | |[[ENST00000500949.2]] |
|cyrano,linc-OIP5 | |cyrano,linc-OIP5 | ||
|NA | |NA | ||
| Line 13,002: | Line 12,690: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289046 HSALNT0289046] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289046 HSALNT0289046] | ||
| − | | | + | |[[Lnc-PRL-6:2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,010: | Line 12,698: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289656 HSALNT0289656] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289656 HSALNT0289656] | ||
| − | |BX118339 | + | |[[BX118339]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,018: | Line 12,706: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0021726 HSALNT0021726] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0021726 HSALNT0021726] | ||
| − | |LINC00538 | + | |[[LINC00538]] |
|Yiya,PROX1UT | |Yiya,PROX1UT | ||
|NA | |NA | ||
| Line 13,026: | Line 12,714: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0273249 HSALNT0273249] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0273249 HSALNT0273249] | ||
| − | |CBR3-AS1 | + | |[[CBR3-AS1]] |
|PlncRNA-1,PlncRNA1 | |PlncRNA-1,PlncRNA1 | ||
|ceRNA | |ceRNA | ||
| Line 13,034: | Line 12,722: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289179 HSALNT0289179] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289179 HSALNT0289179] | ||
| − | | | + | |[[NONHSAT130385]] |
|LOC554202,hsa-lnc-31,LncHIFCAR | |LOC554202,hsa-lnc-31,LncHIFCAR | ||
|ceRNA | |ceRNA | ||
| Line 13,042: | Line 12,730: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288925 HSALNT0288925] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288925 HSALNT0288925] | ||
| − | | | + | |[[NONHSAT096369]] |
|KIAA0114,SNHG13,ANCR,AGU2,lncRNA-ANCR | |KIAA0114,SNHG13,ANCR,AGU2,lncRNA-ANCR | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,050: | Line 12,738: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290329 HSALNT0290329] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290329 HSALNT0290329] | ||
| − | | | + | |[[Uc.388]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,058: | Line 12,746: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289842 HSALNT0289842] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289842 HSALNT0289842] | ||
| − | |FR0348383 | + | |[[FR0348383]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,066: | Line 12,754: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289279 HSALNT0289279] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289279 HSALNT0289279] | ||
| − | |TTTY15 | + | |[[TTTY15]] |
|DKFZP434I143,NCRNA00138 | |DKFZP434I143,NCRNA00138 | ||
|NA | |NA | ||
| Line 13,074: | Line 12,762: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289718 HSALNT0289718] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289718 HSALNT0289718] | ||
| − | | | + | |[[Lnc-IRX3-4:2]] |
|LOC643911,LINC00180,CRNDEP | |LOC643911,LINC00180,CRNDEP | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 13,082: | Line 12,770: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289685 HSALNT0289685] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289685 HSALNT0289685] | ||
| − | |CCND1 | + | |[[CCND1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,090: | Line 12,778: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289935 HSALNT0289935] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289935 HSALNT0289935] | ||
| − | | | + | |[[LincRNA-p21]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,098: | Line 12,786: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290134 HSALNT0290134] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290134 HSALNT0290134] | ||
| − | |PCNCR1 | + | |[[PCNCR1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,106: | Line 12,794: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289492 HSALNT0289492] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289492 HSALNT0289492] | ||
| − | | | + | |[[NONHSAT099821]] |
|DBE-T,DUX4L30 | |DBE-T,DUX4L30 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,114: | Line 12,802: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289455 HSALNT0289455] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289455 HSALNT0289455] | ||
| − | |BANCR | + | |[[BANCR]] |
|LINC00586 | |LINC00586 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,122: | Line 12,810: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0209589 HSALNT0209589] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0209589 HSALNT0209589] | ||
| − | | | + | |[[ENST00000556013.2]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 13,128: | Line 12,816: | ||
|papillary thyroid cancer;thyroid cancer | |papillary thyroid cancer;thyroid cancer | ||
|Endocrine System Diseases;Neoplasms | |Endocrine System Diseases;Neoplasms | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289103 HSALNT0289103] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289103 HSALNT0289103] | ||
| − | |LINC01268 | + | |[[LINC01268]] |
|LOC285758 | |LOC285758 | ||
|NA | |NA | ||
| Line 13,146: | Line 12,826: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289070 HSALNT0289070] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289070 HSALNT0289070] | ||
| − | |LINC00887 | + | |[[LINC00887]] |
|linc-ATP13A4-8,HEIRCC | |linc-ATP13A4-8,HEIRCC | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,154: | Line 12,834: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288931 HSALNT0288931] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288931 HSALNT0288931] | ||
| − | | | + | |[[NONHSAT035954]] |
|C14orf167,PRO1488,AS1DHRS4 | |C14orf167,PRO1488,AS1DHRS4 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,162: | Line 12,842: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288974 HSALNT0288974] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288974 HSALNT0288974] | ||
| − | |FENDRR | + | |[[FENDRR]] |
|FOXF1-AS1,TCONS_00024240,lincFOXF1,onco-lncRNA-21 | |FOXF1-AS1,TCONS_00024240,lincFOXF1,onco-lncRNA-21 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,170: | Line 12,850: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0106473 HSALNT0106473] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0106473 HSALNT0106473] | ||
| − | |LINC01512 | + | |[[LINC01512]] |
|LOC100132354,TCONS_00011120,HI-LNC77 | |LOC100132354,TCONS_00011120,HI-LNC77 | ||
|NA | |NA | ||
| Line 13,178: | Line 12,858: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289059 HSALNT0289059] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289059 HSALNT0289059] | ||
| − | |LINC00673 | + | |[[LINC00673]] |
|HI-LNC75,HILNC75,LUCAIR1,SLNCR,SLNCR1 | |HI-LNC75,HILNC75,LUCAIR1,SLNCR,SLNCR1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,186: | Line 12,866: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289107 HSALNT0289107] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289107 HSALNT0289107] | ||
| − | |LINC01433 | + | |[[LINC01433]] |
|LOC728228 | |LOC728228 | ||
|NA | |NA | ||
| Line 13,194: | Line 12,874: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0143571 HSALNT0143571] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0143571 HSALNT0143571] | ||
| − | | | + | |[[NONHSAT129017]] |
|CARLo-5,onco-lncRNA-40 | |CARLo-5,onco-lncRNA-40 | ||
|ceRNA | |ceRNA | ||
| Line 13,202: | Line 12,882: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289408 HSALNT0289408] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289408 HSALNT0289408] | ||
| − | | | + | |[[ENST00000448587.1]] |
|ENST00000448587.1,FLJ90734,NCRNA00036,LINC00036,onco-lncRNA-16 | |ENST00000448587.1,FLJ90734,NCRNA00036,LINC00036,onco-lncRNA-16 | ||
|translational control | |translational control | ||
| Line 13,210: | Line 12,890: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289152 HSALNT0289152] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289152 HSALNT0289152] | ||
| − | |LNCPRESS1 | + | |[[LNCPRESS1]] |
|lncPRESS1 | |lncPRESS1 | ||
|translational control | |translational control | ||
| Line 13,218: | Line 12,898: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289145 HSALNT0289145] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289145 HSALNT0289145] | ||
| − | |LINC02561 | + | |[[LINC02561]] |
|RP11-445P17.8 | |RP11-445P17.8 | ||
|NA | |NA | ||
| Line 13,226: | Line 12,906: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289065 HSALNT0289065] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289065 HSALNT0289065] | ||
| − | |LINC00850 | + | |[[LINC00850]] |
|KUCG1 | |KUCG1 | ||
|NA | |NA | ||
| Line 13,234: | Line 12,914: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289431 HSALNT0289431] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289431 HSALNT0289431] | ||
| − | |AFAP1-AS1 | + | |[[AFAP1-AS1]] |
|AFAP1A, AFAP1-A,MGC10981 | |AFAP1A, AFAP1-A,MGC10981 | ||
|NA | |NA | ||
| Line 13,242: | Line 12,922: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289519 HSALNT0289519] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289519 HSALNT0289519] | ||
| − | |XACT | + | |[[XACT]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,250: | Line 12,930: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0248684 HSALNT0248684] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0248684 HSALNT0248684] | ||
| − | |GATA6-AS1 | + | |[[GATA6-AS1]] |
|locus5689,BM742401 | |locus5689,BM742401 | ||
|NA | |NA | ||
| Line 13,258: | Line 12,938: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289222 HSALNT0289222] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289222 HSALNT0289222] | ||
| − | | | + | |[[ENST00000430058.1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,266: | Line 12,946: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289655 HSALNT0289655] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289655 HSALNT0289655] | ||
| − | |BTG3-AS1 | + | |[[BTG3-AS1]] |
|ASBEL | |ASBEL | ||
|translational control | |translational control | ||
| Line 13,274: | Line 12,954: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289224 HSALNT0289224] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289224 HSALNT0289224] | ||
| − | | | + | |[[NONHSAT130775]] |
|NONHSAT130775,PTENpg1,PTEN2,ENSG00000237984 | |NONHSAT130775,PTENpg1,PTEN2,ENSG00000237984 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 13,282: | Line 12,962: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290129 HSALNT0290129] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290129 HSALNT0290129] | ||
| − | |PAN | + | |[[PAN]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,290: | Line 12,970: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289939 HSALNT0289939] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289939 HSALNT0289939] | ||
| − | |LINC-ROR | + | |[[LINC-ROR]] |
|lincRNA-RoR,lincRNA-ST8SIA3,ROR | |lincRNA-RoR,lincRNA-ST8SIA3,ROR | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 13,298: | Line 12,978: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290322 HSALNT0290322] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290322 HSALNT0290322] | ||
| − | |UBE3A-ATS | + | |[[UBE3A-ATS]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,306: | Line 12,986: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0091004 HSALNT0091004] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0091004 HSALNT0091004] | ||
| − | |LINC00461 | + | |[[LINC00461]] |
|EyeLinc1,Visc-1a,Visc-1b,Visc-2,LOC645323 | |EyeLinc1,Visc-1a,Visc-1b,Visc-2,LOC645323 | ||
|NA | |NA | ||
| Line 13,314: | Line 12,994: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289491 HSALNT0289491] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289491 HSALNT0289491] | ||
| − | |CTBP1-AS | + | |[[CTBP1-AS]] |
|PCAT10 | |PCAT10 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,322: | Line 13,002: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0037401 HSALNT0037401] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0037401 HSALNT0037401] | ||
| − | | | + | |[[ENST00000441383.1]] |
|LINC00876,AC096655.1-002 | |LINC00876,AC096655.1-002 | ||
|NA | |NA | ||
| Line 13,330: | Line 13,010: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0120344 HSALNT0120344] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0120344 HSALNT0120344] | ||
| − | | | + | |[[NONHSAT119676]] |
|HOXA3as | |HOXA3as | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,338: | Line 13,018: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0091313 HSALNT0091313] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0091313 HSALNT0091313] | ||
| − | | | + | |[[ENST00000511918.1]] |
|SCAL1 | |SCAL1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,346: | Line 13,026: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289425 HSALNT0289425] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289425 HSALNT0289425] | ||
| − | |BLACAT1 | + | |[[BLACAT1]] |
|linc-UBC1,LINC00912,onco-lncRNA-30 | |linc-UBC1,LINC00912,onco-lncRNA-30 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,354: | Line 13,034: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0149012 HSALNT0149012] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0149012 HSALNT0149012] | ||
| − | |GLIDR | + | |[[GLIDR]] |
|LINC01172,MGC21881,TCONS_00015562 | |LINC01172,MGC21881,TCONS_00015562 | ||
|NA | |NA | ||
| Line 13,362: | Line 13,042: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0217561 HSALNT0217561] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0217561 HSALNT0217561] | ||
| − | |PWAR5 | + | |[[PWAR5]] |
|PAR5,PAR-5 | |PAR5,PAR-5 | ||
|NA | |NA | ||
| Line 13,370: | Line 13,050: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289272 HSALNT0289272] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289272 HSALNT0289272] | ||
| − | |TP53TG1 | + | |[[TP53TG1]] |
|TP53AP1,H_RG012D21.9,LINC00096 | |TP53AP1,H_RG012D21.9,LINC00096 | ||
|NA | |NA | ||
| Line 13,378: | Line 13,058: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289598 HSALNT0289598] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289598 HSALNT0289598] | ||
| − | |AK126698 | + | |[[AK126698]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,386: | Line 13,066: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0217598 HSALNT0217598] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0217598 HSALNT0217598] | ||
| − | | | + | |[[NONHSAT041063]] |
|NCRNA00002 | |NCRNA00002 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,394: | Line 13,074: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0143633 HSALNT0143633] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0143633 HSALNT0143633] | ||
| − | |CCAT2 | + | |[[CCAT2]] |
|NCCP1,LINC00873 | |NCCP1,LINC00873 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,402: | Line 13,082: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289026 HSALNT0289026] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289026 HSALNT0289026] | ||
| − | |LINC00261 | + | |[[LINC00261]] |
|C20orf56,NCRNA00261,bA216C10.1,HCCDR1,TCONS_00027846,ALIEN,DEANR1,onco-lncRNA-17 | |C20orf56,NCRNA00261,bA216C10.1,HCCDR1,TCONS_00027846,ALIEN,DEANR1,onco-lncRNA-17 | ||
|NA | |NA | ||
| Line 13,410: | Line 13,090: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289078 HSALNT0289078] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289078 HSALNT0289078] | ||
| − | |LINC00982 | + | |[[LINC00982]] |
|FLJ42875 | |FLJ42875 | ||
|NA | |NA | ||
| Line 13,418: | Line 13,098: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290082 HSALNT0290082] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290082 HSALNT0290082] | ||
| − | |NEAT1_2 | + | |[[NEAT1_2]] |
|NEAT1_2 | |NEAT1_2 | ||
|protein localization | |protein localization | ||
| Line 13,426: | Line 13,106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288989 HSALNT0288989] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288989 HSALNT0288989] | ||
| − | |GATA3-AS1 | + | |[[GATA3-AS1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,434: | Line 13,114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289427 HSALNT0289427] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289427 HSALNT0289427] | ||
| − | |GNG12-AS1 | + | |[[GNG12-AS1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,442: | Line 13,122: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290395 HSALNT0290395] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290395 HSALNT0290395] | ||
| − | |YAM1 | + | |[[YAM1]] |
|Yam-1 | |Yam-1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,450: | Line 13,130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289202 HSALNT0289202] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289202 HSALNT0289202] | ||
| − | |PAX8-AS1 | + | |[[PAX8-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,458: | Line 13,138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0054469 HSALNT0054469] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0054469 HSALNT0054469] | ||
| − | |RASSF1-AS1 | + | |[[RASSF1-AS1]] |
|ANRASSF1 | |ANRASSF1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,466: | Line 13,146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290261 HSALNT0290261] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290261 HSALNT0290261] | ||
| − | |SUMO1P3 | + | |[[SUMO1P3]] |
|SUMO1P3 | |SUMO1P3 | ||
|NA | |NA | ||
| Line 13,474: | Line 13,154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289002 HSALNT0289002] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289002 HSALNT0289002] | ||
| − | |HNF1A-AS1 | + | |[[HNF1A-AS1]] |
|C12orf27,NCRNA00262,FLJ38690,HAS1 | |C12orf27,NCRNA00262,FLJ38690,HAS1 | ||
|ceRNA | |ceRNA | ||
| Line 13,482: | Line 13,162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289377 HSALNT0289377] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289377 HSALNT0289377] | ||
| − | |NIPBL-AS1 | + | |[[NIPBL-AS1]] |
|NIPBL-DT,NIPBL-AS | |NIPBL-DT,NIPBL-AS | ||
|NA | |NA | ||
| Line 13,490: | Line 13,170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289249 HSALNT0289249] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289249 HSALNT0289249] | ||
| − | |SNHG15 | + | |[[SNHG15]] |
|C7orf40,FLJ38860,MYO1GUT,Linc-Myo1g | |C7orf40,FLJ38860,MYO1GUT,Linc-Myo1g | ||
|NA | |NA | ||
| Line 13,498: | Line 13,178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0235898 HSALNT0235898] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0235898 HSALNT0235898] | ||
| − | | | + | |[[ENST00000574306.1]] |
|C17orf91,MGC14376,DKFZp686O06159 | |C17orf91,MGC14376,DKFZp686O06159 | ||
|NA | |NA | ||
| Line 13,506: | Line 13,186: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0235898 HSALNT0235898] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0235898 HSALNT0235898] | ||
| − | | | + | |[[ENST00000574306.1]] |
|C17orf91,MGC14376,DKFZp686O06159 | |C17orf91,MGC14376,DKFZp686O06159 | ||
|NA | |NA | ||
| Line 13,514: | Line 13,194: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288984 HSALNT0288984] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288984 HSALNT0288984] | ||
| − | | | + | |[[ENST00000579368.1]] |
|MTCL1-AS1,HMlincRNA717 | |MTCL1-AS1,HMlincRNA717 | ||
|NA | |NA | ||
| Line 13,522: | Line 13,202: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289369 HSALNT0289369] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289369 HSALNT0289369] | ||
| − | |MIF-AS1 | + | |[[MIF-AS1]] |
|LOC284889,MIF-AS | |LOC284889,MIF-AS | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,530: | Line 13,210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0129086 HSALNT0129086] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0129086 HSALNT0129086] | ||
| − | | | + | |[[NONHSAT123382]] |
|MKLN1-AS1,FLJ43663,PINT,LincRNA-Pint | |MKLN1-AS1,FLJ43663,PINT,LincRNA-Pint | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,538: | Line 13,218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289240 HSALNT0289240] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289240 HSALNT0289240] | ||
| − | | | + | |[[NONHSAT075852]] |
|LINC00913,SChLAP1,PCAT11 | |LINC00913,SChLAP1,PCAT11 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,546: | Line 13,226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0193241 HSALNT0193241] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0193241 HSALNT0193241] | ||
| − | |SOCS2-AS1 | + | |[[SOCS2-AS1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,554: | Line 13,234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0138824 HSALNT0138824] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0138824 HSALNT0138824] | ||
| − | |CASC9 | + | |[[CASC9]] |
|ESCCAL-1,ESSCAL1,LINC00981 | |ESCCAL-1,ESSCAL1,LINC00981 | ||
|NA | |NA | ||
| Line 13,562: | Line 13,242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0267627 HSALNT0267627] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0267627 HSALNT0267627] | ||
| − | |HNF4A-AS1 | + | |[[HNF4A-AS1]] |
|uc002xlx | |uc002xlx | ||
|NA | |NA | ||
| Line 13,570: | Line 13,250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289194 HSALNT0289194] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289194 HSALNT0289194] | ||
| − | |NKILA | + | |[[NKILA]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,578: | Line 13,258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289304 HSALNT0289304] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289304 HSALNT0289304] | ||
| − | |LINC00942 | + | |[[LINC00942]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,586: | Line 13,266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289187 HSALNT0289187] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289187 HSALNT0289187] | ||
| − | |MNX1-AS1 | + | |[[MNX1-AS1]] |
|CCAT5,LOC645249 | |CCAT5,LOC645249 | ||
|NA | |NA | ||
| Line 13,594: | Line 13,274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289518 HSALNT0289518] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289518 HSALNT0289518] | ||
| − | |VPS9D1-AS1 | + | |[[VPS9D1-AS1]] |
|MYU | |MYU | ||
|NA | |NA | ||
| Line 13,602: | Line 13,282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290266 HSALNT0290266] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290266 HSALNT0290266] | ||
| − | |TC0101441 | + | |[[TC0101441]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,610: | Line 13,290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289426 HSALNT0289426] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289426 HSALNT0289426] | ||
| − | |ERLNC1 | + | |[[ERLNC1]] |
|TC0101441,ElncRNA1 | |TC0101441,ElncRNA1 | ||
|NA | |NA | ||
| Line 13,618: | Line 13,298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290050 HSALNT0290050] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290050 HSALNT0290050] | ||
| − | | | + | |[[ENST00000416928.2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,626: | Line 13,306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0043560 HSALNT0043560] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0043560 HSALNT0043560] | ||
| − | | | + | |[[ENST00000416928.2]] |
|HOXD-AS1,Mdgt | |HOXD-AS1,Mdgt | ||
|NA | |NA | ||
| Line 13,634: | Line 13,314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289092 HSALNT0289092] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289092 HSALNT0289092] | ||
| − | |LINC01158 | + | |[[LINC01158]] |
|PANTR1,linc-Brn1a,linc-POU3F3 | |PANTR1,linc-Brn1a,linc-POU3F3 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,642: | Line 13,322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289448 HSALNT0289448] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289448 HSALNT0289448] | ||
| − | |GHET1 | + | |[[GHET1]] |
|lncRNA-GHET1 | |lncRNA-GHET1 | ||
|NA | |NA | ||
| Line 13,650: | Line 13,330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289514 HSALNT0289514] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289514 HSALNT0289514] | ||
| − | |PEG13 | + | |[[PEG13]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,658: | Line 13,338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289183 HSALNT0289183] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289183 HSALNT0289183] | ||
| − | | | + | |[[ENST00000414769.1]] |
|MGC16121,H19X | |MGC16121,H19X | ||
|NA | |NA | ||
| Line 13,666: | Line 13,346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289201 HSALNT0289201] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289201 HSALNT0289201] | ||
| − | | | + | |[[NONHSAT018635]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,674: | Line 13,354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288956 HSALNT0288956] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288956 HSALNT0288956] | ||
| − | |LINC01234 | + | |[[LINC01234]] |
|LCAL84,onco-lncRNA-32 | |LCAL84,onco-lncRNA-32 | ||
|ceRNA | |ceRNA | ||
| Line 13,682: | Line 13,362: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289021 HSALNT0289021] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289021 HSALNT0289021] | ||
| − | |CYTOR | + | |[[CYTOR]] |
|C2orf59,NCRNA00152,MGC4677 | |C2orf59,NCRNA00152,MGC4677 | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 13,690: | Line 13,370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289706 HSALNT0289706] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289706 HSALNT0289706] | ||
| − | |CHRF | + | |[[CHRF]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 13,698: | Line 13,378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0143635 HSALNT0143635] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0143635 HSALNT0143635] | ||
| − | | | + | |[[ENST00000502056.1]] |
|LINC00860,CARLo-1 | |LINC00860,CARLo-1 | ||
|NA | |NA | ||
| Line 13,706: | Line 13,386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0143672 HSALNT0143672] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0143672 HSALNT0143672] | ||
| − | |CASC11 | + | |[[CASC11]] |
|TCONS_00014535,LINC00990,CARLo-7,ENST00000518376 | |TCONS_00014535,LINC00990,CARLo-7,ENST00000518376 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,714: | Line 13,394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289032 HSALNT0289032] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289032 HSALNT0289032] | ||
| − | |LINC00323 | + | |[[LINC00323]] |
|PRED42,FLJ37173 | |PRED42,FLJ37173 | ||
|NA | |NA | ||
| Line 13,722: | Line 13,402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0024655 HSALNT0024655] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0024655 HSALNT0024655] | ||
| − | |LINC01139 | + | |[[LINC01139]] |
|LINK-A,TCONS_00000027 | |LINK-A,TCONS_00000027 | ||
|NA | |NA | ||
| Line 13,730: | Line 13,410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289018 HSALNT0289018] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289018 HSALNT0289018] | ||
| − | |LEF1-AS1 | + | |[[LEF1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,738: | Line 13,418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0247326 HSALNT0247326] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0247326 HSALNT0247326] | ||
| − | |LINC00667 | + | |[[LINC00667]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,746: | Line 13,426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290145 HSALNT0290145] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290145 HSALNT0290145] | ||
| − | |POU3F3 | + | |[[POU3F3]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,754: | Line 13,434: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0199349 HSALNT0199349] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0199349 HSALNT0199349] | ||
| − | |LINC00426 | + | |[[LINC00426]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,762: | Line 13,442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0155974 HSALNT0155974] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0155974 HSALNT0155974] | ||
| − | |LINC00963 | + | |[[LINC00963]] |
|MetaLnc9 | |MetaLnc9 | ||
|NA | |NA | ||
| Line 13,770: | Line 13,450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289211 HSALNT0289211] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289211 HSALNT0289211] | ||
| − | |PCF11-AS1 | + | |[[PCF11-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,778: | Line 13,458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289534 HSALNT0289534] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289534 HSALNT0289534] | ||
| − | |91H | + | |[[91H]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,786: | Line 13,466: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289446 HSALNT0289446] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289446 HSALNT0289446] | ||
| − | |ELFN1-AS1 | + | |[[ELFN1-AS1]] |
|MYCLo-2 | |MYCLo-2 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,794: | Line 13,474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288883 HSALNT0288883] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288883 HSALNT0288883] | ||
| − | |ACTA2-AS1 | + | |[[ACTA2-AS1]] |
|uc001kfo.1,ZXF1 | |uc001kfo.1,ZXF1 | ||
|NA | |NA | ||
| Line 13,802: | Line 13,482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289443 HSALNT0289443] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289443 HSALNT0289443] | ||
| − | | | + | |[[NONHSAT121673]] |
|RSBN1L-AS1 | |RSBN1L-AS1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,810: | Line 13,490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289986 HSALNT0289986] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289986 HSALNT0289986] | ||
| − | | | + | |[[LncRNA-MVIH]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,818: | Line 13,498: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289977 HSALNT0289977] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289977 HSALNT0289977] | ||
| − | | | + | |[[LncRNA-ATB]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 13,826: | Line 13,506: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289622 HSALNT0289622] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289622 HSALNT0289622] | ||
| − | |ATB | + | |[[ATB]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 13,834: | Line 13,514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289586 HSALNT0289586] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289586 HSALNT0289586] | ||
| − | |AK057054 | + | |[[AK057054]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,842: | Line 13,522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0278370 HSALNT0278370] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0278370 HSALNT0278370] | ||
| − | |LINC01315 | + | |[[LINC01315]] |
|lnc-C22orf32-1,C22orf32-1 | |lnc-C22orf32-1,C22orf32-1 | ||
|NA | |NA | ||
| Line 13,850: | Line 13,530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0055601 HSALNT0055601] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0055601 HSALNT0055601] | ||
| − | |ADAMTS9-AS2 | + | |[[ADAMTS9-AS2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,858: | Line 13,538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289383 HSALNT0289383] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289383 HSALNT0289383] | ||
| − | | | + | |[[ENST00000608917.1]] |
|PACER,PTGS2-AS1 | |PACER,PTGS2-AS1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,866: | Line 13,546: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289268 HSALNT0289268] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289268 HSALNT0289268] | ||
| − | |TGFB2-OT1 | + | |[[TGFB2-OT1]] |
|FLJ11812 | |FLJ11812 | ||
|ceRNA | |ceRNA | ||
| Line 13,874: | Line 13,554: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288938 HSALNT0288938] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288938 HSALNT0288938] | ||
| − | |DUBR | + | |[[DUBR]] |
|LINC00883 | |LINC00883 | ||
|ceRNA | |ceRNA | ||
| Line 13,880: | Line 13,560: | ||
|asthma and chronic obstructive pulmonary disease | |asthma and chronic obstructive pulmonary disease | ||
|Respiratory Tract Diseases | |Respiratory Tract Diseases | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289440 HSALNT0289440] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289440 HSALNT0289440] | ||
| − | | | + | |[[Lnc-FOXC1-1:1]] |
|LINC01379,TCONS_00011636 | |LINC01379,TCONS_00011636 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,898: | Line 13,570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288924 HSALNT0288924] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288924 HSALNT0288924] | ||
| − | |CYP51A1-AS1 | + | |[[CYP51A1-AS1]] |
|ENST00000453068,LRRD1-AS1 | |ENST00000453068,LRRD1-AS1 | ||
|NA | |NA | ||
| Line 13,906: | Line 13,578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289395 HSALNT0289395] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289395 HSALNT0289395] | ||
| − | |RPL34-AS1 | + | |[[RPL34-AS1]] |
|FLJ37673,RP11-462C24.1 | |FLJ37673,RP11-462C24.1 | ||
|NA | |NA | ||
| Line 13,914: | Line 13,586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289435 HSALNT0289435] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289435 HSALNT0289435] | ||
| − | |C5orf66-AS1 | + | |[[C5orf66-AS1]] |
|CTC-276P9.1,Epist | |CTC-276P9.1,Epist | ||
|NA | |NA | ||
| Line 13,922: | Line 13,594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289052 HSALNT0289052] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289052 HSALNT0289052] | ||
| − | |LINC00623 | + | |[[LINC00623]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,930: | Line 13,602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289831 HSALNT0289831] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289831 HSALNT0289831] | ||
| − | |FER1L4 | + | |[[FER1L4]] |
|FER1L4 | |FER1L4 | ||
|ceRNA | |ceRNA | ||
| Line 13,938: | Line 13,610: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288985 HSALNT0288985] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288985 HSALNT0288985] | ||
| − | | | + | |[[ENST00000426539.1]] |
|LINC01458,lncRNA-AC130710 | |LINC01458,lncRNA-AC130710 | ||
|NA | |NA | ||
| Line 13,946: | Line 13,618: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288881 HSALNT0288881] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288881 HSALNT0288881] | ||
| − | |ABHD11-AS1 | + | |[[ABHD11-AS1]] |
|WBSCR26,LINC00035,NCRNA00035 | |WBSCR26,LINC00035,NCRNA00035 | ||
|NA | |NA | ||
| Line 13,954: | Line 13,626: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0282263 HSALNT0282263] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0282263 HSALNT0282263] | ||
| − | |ZNF674-AS1 | + | |[[ZNF674-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,962: | Line 13,634: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289207 HSALNT0289207] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289207 HSALNT0289207] | ||
| − | |PCAT29 | + | |[[PCAT29]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,970: | Line 13,642: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289672 HSALNT0289672] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289672 HSALNT0289672] | ||
| − | |CADM1 | + | |[[CADM1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 13,978: | Line 13,650: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289297 HSALNT0289297] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289297 HSALNT0289297] | ||
| − | |LINC01527 | + | |[[LINC01527]] |
|lnc-SPRR2D-1,RP1-13P20.6 | |lnc-SPRR2D-1,RP1-13P20.6 | ||
|NA | |NA | ||
| Line 13,986: | Line 13,658: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289158 HSALNT0289158] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289158 HSALNT0289158] | ||
| − | |LUNAR1 | + | |[[LUNAR1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 13,994: | Line 13,666: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289830 HSALNT0289830] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289830 HSALNT0289830] | ||
| − | | | + | |[[FAR2P-1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,002: | Line 13,674: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289263 HSALNT0289263] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289263 HSALNT0289263] | ||
| − | | | + | |[[ENST00000607033.1]] |
|EYA4-AS1 | |EYA4-AS1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,010: | Line 13,682: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0145373 HSALNT0145373] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0145373 HSALNT0145373] | ||
| − | |MAFA-AS1 | + | |[[MAFA-AS1]] |
|RP11-909N17.3,TCONS_00014882 | |RP11-909N17.3,TCONS_00014882 | ||
|NA | |NA | ||
| Line 14,018: | Line 13,690: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290229 HSALNT0290229] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290229 HSALNT0290229] | ||
| − | |RPLP0P2 | + | |[[RPLP0P2]] |
|RPLP0P2 | |RPLP0P2 | ||
|NA | |NA | ||
| Line 14,026: | Line 13,698: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289291 HSALNT0289291] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289291 HSALNT0289291] | ||
| − | |ZNF295-AS1 | + | |[[ZNF295-AS1]] |
|C21orf121,NCRNA00318,PRED87 | |C21orf121,NCRNA00318,PRED87 | ||
|NA | |NA | ||
| Line 14,034: | Line 13,706: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0084473 HSALNT0084473] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0084473 HSALNT0084473] | ||
| − | |LINC01513 | + | |[[LINC01513]] |
|RP11-1C1.7,TCONS_00009352 | |RP11-1C1.7,TCONS_00009352 | ||
|NA | |NA | ||
| Line 14,042: | Line 13,714: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289471 HSALNT0289471] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289471 HSALNT0289471] | ||
| − | |IRAIN | + | |[[IRAIN]] |
|IGF1R-AS | |IGF1R-AS | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,050: | Line 13,722: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290402 HSALNT0290402] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290402 HSALNT0290402] | ||
| − | |ZNRD1-AS1 | + | |[[ZNRD1-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,058: | Line 13,730: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289504 HSALNT0289504] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289504 HSALNT0289504] | ||
| − | |LCAL1 | + | |[[LCAL1]] |
|onco-lncRNA-27 | |onco-lncRNA-27 | ||
|NA | |NA | ||
| Line 14,066: | Line 13,738: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289169 HSALNT0289169] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289169 HSALNT0289169] | ||
| − | |MHRT | + | |[[MHRT]] |
|Myheart | |Myheart | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,074: | Line 13,746: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289859 HSALNT0289859] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289859 HSALNT0289859] | ||
| − | |HA117 | + | |[[HA117]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,082: | Line 13,754: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0026673 HSALNT0026673] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0026673 HSALNT0026673] | ||
| − | | | + | |[[ENST00000414795.1]] |
|lncRNA-CMPK2 | |lncRNA-CMPK2 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,090: | Line 13,762: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289887 HSALNT0289887] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289887 HSALNT0289887] | ||
| − | |LET | + | |[[LET]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,098: | Line 13,770: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0007921 HSALNT0007921] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0007921 HSALNT0007921] | ||
| − | |NFIA-AS1 | + | |[[NFIA-AS1]] |
|RP5-833A20.1 | |RP5-833A20.1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,106: | Line 13,778: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0247156 HSALNT0247156] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0247156 HSALNT0247156] | ||
| − | |GAPLINC | + | |[[GAPLINC]] |
|LINC01540,TCONS_00026238,lncRNA-uc002kmd.1 | |LINC01540,TCONS_00026238,lncRNA-uc002kmd.1 | ||
|siRNA | |siRNA | ||
| Line 14,114: | Line 13,786: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288917 HSALNT0288917] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288917 HSALNT0288917] | ||
| − | |CERNA2 | + | |[[CERNA2]] |
|HOST2,lncRNA-HOST2 | |HOST2,lncRNA-HOST2 | ||
|ceRNA | |ceRNA | ||
| Line 14,122: | Line 13,794: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289113 HSALNT0289113] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289113 HSALNT0289113] | ||
| − | |LINC01564 | + | |[[LINC01564]] |
|TCONS_00011314 | |TCONS_00011314 | ||
|NA | |NA | ||
| Line 14,130: | Line 13,802: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289088 HSALNT0289088] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289088 HSALNT0289088] | ||
| − | |LINC01105 | + | |[[LINC01105]] |
|FLJ30594,LOC150622 | |FLJ30594,LOC150622 | ||
|NA | |NA | ||
| Line 14,138: | Line 13,810: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289464 HSALNT0289464] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289464 HSALNT0289464] | ||
| − | |AGAP2-AS1 | + | |[[AGAP2-AS1]] |
|LOC100130776,PUNISHER | |LOC100130776,PUNISHER | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,146: | Line 13,818: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288960 HSALNT0288960] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288960 HSALNT0288960] | ||
| − | |EWSAT1 | + | |[[EWSAT1]] |
|TMEM84,NCRNA00277,LINC00277,FLJ33768 | |TMEM84,NCRNA00277,LINC00277,FLJ33768 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,154: | Line 13,826: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289242 HSALNT0289242] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289242 HSALNT0289242] | ||
| − | |SLC25A25-AS1 | + | |[[SLC25A25-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,162: | Line 13,834: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289317 HSALNT0289317] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289317 HSALNT0289317] | ||
| − | |KCNK15-AS1 | + | |[[KCNK15-AS1]] |
|RP11-445H22.4 | |RP11-445H22.4 | ||
|NA | |NA | ||
| Line 14,170: | Line 13,842: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289864 HSALNT0289864] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289864 HSALNT0289864] | ||
| − | |HIF2PUT | + | |[[HIF2PUT]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,178: | Line 13,850: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289267 HSALNT0289267] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289267 HSALNT0289267] | ||
| − | |TEX41 | + | |[[TEX41]] |
|DKFZp686O1327,LINC00953 | |DKFZp686O1327,LINC00953 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,186: | Line 13,858: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290361 HSALNT0290361] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290361 HSALNT0290361] | ||
| − | |UFC1 | + | |[[UFC1]] |
|NA | |NA | ||
|transcriptional regulation;ceRNA | |transcriptional regulation;ceRNA | ||
| Line 14,194: | Line 13,866: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289886 HSALNT0289886] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289886 HSALNT0289886] | ||
| − | |LEIGC | + | |[[LEIGC]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,202: | Line 13,874: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289367 HSALNT0289367] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289367 HSALNT0289367] | ||
| − | |MDC1-AS1 | + | |[[MDC1-AS1]] |
|MDC1-AS | |MDC1-AS | ||
|NA | |NA | ||
| Line 14,210: | Line 13,882: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289190 HSALNT0289190] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289190 HSALNT0289190] | ||
| − | |NBAT1 | + | |[[NBAT1]] |
|CASC14,NBAT-1 | |CASC14,NBAT-1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,218: | Line 13,890: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0234826 HSALNT0234826] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0234826 HSALNT0234826] | ||
| − | |LINC00917 | + | |[[LINC00917]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,226: | Line 13,898: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289419 HSALNT0289419] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289419 HSALNT0289419] | ||
| − | |LINC00173 | + | |[[LINC00173]] |
|NCRNA00173,FLJ42957 | |NCRNA00173,FLJ42957 | ||
|NA | |NA | ||
| Line 14,234: | Line 13,906: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290138 HSALNT0290138] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290138 HSALNT0290138] | ||
| − | |PEG10 | + | |[[PEG10]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,242: | Line 13,914: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289136 HSALNT0289136] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289136 HSALNT0289136] | ||
| − | |LINC02224 | + | |[[LINC02224]] |
|BRCAT107,ENST00000505706 | |BRCAT107,ENST00000505706 | ||
|NA | |NA | ||
| Line 14,250: | Line 13,922: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289866 HSALNT0289866] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289866 HSALNT0289866] | ||
| − | |HIT | + | |[[HIT]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,258: | Line 13,930: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0003927 HSALNT0003927] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0003927 HSALNT0003927] | ||
| − | |SNHG12 | + | |[[SNHG12]] |
|ASLNC04080,C1orf79,LINC00100,NCRNA00100,PNAS-123 | |ASLNC04080,C1orf79,LINC00100,NCRNA00100,PNAS-123 | ||
|NA | |NA | ||
| Line 14,266: | Line 13,938: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289099 HSALNT0289099] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289099 HSALNT0289099] | ||
| − | |LINC01225 | + | |[[LINC01225]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,274: | Line 13,946: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290047 HSALNT0290047] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290047 HSALNT0290047] | ||
| − | |MALAT2 | + | |[[MALAT2]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,282: | Line 13,954: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0176345 HSALNT0176345] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0176345 HSALNT0176345] | ||
| − | | | + | |[[NONHSAT021826]] |
|LINC00057,NCRNA00057,U22HG,UHG,lncRNA16 | |LINC00057,NCRNA00057,U22HG,UHG,lncRNA16 | ||
|NA | |NA | ||
| Line 14,290: | Line 13,962: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0094592 HSALNT0094592] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0094592 HSALNT0094592] | ||
| − | |WSPAR | + | |[[WSPAR]] |
|TCONS_00009511-XLOC_004555,lncTCF7 | |TCONS_00009511-XLOC_004555,lncTCF7 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,298: | Line 13,970: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289308 HSALNT0289308] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289308 HSALNT0289308] | ||
| − | |LINC00511 | + | |[[LINC00511]] |
|onco-lncRNA-12 | |onco-lncRNA-12 | ||
|NA | |NA | ||
| Line 14,306: | Line 13,978: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289452 HSALNT0289452] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289452 HSALNT0289452] | ||
| − | |FAM83H-AS1 | + | |[[FAM83H-AS1]] |
|onco-lncRNA-3 | |onco-lncRNA-3 | ||
|NA | |NA | ||
| Line 14,314: | Line 13,986: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289041 HSALNT0289041] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289041 HSALNT0289041] | ||
| − | |LINC00472 | + | |[[LINC00472]] |
|C6orf155,dJ288M22.3,FLJ13189 | |C6orf155,dJ288M22.3,FLJ13189 | ||
|NA | |NA | ||
| Line 14,322: | Line 13,994: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289925 HSALNT0289925] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289925 HSALNT0289925] | ||
| − | | | + | |[[Linc-ITGB1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,330: | Line 14,002: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0016239 HSALNT0016239] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0016239 HSALNT0016239] | ||
| − | |LINC01133 | + | |[[LINC01133]] |
|lncRNA-PAGBC | |lncRNA-PAGBC | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,338: | Line 14,010: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289489 HSALNT0289489] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289489 HSALNT0289489] | ||
| − | |CCEPR | + | |[[CCEPR]] |
|CCHE1,lncRNA-CCHE1 | |CCHE1,lncRNA-CCHE1 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,346: | Line 14,018: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289402 HSALNT0289402] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289402 HSALNT0289402] | ||
| − | |SOX21-AS1 | + | |[[SOX21-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,354: | Line 14,026: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288905 HSALNT0288905] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288905 HSALNT0288905] | ||
| − | |CASC15 | + | |[[CASC15]] |
|LINC00340,lnc-SOX4-1 | |LINC00340,lnc-SOX4-1 | ||
|NA | |NA | ||
| Line 14,362: | Line 14,034: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289555 HSALNT0289555] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289555 HSALNT0289555] | ||
| − | |AC104699.1 | + | |[[AC104699.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,370: | Line 14,042: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0096322 HSALNT0096322] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0096322 HSALNT0096322] | ||
| − | |CLMAT3 | + | |[[CLMAT3]] |
|SPARC-AS1 | |SPARC-AS1 | ||
|NA | |NA | ||
| Line 14,378: | Line 14,050: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289233 HSALNT0289233] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289233 HSALNT0289233] | ||
| − | |RGMB-AS1 | + | |[[RGMB-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,386: | Line 14,058: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289908 HSALNT0289908] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289908 HSALNT0289908] | ||
| − | |LINC01419 | + | |[[LINC01419]] |
|LVCAT7,TCONS_00014497 | |LVCAT7,TCONS_00014497 | ||
|NA | |NA | ||
| Line 14,394: | Line 14,066: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289541 HSALNT0289541] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289541 HSALNT0289541] | ||
| − | |AB209630 | + | |[[AB209630]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,402: | Line 14,074: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289608 HSALNT0289608] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289608 HSALNT0289608] | ||
| − | |AOC4P | + | |[[AOC4P]] |
|AOC4P | |AOC4P | ||
|NA | |NA | ||
| Line 14,410: | Line 14,082: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289082 HSALNT0289082] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289082 HSALNT0289082] | ||
| − | | | + | |[[LINC01021]] |
|LINC01021,LOC643401,RP11-46C20.1 | |LINC01021,LOC643401,RP11-46C20.1 | ||
|NA | |NA | ||
| Line 14,418: | Line 14,090: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0196121 HSALNT0196121] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0196121 HSALNT0196121] | ||
| − | |LINC01089 | + | |[[LINC01089]] |
|LIMT | |LIMT | ||
|NA | |NA | ||
| Line 14,426: | Line 14,098: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0123080 HSALNT0123080] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0123080 HSALNT0123080] | ||
| − | |EGFR-AS1 | + | |[[EGFR-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,434: | Line 14,106: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289539 HSALNT0289539] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289539 HSALNT0289539] | ||
| − | |AB073614 | + | |[[AB073614]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,442: | Line 14,114: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0242418 HSALNT0242418] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0242418 HSALNT0242418] | ||
| − | |CACNA1G-AS1 | + | |[[CACNA1G-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,450: | Line 14,122: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0170814 HSALNT0170814] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0170814 HSALNT0170814] | ||
| − | |MIR210HG | + | |[[MIR210HG]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,458: | Line 14,130: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288979 HSALNT0288979] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288979 HSALNT0288979] | ||
| − | |FOXC2-AS1 | + | |[[FOXC2-AS1]] |
|ODRUL | |ODRUL | ||
|NA | |NA | ||
| Line 14,466: | Line 14,138: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289022 HSALNT0289022] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289022 HSALNT0289022] | ||
| − | |LINC00160 | + | |[[LINC00160]] |
|C21orf52,NCRNA00160 | |C21orf52,NCRNA00160 | ||
|NA | |NA | ||
| Line 14,474: | Line 14,146: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0105274 HSALNT0105274] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0105274 HSALNT0105274] | ||
| − | |LINC01016 | + | |[[LINC01016]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,482: | Line 14,154: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288904 HSALNT0288904] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288904 HSALNT0288904] | ||
| − | |CARMN | + | |[[CARMN]] |
|MIR143HG,CARMEN | |MIR143HG,CARMEN | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,490: | Line 14,162: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289123 HSALNT0289123] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289123 HSALNT0289123] | ||
| − | |LINC01630 | + | |[[LINC01630]] |
|LOC100287225 | |LOC100287225 | ||
|NA | |NA | ||
| Line 14,498: | Line 14,170: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288971 HSALNT0288971] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288971 HSALNT0288971] | ||
| − | |FAM30A | + | |[[FAM30A]] |
|C14orf110,KIAA0125,HSPC053 | |C14orf110,KIAA0125,HSPC053 | ||
|NA | |NA | ||
| Line 14,506: | Line 14,178: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289506 HSALNT0289506] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289506 HSALNT0289506] | ||
| − | |LINC00346 | + | |[[LINC00346]] |
|C13orf29,NCRNA00346 | |C13orf29,NCRNA00346 | ||
|NA | |NA | ||
| Line 14,514: | Line 14,186: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289643 HSALNT0289643] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289643 HSALNT0289643] | ||
| − | |BC032469 | + | |[[BC032469]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 14,522: | Line 14,194: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289580 HSALNT0289580] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289580 HSALNT0289580] | ||
| − | |AK024171 | + | |[[AK024171]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,530: | Line 14,202: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290187 HSALNT0290187] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290187 HSALNT0290187] | ||
| − | |RP11-284N8.3.1 | + | |[[RP11-284N8.3.1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,538: | Line 14,210: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289839 HSALNT0289839] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289839 HSALNT0289839] | ||
| − | |FMR6 | + | |[[FMR6]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,546: | Line 14,218: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290152 HSALNT0290152] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290152 HSALNT0290152] | ||
| − | |PRAL | + | |[[PRAL]] |
|lncRNA-PRAL | |lncRNA-PRAL | ||
|NA | |NA | ||
| Line 14,554: | Line 14,226: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289380 HSALNT0289380] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289380 HSALNT0289380] | ||
| − | |NORAD | + | |[[NORAD]] |
|LINC00657 | |LINC00657 | ||
|transcriptional regulation;translational control | |transcriptional regulation;translational control | ||
| Line 14,562: | Line 14,234: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0086803 HSALNT0086803] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0086803 HSALNT0086803] | ||
| − | |LIFR-AS1 | + | |[[LIFR-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,570: | Line 14,242: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0076183 HSALNT0076183] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0076183 HSALNT0076183] | ||
| − | |PANCR | + | |[[PANCR]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,578: | Line 14,250: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288975 HSALNT0288975] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288975 HSALNT0288975] | ||
| − | |FEZF1-AS1 | + | |[[FEZF1-AS1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,586: | Line 14,258: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0238475 HSALNT0238475] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0238475 HSALNT0238475] | ||
| − | |CCDC144NL-AS1 | + | |[[CCDC144NL-AS1]] |
|NA | |NA | ||
|ceRNA | |ceRNA | ||
| Line 14,594: | Line 14,266: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290102 HSALNT0290102] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290102 HSALNT0290102] | ||
| − | |NR_026689 | + | |[[NR_026689]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,602: | Line 14,274: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289522 HSALNT0289522] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289522 HSALNT0289522] | ||
| − | |ADARB2-AS1 | + | |[[ADARB2-AS1]] |
|C10orf109,NCRNA00168,bA466B20.1 | |C10orf109,NCRNA00168,bA466B20.1 | ||
|NA | |NA | ||
| Line 14,610: | Line 14,282: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288936 HSALNT0288936] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288936 HSALNT0288936] | ||
| − | |DPP10-AS1 | + | |[[DPP10-AS1]] |
|BC032913 | |BC032913 | ||
|NA | |NA | ||
| Line 14,618: | Line 14,290: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289474 HSALNT0289474] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289474 HSALNT0289474] | ||
| − | |GAS8-AS1 | + | |[[GAS8-AS1]] |
|C16orf3 | |C16orf3 | ||
|NA | |NA | ||
| Line 14,626: | Line 14,298: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289063 HSALNT0289063] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289063 HSALNT0289063] | ||
| − | | | + | |[[LINC00704]] |
|LINC00704 | |LINC00704 | ||
|NA | |NA | ||
| Line 14,634: | Line 14,306: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289238 HSALNT0289238] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289238 HSALNT0289238] | ||
| − | |SAMMSON | + | |[[SAMMSON]] |
|LINC01212 | |LINC01212 | ||
|NA | |NA | ||
| Line 14,642: | Line 14,314: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289027 HSALNT0289027] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289027 HSALNT0289027] | ||
| − | |LINC00302 | + | |[[LINC00302]] |
|C1orf46,NCRNA00302,XP33 | |C1orf46,NCRNA00302,XP33 | ||
|NA | |NA | ||
| Line 14,650: | Line 14,322: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0245543 HSALNT0245543] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0245543 HSALNT0245543] | ||
| − | |SNHG20 | + | |[[SNHG20]] |
|C17orf86,NCRNA00338,LINC00338,PRO0872,FLJ25582,DKFZp686L05235,SCARNA16HG | |C17orf86,NCRNA00338,LINC00338,PRO0872,FLJ25582,DKFZp686L05235,SCARNA16HG | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,658: | Line 14,330: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0015631 HSALNT0015631] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0015631 HSALNT0015631] | ||
| − | |DCST1-AS1 | + | |[[DCST1-AS1]] |
|RP11-307C12.11 | |RP11-307C12.11 | ||
|NA | |NA | ||
| Line 14,666: | Line 14,338: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0149810 HSALNT0149810] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0149810 HSALNT0149810] | ||
| − | |PGM5-AS1 | + | |[[PGM5-AS1]] |
|FAM233A,LOC572558 | |FAM233A,LOC572558 | ||
|NA | |NA | ||
| Line 14,674: | Line 14,346: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290236 HSALNT0290236] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290236 HSALNT0290236] | ||
| − | |SBF2-AS1 | + | |[[SBF2-AS1]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,682: | Line 14,354: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290325 HSALNT0290325] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290325 HSALNT0290325] | ||
| − | | | + | |[[Uc.338]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,688: | Line 14,360: | ||
|hepatocellular cancer;lung cancer | |hepatocellular cancer;lung cancer | ||
|Respiratory Tract Diseases;Neoplasms;Digestive System Diseases | |Respiratory Tract Diseases;Neoplasms;Digestive System Diseases | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290002 HSALNT0290002] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0290002 HSALNT0290002] | ||
| − | |LOC100130476 | + | |[[LOC100130476]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,706: | Line 14,370: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289049 HSALNT0289049] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289049 HSALNT0289049] | ||
| − | | | + | |[[Lnc-TNKS-1:1]] |
|Rncr3 | |Rncr3 | ||
|NA | |NA | ||
| Line 14,714: | Line 14,378: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0020406 HSALNT0020406] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0020406 HSALNT0020406] | ||
| − | |LINC00628 | + | |[[LINC00628]] |
|NA | |NA | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,722: | Line 14,386: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289478 HSALNT0289478] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289478 HSALNT0289478] | ||
| − | |DSCR4 | + | |[[DSCR4]] |
|DCRB | |DCRB | ||
|NA | |NA | ||
| Line 14,730: | Line 14,394: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0017675 HSALNT0017675] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0017675 HSALNT0017675] | ||
| − | |GAS5-AS1 | + | |[[GAS5-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,738: | Line 14,402: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289523 HSALNT0289523] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289523 HSALNT0289523] | ||
| − | |HCG11 | + | |[[HCG11]] |
|bK14H9.3,FLJ14049,FLJ30357 | |bK14H9.3,FLJ14049,FLJ30357 | ||
|NA | |NA | ||
| Line 14,746: | Line 14,410: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0134828 HSALNT0134828] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0134828 HSALNT0134828] | ||
| − | |LINC02099 | + | |[[LINC02099]] |
|AC145110.1 | |AC145110.1 | ||
|NA | |NA | ||
| Line 14,754: | Line 14,418: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0209098 HSALNT0209098] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0209098 HSALNT0209098] | ||
| − | |G2E3-AS1 | + | |[[G2E3-AS1]] |
|CAT1647 | |CAT1647 | ||
|NA | |NA | ||
| Line 14,762: | Line 14,426: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289139 HSALNT0289139] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289139 HSALNT0289139] | ||
| − | |LINC02245 | + | |[[LINC02245]] |
|lnc-SERTAD2-3,AC007386.2 | |lnc-SERTAD2-3,AC007386.2 | ||
|NA | |NA | ||
| Line 14,770: | Line 14,434: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0008167 HSALNT0008167] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0008167 HSALNT0008167] | ||
| − | |FOXD3-AS1 | + | |[[FOXD3-AS1]] |
|pasFOXD3 | |pasFOXD3 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,778: | Line 14,442: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289335 HSALNT0289335] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289335 HSALNT0289335] | ||
| − | |LINC00998 | + | |[[LINC00998]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,786: | Line 14,450: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289379 HSALNT0289379] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289379 HSALNT0289379] | ||
| − | |NNT-AS1 | + | |[[NNT-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,794: | Line 14,458: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0055497 HSALNT0055497] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0055497 HSALNT0055497] | ||
| − | |PSMD6-AS1 | + | |[[PSMD6-AS1]] |
|ENST00000462717,lnc00462717 | |ENST00000462717,lnc00462717 | ||
|NA | |NA | ||
| Line 14,802: | Line 14,466: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289130 HSALNT0289130] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289130 HSALNT0289130] | ||
| − | |LINC02081 | + | |[[LINC02081]] |
|CTD-2357A8.3,XLOC_012582 | |CTD-2357A8.3,XLOC_012582 | ||
|NA | |NA | ||
| Line 14,810: | Line 14,474: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289306 HSALNT0289306] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289306 HSALNT0289306] | ||
| − | |LINC00052 | + | |[[LINC00052]] |
|TMEM83,NCRNA00052,FLJ31461 | |TMEM83,NCRNA00052,FLJ31461 | ||
|ceRNA | |ceRNA | ||
| Line 14,818: | Line 14,482: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0199070 HSALNT0199070] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0199070 HSALNT0199070] | ||
| − | |PLUT | + | |[[PLUT]] |
|PDX1-AS1,PLUTO,HI-LNC71 | |PDX1-AS1,PLUTO,HI-LNC71 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,826: | Line 14,490: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289341 HSALNT0289341] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289341 HSALNT0289341] | ||
| − | |LINC01505 | + | |[[LINC01505]] |
|RP11-308N19.1 | |RP11-308N19.1 | ||
|NA | |NA | ||
| Line 14,834: | Line 14,498: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289315 HSALNT0289315] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289315 HSALNT0289315] | ||
| − | |LINC01116 | + | |[[LINC01116]] |
|TALNEC2 | |TALNEC2 | ||
|transcriptional regulation | |transcriptional regulation | ||
| Line 14,842: | Line 14,506: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0006439 HSALNT0006439] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0006439 HSALNT0006439] | ||
| − | |FOXD2-AS1 | + | |[[FOXD2-AS1]] |
|MGC12982 | |MGC12982 | ||
|NA | |NA | ||
| Line 14,850: | Line 14,514: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0252387 HSALNT0252387] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0252387 HSALNT0252387] | ||
| − | |LINC00305 | + | |[[LINC00305]] |
|C18orf20,NCRNA00305,MGC39571,HsT1235 | |C18orf20,NCRNA00305,MGC39571,HsT1235 | ||
|NA | |NA | ||
| Line 14,858: | Line 14,522: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289473 HSALNT0289473] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289473 HSALNT0289473] | ||
| − | |FBXL19-AS1 | + | |[[FBXL19-AS1]] |
|NCRNA00095,MGC125469,MGC125470,MGC125472 | |NCRNA00095,MGC125469,MGC125470,MGC125472 | ||
|NA | |NA | ||
| Line 14,866: | Line 14,530: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0187807 HSALNT0187807] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0187807 HSALNT0187807] | ||
| − | |LINC02555 | + | |[[LINC02555]] |
|AC079630.2 | |AC079630.2 | ||
|NA | |NA | ||
| Line 14,874: | Line 14,538: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0251493 HSALNT0251493] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0251493 HSALNT0251493] | ||
| − | |LINC01929 | + | |[[LINC01929]] |
|CTD-2171N6.1 | |CTD-2171N6.1 | ||
|NA | |NA | ||
| Line 14,882: | Line 14,546: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0244776 HSALNT0244776] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0244776 HSALNT0244776] | ||
| − | |LINC01152 | + | |[[LINC01152]] |
|TCONS_00025128,CMPD | |TCONS_00025128,CMPD | ||
|NA | |NA | ||
| Line 14,890: | Line 14,554: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0284591 HSALNT0284591] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0284591 HSALNT0284591] | ||
| − | |DIAPH2-AS1 | + | |[[DIAPH2-AS1]] |
|NA | |NA | ||
|NA | |NA | ||
| Line 14,898: | Line 14,562: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289226 HSALNT0289226] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289226 HSALNT0289226] | ||
| − | |PWAR1 | + | |[[PWAR1]] |
|PAR1,PAR-1 | |PAR1,PAR-1 | ||
|NA | |NA | ||
| Line 14,906: | Line 14,570: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289339 HSALNT0289339] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289339 HSALNT0289339] | ||
| − | |LINC00950 | + | |[[LINC00950]] |
|FP588 | |FP588 | ||
|NA | |NA | ||
| Line 14,914: | Line 14,578: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289740 HSALNT0289740] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289740 HSALNT0289740] | ||
| − | |DGCR12 | + | |[[DGCR12]] |
|DGS-E | |DGS-E | ||
|NA | |NA | ||
| Line 14,922: | Line 14,586: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0275220 HSALNT0275220] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0275220 HSALNT0275220] | ||
| − | |DGCR9 | + | |[[DGCR9]] |
|DGS-A,POM121L5P | |DGS-A,POM121L5P | ||
|NA | |NA | ||
| Line 14,930: | Line 14,594: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288929 HSALNT0288929] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0288929 HSALNT0288929] | ||
| − | |DGCR10 | + | |[[DGCR10]] |
|DGS-B | |DGS-B | ||
|NA | |NA | ||
| Line 14,938: | Line 14,602: | ||
|- | |- | ||
|[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289494 HSALNT0289494] | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289494 HSALNT0289494] | ||
| − | |DGCR11 | + | |[[DGCR11]] |
|DGS-D | |DGS-D | ||
|NA | |NA | ||
|pathogenic process | |pathogenic process | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0267755 HSALNT0267755] | ||
| + | |[[LINC02597]] | ||
| + | |Long intergenic non-protein coding RNA 2597, LOC101929866 | ||
| + | |Transcriptional regulation | ||
| + | |Pathogenic process | ||
| + | |Postmenopausal osteoporosis (PMOP) | ||
| + | |Musculoskeletal Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0178412 HSALNT0178412] | ||
| + | |[[UVRAG-DT]] | ||
| + | |UVRAG divergent transcript, LOC100506113 | ||
| + | |Transcriptional regulation | ||
| + | |Pathogenic process | ||
| + | |Postmenopausal osteoporosis (PMOP) | ||
| + | |Musculoskeletal Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0185540 HSALNT0185540] | ||
| + | |[[LINC02598]] | ||
| + | |Long intergenic non-protein coding RNA 2598, RP11-277P12.9 | ||
| + | |_ | ||
| + | |Pathogenic process | ||
| + | |Lung squamous cell carcinoma (LUSC) | ||
| + | |Neoplasms; Respiratory Tract Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0278274 HSALNT0278274] | ||
| + | |[[SREBF2-AS1]] | ||
| + | |SREBF2 antisense RNA 1, RP5-821D11.7 | ||
| + | |_ | ||
| + | |Pathogenic process | ||
| + | |Lung squamous cell carcinoma (LUSC) | ||
| + | |Neoplasms; Respiratory Tract Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0021177 HSALNT0021177] | ||
| + | |[[LINC02602]] | ||
| + | |Long intergenic non-protein coding RNA 2602, TCONS_00001798 | ||
| + | |_ | ||
| + | |Pathogenic process | ||
| + | |Non-small cell lung cancer (NSCLC) | ||
| + | |Neoplasms; Respiratory Tract Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0021052 HSALNT0021052] | ||
| + | |[[MIR205HG]] | ||
| + | |MIR205 host gene, LINC00510 | ||
| + | |CeRNA | ||
| + | |Pathogenic process | ||
| + | |Head & neck squamous cell carcinoma (HNSCC) | ||
| + | |Neoplasms | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0107588 HSALNT0107588] | ||
| + | |[[ZNF451-AS1]] | ||
| + | |ZNF451 regulatory antisense RNA 1, BC032020 | ||
| + | |Transcriptional regulation | ||
| + | |Pathogenic process | ||
| + | |Pancreatic ductal adenocarcinoma (PDAC) | ||
| + | |Neoplasms | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0189537 HSALNT0189537] | ||
| + | |[[SCAT2]] | ||
| + | |S-phase cancer associated transcript 2, CBX5-AS1 | ||
| + | |_ | ||
| + | |Pathogenic process | ||
| + | |Kidney clear cell carcinoma (KIRC) | ||
| + | |Neoplasm | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0107867 HSALNT0107867] | ||
| + | |[[SCAT8]] | ||
| + | |S-phase cancer associated transcript 8, EYS-AS1 | ||
| + | |_ | ||
| + | |Pathogenic process | ||
| + | |Kidney clear cell carcinoma (KIRC) | ||
| + | |Neoplasm | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0158500 HSALNT0158500] | ||
| + | |[[LINC00707]] | ||
| + | |long intergenic non-protein coding RNA 707 | ||
| + | |Transcriptional regulation | ||
| + | |Pathogenic process | ||
| + | |Lung cancer (LC) | ||
| + | |Neoplasms; Respiratory Tract Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0185476 HSALNT0185476] | ||
| + | |[[LINC02470]] | ||
| + | |long intergenic non-protein coding RNA 2470, AC091814.2 | ||
| + | |_ | ||
| + | |Pathogenic process | ||
| + | |Non-small cell lung cancer (NSCLC) and overian cancer | ||
| + | |Neoplasm | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0068302 HSALNT0068302] | ||
| + | |[[LINC02600]] | ||
| + | |long intergenic non-protein coding RNA 2600, AC141928.1 | ||
| + | |_ | ||
| + | |Pathogenic process | ||
| + | |Non-small cell lung cancer (NSCLC) and overian cancer | ||
| + | |Neoplasm | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0123915 HSALNT0123915] | ||
| + | |[[LINC02604]] | ||
| + | |long intergenic non-protein coding RNA 2604, lncHERG | ||
| + | |CeRNA | ||
| + | |Pathogenic process | ||
| + | |Glioblastoma | ||
| + | |Neoplasms | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0160932 HSALNT0160932] | ||
| + | |[[MACORIS]] | ||
| + | |macrophage enriched lincRNA repressor of IFN-gamma signaling, MacORIS | ||
| + | |Transcriptional regulation | ||
| + | |_ | ||
| + | |Cardiometabolic Diseases | ||
| + | |Cardiovascular Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0171022 HSALNT0171022] | ||
| + | |[[KRTAP5-AS1]] | ||
| + | |KRTAP5-1/KRTAP5-2 antisense RNA 1 | ||
| + | |CeRNA | ||
| + | |Pathogenic process | ||
| + | |Gastric Cancer | ||
| + | |Neoplasms; Digestive System Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0215076 HSALNT0215076] | ||
| + | |[[GSC-DT]] | ||
| + | |GSC divergent transcript, DIGIT | ||
| + | |_ | ||
| + | | Developmental process | ||
| + | |_ | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0072605 HSALNT0072605] | ||
| + | |[[CHAER1]] | ||
| + | |Cardiac hypertrophy associated epigenetic regulator 1, Chaer | ||
| + | |Translational control | ||
| + | |Pathogenic process | ||
| + | |Cardiac hypertrophy | ||
| + | |Cardiovascular Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0027291 HSALNT0027291] | ||
| + | |[[ODC1-DT]] | ||
| + | |ODC1 divergent transcript, lncRNA-MIF | ||
| + | |CeRNA | ||
| + | |Pathogenic process | ||
| + | |Head and neck carcinoma | ||
| + | |Neoplasm | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0039409 HSALNT0039409] | ||
| + | |[[MAP3K2-DT]] | ||
| + | |MAP3K2 divergent transcript, ENST00000433673 | ||
| + | |_ | ||
| + | |Pathogenic process | ||
| + | |Polycystic ovary syndrome (PCOS) | ||
| + | |Female Urogenital Diseases and Pregnancy Complications | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0208284 HSALNT0208284] | ||
| + | |[[ZFHX2-AS1]] | ||
| + | |ZFHX2 antisense RNA 1 | ||
| + | |Transcriptional regulation | ||
| + | |Developmental process | ||
| + | |_ | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0152349 HSALNT0152349] | ||
| + | |[[LINC02603]] | ||
| + | |long intergenic non-protein coding RNA 2603, MIRLET7DHG | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0081596 HSALNT0081596] | ||
| + | |[[TENM3-AS1]] | ||
| + | |TENM3 antisense RNA 1 | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0165522 HSALNT0165522] | ||
| + | |[[LINC00858]] | ||
| + | |long intergenic non-protein coding RNA 858, LOC170425, CRCAL-2 | ||
| + | |_ | ||
| + | |_ | ||
| + | |non-small cell lung cancer | ||
| + | | Respiratory Tract Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0281930 HSALNT0281930] | ||
| + | |[[SCAT1]] | ||
| + | |S-phase cancer associated transcript 1 LINC02081, CTD-2357A8.3, XLOC_012582 | ||
| + | |_ | ||
| + | |_ | ||
| + | |esophagal cancer | ||
| + | |Digestive system Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0191750 HSALNT0191750] | ||
| + | |[[LNCOG]] | ||
| + | |lncRNA osteogenesis associated, LINC02407, RP11-54A9.1, lncRNA-OG | ||
| + | |_ | ||
| + | |_ | ||
| + | |osteogenic differenciation | ||
| + | |Musculoskeletal Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0246388 HSALNT0246388] | ||
| + | |[[DCXR-DT]] | ||
| + | |DCXR divergent transcript RP13-650J16.1 | ||
| + | |_ | ||
| + | |_ | ||
| + | |prostate cancer | ||
| + | |Male Urogenital Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0209659 HSALNT0209659] | ||
| + | |[[NKX2-1-AS1]] | ||
| + | |NKX2-1 antisense RNA 1 | ||
| + | |_ | ||
| + | |_ | ||
| + | |lung cancer | ||
| + | | Respiratory Tract Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0038250 HSALNT0038250] | ||
| + | |[[ACTR3-AS1]] | ||
| + | |ACTR3 antisense RNA 1, AC104653.1 | ||
| + | |_ | ||
| + | |_ | ||
| + | |glioblastoma | ||
| + | |Nervous system diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0043145 HSALNT0043145] | ||
| + | |[[ITGA6-AS1]] | ||
| + | |ITGA6 antisense RNA 1, AC078883.3 | ||
| + | |_ | ||
| + | |_ | ||
| + | |glioblastoma | ||
| + | |Nervous system diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0281822 HSALNT0281822] | ||
| + | |[[LINC02601]] | ||
| + | |long intergenic non-protein coding RNA 2601, RP5-1172N10.2 | ||
| + | |_ | ||
| + | |_ | ||
| + | |glioblastoma | ||
| + | |Nervous system diseases | ||
| + | |- | ||
| + | |NA | ||
| + | |[[ZKSCAN7-AS1]] | ||
| + | |ZKSCAN7 ZNF cluster antisense RNA 1, RP11-944L7.4, FLJ12738, ZFP, ZNF167, ZNF448, ZNF64, ZSCAN39 | ||
| + | |_ | ||
| + | |_ | ||
| + | |glioblastoma | ||
| + | |Nervous system diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0120721 HSALNT0120721] | ||
| + | |[[GARS-DT ]] | ||
| + | |GARS divergent transcript, AC005154.6, AC005154.1 | ||
| + | |_ | ||
| + | |_ | ||
| + | |heroine addiction | ||
| + | |Nervous system diseases | ||
| + | |- | ||
| + | |NA | ||
| + | |[[GPRACR]] | ||
| + | |GPR107 adjacent cis regulating lncRNA, LncGPR107 | ||
| + | |_ | ||
| + | |_ | ||
| + | |liver cancer | ||
| + | |Digestive system Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0082561 HSALNT0082561] | ||
| + | |[[LINC01060]] | ||
| + | |long intergenic non-protein coding RNA 1060 | ||
| + | |_ | ||
| + | |_ | ||
| + | |pancreatic cancer | ||
| + | |Digestive system Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0058704 HSALNT0058704] | ||
| + | |[[TBILA]] | ||
| + | |TGF-beta induced lncRNA, RP11-757F18.5 | ||
| + | |_ | ||
| + | |_ | ||
| + | |non-small cell lung cancer | ||
| + | | Respiratory Tract Diseases | ||
| + | |- | ||
| + | |NA | ||
| + | |[[UGDH-AS1]] | ||
| + | |UGDH antisense RNA 1 | ||
| + | |_ | ||
| + | |_ | ||
| + | |invertebral disc degeneration | ||
| + | |Musculoskeletal Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0245777 HSALNT0245777] | ||
| + | |[[TNRC6C-AS1]] | ||
| + | |NA | ||
| + | |_ | ||
| + | |_ | ||
| + | |Thyroid cancer | ||
| + | |Endocrine system Disease | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0225753 HSALNT0225753] | ||
| + | |[[LINC02244]] | ||
| + | |long intergenic non-protein coding RNA 2244, RP11-20G13.3 | ||
| + | |_ | ||
| + | |_ | ||
| + | |obesity | ||
| + | |Digestive system Diseases | ||
| + | |- | ||
| + | |NA | ||
| + | |[[NKAIN3-IT1]] | ||
| + | |NKAIN3 intronic transcript, LOC643763 | ||
| + | |_ | ||
| + | |_ | ||
| + | |glioblastoma | ||
| + | |Nervous system diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0013113 HSALNT0013113] | ||
| + | |[[NGF-AS1]] | ||
| + | |NA | ||
| + | |_ | ||
| + | |_ | ||
| + | |dysmenorhea | ||
| + | |Female Urogenital Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0031057 HSALNT0031057] | ||
| + | |[[LINC01121]] | ||
| + | |long intergenic non-protein coding RNA 1121, UNQ6975 | ||
| + | |_ | ||
| + | |_ | ||
| + | |pancreatic cancer | ||
| + | |Digestive system Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0234176 HSALNT0234176] | ||
| + | |[[ARLNC1]] | ||
| + | |androgen receptor regulated long noncoding RNA 1, LINC02170, PRCAT47 | ||
| + | |_ | ||
| + | |_ | ||
| + | |prostate cancer | ||
| + | |Male Urogenital Diseases | ||
| + | |- | ||
| + | |NA | ||
| + | |[[MPPED2-AS1]] | ||
| + | |MPPED2 antisense RNA 1, RP5-1024C24.1 | ||
| + | |_ | ||
| + | |_ | ||
| + | |thyroid neoplasias | ||
| + | |Endocrine system Disease | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC01703]] | ||
| + | |NA | ||
| + | |_ | ||
| + | |_ | ||
| + | |Hepatocellular carcinoma | ||
| + | |Digestive system Diseases | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0144162 HSALNT0144162] | ||
| + | |[[HPYR1]] | ||
| + | |Helicobacter pylori responsive 1, LINC00027 | ||
| + | |_ | ||
| + | |pathogenic process | ||
| + | |H. pylori infection | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0172266 HSALNT0172266] | ||
| + | |[[LINC00958]] | ||
| + | |long intergenic non-protein coding RNA 958, | ||
| + | |protein localization,transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |bladder cancer, glioma | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0167574 HSALNT0167574] | ||
| + | |[[SH3PXD2A-AS1]] | ||
| + | |SH3PXD2A antisense RNA 1 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |colorectal cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[SSTR5-AS1]] | ||
| + | |SSTR5 antisense RNA 1 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |neuroendocrine prostate cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[TSPOAP1-AS1]] | ||
| + | |TSPOAP1, SUPT4H1 and RNF43 antisense RNA 1 | ||
| + | |_ | ||
| + | |pathogenic process | ||
| + | |breast cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC00174]] | ||
| + | |long intergenic non-protein coding RNA 174 | ||
| + | |ceRNA | ||
| + | |pathogenic process | ||
| + | |colorectal carcinoma | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0169064 HSALNT0169064] | ||
| + | |[[LINC01561]] | ||
| + | |long intergenic non-protein coding RNA 1561 | ||
| + | |ceRNA | ||
| + | |pathogenic process | ||
| + | |breast cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC00514]] | ||
| + | |long intergenic non-protein coding RNA 514 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |neuroendocrine prostate cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0282164 HSALNT0282164] | ||
| + | |[[LINC02595]] | ||
| + | |long intergenic non-protein coding RNA 2595, AK098783 | ||
| + | |_ | ||
| + | |pathogenic process | ||
| + | |colorectal cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0197396 HSALNT0197396] | ||
| + | |[[FZD10-AS1]] | ||
| + | |FZD10 antisense divergent transcript | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC01567]] | ||
| + | |long intergenic non-protein coding RNA 1567, LOCCS | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |colon cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[ADPGK-AS1]] | ||
| + | |ADPGK antisense RNA 1 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |pancreatic cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0255381 HSALNT0255381] | ||
| + | |[[RAB11B-AS1]] | ||
| + | |RAB11B antisense RNA 1 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |osteosarcoma | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0237805 HSALNT0237805] | ||
| + | |[[SNHG29]] | ||
| + | |Small nucleolar RNA host gene 29, LRRC75A-AS1, C17orf76-AS1 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |acute myeloid leukemia, rheumatoid arthritis | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[SNHG17]] | ||
| + | |small nucleolar RNA host gene 17 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |colorectal cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0215138 HSALNT0215138] | ||
| + | |[[DICER1-AS1]] | ||
| + | |DICER1 antisense RNA 1 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |osteosarcoma | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0043929 HSALNT0043929] | ||
| + | |[[TTN-AS1]] | ||
| + | |TTN antisense RNA 1 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |esophageal squamous cell carcinoma | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0152594 HSALNT0152594] | ||
| + | |[[LINC00092]] | ||
| + | |long intergenic non-protein coding RNA 92 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |ovarian cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0050704 HSALNT0050704] | ||
| + | |[[THUMPD3-AS1]] | ||
| + | |THUMPD3 antisense RNA 1, SETD5-AS1 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |Neuron death in stroke | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0205980 HSALNT0205980] | ||
| + | |[[LINC00554]] | ||
| + | |long intergenic non-protein coding RNA 554, lncZic2 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |liver cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0141703 HSALNT0141703] | ||
| + | |[[ZFPM2-AS1]] | ||
| + | |ZFPM2 antisense RNA 1, SCAT3 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |multiple cancers, gastric carcinogenesis | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[HOXB-AS1]] | ||
| + | |HOXB cluster antisense RNA 1 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |autosomal dominant polycistic kidney disease | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0167650 HSALNT0167650] | ||
| + | |[[CFAP58-DT]] | ||
| + | |CFAP58 divergent transcript, ITPRIP-1 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |innate immune response to viral infection | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[FAM230A]] | ||
| + | |family with sequence similarity 230 member A | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[CPNE8-AS1]] | ||
| + | |CPNE8 antisense RNA 1, RP11-396F22.1 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |cervical cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[THORLNC]] | ||
| + | |testis associated oncogenic lncRNA | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |melanoma, skin squamous cell carcinoma,osteosarcoma, renal cell carcinoma | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[IATPR]] | ||
| + | |ITGB1 adjacent tumor promoting lncRNA | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |breast cancer, gallbladder cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0242280 HSALNT0242280] | ||
| + | |[[PICART1]] | ||
| + | |p53 inducible cancer associated RNA transcript 1, AC009720.1, NR_038230, LOC84080 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |breast cancer, colorectal cancer, lung cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02599]] | ||
| + | |long intergenic non-protein coding RNA 2599, AC026904.1 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |breast cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0183231 HSALNT0183231] | ||
| + | |[[ETS1-AS1]] | ||
| + | |ETS1 antisense RNA 1, pancEts-1, Ets-1 promoter-associated noncoding RNA | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |gastric cancer, neuroblastoma | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[MAPK6-DT]] | ||
| + | |MAPK6 divergent transcript, lncMAPK6 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |liver cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0036655 HSALNT0036655] | ||
| + | |[[IL1R1-AS1]] | ||
| + | |IL1R1 antisense RNA 1, AC007271.3 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |Oral squamous cell carcinoma, breast cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0001134 HSALNT0001134] | ||
| + | |[[LINC01672]] | ||
| + | |long intergenic non-protein coding RNA 1672, long intergenic non-protein coding RNA 1672 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | | Esophageal squamous cell carcinoma | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0135857 HSALNT0135857] | ||
| + | |[[SIRLNT]] | ||
| + | |SIRT1 regulating lncRNA tumor promoter, SIRT1 regulating lncRNA tumor promoter, | ||
| + | |ceRNA | ||
| + | |pathogenic process | ||
| + | | Breast cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0135484 HSALNT0135484] | ||
| + | |[[LINC01605]] | ||
| + | |long intergenic non-protein coding RNA 1605, TCONS_00014973, LincDUSP | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |Colon Cancer, Bladder cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0184552 HSALNT0184552] | ||
| + | |[[GAU1]] | ||
| + | |GALNT8 antisense upstream 1, GALNT8 divergent transcript | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |Neuroblastoma and retinoblastoma | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0287294 HSALNT0287294] | ||
| + | |[[LINC00894]] | ||
| + | |long intergenic non-protein coding RNA 894 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |Lung adenocarcinoma | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0000250 HSALNT0000250] | ||
| + | |[[LINC02593]] | ||
| + | |long intergenic non-protein coding RNA 2593, AL645608.1 | ||
| + | |_ | ||
| + | |pathogenic process | ||
| + | |breast cancer, hepatocellular carcinoma | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0241060 HSALNT0241060] | ||
| + | |[[LINC02594]] | ||
| + | |long intergenic non-protein coding RNA 2594, CTC‐501O10.1 | ||
| + | |_ | ||
| + | |_ | ||
| + | |gastric cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0022481 HSALNT0022481] | ||
| + | |[[LINC01705]] | ||
| + | |long intergenic non-protein coding RNA 1705, RP11-400N13.3 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |gastric cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0022477 HSALNT0022477] | ||
| + | |[[LINC02474]] | ||
| + | |long intergenic non-protein coding RNA 2474, RP11-400N13.2 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |gastric cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0030809 HSALNT0030809] | ||
| + | |[[LINC02590]] | ||
| + | |long intergenic non-protein coding RNA 2590, AC016735.2 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |gastric cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0170966 HSALNT0170966] | ||
| + | |[[MUC5B-AS1]] | ||
| + | |MUC5B antisense RNA 1 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | | lung adenocarcinoma | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0275151 HSALNT0275151] | ||
| + | |[[FAM230D]] | ||
| + | |family with sequence similarity 230 member D, LINC02592: long intergenic non-protein coding RNA 2592, AC008079.1 | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0275163 HSALNT0275163 ] | ||
| + | |[[FAM230E]] | ||
| + | |family with sequence similarity 230 member E, LINC01662: long intergenic non-protein coding RNA 1662 | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0275179 HSALNT0275179 ] | ||
| + | |[[FAM230F]] | ||
| + | |family with sequence similarity 230 member F, LINC01663: long intergenic non-protein coding RNA 1663 | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[FAM230G]] | ||
| + | |family with sequence similarity 230 member G, AC007731.1 | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[FAM230H]] | ||
| + | |family with sequence similarity 230 member H, AP000552.1 | ||
| + | |_ | ||
| + | |_ | ||
| + | |Papillary thyroid carcinoma | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[FAM230I]] | ||
| + | |family with sequence similarity 230 member I, LINC01658: long intergenic non-protein coding RNA 1658 | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0275150 HSALNT0275150] | ||
| + | |[[FAM230J]] | ||
| + | |family with sequence similarity 230 member J, LINC01660: long intergenic non-protein coding RNA 1660 | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0103387 HSALNT0103387] | ||
| + | |[[HCG14]] | ||
| + | |HLA complex group 14, dJ111M5.4 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |Celiac disease, Nutritional and Metabolic Diseases | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC01510]] | ||
| + | |long intergenic non-protein coding RNA 1510 | ||
| + | |transcriptional regulation, ceRNA | ||
| + | |pathogenic process | ||
| + | |Colorectal cancer, Non-small cell lung cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LNCOC1]] | ||
| + | |lncRNA associated with ovarian cancer 1, Lnc-OC1 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |Ovarian cancer | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LGALSL-DT]] | ||
| + | |LGALSL divergent transcript, LOC105374771 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |Postmenopausal osteoporosis (PMOP) | ||
| + | |_ | ||
| + | |- | ||
| + | |[https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0002862 HSALNT0002862] | ||
| + | |[[LINC02596]] | ||
| + | |long intergenic non-protein coding RNA 2596, LOC105376834 | ||
| + | |transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |Postmenopausal osteoporosis (PMOP) | ||
| + | |_ | ||
| + | |- | ||
| + | |NA | ||
| + | |[[DEC1]] | ||
| + | |deleted in esophageal cancer 1, CTS9, Candidate Tumor Suppressor CTS9 | ||
| + | |NA | ||
| + | |pathogenic process | ||
| + | |esophageal squamous cell carcinoma | ||
| + | |Neoplasms | ||
| + | |- | ||
| + | |NA | ||
| + | |[[MYOPARR]] | ||
| + | |myogenin promoter-associated myogenic regulatory antisense long non-coding RNA | ||
| + | |transcriptional regulation | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[PCED1B-AS1]] | ||
| + | |PCED1B antisense RNA 1 | ||
| + | |ceRNA | ||
| + | |pathogenic process | ||
| + | |Tuberculosis | ||
| + | |Bacterial Infections and Mycoses | ||
| + | |- | ||
| + | |NA | ||
| + | |[[UMLILO]] | ||
| + | |upstream master lncRNA of the inflammatory chemokine locus | ||
| + | |transcriptional regulation | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02631]] | ||
| + | |long intergenic non-protein coding RNA 2631, AC092620.3 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[BMNCR]] | ||
| + | |bone marrow associated non-coding RNA | ||
| + | |transcriptional regulation | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[ZEBTR]] | ||
| + | |ZEB1 transcriptional regulator RNA, LncRNA-BX111 | ||
| + | |NA | ||
| + | |pathogenic process | ||
| + | |Pancreatic cancer | ||
| + | |Neoplasms | ||
| + | |- | ||
| + | |NA | ||
| + | |[[SNHG31]] | ||
| + | |small nucleolar RNA host gene 31 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC00574]] | ||
| + | |long intergenic non-protein coding RNA 574, C6orf208, FLJ13162, dJ182D15.1, CRALA | ||
| + | |NA | ||
| + | |pathogenic process | ||
| + | |Primary breast cance | ||
| + | |Neoplasms | ||
| + | |- | ||
| + | |NA | ||
| + | |[[RCC2-AS1]] | ||
| + | |RCC2 antisense RNA 1 | ||
| + | |NA | ||
| + | |pathogenic process | ||
| + | |non-small cell lung cancer | ||
| + | |Neoplasms | ||
| + | |- | ||
| + | |NA | ||
| + | |[[PRDM16-DT]] | ||
| + | |lnc-dPrdm16 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[BCL6-AS1]] | ||
| + | |BCL6 antisense RNA 1, lnc-RP11-211G3.3.1-1 | ||
| + | |NA | ||
| + | |pathogenic process | ||
| + | |diffuse large B-cell lymphoma | ||
| + | |Neoplasms; Immune System Diseases | ||
| + | |- | ||
| + | |NA | ||
| + | |[[C1orf220]] | ||
| + | |chromosome 1 open reading frame 220, FLJ35530 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[MIR122HG]] | ||
| + | |lnc-pri-miR-122 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[PANTR1]] | ||
| + | |linc-POU3F3, linc-Brn1a, LINC01158 | ||
| + | |NA | ||
| + | |developmental process | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[C11orf72]] | ||
| + | |FLJ90834, chromosome 11 open reading frame 72 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[CT66]] | ||
| + | |cancer/testis antigen 66, cancer/testis associated transcript 66 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[CT75]] | ||
| + | |cancer/testis antigen 75 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[MIR9-3HG]] | ||
| + | |MIR9-3 host gene, LINC00925, long intergenic non-protein coding RNA 925 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[RN7SL2]] | ||
| + | |RNA component of signal recognition particle 7SL2, RNA7SL, cytoplasmic 2, 7SL1c, 7L30.1, RNSRP2 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[RN7SL3]] | ||
| + | |RNA component of signal recognition particle 7SL3, RN7SL631P, (RNA,7SL, cytoplasmic 631, pseudogene), (RNA, 7SL, cytoplasmic 3) | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[CT70]] | ||
| + | |cancer/testis associated transcript 70, cancer/testis antigen 70, LeXis | ||
| + | |ceRNA, transcriptional regulation | ||
| + | |pathogenic process | ||
| + | |osteosarcoma, colon adenocarcinoma | ||
| + | |Neoplasms | ||
| + | |- | ||
| + | |NA | ||
| + | |[[CT69]] | ||
| + | |cancer/testis associated transcript 69, cancer/testis associated transcript 69 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[C10orf91]] | ||
| + | |chromosome 10 open reading frame 91 (putative), chromosome 10 open reading frame 91, bA432J24.4 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[CTBP1-DT]] | ||
| + | |CTBP1 divergent transcript, C4orf42, CTBP1-AS1, CTBP1-AS2, chromosome 4 open reading frame 42, CTBP1 antisense RNA 1 (head to head), CTBP1 antisense RNA 2 (head to head) | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[FAM201B]] | ||
| + | |family with sequence similarity 201 member B, | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[MAFG-DT]] | ||
| + | |MAFG divergent transcript, MAFG antisense RNA 1 (non-protein coding), MAFG antisense RNA 1, MAFG antisense RNA 1 (head to head) | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[RPP38-DT]] | ||
| + | |RPP38 divergent transcript, C10orf111, chromosome 10 open reading frame 111, MGC35468, bA455B2.4 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[CDRT3]] | ||
| + | |CMT1A duplicated region transcript 3 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[DLEU2L]] | ||
| + | |deleted in lymphocytic leukemia 2 like, BCMS upstream neighbor-like, BCMSUNL | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[ARHGAP42-AS1]] | ||
| + | |AK124326 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0116707 HSALNG0116707] | ||
| + | |[[ASB16-AS1]] | ||
| + | |DKFZp762C2414,C17orf65 | ||
| + | CeRNA | ||
| + | |NA | ||
| + | Osteosarcoma | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[BAIAP2-DT]] | ||
| + | |lnc-BAIAP2,BAIAP2-AS1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0289434 HSALNT0289434] | ||
| + | |[[BASP1-AS1]] | ||
| + | |LOC285696 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[BCAN-AS1]] | ||
| + | |RP11-284F21.9 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[C2ORF27A]] | ||
| + | |C2orf27 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[CALHM6-AS1]] | ||
| + | |RP1-93H18.6 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[CAVIN2-AS1]] | ||
| + | |LOC105373813 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0108275 HSALNG0108275] | ||
| + | |[[CHASERR]] | ||
| + | |LINC01578 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[CHROMR]] | ||
| + | |CHROME,PRKRA-AS1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0119714 HSALNG0119714] | ||
| + | |[[DLGAP1-AS1]] | ||
| + | |HsT914,FLJ35776 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0119716 HSALNG0119716] | ||
| + | |[[DLGAP1-AS2]] | ||
| + | |MGC11082 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[EGILA]] | ||
| + | |Lnc-EGFR | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[ELDR]] | ||
| + | |Fabl,LINC01156 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[EMSLR]] | ||
| + | |EMS | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[EPCART]] | ||
| + | |TPCAT-2-180961,PRCAT122,PCAT-2-180961 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[EVA1A-AS]] | ||
| + | |EVA1A-AS1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0082135 HSALNG0082135] | ||
| + | |[[FAM99A]] | ||
| + | |FLJ42833 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0082137 HSALNG0082137] | ||
| + | |[[FAM99B]] | ||
| + | |DKFZp781M09150 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[FAM218A]] | ||
| + | |FLJ31659,TRIM61-AS1,C4orf39 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0099631 HSALNG0099631] | ||
| + | |[[GAS6-DT]] | ||
| + | |FLJ44054,GAS6-AS2 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0048545 HSALNT0048545] | ||
| + | |[[GCSIR]] | ||
| + | |Lnc-ITM2C-1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0047439 HSALNG0047439] | ||
| + | |[[GMDS-DT]] | ||
| + | |GMDS-AS1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0026700 HSALNT0026700] | ||
| + | |[[GRASLND]] | ||
| + | |RNF144A-AS1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[HOXC13-AS]] | ||
| + | |HOXC-AS5 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[IGFL2-AS1]] | ||
| + | |AC006262.5 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0082653 HSALNG0082653] | ||
| + | |[[IRAG1-AS1]] | ||
| + | |MRVI1-AS1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0129814 HSALNT0129814] | ||
| + | |[[KDM7A-DT]] | ||
| + | |JHDM1D-AS1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0025249 HSALNT0025249] | ||
| + | |[[KIF26B-AS1]] | ||
| + | |RP11-62I21.1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[KLRK1-AS1]] | ||
| + | |LOC101928100 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LASTR]] | ||
| + | |LINC02657 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0069631 HSALNG0069631] | ||
| + | |[[LDLR-AS1]] | ||
| + | |BM450697 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0131739 HSALNG0131739] | ||
| + | |[[LINC00266-1]] | ||
| + | |bA476I15.3,RBRP,C20orf69,NCRNA00266,NCRNA00266-1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0097328 HSALNG0097328] | ||
| + | |[[LINC00458]] | ||
| + | |LncRNA-ES3,ES3 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC00515]] | ||
| + | |PRED21,C21orf71 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0104041 HSALNG0104041] | ||
| + | |[[LINC00637]] | ||
| + | |HITT | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0122571 HSALNG0122571] | ||
| + | |[[LINC00908]] | ||
| + | |ASRPS | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0112089 HSALNG0112089] | ||
| + | |[[LINC00920]] | ||
| + | |CALIC | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0035402 HSALNG0035402] | ||
| + | |[[LINC01094]] | ||
| + | |CTEPHA1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0131038 HSALNT0131038] | ||
| + | |[[LINC01287]] | ||
| + | |TCONS_l2_00027522 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC01551]] | ||
| + | |C14orf23 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0004816 HSALNG0004816] | ||
| + | |[[LINC01555]] | ||
| + | |FLJ35487,C1orf180 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02145]] | ||
| + | |FLJ33360 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02250]] | ||
| + | |TCONS_00023273 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02303]] | ||
| + | |TRMP | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02476]] | ||
| + | |LVCAT5,lnc-TSPAN12 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0006451 HSALNT0006451] | ||
| + | |[[LINC02605]] | ||
| + | |RP11-79H23.3,IL-7,AS | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02620]] | ||
| + | |BCRT1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02682]] | ||
| + | |TCONS_00019584,lnc-SOX6-1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02835]] | ||
| + | |lncMER52A | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02859]] | ||
| + | |LncRNA-LOC101928316 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02861]] | ||
| + | |RP11-462G12.2 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02862]] | ||
| + | |AC073284.4 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02864]] | ||
| + | |RP11-169F17.1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02867]] | ||
| + | |LA16c-313D11.9 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02882]] | ||
| + | |RP11-81H3.2 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02883]] | ||
| + | |KMU15 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02886]] | ||
| + | |RP11-697M17.1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINC02891]] | ||
| + | |lnc-RTN4R-1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LINCADL]] | ||
| + | |linc-ADAL | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LNC-LBCS]] | ||
| + | |LBCS | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LNCDAT]] | ||
| + | |YYLNCT | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LNCNEF]] | ||
| + | |lncRNA-NEF,LINC01384 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[LNCTAM34A]] | ||
| + | |GUARDIN,LINC01759 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0047822 HSALNG0047822] | ||
| + | |[[LY86-AS1]] | ||
| + | |FLJ33708,LY86AS,LY86-AS | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0067477 HSALNG0067477] | ||
| + | |[[MAILR]] | ||
| + | |MAIL1,AZIN1-AS1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[MIR9-1HG]] | ||
| + | |CROC4,C1orf61 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[MIR23AHG]] | ||
| + | |LOC284454 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0159828 HSALNT0159828] | ||
| + | |[[MIR1915HG]] | ||
| + | |bA418C1.3,C10orf114,CASC10 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[NR4A1AS]] | ||
| + | |NR4A1-AS1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[NRAD1]] | ||
| + | |NCRNA00284,LINC00284 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0140217 HSALNT0140217] | ||
| + | |[[OTUD6B-AS1]] | ||
| + | |GS1-251I9.4 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0041428 HSALNG0041428] | ||
| + | |[[OXCT1-AS1]] | ||
| + | |SARRAH | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[PCSEAT]] | ||
| + | |PRCAT38 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0268592 HSALNT0268592] | ||
| + | |[[PELATON]] | ||
| + | |GCRL1,LINC01272,SMIM25 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0069519 HSALNG0069519] | ||
| + | |[[PGM5P3-AS1]] | ||
| + | |FAM233B | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0180290 HSALNT0180290] | ||
| + | |[[PGR-AS1]] | ||
| + | |AT1,AT2,AT3 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0114603 HSALNT0114603] | ||
| + | |[[PHACTR2-AS1]] | ||
| + | |NR027113,lncIHS | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0092289 HSALNG0092289] | ||
| + | |[[PRANCR]] | ||
| + | |LINC01481,CNOT2-DT | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[PSLNR]] | ||
| + | |LA16c-83F12.6 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0049455 HSALNG0049455] | ||
| + | |[[PSMB8-AS1]] | ||
| + | |XXbac-BPG246D15.8,TAP1-AS1,TAPSAR1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0055664 HSALNG0055664] | ||
| + | |[[PSMG3-AS1]] | ||
| + | |KIAA1908 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0094500 HSALNG0094500] | ||
| + | |[[PXN-AS1]] | ||
| + | |EyeLinc4 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0289231 HSALNT0289231] | ||
| + | |[[RCAN3AS]] | ||
| + | |TCONS_00001428 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0289236 HSALNT0289236] | ||
| + | |[[ROCR]] | ||
| + | |LINC02095 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[SAP30-DT]] | ||
| + | |ENST00000608794 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[SCP2D1-AS1]] | ||
| + | |dJ1068E13.1,C20orf78 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[SFTA1P]] | ||
| + | |SFTPF | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0108960 HSALNG0108960] | ||
| + | |[[SNHG9]] | ||
| + | |DKFZp686N06141,NCRNA00062 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0104616 HSALNT0104616] | ||
| + | |[[SNHG32]] | ||
| + | |D6S57,G8,C6orf48 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0118528 HSALNG0118528] | ||
| + | |[[SOX9-AS1]] | ||
| + | |FLJ37644 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[SPATA8]] | ||
| + | |MGC44294,SRG8 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[THY1-AS1]] | ||
| + | |RP11-334E6.12 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[TMEM18-DT]] | ||
| + | |AC092159.2 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[TNRC17]] | ||
| + | |CAGL234 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[TP73-AS2]] | ||
| + | |RP5-1092A11.2 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/transcript?transid=HSALNT0289424 HSALNT0289424] | ||
| + | |[[TTTY22]] | ||
| + | |NCRNA00147 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[UICLM]] | ||
| + | |CROCC2-AS1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |[https://ngdc.cncb.ac.cn/lncbook/gene?geneid=HSALNG0078695 HSALNG0078695] | ||
| + | |[[UNC5B-AS1]] | ||
| + | |UASR1 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[VPS13B-DT]] | ||
| + | |OLC8 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[WAKMAR2]] | ||
| + | |Lnc-TNFAIP3 | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |NA | ||
| + | |- | ||
| + | |NA | ||
| + | |[[ZKSCAN2-DT]] | ||
| + | |CTD-2547G23.4 | ||
| + | |NA | ||
| + | |NA | ||
|NA | |NA | ||
|NA | |NA | ||
|- | |- | ||
|} | |} | ||
Latest revision as of 13:55, 12 June 2021
| LncBook ID | Symbol | Synonyms | Functional Mechanism | Biological Process | Disease | Mesh Ontology |
|---|---|---|---|---|---|---|
| HSALNT0289501 | HPVC1 | PE5L,HPV18E5L | NA | pathogenic process | NA | NA |
| HSALNT0289605 | NONHSAT104559 | lnc-C9orf53-2:1 | NA | NA | NA | NA |
| HSALNT0199632 | N4BP2L2-IT2 | CG030 | NA | NA | NA | NA |
| HSALNT0171094 | LINC01150 | 2G7,TCONS_00019134 | NA | pathogenic process | Wilms' tumor | Neoplasms |
| HSALNT0289115 | LINC01587 | C4orf6,aC1 | NA | pathogenic process | neuroblastoma | Neoplasms |
| HSALNT0290105 | NONHSAT115106 | NONHSAT115106 | NA | NA | NA | NA |
| HSALNT0289234 | RNF217-AS1 | STL | NA | pathogenic process | acute lymphoblastic leukemia | Immune System Diseases;Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0280481 | INE2 | NCRNA00011 | NA | NA | NA | NA |
| HSALNT0289485 | INE1 | NCRNA00010 | NA | NA | NA | NA |
| HSALNT0289511 | LINC01565 | C3orf27,GR6 | NA | pathogenic process | leukemia | Neoplasms |
| HSALNT0289068 | LINC00869 | KIAA0493 | NA | NA | NA | NA |
| HSALNT0289430 | ERC2-IT1 | C1orf1,C3orf51,Po42 | NA | pathogenic process | NA | NA |
| HSALNT0290394 | Lnc-PDIA4-1:1 | lnc-PDIA4-1:1 | NA | NA | NA | NA |
| HSALNT0289195 | NOP14-AS1 | C4orf10,RES4-24 | NA | NA | NA | NA |
| HSALNT0290309 | NONHSAT022116 | NONHSAT022116,AF080092,TSU | NA | developmental process | NA | NA |
| HSALNT0289243 | SMAD5-AS1 | SMAD5O,DAMS | NA | pathogenic process | malignant hematopoietic | Cell Physiological Phenomena |
| HSALNT0289025 | LINC00244 | C7orf4,NCRNA00244 | NA | pathogenic process | preaxial polydactyly | NA |
| HSALNT0289017 | KIF25-AS1 | C6orf54,NCRNA00300,HGC6.1.1 | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289332 | LINC01558 | C6orf123,LINC01557,HGC6.2,dJ431P23.4 | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289438 | AFDN-AS1 | C6orf124,MLLT4-AS1,HGC6.4,dJ431P23.3 | NA | pathogenic process | NA | NA |
| HSALNT0289232 | RFPL3S | RFPL3-AS1,RFPL3-A, NCRNA00005 | NA | pathogenic process | opitz syndrome | NA |
| HSALNT0289393 | RFPL1S | RFPL1-AS1,RFPL1-A, NCRNA00006 | NA | pathogenic process | NA | NA |
| HSALNT0289500 | HCG4B | HCG4P6,HCGIV-6,HCGIV.5,HCGIV-06,bCX67J3.3,Em:AB023056.16,bPG309N1.1,bQB90C11.3 | NA | NA | NA | NA |
| HSALNT0289894 | LINC00294 | NA | NA | NA | NA | NA |
| HSALNT0289345 | LINC00893 | NA | NA | pathogenic process | hunter syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| HSALNT0290133 | PCBP3-OT1 | PCBP3-OT1,FLJ44028 | NA | NA | NA | NA |
| HSALNT0289488 | ENST00000418282.1 | NCRNA00187 | NA | pathogenic process | blepharophimosis syndrome | Eye Diseases |
| HSALNT0289712 | COPG2IT1 | CIT1,NCRNA00170,COPG2AS | NA | NA | NA | NA |
| HSALNT0265040 | LINC00652 | HSPC072 | NA | developmental process | NA | NA |
| HSALNT0289282 | WASIR2 | NCRNA00286A | NA | NA | NA | NA |
| HSALNT0246856 | LINC00470 | C18orf2 | NA | pathogenic process | age-related macular degeneration | Eye Diseases |
| HSALNT0289507 | LINC00588 | C8orf71,DKFZP434F122 | NA | NA | NA | NA |
| HSALNT0276604 | TTC28-AS1 | TTC28AS,TTC28-AS,KIAA1648 | NA | NA | NA | NA |
| HSALNT0237577 | CDRT7 | NCRNA00025,LINC00025 | NA | NA | NA | NA |
| HSALNT0288912 | CDRT8 | NA | NA | NA | NA | NA |
| HSALNT0275048 | CECR3 | NA | NA | pathogenic process | cat eye syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| HSALNT0288915 | CECR9 | NA | NA | pathogenic process | cat eye syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| HSALNT0288998 | HDHD5-AS1 | CECR4,CECR5-AS1,NCRNA00017 | NA | pathogenic process | cat eye syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| HSALNT0288914 | CECR5-AS1 | NCRNA00017 | NA | pathogenic process | cat eye syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| HSALNT0288919 | CLRN1-AS1 | CLRN1O,UCRP | NA | pathogenic process | usher syndrome type 3 | NA |
| HSALNT0289271 | TMEM9B-AS1 | C11orf18 | NA | NA | NA | NA |
| HSALNT0289324 | LINC01547 | C21orf69,C21orf67 | NA | pathogenic process | Down syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0270409 | LINC00029 | C20orf51,NCRNA00029,bA305P22.4 | NA | NA | NA | NA |
| HSALNT0289336 | LINC00529 | C8orf8 | NA | pathogenic process | keratolytic winter erythema | NA |
| HSALNT0288978 | FLVCR1-AS1 | FLVCR1-DT,LQK1 | NA | NA | NA | NA |
| HSALNT0238050 | SMCR2 | NA | NA | pathogenic process | Smith-Magenis syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0289401 | SMCR5 | NCRNA00034 | NA | pathogenic process | Smith-Magenis syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0290246 | SMCR6 | NA | NA | pathogenic process | Smith-Magenis syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0274626 | LINC00205 | C21orf86,NCRNA00205, | NA | pathogenic process | NA | NA |
| HSALNT0271512 | C21orf91-OT1 | NCRNA00285,D21S2089E | NA | NA | NA | NA |
| HSALNT0272596 | LINC00307 | NCRNA00307,D21S2091E | NA | NA | NA | NA |
| HSALNT0274502 | TSPEAR-AS2 | C21orf90 | NA | NA | NA | NA |
| HSALNT0274807 | MCM3AP-AS1 | C21orf85,MCM3APAS,MCM3AP-AS,FLJ10508,NCRNA00031 | NA | NA | NA | NA |
| HSALNT0288888 | B3GALT5-AS1 | C21orf88 | NA | NA | NA | NA |
| HSALNT0288898 | BRWD1-AS2 | C21orf87,NCRNA00257,BRWD1-IT2 | NA | NA | NA | NA |
| HSALNT0289031 | LINC00315 | C21orf93,NCRNA00315 | NA | NA | NA | NA |
| HSALNT0289033 | LINC00334 | C21orf89,NCRNA00334 | NA | NA | NA | NA |
| HSALNT0289322 | LINC00314 | C21orf94,NCRNA00314 | NA | NA | NA | NA |
| HSALNT0271821 | LINC00308 | C21orf74,NCRNA00308,PRED16 | NA | pathogenic process | NA | NA |
| HSALNT0289023 | LINC00189 | C21orf109,NCRNA00189 | NA | pathogenic process | NA | NA |
| HSALNT0289375 | NCRUPAR | ncR-uPAR,ncRuPAR,NCRNA00193 | transcriptional regulation | developmental process | NA | NA |
| HSALNT0273467 | DSCR10 | NA | NA | NA | NA | NA |
| HSALNT0289480 | DSCR9 | NCRNA00038 | NA | NA | NA | NA |
| HSALNT0290051 | MDS2 | NA | NA | pathogenic process | myelodysplastic syndrome | Hemic and Lymphatic Diseases |
| HSALNT0127810 | ST7-AS2 | ST7OT2,ST7AS2 | NA | pathogenic process | autism | Mental Disorders |
| HSALNT0127813 | ST7-OT3 | ST7OT3,NCRNA00026 | NA | pathogenic process | autism | Mental Disorders |
| HSALNT0290258 | ST7-OT4 | NA | NA | pathogenic process | autism | Mental Disorders |
| HSALNT0290257 | NONHSAT122926 | NONHSAT122926 | NA | NA | NA | NA |
| HSALNT0289372 | MIR600HG | C9orf45,NCRNA00287,GL012,FLJ22161 | NA | NA | NA | NA |
| HSALNT0013239 | ATP1A1-AS1 | C1orf203,ATP1A1OS,MGC16179 | NA | NA | NA | NA |
| HSALNT0048563 | SPATA3-AS1 | NA | NA | NA | NA | NA |
| HSALNT0050859 | LINC00852 | C3orf42,GHRLOS2,NAG73,GHRL-AS2 | NA | NA | NA | NA |
| HSALNT0069395 | LINC01096 | NA | NA | NA | NA | NA |
| HSALNT0072367 | LINC02260 | NA | NA | NA | NA | NA |
| HSALNT0077259 | LINC01091 | NA | NA | NA | NA | NA |
| HSALNT0096480 | SAP30L-AS1 | FLJ38109,GALNT10-AS1 | NA | NA | NA | NA |
| HSALNT0098558 | PRR7-AS1 | NA | NA | NA | NA | NA |
| HSALNT0099356 | LINC01622 | TCONS_00011202 | NA | NA | NA | NA |
| HSALNT0113415 | LINC01312 | MGC34034 | NA | NA | NA | NA |
| HSALNT0134652 | EXTL3-AS1 | C8orf50 | NA | NA | NA | NA |
| HSALNT0138253 | C8orf34-AS1 | NA | NA | NA | NA | NA |
| HSALNT0154876 | PSMD5-AS1 | NA | NA | NA | NA | NA |
| HSALNT0163228 | LINC01553 | C10orf40,AC023904.2 | NA | NA | NA | NA |
| HSALNT0175689 | LINC00301 | C11orf64,NCRNA00301,MGC39681 | NA | NA | NA | NA |
| HSALNT0247235 | DLGAP1-AS3 | NA | NA | NA | NA | NA |
| HSALNT0254200 | CIRBP-AS1 | C19orf23,MGC39338 | NA | NA | NA | NA |
| HSALNT0257335 | LINC01785 | NA | NA | NA | NA | NA |
| HSALNT0261582 | LINC01869 | MGC45922 | NA | NA | NA | NA |
| HSALNT0269743 | LINC01711 | MGC4294 | NA | NA | NA | NA |
| HSALNT0288468 | FAM41AY1 | FAM41AY | NA | NA | NA | NA |
| HSALNT0288899 | C5orf66-AS2 | NA | NA | NA | NA | NA |
| HSALNT0288922 | CSTF3-AS1 | CSTF3-DT | NA | NA | NA | NA |
| HSALNT0288923 | CYP1B1-AS1 | C2orf58,MGC34824 | NA | NA | NA | NA |
| HSALNT0288957 | ENTPD3-AS1 | FLJ36665 | NA | NA | NA | NA |
| HSALNT0288970 | FAM27E3 | MGC42630 | NA | NA | NA | NA |
| HSALNT0288972 | FAM41C | NA | NA | NA | NA | NA |
| HSALNT0288977 | FLG-AS1 | NA | NA | NA | NA | NA |
| HSALNT0288983 | GABPB1-IT1 | FLJ10038 | NA | NA | NA | NA |
| HSALNT0289010 | ILF3-AS1 | ILF3-DT | NA | NA | NA | NA |
| HSALNT0289034 | LINC00347 | NA | NA | NA | NA | NA |
| HSALNT0289039 | LINC00466 | NA | NA | NA | NA | NA |
| HSALNT0289040 | LINC00471 | C2orf52,MGC43122 | NA | NA | NA | NA |
| HSALNT0289044 | LINC00526 | C18orf18,MGC17515,HsT959 | NA | NA | NA | NA |
| HSALNT0289048 | LINC00593 | C15orf50,MGC42951 | NA | NA | NA | NA |
| HSALNT0289050 | LINC00608 | NA | NA | NA | NA | NA |
| HSALNT0289054 | LINC00638 | MGC23270 | NA | NA | NA | NA |
| HSALNT0289056 | LINC00661 | NA | NA | NA | NA | NA |
| HSALNT0289057 | LINC00662 | NA | NA | NA | NA | NA |
| HSALNT0289062 | LINC00692 | NA | NA | NA | NA | NA |
| HSALNT0289064 | LINC00705 | NA | NA | NA | NA | NA |
| HSALNT0289067 | LINC00868 | C17orf52 | NA | NA | NA | NA |
| HSALNT0130693 | LINC00996 | NA | NA | NA | NA | NA |
| HSALNT0289101 | LINC01252 | NA | NA | NA | NA | NA |
| HSALNT0289131 | LINC02135 | NA | NA | NA | NA | NA |
| HSALNT0289193 | NIFK-AS1 | NA | NA | NA | NA | NA |
| HSALNT0289244 | SMG7-AS1 | DKFZP564C196 | NA | NA | NA | NA |
| HSALNT0235326 | SNAI3-AS1 | MGC23284 | NA | NA | NA | NA |
| HSALNT0215205 | SNHG10 | C14orf62,FLJ40557,NCRNA00063,LINC00063 | NA | NA | NA | NA |
| HSALNT0289290 | ZNF205-AS1 | MGC3771 | NA | NA | NA | NA |
| HSALNT0289294 | LINC00260 | C1orf217,NCRNA00260,MGC5457 | NA | NA | NA | NA |
| HSALNT0289295 | LINC00337 | C1orf211,NCRNA00337,MGC40168 | NA | NA | NA | NA |
| HSALNT0289298 | WAC-AS1 | NA | NA | NA | NA | NA |
| HSALNT0289299 | LINC00839 | NA | NA | NA | NA | NA |
| HSALNT0289303 | LINC00612 | C12orf33,MGC40170,FLJ41814 | NA | NA | NA | NA |
| HSALNT0289312 | LINC00663 | MGC39821 | NA | NA | NA | NA |
| HSALNT0289320 | LINC00494 | NA | NA | NA | NA | NA |
| HSALNT0289330 | LINC01019 | NA | NA | NA | NA | NA |
| HSALNT0289333 | LINC00265 | NCRNA00265,NCRNA00265-1 | NA | NA | NA | NA |
| HSALNT0289334 | LINC00689 | NA | NA | NA | NA | NA |
| HSALNT0289337 | LINC01591 | NA | NA | NA | NA | NA |
| HSALNT0289340 | LINC01501 | NA | NA | NA | NA | NA |
| HSALNT0289346 | LINC01560 | CXorf24 | NA | NA | NA | NA |
| HSALNT0289352 | LINC01959 | NA | NA | NA | NA | NA |
| HSALNT0289353 | LINC02175 | NA | NA | NA | NA | NA |
| HSALNT0289354 | LINC02209 | FAM183CP | NA | NA | NA | NA |
| HSALNT0289359 | LINGO1-AS1 | NA | NA | NA | NA | NA |
| HSALNT0289362 | MAFG-AS1 | MAFG-DT | NA | NA | NA | NA |
| HSALNT0289373 | MORF4L2-AS1 | NA | NA | NA | NA | NA |
| HSALNT0289381 | NPHP3-AS1 | NCRNA00119 | NA | NA | NA | NA |
| HSALNT0289385 | PAXIP1-AS1 | NA | NA | NA | NA | NA |
| HSALNT0289413 | TOLLIP-AS1 | NA | NA | NA | NA | NA |
| HSALNT0289416 | LINC00311 | TMEM148,NCRNA00311,MGC22001 | NA | NA | NA | NA |
| HSALNT0289422 | ZNF252P-AS1 | C8orf77 | NA | NA | NA | NA |
| HSALNT0289423 | ZNF436-AS1 | C1orf213,FLJ90508 | NA | NA | NA | NA |
| HSALNT0289429 | BFSP2-AS1 | MGC2848 | NA | NA | NA | NA |
| HSALNT0289432 | CTBP1-DT | C4orf42,CTBP1-AS1,CTBP1-DT,MGC21675 | NA | NA | NA | NA |
| HSALNT0289436 | EXOC3-AS1 | C5orf55 | NA | NA | NA | NA |
| HSALNT0289441 | HCG27 | bPG299F13.9,bCX101P6.9,bQB115I13.2,FLJ40123 | NA | NA | NA | NA |
| HSALNT0289450 | BAALC-AS2 | C8orf56,BAALCOS,MGC39526 | NA | NA | NA | NA |
| HSALNT0289453 | FAM87A | NA | NA | NA | NA | NA |
| HSALNT0289459 | JMJD1C-AS1 | NA | NA | NA | NA | NA |
| HSALNT0289465 | ATP2B1-AS1 | LINC00936 | NA | NA | NA | NA |
| HSALNT0289466 | CEP83-AS1 | CEP83-DT | NA | NA | NA | NA |
| HSALNT0289470 | HEXA-AS1 | C15orf34,FLJ13315 | NA | NA | NA | NA |
| HSALNT0289487 | BIN3-IT1 | FLJ14107 | NA | NA | NA | NA |
| HSALNT0289490 | CSNK1G2-AS1 | C19orf34,MGC39696 | NA | NA | NA | NA |
| HSALNT0289508 | LINC00634 | NA | NA | NA | NA | NA |
| HSALNT0289510 | LINC00685 | CXYorf10,NCRNA00107,PPP2R3B-AS1,OTTHUMT00000055574 | NA | NA | NA | NA |
| HSALNT0289515 | SHANK2-AS3 | C11orf76 | NA | NA | NA | NA |
| HSALNT0290073 | NCBP2-AS2 | NA | NA | NA | NA | NA |
| HSALNT0289502 | NONHSAT095745 | NCRNA00099,UM9-5 | NA | NA | NA | NA |
| HSALNT0289856 | GTSCR1 | NA | NA | pathogenic process | Gilles de la Tourette syndrome | Mental Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0289325 | LINC00272 | C1orf120,NCRNA00272,RP1-223H12.3 | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0288512 | TTTY9B | NCRNA00132 | NA | NA | NA | NA |
| HSALNT0290155 | Prion-associated RNAs | NA | NA | pathogenic process | prion disease | Nervous System Diseases |
| HSALNT0289444 | BLACE | NA | NA | pathogenic process | acute B lymphoblastic leukemias | Hemic and Lymphatic Diseases |
| HSALNT0060411 | H1FX-AS1 | C3orf47,FLJ34151 | NA | NA | NA | NA |
| HSALNT0186668 | LINC00477 | C12orf67,FLJ32894,FAM191B | NA | NA | NA | NA |
| HSALNT0275096 | LINC00528 | C22orf37,FLJ40542 | NA | NA | NA | NA |
| HSALNT0287824 | ASMTL-AS1 | CXYorf2,NCRNA00105,ASMTLAS,ASMTL-AS,FLJ13330 | NA | NA | NA | NA |
| HSALNT0288887 | ANP32A-IT1 | C15orf28,NCRNA00321,FLJ11722,HsT18971 | NA | NA | NA | NA |
| HSALNT0289396 | RUSC1-AS1 | C1orf104,FLJ35976 | NA | NA | NA | NA |
| HSALNT0084628 | LINC01194 | CT49,TAG | NA | pathogenic process | melanoma | Neoplasms |
| HSALNT0289468 | NONHSAT040032 | C14orf134,NCRNA00041,DIO3-AS1,NONHSAT040032,NONHSAT040039,BC111049 | NA | NA | NA | NA |
| HSALNT0121060 | NPSR1-AS1 | AAA1,IMAGE:4827585 | NA | NA | NA | NA |
| HSALNT0074370 | LINC00575 | C4orf11 | NA | pathogenic process | NA | NA |
| HSALNT0137345 | LINC01602 | T1560 | NA | pathogenic process | NA | NA |
| HSALNT0289433 | FAM13A-AS1 | FAM13A1OS,FAM13AOS,NCRNA00039 | NA | NA | NA | NA |
| HSALNT0289186 | MIRLET7DHG | NA | NA | NA | NA | NA |
| HSALNT0155254 | MIR181A2HG | NA | NA | NA | NA | NA |
| HSALNT0289283 | WDFY3-AS2 | C4orf12,NCRNA00247,FBI4 | NA | NA | NA | NA |
| HSALNT0154555 | PAPPA-AS1 | PAPPAS,PAPPA-AS,DIPAS,TAF4B,TAF2C2,TAFII105,NCRNA00156 | NA | NA | NA | NA |
| HSALNT0136307 | LINC00293 | BEYLA | NA | developmental process | NA | NA |
| HSALNT0030983 | SIX3-AS1 | SIX3OS | NA | developmental process | NA | NA |
| HSALNT0211503 | Lnc-C14orf101-5:1 | OTX2OS1 | NA | developmental process | NA | NA |
| HSALNT0063422 | LINC01192 | CT64 | NA | NA | NA | NA |
| HSALNT0217123 | LINC01193 | CT60,LOC348120 | NA | NA | NA | NA |
| HSALNT0289664 | C1QTNF9B-AS1 | PCOTH | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289623 | ATP6V1G2-DDX39B | NA | NA | pathogenic process | dilated cardiomyopathy | Cardiovascular Diseases |
| HSALNT0289498 | FAM226B | CXorf50B,NCRNA00246B,LINC00246B | NA | NA | NA | NA |
| HSALNT0289321 | LINC00163 | C21orf134,NCRNA00163,NLC1-A,NLC1A | NA | pathogenic process | narcolepsy | Mental Disorders;Nervous System Diseases |
| HSALNT0289505 | LINC00165 | C21orf135,NCRNA00165,NLC1-B | NA | NA | NA | NA |
| HSALNT0290297 | NONHSAT035776 | ENSG00000251002 | NA | NA | NA | NA |
| HSALNT0274212 | LINC00322 | C21orf136,NCRNA00322,FLJ16545 | NA | NA | NA | NA |
| HSALNT0289741 | NONHSAT102417 | DHFR minor transcript 5'-UTR,ENSG00000228716,NONHSAT102417 | transcriptional regulation | NA | NA | NA |
| HSALNT0289527 | NONHSAT128494 | ncRNA 21A,NONHSAT128494 | NA | NA | NA | NA |
| HSALNT0289409 | TLX1NB | TD1,TDI,APT-B7 | NA | pathogenic process | leukemogenesis | Hemic and Lymphatic Diseases |
| HSALNT0289662 | C15orf2 | NA | NA | pathogenic process | Angelman syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0290097 | NPAP1 | NA | NA | pathogenic process | Angelman syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0217406 | NONHSAT040875 | NCRNA00199 | NA | pathogenic process | Prader-Willi syndrome | Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0289227 | NONHSAT040920 | NCRNA00198 | NA | pathogenic process | Prader-Willi syndrome | Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0262816 | MIMT1 | MIM1,NCRNA00067,LINC00067 | NA | NA | NA | NA |
| HSALNT0289180 | MIR34AHG | NA | NA | NA | NA | NA |
| HSALNT0289357 | LINC02570 | XXbac-BPG27H4.8 | NA | pathogenic process | MHC-associated diseases | Immune System Diseases |
| HSALNT0290177 | RNY1 | NA | NA | pathogenic process | cervix cancer;prostate cancer;colorectal cancer;bladder cancer;kidney cancer;lung cancer | Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases |
| HSALNT0289378 | NKX2-2-AS1 | NKX2-2AS | transcriptional regulation | pathogenic process | NA | NA |
| HSALNT0290151 | NONHSAT023851 | FJ515872.1,NONHSAT023851 | transcriptional regulation | NA | NA | NA |
| HSALNT0289607 | Anti-NOS2A | NA | NA | pathogenic process | meningioma;glioblastoma | Neoplasms;Nervous System Diseases |
| HSALNT0289687 | CDKN1A-AS1 | p21NAT | transcriptional regulation | NA | NA | NA |
| HSALNT0116668 | RPS6KA2-AS1 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289384 | PAPPA-AS2 | AGU1 | NA | NA | NA | NA |
| HSALNT0262802 | ZIM2-AS1 | ZIM2as | NA | NA | NA | NA |
| HSALNT0289824 | Lnc-DLX5-3:1 | Evf-2,Dlx6as1,Dlx6os1,ENSG00000231764, ENST00000430027.2,lnc-DLX5-3:1 | transcriptional regulation | NA | NA | NA |
| HSALNT0289481 | ADORA2A-AS1 | C22orf45,FLJ34651 | NA | NA | NA | NA |
| HSALNT0290146 | POU5F1P4 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290033 | LSINCT1 | NA | NA | pathogenic process | lung cancer;breast cancer | Respiratory Tract Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290034 | LSINCT10 | NA | NA | pathogenic process | lung cancer;breast cancer | Respiratory Tract Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290035 | LSINCT11 | NA | NA | pathogenic process | lung cancer;breast cancer | Respiratory Tract Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290036 | LSINCT12 | NA | NA | pathogenic process | lung cancer;breast cancer | Respiratory Tract Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290037 | LSINCT2 | NA | NA | pathogenic process | lung cancer;breast cancer | Respiratory Tract Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290038 | LSINCT3 | NA | NA | pathogenic process | lung cancer;breast cancer | Respiratory Tract Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290039 | LSINCT4 | NA | NA | pathogenic process | lung cancer;breast cancer | Respiratory Tract Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290041 | LSINCT6 | NA | NA | pathogenic process | lung cancer;breast cancer | Respiratory Tract Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290042 | LSINCT7 | NA | NA | pathogenic process | lung cancer;breast cancer | Respiratory Tract Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290043 | LSINCT8 | NA | NA | pathogenic process | lung cancer;breast cancer | Respiratory Tract Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290044 | LSINCT9 | NA | NA | pathogenic process | lung cancer;breast cancer | Respiratory Tract Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289676 | NONHSAT016928 | FLJ31066,NONHSAT016928,lnc-FANK1-3:1 | transcriptional regulation | NA | NA | NA |
| HSALNT0290032 | LRRC3DN | C21orf30,DKFZP434C128 | transcriptional regulation | NA | NA | NA |
| HSALNT0266984 | SNHG11 | C20orf198,LINC00101,NCRNA00101 | NA | pathogenic process | obesity | Nutritional and Metabolic Diseases |
| HSALNT0289880 | NONHSAT113225 | NONHSAT113225,ENSG00000220635 | ceRNA | NA | NA | NA |
| HSALNT0006368 | ENST00000444042.2 | ncRNA-a3 | transcriptional regulation | NA | NA | NA |
| HSALNT0027470 | ENST00000417473.2 | ncRNA-a5 | transcriptional regulation | NA | NA | NA |
| HSALNT0289066 | ENST00000429328.2 | PDZK1IP1-AS1,ncRNA-a4 | transcriptional regulation | NA | NA | NA |
| HSALNT0289936 | NONHSAT059436 | ROR,lincRNA-ST8SIA3,ENSG00000258609,NONHSAT059436 | NA | NA | NA | NA |
| HSALNT0289705 | CHL1-AS2 | NA | NA | pathogenic process | adolescent idiopathic scoliosis | Musculoskeletal Diseases |
| HSALNT0076084 | SEC24B-AS1 | 1/2-SBSRNA4 | siRNA | NA | NA | NA |
| HSALNT0290137 | PDZRN3-AS1 | NA | NA | pathogenic process | type 2 diabetes | Nutritional and Metabolic Diseases;Endocrine System Diseases |
| HSALNT0290237 | SCAANT1 | ATXN7-AS1 | transcriptional regulation | pathogenic process | spinocerebellar ataxia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0289594 | AK123790 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289911 | LINC01451 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290401 | ZNF350-AS1 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289845 | GADD45G | NA | NA | pathogenic process | pituitary adenoma | Endocrine System Diseases;Neoplasms;Nervous System Diseases |
| HSALNT0289410 | Lnc-RASA1-3:23 | AK082072,linc-POLR3G-8,ENSG00000247828 | NA | NA | NA | NA |
| HSALNT0289736 | DAPK1 | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | Neoplasms |
| HSALNT0290048 | MAP3K14 | MAP3K14 | NA | pathogenic process | Pancreatic ductal adenocarcinoma | Neoplasms |
| HSALNT0290150 | PPP3CB | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | Neoplasms |
| HSALNT0151531 | DAPK1-IT1 | NA | NA | pathogenic process | NA | NA |
| HSALNT0288990 | GDNF-AS1 | GDNFOS | transcriptional regulation | pathogenic process | Alzheimer's disease | Mental Disorders;Nervous System Diseases |
| HSALNT0029702 | BIRC6-AS2 | megamind | NA | developmental process | NA | NA |
| HSALNT0029692 | BIRC6-AS1 | NA | NA | NA | NA | NA |
| HSALNT0289310 | LINC00854 | NA | NA | NA | NA | NA |
| HSALNT0290332 | Uc.73 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289841 | FR0257520 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290104 | NRG1 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289689 | CDKN2B-AS11 | NA | NA | pathogenic process;developmental process | stroke | Cardiovascular Diseases;Nervous System Diseases |
| HSALNT0289690 | CDKN2B-AS12 | NA | NA | pathogenic process | glioma | Neoplasms |
| HSALNT0289691 | CDKN2B-AS13 | NA | NA | pathogenic process | plexiform neurofibroma | Neoplasms;Nervous System Diseases |
| HSALNT0289697 | CDKN2B-AS7 | NA | NA | pathogenic process | acute lymphoblastic leukemia | Immune System Diseases;Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0289826 | FADS1 | NA | NA | pathogenic process | lipid metabolism disorder | Nutritional and Metabolic Diseases |
| HSALNT0289698 | CDKN2B-AS8 | NA | NA | pathogenic process | melanoma | Neoplasms |
| HSALNT0289696 | CDKN2B-AS6 | NA | NA | pathogenic process | neuroblastoma | Neoplasms |
| HSALNT0289699 | CDKN2B-AS9 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289688 | CDKN2B-AS10 | NA | NA | pathogenic process | stroke | Cardiovascular Diseases;Nervous System Diseases |
| HSALNT0288950 | ENST00000456816 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290021 | LOC389332 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290306 | TMEM72 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289641 | BC029135 | NA | NA | pathogenic process | renal clear cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290374 | X91348 | NA | NA | pathogenic process | renal clear cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289694 | CDKN2B-AS4 | NA | NA | pathogenic process | cancer | Neoplasms |
| HSALNT0289692 | CDKN2B-AS2 | NA | NA | pathogenic process | coronary heart disease | Cardiovascular Diseases |
| HSALNT0289693 | CDKN2B-AS3 | NA | NA | pathogenic process | intracranial aneurysm | Cardiovascular Diseases;Nervous System Diseases |
| HSALNT0289695 | CDKN2B-AS5 | NA | NA | pathogenic process | type 2 diabetes | Nutritional and Metabolic Diseases;Endocrine System Diseases |
| HSALNT0290319 | T-UCRs | NA | NA | pathogenic process | neuroblastoma | Neoplasms |
| HSALNT0289530 | 51A | NA | splicing regulation | pathogenic process | Alzheimer's disease | Mental Disorders;Nervous System Diseases |
| HSALNT0290163 | RAB4B-EGLN2 | NA | NA | pathogenic process | cancer | Neoplasms |
| HSALNT0290167 | RERT | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0265263 | LINC00237 | NCRNA00237 | NA | pathogenic process | macrocephaly;obesity | Musculoskeletal Diseases;Pathological Conditions, Signs and Symptoms;Nutritional and Metabolic Diseases;Physiological Phenomena |
| HSALNT0267186 | LINC01370 | HI-LNC25,HILNC25 | NA | pathogenic process | type 2 diabetes | Nutritional and Metabolic Diseases;Endocrine System Diseases |
| HSALNT0289114 | LINC01574 | HI-LNC12,TCONS_00009551 | NA | pathogenic process | type 2 diabetes | Nutritional and Metabolic Diseases;Endocrine System Diseases |
| HSALNT0290159 | PTHLH | NA | NA | pathogenic process | brachydactyly | Musculoskeletal Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| HSALNT0189394 | NONHSAT028496 | CISTR-ACT,CISTRACT,re52431 | transcriptional regulation | pathogenic process | brachydactyly | Musculoskeletal Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| HSALNT0289862 | HELLPAR | LINC-HELLP | NA | pathogenic process | HELLP syndrome | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289904 | LINC01125 | NA | NA | pathogenic process | uremia | Male Urogenital Diseases |
| HSALNT0289544 | AC002511.1 | LINC01531 | NA | pathogenic process | enterovirus 71 infection | Virus Diseases |
| HSALNT0289609 | AP000688.29 | AP000688.2 | NA | pathogenic process | enterovirus 71 infection | Virus Diseases |
| HSALNT0289832 | FFAR2 | NA | NA | pathogenic process | enterovirus 71 infection | Virus Diseases |
| HSALNT0290222 | RP4-620F22.3 | AC099063.2 | NA | pathogenic process | enterovirus 71 infection | Virus Diseases |
| HSALNT0290227 | RP5-843L14.1 | LINC01716 | NA | pathogenic process | enterovirus 71 infection | Virus Diseases |
| HSALNT0287285 | MAGEA8-AS1 | RP5-869M20.2 | NA | NA | NA | NA |
| HSALNT0289019 | LHX5-AS1 | locus4010 | NA | NA | NA | NA |
| HSALNT0288902 | CAPN10-AS1 | CAPN10-DT,locus959 | NA | NA | NA | NA |
| HSALNT0289404 | STAM-AS1 | locus3182 | NA | NA | NA | NA |
| HSALNT0148276 | PTENP1-AS | PTENpg1-asRNA | transcriptional regulation | NA | NA | NA |
| HSALNT0289562 | AF116616 | NA | NA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0289589 | AK094838 | NA | NA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0289620 | ASLNC00339 | NA | NA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0289629 | BC002350 | NA | NA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0289651 | BC091525 | NA | NA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0289652 | BE503655 | NA | NA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0289753 | ENO1 | NA | NA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0289835 | FKBP10 | NA | NA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0290064 | MYHAS | NA | NA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0289985 | LncRNA-LALR1 | NA | transcriptional regulation | pathogenic process | liver cancer | Neoplasms;Digestive System Diseases |
| HSALNT0091577 | NR2F1-AS1 | FLJ42709 | NA | NA | NA | NA |
| HSALNT0289709 | CK19 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289943 | Llme23 | NA | NA | pathogenic process | melanoma | Neoplasms |
| HSALNT0289553 | AC096655.1 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289178 | ENST00000602507.1 | Lnc-Ang362 | NA | pathogenic process | Ang II-associated cardiovascular disease | Cardiovascular Diseases |
| HSALNT0289261 | STX18-AS1 | LOC100507266 | NA | pathogenic process | atrial septal defect | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289849 | GHSR | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289210 | ENST00000452148.2 | PCAN-R2 | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289702 | CES1P1 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289892 | LINC00210 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290006 | LOC100506974 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290219 | RP3-508I15.14 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290243 | SLC6A6 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290342 | Uc003bgl.1 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289075 | LINC00970 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0211868 | SALRNA1 | SAL-RNA1,XLOC_023166 | NA | developmental process | NA | NA |
| HSALNT0222267 | SALRNA3 | SAL-RNA3,XLOC_025918 | NA | developmental process | NA | NA |
| HSALNT0222274 | SALRNA2 | SAL-RNA2,XLOC_025931 | NA | developmental process | NA | NA |
| HSALNT0289428 | NONHSAT076558 | GPR1-AS1,GPR1AS | transcriptional regulation | NA | NA | NA |
| HSALNT0226207 | LINC00235 | NA | NA | pathogenic process | anorexia nervosa | Mental Disorders |
| HSALNT0289526 | 1B FGF-antisense transcripts | NA | NA | pathogenic process | endometriosis | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0290171 | RNA polymerase III-dependent lncRNAs | NA | NA | pathogenic process | diffuse cerebral hypomyelination | NA |
| HSALNT0290168 | REST/CoREST-regulated lncRNAs | NA | NA | pathogenic process | Huntington disease | Mental Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0289606 | Alu lncRNAs | NA | NA | pathogenic process | macular degeneration | Eye Diseases |
| HSALNT0290358 | UCH1LAS | NA | NA | pathogenic process | Parkinson's disease | Nervous System Diseases |
| HSALNT0290244 | SLC7A2-IT1A/B | NA | NA | pathogenic process | progressive encephalopathy with severe infantile anorexia | Nervous System Diseases |
| HSALNT0289877 | Kcna2-AS | NA | NA | pathogenic process | neuropathic pain | Nervous System Diseases |
| HSALNT0289191 | NCOA7-AS1 | NA | NA | pathogenic process | NA | NA |
| HSALNT0290020 | LOC389023 | NA | transcriptional regulation | pathogenic process | psychiatric disease | Nervous System Diseases |
| HSALNT0175124 | PTPRJ-AS1 | NA | transcriptional regulation | NA | NA | NA |
| HSALNT0289654 | BM742401 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289331 | LINC00951 | lincRNA-uc003opf.1,FLJ41649 | NA | pathogenic process | esophageal squamous cell cancer | Neoplasms |
| HSALNT0290130 | PAWR | NA | NA | pathogenic process | acute lymphoblastic leukemia | Immune System Diseases;Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0290264 | T-ALL-R-LncR1 | NA | NA | pathogenic process | acute lymphoblastic leukemia | Immune System Diseases;Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0289599 | AK130977 | NA | NA | pathogenic process | malignant pleural mesothelioma | Neoplasms |
| HSALNT0289625 | AX746718 | NA | NA | pathogenic process | malignant pleural mesothelioma | Neoplasms |
| HSALNT0289738 | DDR2 | NA | NA | pathogenic process | malignant pleural mesothelioma | Neoplasms |
| HSALNT0290003 | LOC100131831 | NA | NA | pathogenic process | malignant pleural mesothelioma | Neoplasms |
| HSALNT0290144 | POT1-AS1 | NA | NA | pathogenic process | malignant pleural mesothelioma | Neoplasms |
| HSALNT0290253 | SNORA17B | NA | NA | pathogenic process | malignant pleural mesothelioma | Neoplasms |
| HSALNT0207421 | GAS6-AS1 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289838 | FMR5 | NA | NA | pathogenic process | fragile X syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0208907 | FOXG1-AS1 | FOXG1-AS | NA | pathogenic process | autism spectrum disorder | Mental Disorders |
| HSALNT0290263 | SYNGAP1-AS1 | SYNGAP1-AS | NA | pathogenic process | autism spectrum disorder | Mental Disorders |
| HSALNT0290176 | RNase MRP | NA | NA | pathogenic process | cartilage hair hypoplaisia | Cardiovascular Diseases |
| HSALNT0289469 | GABPB1-AS1 | NA | NA | pathogenic process | NA | NA |
| HSALNT0289009 | IDI2-AS1 | C10orf110,IDI2-A,HT009,Em:AC022536.4 | NA | NA | NA | NA |
| HSALNT0289093 | LINC01184 | FLJ33630 | NA | NA | NA | NA |
| HSALNT0290108 | OGT | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290077 | NcNRFR | NA | transcriptional regulation | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290337 | Uc001lsz | NA | NA | pathogenic process | gastric cancer;prostate cancer;liver cancer;lung cancer | Respiratory Tract Diseases;Male Urogenital Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289087 | LINC01090 | NA | NA | pathogenic process | post-traumatic stress disorder | Mental Disorders |
| HSALNT0289981 | LncRNA-DQ786227 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289876 | JADRR | LINC00915,lncRNA-JADE | transcriptional regulation | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290254 | SOX2OT-S1 | NA | NA | pathogenic process | esophageal squamous cell cancer | Neoplasms |
| HSALNT0289870 | HOXA13 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0078946 | SMAD1-AS1 | ENST00000513542 | NA | pathogenic process | ventricular septal defects | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0087329 | FGF10-AS1 | RP11-473L15.2 | transcriptional regulation | pathogenic process | ventricular septal defects | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0290318 | TUC339 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289819 | Lnc-CHRAC1-2:1 | LINC01130,TCONS_00014875,ERIC | transcriptional regulation | pathogenic process | retinoblastoma | Neoplasms |
| HSALNT0289615 | ARA | NA | NA | pathogenic process | cancer | Neoplasms |
| HSALNT0289822 | ESCCAL-5 | NA | NA | pathogenic process | esophageal squamous cell cancer | Neoplasms |
| HSALNT0290074 | NcC11orf49 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290076 | NcHDAC5 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290078 | NcRAB31 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290080 | NcSRPK1 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0018253 | ENST00000442621.1 | LINC01131,OVAL | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289884 | LALR | NA | transcriptional regulation | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289701 | CEACAMP8 | CEACAMP8 | NA | pathogenic process | pre-eclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0290018 | LOC284100 | NA | NA | pathogenic process | pre-eclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0290023 | LOC391533 | NA | NA | pathogenic process | pre-eclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0189558 | LINC01154 | NA | NA | NA | NA | NA |
| HSALNT0196616 | Lnc-DHX37-1:1 | BRI3BP-AS1,BRI3BPAS1,Linc1992,TCONS_00020260 | transcriptional regulation | pathogenic process | Kawasaki disease | Cardiovascular Diseases |
| HSALNT0289235 | RNF219-AS1 | NA | NA | pathogenic process | blood pressure | Cardiovascular Diseases |
| HSALNT0289561 | AF086415 | NA | NA | pathogenic process | nasopharyngeal cancer | Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0289583 | AK056098 | NA | NA | pathogenic process | nasopharyngeal cancer | Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0289590 | AK095147 | NA | NA | pathogenic process | nasopharyngeal cancer | Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0289600 | AK294004 | NA | transcriptional regulation | pathogenic process | nasopharyngeal cancer | Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0289612 | AP5M1 | NA | NA | pathogenic process | nasopharyngeal cancer | Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0290110 | ORAOV1 | NA | NA | pathogenic process | nasopharyngeal cancer | Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0290210 | RP1-179N16.3 | Z95152.1 | NA | pathogenic process | nasopharyngeal cancer | Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0037026 | LINC01159 | linc-Brn1b | NA | developmental process | NA | NA |
| HSALNT0289014 | ENST00000604849.1 | KDM5C adjacent non-coding transcript | NA | developmental process | NA | NA |
| HSALNT0289905 | LINC01157 | TCONS_00010378,linc-Enc1 | NA | developmental process | NA | NA |
| HSALNT0289460 | ENST00000444200.1 | NA | transcriptional regulation | NA | NA | NA |
| HSALNT0290400 | ZNF300P1 | ZNF300P1 | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289750 | EEF1A1P9 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | Neoplasms |
| HSALNT0289796 | ENST00000318333 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | Neoplasms |
| HSALNT0289797 | ENST00000374520 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | Neoplasms |
| HSALNT0289800 | ENST00000422362 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | Neoplasms |
| HSALNT0289808 | ENST00000455912 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | Neoplasms |
| HSALNT0289809 | ENST00000456007 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | Neoplasms |
| HSALNT0289810 | ENST00000456185 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | Neoplasms |
| HSALNT0289817 | EPOR | NA | NA | pathogenic process | gastric cardia adenocarcinoma | Neoplasms |
| HSALNT0289913 | LINC01550 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | Neoplasms |
| HSALNT0290142 | PMS2P5 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | Neoplasms |
| HSALNT0290269 | TCF7 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | Neoplasms |
| HSALNT0290345 | Uc003jfz.2 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | Neoplasms |
| HSALNT0289095 | ENST00000412690.1 | VIN,lnc-ACTR3 | transcriptional regulation | pathogenic process | influenza A virus | Virus Diseases |
| HSALNT0288976 | ENST00000427391.1 | LINC01200 | transcriptional regulation | NA | NA | NA |
| HSALNT0289097 | LINC01202 | NA | NA | NA | NA | NA |
| HSALNT0290271 | TCONS_00014512 | NA | NA | pathogenic process | hepatoblastoma | Neoplasms |
| HSALNT0290272 | TCONS_00014978 | NA | NA | pathogenic process | hepatoblastoma | Neoplasms |
| HSALNT0290274 | TCONS_00024647 | NA | NA | pathogenic process | hepatoblastoma | Neoplasms |
| HSALNT0290279 | TCONS_00090092_MEG3 | NA | NA | pathogenic process | hepatoblastoma | Neoplasms |
| HSALNT0290280 | TCONS_l2_00000179 | NA | NA | pathogenic process | hepatoblastoma | Neoplasms |
| HSALNT0290283 | TCONS_l2_00004424 | NA | NA | pathogenic process | hepatoblastoma | Neoplasms |
| HSALNT0290284 | TCONS_l2_00006843 | NA | NA | pathogenic process | hepatoblastoma | Neoplasms |
| HSALNT0290289 | TCONS_l2_00014091 | NA | NA | pathogenic process | hepatoblastoma | Neoplasms |
| HSALNT0290291 | TCONS_l2_00018070 | NA | NA | pathogenic process | hepatoblastoma | Neoplasms |
| HSALNT0290292 | TCONS_l2_00020565 | NA | NA | pathogenic process | hepatoblastoma | Neoplasms |
| HSALNT0290293 | TCONS_l2_00021262 | NA | NA | pathogenic process | hepatoblastoma | Neoplasms |
| HSALNT0290296 | TCONS_l2_00030560 | NA | NA | pathogenic process | hepatoblastoma | Neoplasms |
| HSALNT0289927 | LincRNA1611 | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | Neoplasms |
| HSALNT0290149 | Ppp3ca | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | Neoplasms |
| HSALNT0290265 | TC0100223 | NA | NA | pathogenic process | epithelial ovarian cancer | Neoplasms |
| HSALNT0290267 | TC0101686 | NA | NA | pathogenic process | epithelial ovarian cancer | Neoplasms |
| HSALNT0290268 | TC1500845 | NA | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289318 | LAMP5-AS1 | NA | NA | pathogenic process | acute lymphoblastic leukemia | Immune System Diseases;Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0234022 | LINC01228 | lincRNA-DYNLRB2-2 | NA | pathogenic process | NA | NA |
| HSALNT0162654 | SGMS1-AS1 | NA | NA | pathogenic process | NA | NA |
| HSALNT0289206 | PCAT19 | LOC100505495,LINC01190 | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289521 | ABHD15-AS1 | linc-TP53I13,lnc-TP53I13 | NA | pathogenic process | cardiometabolic disease | Cardiovascular Diseases |
| HSALNT0289100 | LINC01230 | linc-DMRT2,lnc-DRMT2,TCONS_00015639 | NA | pathogenic process | cardiometabolic disease | Cardiovascular Diseases |
| HSALNT0249183 | PCAT18 | LINC01092 | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290029 | LOC728606 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0288956 | ENST00000547963.1 | NA | NA | pathogenic process | esophageal squamous cell cancer | Neoplasms |
| HSALNT0289802 | ENST00000435885 | NA | NA | pathogenic process | oesophageal squamous cell cancer | Neoplasms |
| HSALNT0205898 | LINC01232 | FLJ41590,TCONS_00021520 | NA | pathogenic process | NA | NA |
| HSALNT0257311 | LINC01233 | XLOC_013014 | NA | pathogenic process | NA | NA |
| HSALNT0183247 | ENST00000526269.2 | FLI1-AS1 | NA | pathogenic process | vascular SMC phenotype | Cardiovascular Diseases |
| HSALNT0289296 | LINC00467 | C1orf97,MGC14801 | NA | pathogenic process | neuroblastoma | Neoplasms |
| HSALNT0143586 | CASC21 | LINC01244,CARLo-2 | NA | pathogenic process | NA | NA |
| HSALNT0288906 | CASC19 | LINC01245,CARLo-6 | NA | pathogenic process | NA | NA |
| HSALNT0289754 | ENSG00000135253.9 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289755 | ENSG00000147753.5 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289756 | ENSG00000196096 | AC079610.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289757 | ENSG00000197251.3 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289758 | ENSG00000203325 | AL445248.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289759 | ENSG00000206129 | AC006305.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289760 | ENSG00000215231.3 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289761 | ENSG00000215374.4 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289762 | ENSG00000215808.2 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289763 | ENSG00000226496.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289764 | ENSG00000229563.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289765 | ENSG00000230133.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289766 | ENSG00000230544.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289767 | ENSG00000231133.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289768 | ENSG00000231185 | AC010317.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289769 | ENSG00000232021.2 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289770 | ENSG00000232046.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289771 | ENSG00000232956.3 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289772 | ENSG00000233154.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289773 | ENSG00000233251 | AC007743.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289774 | ENSG00000235285.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289775 | ENSG00000237036.3 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289776 | ENSG00000237548.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289777 | ENSG00000240453.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289778 | ENSG00000241269.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289779 | ENSG00000245910.3 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289780 | ENSG00000248176 | AC109349.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289781 | ENSG00000249364 | AC112206.2 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289782 | ENSG00000249772 | AC026427.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289783 | ENSG00000250195 | AC109927.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289784 | ENSG00000250608 | AC010210.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289785 | ENSG00000254154 | AL359075.2 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289786 | ENSG00000255471 | AP001528.2 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289787 | ENSG00000256218 | AC007848.2 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289788 | ENSG00000259150.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289789 | ENSG00000259334.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289790 | ENSG00000259484.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289791 | ENSG00000259758.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289793 | ENSG00000263753.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289794 | ENSG00000264772 | AC016876.2 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289795 | ENSG00000266952.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289828 | FAM66B | FAM66E | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289895 | LINC00336 | C6orf227,NCRNA00336 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289899 | LINC00929 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289906 | LINC01204 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289912 | LINC01538 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289915 | LINC01721 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289916 | LINC01762 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289917 | LINC01798 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0290247 | SMIM2-IT1 | C13orf44-IT1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0290316 | TTTY7 | CLONE795723,LINC00129,NCRNA00129A,TTTY7B,TTY7,TTTY7 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0290175 | RNA-a | NA | transcriptional regulation | pathogenic process | Opitz-Kaveggia syndrome | NA |
| HSALNT0289525 | 116HG | NA | transcriptional regulation | pathogenic process | Prader-Willi syndrome | Nervous System Diseases |
| HSALNT0290320 | U1 spliceosomal lncRNA | NA | NA | pathogenic process | Parkinson's disease | Nervous System Diseases |
| HSALNT0289102 | LINC01262 | TCONS_l2_00021807,RP11-462G22.1 | ceRNA | pathogenic process | Parkinson's disease | Nervous System Diseases |
| HSALNT0289681 | CCAT1-L | NA | transcriptional regulation | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290062 | MT-LIPCAR | uc022bqs.1,LIPCAR | NA | pathogenic process | heart disease | Cardiovascular Diseases |
| HSALNT0289941 | LIPCAR | NA | NA | pathogenic process | heart failure | Pathological Conditions, Signs and Symptoms;Cardiovascular Diseases |
| HSALNT0200965 | TUSC8 | LINC01071,XLOC_010588 | NA | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0161787 | LINC01264 | RP11-124O11.2 | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289733 | D4Z4 | NA | NA | pathogenic process;developmental process | facioscapulohumeral muscular dystrophy | Musculoskeletal Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0289678 | CARL | NA | ceRNA | pathogenic process | myocardial infarction | Cardiovascular Diseases |
| HSALNT0289923 | Linc-CBR1-2 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0243354 | Lnc-HEATR6-1:4 | WAP four-disulfide core domain 21,pseudogene | transcriptional regulation | pathogenic process | DC dysfunction | NA |
| HSALNT0290232 | RUNX1 | NA | NA | pathogenic process | acute myeloid leukemia | Neoplasms |
| HSALNT0290234 | RUNXOR | NA | NA | pathogenic process | hematopoietic malignancies | Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0289979 | LncRNA-CIR | NA | NA | pathogenic process | osteoarthritis | Musculoskeletal Diseases |
| HSALNT0290368 | VIM2P | NA | NA | pathogenic process | osteoarthritis | Musculoskeletal Diseases |
| HSALNT0289879 | KRAS1P | NA | NA | pathogenic process | cancer | Neoplasms |
| HSALNT0290054 | MINA | NA | NA | pathogenic process | esophageal squamous cell cancer;gastric cancer;lung cancer;hepatocelluar cancer | Respiratory Tract Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289270 | TMEM92-AS1 | RP11-893F2.9,lncRNA-508851,TCONS_00025237 | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0288900 | ENST00000604200.1 | LINC00468 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289593 | AK123657 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289659 | BX648207 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289660 | BX649059 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289846 | GAS2L3 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289633 | BC011663 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289867 | HIV1230 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290045 | M14574 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290245 | SLCO5A1 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290326 | Uc.341 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290344 | Uc003iqu | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290346 | Uc003tfx | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289950 | Lnc-AL355149.1-1 | NA | NA | pathogenic process | nasopharyngeal cancer | Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0290001 | Lnc-ZNF674-1 | NA | NA | pathogenic process | nasopharyngeal cancer | Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0286909 | LINC00632 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289105 | LINC01317 | NA | NA | NA | NA | NA |
| HSALNT0234804 | LINC01081 | TCONS_00024764 | transcriptional regulation | pathogenic process | alveolar capillary dysplasia | Respiratory Tract Diseases |
| HSALNT0289840 | FOSB | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289587 | AK093543 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289732 | D16366 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289814 | ENST00000501583 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289907 | LINC01374 | TCONS_00018278 | NA | pathogenic process | NA | NA |
| HSALNT0231106 | CASC22 | LINC01373,TCONS_00024290,LincRNA-ENST00000515084 | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0058246 | LINC00882 | NA | ceRNA | pathogenic process | airway diseases | Respiratory Tract Diseases |
| HSALNT0018288 | KIAA1614-AS1 | RP11-46A10.4 | ceRNA | pathogenic process | airway smooth muscle (ASM) disease | Respiratory Tract Diseases |
| HSALNT0142310 | LINC00536 | NA | NA | pathogenic process | trichorhinophalangeal syndrome | NA |
| HSALNT0034200 | LBX2-AS1 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0149799 | ENST00000414223 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290012 | LOC105374631 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290305 | TMEM179 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290315 | TSPAN8 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290334 | Uc001aka.2 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290339 | Uc001vjj.1 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290343 | Uc003erl.1 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290354 | Uc009wkz.1 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0027893 | ENST00000433810.1 | MYCNUN,lncUSMycN | NA | pathogenic process | neuroblastoma | Neoplasms |
| HSALNT0273205 | LINC01436 | AP000688.8 | NA | pathogenic process | Down syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0266116 | MIR663AHG | RP3-410C9.1 | NA | pathogenic process | turner syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Cardiovascular Diseases;Endocrine System Diseases |
| HSALNT0289108 | LINC01435 | RP11-215N21.1,TCONS_00018040 | NA | pathogenic process | NA | NA |
| HSALNT0289674 | CADM3-AS1 | NA | NA | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289882 | KRT19P3 | NA | NA | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290310 | TNXA | NA | NA | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0008750 | ZRANB2-AS2 | NA | NA | NA | NA | NA |
| HSALNT0289745 | DMTF1 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290059 | MRUL | NA | transcriptional regulation | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0185163 | FAM66C | NA | NA | NA | NA | NA |
| HSALNT0289476 | ENST00000357401.3 | NA | NA | NA | NA | NA |
| HSALNT0289535 | AA174084 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0266298 | ABALON | INXS | splicing regulation | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290370 | VTRNA2-1 | CBL-3,CBL3,MIR886,MIRN886,VTRNA2,hsa-mir-886,hvg-5,nc886,svtRNA2-1a | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289619 | ASK00420 | NA | NA | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289749 | EBIC | NA | transcriptional regulation | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290299 | TI09485 | NA | NA | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290300 | TI10124 | NA | NA | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290301 | TI13831 | NA | NA | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290302 | TI18318 | NA | NA | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290303 | TI21327 | NA | NA | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290304 | TI22687 | NA | NA | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290307 | TMPOP2 | NA | transcriptional regulation | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289570 | AK021444 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289601 | AK307796 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289801 | ENST00000425785 | SEC63P1 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289871 | HOXB-AS3 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290367 | URHC | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289085 | LINC01080 | TCONS_00021856 | NA | pathogenic process | Alzheimer's disease | Mental Disorders;Nervous System Diseases |
| HSALNT0289751 | EFNA3 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289798 | ENST00000395084 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289829 | FAM83A-AS1 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290164 | RAD1 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289585 | AK056988 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289638 | BC017743 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290156 | PRR26 | C10orf108 | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290349 | Uc003yqb.1 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289675 | CAI2 | NA | NA | pathogenic process | neuroblastoma | Neoplasms |
| HSALNT0290313 | TSLC1-AS1 | NA | NA | pathogenic process | glioma | Neoplasms |
| HSALNT0013359 | LINC01525 | lnc-MAN1A2-1 | NA | pathogenic process | squamous cell cancer | Neoplasms |
| HSALNT0109106 | LINC01526 | Lnc-FAM46A-1 | NA | pathogenic process | squamous cell cancer | Neoplasms |
| HSALNT0162774 | LINC01468 | lnc-MBL2-4 | NA | pathogenic process | squamous cell cancer | Neoplasms |
| HSALNT0289110 | LINC01503 | lnc-PPP2R4-5 | NA | pathogenic process | tongue squamous cell cancer | Neoplasms |
| HSALNT0289968 | Lnc-MBL2-4:3 | NA | NA | pathogenic process | tongue squamous cell cancer | Neoplasms |
| HSALNT0289993 | Lnc-STXBP5-1 | NA | NA | pathogenic process | tongue squamous cell cancer | Neoplasms |
| HSALNT0289563 | AF118081 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289597 | AK124939 | NA | NA | pathogenic process | pulmonary adenocarcinoma | Neoplasms |
| HSALNT0290153 | PRAS | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290249 | SNAR-A1 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289929 | LincRNA-BC2 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289930 | LincRNA-BC4 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289931 | LincRNA-BC5 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289932 | LincRNA-BC8 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0083190 | LINC01511 | RP11-325I22.2 | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290026 | LOC440905 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289552 | AC079776.2 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289720 | CTA-363E6.2 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289901 | LINC00987 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290185 | RP11-1C1.7 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290197 | RP11-445K13.2 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290199 | RP11-473M20.11 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290213 | RP11-893F2.6 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290217 | RP13-514E23.1 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290218 | RP1-90D4.3 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290220 | RP4-575N6.5 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290226 | RP5-826L7.1 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290378 | XLOC_003286 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290379 | XLOC_003405 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290389 | XLOC_012255 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290056 | MIR21 | NA | NA | pathogenic process | laryngeal squamous cell cancer | Neoplasms |
| HSALNT0289621 | ASncmtRNAs | NA | transcriptional regulation | pathogenic process | cancer | Neoplasms |
| HSALNT0289316 | LINC01614 | LCAL4,TCONS_00003105 | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289982 | LncRNA-FER1L4 | NA | ceRNA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290016 | LOC283177 | NA | NA | pathogenic process | diffuse large B-cell lymphoma | Hemic and Lymphatic Diseases |
| HSALNT0289003 | HORMAD2-AS1 | MTMR3-AS1,NONHSAG033653 | NA | pathogenic process | type 1 diabetes;bowel disease | Nutritional and Metabolic Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0290372 | WNT4 | NA | NA | pathogenic process | endometriosis | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289540 | AB074278 | NA | NA | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290166 | RCCRT1 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289043 | LINC00491 | BC008363 | NA | pathogenic process | pancreatic ductal adenocarcinoma | Neoplasms |
| HSALNT0289858 | H1.3 | NA | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289896 | LINC00582 | NA | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289301 | LINC01537 | RP11-169D4.1-001 | NA | pathogenic process | laryngeal squamous cell cancer | Neoplasms |
| HSALNT0289551 | AC026166.2 | MTCO1P5 | NA | pathogenic process | laryngeal squamous cell cancer | Neoplasms |
| HSALNT0290184 | RP11-169D4.1-001 | NA | NA | pathogenic process | laryngeal squamous cell cancer | Neoplasms |
| HSALNT0289545 | AC006050.3 | NA | NA | pathogenic process | lung squamous cell cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289556 | AC138128.1 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289818 | ERCC1 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290061 | MT1DP | MT1DP | NA | pathogenic process | liver cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289578 | AK023096 | NA | NA | pathogenic process | Wilmsâ tumor;uterine leiomyomas | Neoplasms |
| HSALNT0289112 | LINC01562 | RP11-296A18.3 | transcriptional regulation | pathogenic process | intervertebral disc degeneration | Musculoskeletal Diseases |
| HSALNT0289567 | AK000974 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289579 | AK024118 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289645 | BC040204 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290321 | U79277 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289869 | HOST2 | NA | ceRNA | pathogenic process | epithelial ovarian cancer | Neoplasms |
| HSALNT0289368 | MGAT3-AS1 | TapSAKI | NA | pathogenic process | acute kidney injury | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289624 | ATXN7L3B | NA | NA | pathogenic process | spinocerebellar ataxia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0289990 | Lnc-SCA7 | NA | ceRNA | pathogenic process | spinocerebellar ataxia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0290004 | LOC100287482 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290383 | XLOC_007697 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290384 | XLOC_008559 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290385 | XLOC_009911 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289813 | ENST00000480739 | RPL13AP23 | NA | pathogenic process | Pancreatic ductal adenocarcinoma | Neoplasms |
| HSALNT0290111 | OS9 | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | Neoplasms |
| HSALNT0290324 | Uc.283-plus | NA | NA | pathogenic process | glioma | Neoplasms |
| HSALNT0289117 | LINC01611 | RP1-90L14.1,TCONS_l2_00025430 | NA | pathogenic process | diabetic retinopathy | Endocrine System Diseases;Male Urogenital Diseases;Cardiovascular Diseases |
| HSALNT0289529 | 2900055J20Rik | 2900055J20Rik | NA | pathogenic process | left ventricular hypertrophy | Pathological Conditions, Signs and Symptoms;Cardiovascular Diseases |
| HSALNT0289792 | ENSG00000261777 | AC012184.3 | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289618 | Asb3 | NA | NA | pathogenic process | cardiovascular and renal disease | Cardiovascular Diseases |
| HSALNT0289703 | Chac2 | NA | NA | pathogenic process | cardiovascular and renal disease | Cardiovascular Diseases |
| HSALNT0290139 | Pex11b | NA | NA | pathogenic process | cardiovascular and renal disease | Cardiovascular Diseases |
| HSALNT0290255 | Sp5 | NA | NA | pathogenic process | cardiovascular and renal disease | Cardiovascular Diseases |
| HSALNT0211639 | PSMA3-AS1 | FLJ31306 | NA | pathogenic process | NA | NA |
| HSALNT0289319 | LINC00493 | LOC388789 | NA | pathogenic process | NA | NA |
| HSALNT0288903 | CARD8-AS1 | LOC100505812 | transcriptional regulation | pathogenic process | leukemia and neuroblastoma | Neoplasms |
| HSALNT0064729 | KCNMB2-AS1 | RP11-385J1.2 | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289548 | AC013264.2 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289857 | GUCY1B2 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290190 | RP11-385J1.2 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290216 | RP1-317E23.3 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290317 | TUBA4B | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290375 | XLOC_000371 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290397 | Z82214.3 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289735 | DALIR | DALI | transcriptional regulation | NA | NA | NA |
| HSALNT0290376 | XLOC_000620 | NA | NA | pathogenic process | H. pylori-related diseases | Bacterial Infections and Mycoses |
| HSALNT0290380 | XLOC_004122 | NA | NA | pathogenic process | H. pylori-related diseases | Bacterial Infections and Mycoses |
| HSALNT0290381 | XLOC_004562 | NA | NA | pathogenic process | H. pylori-related diseases | Bacterial Infections and Mycoses |
| HSALNT0290382 | XLOC_005912 | NA | NA | pathogenic process | H. pylori-related diseases | Bacterial Infections and Mycoses |
| HSALNT0290391 | XLOC_014388 | NA | NA | pathogenic process | H. pylori-related diseases | Bacterial Infections and Mycoses |
| HSALNT0290028 | LOC652276 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290162 | R05532 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0098175 | LINC01411 | RP11-267A15.1 | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290025 | LOC401317 | NA | NA | pathogenic process | nasopharyngeal cancer | Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0289726 | CTD-2574D22.4 | AC120114.2 | NA | pathogenic process | osteoarthritis | Musculoskeletal Diseases |
| HSALNT0290141 | PMS2L2 | NA | NA | pathogenic process | osteoarthritis | Musculoskeletal Diseases |
| HSALNT0289974 | LncRNA-422 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289520 | AATBC | NA | NA | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289311 | LINC00974 | NA | ceRNA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0089943 | ZBED3-AS1 | NA | NA | developmental process | NA | NA |
| HSALNT0289116 | LINC01589 | CTA-941F9.9,TCONS_00029353 | NA | pathogenic process | NA | NA |
| HSALNT0289910 | LINC01426 | NA | NA | pathogenic process | esophageal squamous cell cancer | Neoplasms |
| HSALNT0290341 | Uc002yug.2 | NA | splicing regulation | pathogenic process | esophageal squamous cell cancer | Neoplasms |
| HSALNT0290250 | SNCG | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289996 | Lnc-uc003wbd | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289559 | AF085935 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290347 | Uc003wbd | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290098 | NR_001284 | TNXA | NA | pathogenic process | chronic thromboembolic pulmonary hypertension | Cardiovascular Diseases |
| HSALNT0290327 | Uc.343 | NA | NA | pathogenic process | osteoarthritis | Musculoskeletal Diseases |
| HSALNT0289196 | NRAV | DYNLL1-AS1 | transcriptional regulation | pathogenic process | influenza A virus | Virus Diseases |
| HSALNT0290140 | PLEC | NA | NA | pathogenic process | chronic obstructive pulmonary disease | Respiratory Tract Diseases |
| HSALNT0290172 | RNA44121 | NA | NA | pathogenic process | chronic obstructive pulmonary disease | Respiratory Tract Diseases |
| HSALNT0290173 | RNA50010 | NA | NA | pathogenic process | chronic obstructive pulmonary disease | Respiratory Tract Diseases |
| HSALNT0290174 | RNA58351 | NA | NA | pathogenic process | chronic obstructive pulmonary disease | Respiratory Tract Diseases |
| HSALNT0289714 | CR613944 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289933 | LincRNA-CALCA | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290200 | RP11-501G6.1 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290208 | RP11-672F9.1 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290405 | C14orf132 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289937 | LincRNA-TSPAN8 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290225 | RP5-1014O16.1 | AC244098.1 | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290275 | TCONS_00026102 | NA | NA | pathogenic process | atrial fibrillation | Pathological Conditions, Signs and Symptoms;Cardiovascular Diseases |
| HSALNT0290277 | TCONS_00032546 | NA | NA | pathogenic process | atrial fibrillation | Pathological Conditions, Signs and Symptoms;Cardiovascular Diseases |
| HSALNT0289037 | LINC00441 | RB1-DT,ncRNA-RB1 | NA | pathogenic process | NA | NA |
| HSALNT0289661 | C1401f132 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289141 | LINC02365 | LVCAT8 | NA | pathogenic process | NA | NA |
| HSALNT0288885 | ADGRD1-AS1 | LACAT8 | NA | NA | NA | NA |
| HSALNT0289142 | LINC02475 | LVCAT1 | NA | NA | NA | NA |
| HSALNT0289542 | Abhd11os | NA | NA | pathogenic process | neurodegenerative diseases | Nervous System Diseases |
| HSALNT0288895 | BISPR | NA | NA | pathogenic process | virus infection | Virus Diseases |
| HSALNT0233975 | MAFTRR | linc-MAF-4 | transcriptional regulation | NA | NA | NA |
| HSALNT0290058 | MRAK052686 | NA | NA | pathogenic process | nonalcoholic fatty liver disease | Digestive System Diseases |
| HSALNT0290221 | RP4-583P15.10 | AL121845.1 | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0211341 | KTN1-AS1 | C14orf33,MYCLo-3 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0266752 | DLGAP4-AS1 | CCAT7 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289682 | CCAT3 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289684 | CCAT8 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289898 | LINC00659 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289627 | BALR-2 | NA | NA | pathogenic process | B cell acute lymphoblastic leukemia | Immune System Diseases;Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0289948 | Lnc-ACACA-1 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289953 | Lnc-BMP2-2 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289955 | Lnc-CPN2-1 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289958 | Lnc-FOXG1-2 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289960 | Lnc-FZD1-2 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289962 | Lnc-ITPR2-3 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289965 | Lnc-LCP2-2 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289988 | Lnc-RP3-368B9 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289991 | Lnc-SLC30A4-1 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289992 | Lnc-SPAM1-6 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289995 | Lnc-TTC34-3 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0222064 | DRAIC | NA | NA | pathogenic process | prostate cancer;glioma;cancer;bladder cancer;renal clear cell cancer;skin melanoma;hepatocellular cancer;lung adenocarcinoma;stomach adenocarcinoma | Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases |
| HSALNT0290390 | XLOC_014172 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290014 | LOC149086 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290183 | RP11-160H22.5 | AL121983.2 | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289945 | LNC00964-3 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289616 | Arid2-IR | NA | NA | pathogenic process | renal inflammation | NA |
| HSALNT0289716 | CR619813 | NA | NA | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289739 | DDX6P1 | NA | NA | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289938 | LincRNA-ZNF532 | NA | NA | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0290011 | LOC105372753 | NA | NA | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0290013 | LOC105377769 | NA | NA | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0290205 | RP11-58D2.1 | NA | NA | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0288946 | ENST00000434223 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0288947 | ENST00000442037 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0288953 | ENST00000540136 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290103 | NR_038125 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290136 | PDLIM3 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290335 | Uc001gch.1 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290336 | Uc001gzl.3 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290351 | Uc004bbl.1 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290369 | VNN2 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289577 | AK022798 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289663 | C1orf74 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289602 | AKR7L | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289711 | COL3A1 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289878 | KCNE2 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289636 | BC015134 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289713 | CR594506 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289928 | LincRNA-BBOX1-2 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0271719 | LINC00320 | PRED14,FLJ37539 | NA | pathogenic process;developmental process | cortical white matter | Nervous System Diseases |
| HSALNT0289823 | EVADR | NA | NA | pathogenic process | pancreatic cancer;lung cancer;colorectal cancer;rectal cancer | Respiratory Tract Diseases;Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289952 | Lnc-bc060912 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289613 | APF | NA | ceRNA | pathogenic process | myocardial infarction | Cardiovascular Diseases |
| HSALNT0289617 | AS Uchl1 | NA | NA | pathogenic process | Parkinson's disease | Nervous System Diseases |
| HSALNT0289104 | LINC01296 | FLJ39632 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290403 | ZXF2 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290113 | P14695 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290114 | P16984 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290115 | P19780 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290116 | P23099 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290117 | P24363 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290118 | P28210 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290120 | P33863 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290121 | P4091 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290122 | P6391 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290123 | P6488 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290124 | P700 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290125 | P8611 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290126 | P8725 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290127 | P8860 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290128 | P9745 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289269 | TH2LCRR | TH2-LCR | transcriptional regulation | pathogenic process | allergic asthma | Respiratory Tract Diseases;Immune System Diseases |
| HSALNT0289964 | Lnc-LCE5A-1 | NA | NA | pathogenic process | laryngeal cancer;head and neck squamous cell cancer | Respiratory Tract Diseases;Otorhinolaryngologic Diseases;Neoplasms |
| HSALNT0055198 | FAM3D-AS1 | lnc-KCTD6-3 | NA | pathogenic process | tongue cancer;pharyngeal cancer;head and neck squamous cell cancer;laryngeal cancer | Respiratory Tract Diseases;Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0289843 | FRLnc1 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0242005 | ENST00000575202 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0288952 | ENST00000539009 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0288954 | ENST00000544591 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289752 | EHHADH-AS1 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289812 | ENST00000468960 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290276 | TCONS_00026506 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0189952 | LRP1-AS | NA | transcriptional regulation | pathogenic process | Alzheimer's disease | Mental Disorders;Nervous System Diseases |
| HSALNT0032045 | LINC01122 | FLJ30838,AC007092.1 | NA | NA | NA | NA |
| HSALNT0289565 | AI364715 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289921 | LINC0949 | NA | NA | pathogenic process | systemic lupus erythematosus | Immune System Diseases;Skin and Connective Tissue Diseases |
| HSALNT0289680 | CCAL | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289079 | LINC00993 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289811 | ENST00000460164 | NA | NA | pathogenic process | triple-negative breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290282 | TCONS_l2_00003938 | NA | NA | pathogenic process | triple-negative breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289888 | LGALS3 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0289963 | Lnc-KCMF1-2:1 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0289967 | Lnc-LLPH-2:1 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0289971 | Lnc-PLA2R1-1:1 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0289972 | Lnc-PSD4-1:14 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0290066 | N335550 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0290070 | N340790 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0290072 | N386477 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0290286 | TCONS_l2_00010365 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0289118 | LINC01612 | RP11-789C1.1,TCONS_00008319 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289610 | AP001439.2 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289671 | CACNAICAS3 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289853 | GS1-5L10.1 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290065 | MYLK-AS1 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290157 | PRSS21 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290202 | RP11-528G1.2 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290207 | RP11-643M14.1 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290209 | RP11-789C1.1 | LINC01612 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290314 | TSNAX-DISC1 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290386 | XLOC_010235 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289558 | AF075041 | NA | NA | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289564 | AF339813 | NA | NA | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289575 | AK022029 | NA | NA | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289576 | AK022159 | NA | NA | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289604 | AL389956 | NA | NA | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289640 | BC023629 | NA | NA | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0290096 | NONHSAT125629 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290393 | XR_250621.1 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0288951 | ENST00000503938 | NA | NA | pathogenic process | triple-negative breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290085 | NONHSAT012762 | NA | NA | pathogenic process | triple-negative breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289151 | LMCD1-AS1 | NA | NA | pathogenic process | acute kidney injury | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289926 | Linc-PXN-1 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290281 | TCONS_l2_00001418 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290285 | TCONS_l2_00008237 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290287 | TCONS_l2_00011130 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290288 | TCONS_l2_00013175 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290294 | TCONS_l2_00022611 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290295 | TCONS_l2_00022670 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290352 | Uc004bdv.3 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290363 | ULK4P2 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289942 | LK4P2 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289538 | AB019562 | NA | NA | pathogenic process | hypopharyngeal squamous cell cancer | Neoplasms |
| HSALNT0091661 | ENST00000503710 | NA | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289806 | ENST00000445734 | NA | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289807 | ENST00000448093 | NA | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289815 | ENST00000502941 | NA | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290340 | Uc002nbr.3 | NA | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290356 | Uc021re1.1 | NA | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289549 | AC016745.3 | AC016745.1 | NA | pathogenic process | glioma | Neoplasms |
| HSALNT0290180 | RP11-128A17.1 | AC078909.1 | NA | pathogenic process | glioma | Neoplasms |
| HSALNT0290377 | XLOC_001711 | NA | NA | pathogenic process | glioma | Neoplasms |
| HSALNT0289975 | LncRNA-AK058003 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289061 | LINC00682 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289305 | LINC01559 | FLJ33810 | NA | pathogenic process | Huntington disease | Mental Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0289854 | GSTT1-AS1 | NA | transcriptional regulation | pathogenic process | mycobacterium tuberculosis infection | Bacterial Infections and Mycoses |
| HSALNT0289978 | LncRNA-CD244 | NA | transcriptional regulation | pathogenic process | tuberculosis infection | Bacterial Infections and Mycoses |
| HSALNT0289237 | SAMD12-AS1 | NA | NA | pathogenic process | neuroblastoma | Neoplasms |
| HSALNT0290179 | RP11-119F7.4 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290278 | TCONS_00068220 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0285573 | DANT1 | NA | transcriptional regulation | NA | NA | NA |
| HSALNT0288926 | DANT2 | NA | transcriptional regulation | NA | NA | NA |
| HSALNT0290399 | ZMAT1 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289554 | AC100865.1 | NA | NA | pathogenic process | coronary artery disease | Cardiovascular Diseases |
| HSALNT0289228 | RAD51-AS1 | TODRA | transcriptional regulation | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289743 | DKFZP434K028 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289630 | BC002811 | NA | NA | pathogenic process | astrocytoma | Neoplasms |
| HSALNT0290387 | XLOC_010967 | NA | NA | pathogenic process | astrocytoma | Neoplasms |
| HSALNT0288955 | ENST00000545440 | NA | NA | pathogenic process | pediatric acute myeloid leukemia | Hemic and Lymphatic Diseases |
| HSALNT0288981 | FRGCA | LncRNA-AP001631.9 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289976 | LncRNA-AP001631.9 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289686 | CD99P1 | NA | ceRNA | pathogenic process | idiopathic pulmonary fibrosis | Respiratory Tract Diseases |
| HSALNT0289119 | LINC01613 | n341773 | NA | pathogenic process | idiopathic pulmonary fibrosis | Respiratory Tract Diseases |
| HSALNT0289844 | FTH1P3 | FTH1P3 | NA | pathogenic process | oral squamous cell cancer | Neoplasms |
| HSALNT0289855 | GTF2IRD2P1 | GTF2IRD2P1 | NA | pathogenic process | oral squamous cell cancer | Neoplasms |
| HSALNT0290135 | PDIA3F | NA | NA | pathogenic process | oral squamous cell cancer | Neoplasms |
| HSALNT0289329 | LINC00994 | NA | NA | pathogenic process | inflammatory bowel disease | Digestive System Diseases |
| HSALNT0289208 | PCAT5 | LINC01452,TPCAT-10-36067 | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0114870 | LUADT1 | NA | transcriptional regulation | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289154 | LOXL1-AS1 | NA | NA | pathogenic process | exfoliation syndrome | Eye Diseases |
| HSALNT0289734 | DACOR1 | TCONS_00023265 | transcriptional regulation | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289060 | LINC00675 | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | Neoplasms |
| HSALNT0288889 | B4GALT1-AS1 | NA | transcriptional regulation | pathogenic process | NA | NA |
| HSALNT0289348 | LINC01616 | n341006 | NA | pathogenic process | Alzheimer's disease | Mental Disorders;Nervous System Diseases |
| HSALNT0290068 | N336934 | NA | NA | pathogenic process | Alzheimer's disease | Mental Disorders;Nervous System Diseases |
| HSALNT0290240 | SIRT1-AS | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290198 | RP11-457M11.2 | NA | ceRNA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0150768 | LINC01507 | XLOC_000303 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289903 | LINC01057 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289914 | LINC01617 | C8orf23,NCRNA00249,XLOC_006844 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290015 | LOC152578 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0072252 | LINC01618 | LOC152578 | NA | pathogenic process | NA | NA |
| HSALNT0156870 | NALT1 | MIR4674HG,LINC01573,TCONS_l2_00029132 | transcriptional regulation | pathogenic process | acute lymphoblastic leukemia | Immune System Diseases;Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0289083 | MALINC1 | LINC01024,MA-linc1 | NA | pathogenic process | human breast and lung cancer | Neoplasms |
| HSALNT0289902 | LINC01024 | MA-linc1 | NA | pathogenic process | osteosarcoma;lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289120 | LINC01627 | RP11-397D12.4 | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289121 | LINC01628 | AC007403.1 | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289820 | ERICH1-AS1 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290193 | RP11-397D12.4 | LINC01627 | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289122 | LINC01629 | linc-KIAA1737-2 | transcriptional regulation | pathogenic process | hypoxic and inflammatory renal epithelial injury | NA |
| HSALNT0290161 | PTPRG-AS1 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289980 | LncRNA-DLEU1 | NA | ceRNA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289983 | LncRNA-Hh | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0288986 | GAS1RR | LncRNA-Hh | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0288908 | CCDC18-AS1 | ENST00000440778.1 | NA | pathogenic process | adolescent idiopathic scoliosis | Musculoskeletal Diseases |
| HSALNT0289055 | LINC00649 | TCONS_00028768 | NA | pathogenic process | adolescent idiopathic scoliosis | Musculoskeletal Diseases |
| HSALNT0289219 | PRKCQ-AS1 | ENST00000414894.1 | NA | pathogenic process | adolescent idiopathic scoliosis | Musculoskeletal Diseases |
| HSALNT0290203 | RP11-567G11.1 | LINC02041 | NA | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289805 | ENST00000438550 | RPS24P1 | NA | pathogenic process | nasopharyngeal cancer | Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0290083 | NONHSAG011351 | NA | NA | pathogenic process | type 1 diabetes | Nutritional and Metabolic Diseases;Endocrine System Diseases |
| HSALNT0290049 | MCHR2-AS1 | NA | NA | pathogenic process | psychiatric disease | Nervous System Diseases |
| HSALNT0289799 | ENST00000414355 | NA | NA | pathogenic process | cadmium toxicology | Disorders of Environmental Origin |
| HSALNT0290241 | SKP2 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289837 | FLJ90757 | NA | ceRNA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290017 | LOC283663 | NA | ceRNA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290019 | LOC338651 | NA | ceRNA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290132 | PCATs | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0086786 | EGFLAM-AS1 | lncRNA-LOWEG | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290031 | LOWEG | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289635 | BC014579 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289721 | CTB-167B5.2 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289863 | HELLS | NA | NA | pathogenic process | leukemia | Neoplasms |
| HSALNT0290195 | RP11-401P9.4 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290252 | SNHG19 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289557 | AF070632 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289569 | AK021443 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289728 | CTD-3080P12.3 | NA | ceRNA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289987 | LncRNA-n336928 | NA | NA | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289723 | CTC-523E23.5 | AC008555.2 | NA | pathogenic process | intervertebral disc degeneration | Musculoskeletal Diseases |
| HSALNT0289724 | CTD-2246P4.1 | NA | NA | pathogenic process | intervertebral disc degeneration | Musculoskeletal Diseases |
| HSALNT0290055 | MIR132 | MIRN132,miRNA132,mir-132 | NA | pathogenic process | intervertebral disc degeneration | Musculoskeletal Diseases |
| HSALNT0290189 | RP11-363G2.4 | NA | NA | pathogenic process | intervertebral disc degeneration | Musculoskeletal Diseases |
| HSALNT0290191 | RP11-38F22.1 | LINC02424 | NA | pathogenic process | intervertebral disc degeneration | Musculoskeletal Diseases |
| HSALNT0290223 | RP4-639J15.1 | AC006967.2 | NA | pathogenic process | intervertebral disc degeneration | Musculoskeletal Diseases |
| HSALNT0290233 | RUNX1-IT1 | C21orf96 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0288943 | ENST00000415964 | NA | NA | pathogenic process | pediatric acute myeloid leukemia | Hemic and Lymphatic Diseases |
| HSALNT0290009 | LOC101927497 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289956 | Lnc-CYP4A22-2/3 | NA | NA | pathogenic process | clear cell renal cell cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289999 | Lnc-ZNF180-2 | NA | NA | pathogenic process | renal clear cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290086 | NONHSAT037832 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0289658 | BX647187 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289584 | AK056155 | NA | NA | pathogenic process | Loeys-Dietz syndrome | Musculoskeletal Diseases |
| HSALNT0290057 | MR1 | NA | NA | pathogenic process | Loeys-Dietz syndrome | Musculoskeletal Diseases |
| HSALNT0289543 | AC002454.1 | AC002454.1 | NA | pathogenic process | endometriosis | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289909 | LINC01420 | NA | NA | pathogenic process | systemic lupus erythematosus | Immune System Diseases;Skin and Connective Tissue Diseases |
| HSALNT0289531 | 53BP1 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290101 | NR_024118 | NA | NA | pathogenic process | rheumatoid arthritis | Immune System Diseases;Musculoskeletal Diseases;Skin and Connective Tissue Diseases |
| HSALNT0290239 | SGO1-AS1 | SGOL1-AS1 | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289293 | ZNF667-AS1 | MORT | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289984 | LncRNA-HIF2PUT | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0288945 | ENST00000433673 | AC068282.1 | NA | pathogenic process | polycystic ovary syndrome | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0288948 | ENST00000454271 | AL021940.1 | NA | pathogenic process | polycystic ovary syndrome | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289495 | ENST00000432431 | AC023128.1 | NA | pathogenic process | polycystic ovary syndrome | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289918 | LINC01828 | NA | NA | pathogenic process | polycystic ovary syndrome | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0290388 | XLOC_011402 | NA | NA | pathogenic process | polycystic ovary syndrome | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289873 | ICAM-1 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289666 | C5-OT1 | C5T1lncRNA | NA | pathogenic process | rheumatoid arthritis | Immune System Diseases;Musculoskeletal Diseases;Skin and Connective Tissue Diseases |
| HSALNT0289626 | AX800134 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290338 | Uc001ncr | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290330 | Uc.48+ | NA | NA | pathogenic process | diabetic neuropathic pain | Male Urogenital Diseases |
| HSALNT0289098 | LINC01207 | NA | transcriptional regulation | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289628 | BALR-6 | NA | transcriptional regulation | pathogenic process | B-lymphoblastic leukemia | Hemic and Lymphatic Diseases |
| HSALNT0290022 | LOC389641 | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | Neoplasms |
| HSALNT0289725 | CTD-2541M15 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289940 | LINK-A | NA | NA | pathogenic process | triple-negative breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290107 | NUTF2P3 | NUTF2P3 | NA | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0290095 | NONHSAT123350 | NA | NA | pathogenic process | renal clear cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290362 | UHRF1 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290366 | UPAT | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289307 | LINC00324 | FLJ34790,MGC104931 | NA | pathogenic process | NA | NA |
| HSALNT0289969 | Lnc-MX1-1 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290024 | LOC400891 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289883 | LA16c-313D11.11 | NA | ceRNA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290192 | RP11-395G23.3 | AC027031.2 | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289581 | AK027294 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290371 | WISP1 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0206117 | FGF14-AS2 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290131 | PCAT2 | CARLo-4,PCA2,TCONS_00015167 | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289528 | 2700086A05Rik | 2700086A05Rik | NA | pathogenic process | idiopathic pulmonary fibrosis | Respiratory Tract Diseases |
| HSALNT0290251 | SNED1 | NA | NA | pathogenic process | Idiopathic pulmonary fibrosis | Respiratory Tract Diseases |
| HSALNT0290333 | Uc.77 | NA | NA | pathogenic process | idiopathic pulmonary fibrosis | Respiratory Tract Diseases |
| HSALNT0289816 | ENST00000537266 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0289860 | HAGLROS | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0289881 | KRT18P55 | KRT18P55 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0229266 | IL21R-AS1 | NA | NA | pathogenic process | coronary artery disease | Cardiovascular Diseases |
| HSALNT0290112 | OTTHUMT00000387022 | NA | NA | pathogenic process | coronary artery disease | Cardiovascular Diseases |
| HSALNT0000551 | PRKCZ-AS1 | RP11-181G12.2 | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0030981 | LINC01833 | RP11-89,K21.1 | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290214 | RP11-89K21 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0165271 | LINC00857 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290109 | OR3A4 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290046 | MAGI1-IT1 | NA | ceRNA | pathogenic process | cardiac hypertrophy | Cardiovascular Diseases |
| HSALNT0290242 | SLC26A4-AS1 | NA | ceRNA | pathogenic process | cardiac hypertrophy | Cardiovascular Diseases |
| HSALNT0289302 | KRT7-AS | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0218672 | LINC01852 | ENST00000434223 | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290178 | RP11-1008C21.2 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289592 | AK123072 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289573 | AK021954 | NA | NA | pathogenic process | atherosclerosis | Cardiovascular Diseases |
| HSALNT0288916 | CERNA1 | LOC100129973 | ceRNA | pathogenic process | cardiovascular disease | Cardiovascular Diseases |
| HSALNT0018525 | LAMC1-AS1 | lnc-LAMC2-1:1 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290087 | NONHSAT040387 | NA | NA | pathogenic process | atrial fibrillation | Pathological Conditions, Signs and Symptoms;Cardiovascular Diseases |
| HSALNT0290092 | NONHSAT098586 | NA | NA | pathogenic process | atrial fibrillation | Pathological Conditions, Signs and Symptoms;Cardiovascular Diseases |
| HSALNT0289213 | PCSK6-AS1 | NA | NA | NA | NA | NA |
| HSALNT0289637 | BC016831 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289874 | IGKV | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290196 | RP11-434D9.1 | AC112206.2 | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289885 | LCAL6 | NA | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289650 | BC088254 | NA | NA | pathogenic process | myocardial hypertrophy | Cardiovascular Diseases |
| HSALNT0289596 | AK124454 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289731 | CYP4B1-PS1 | NA | NA | pathogenic process | diabetic nephropathy | Endocrine System Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289106 | LINC01405 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290259 | ST8SIA6-AS1 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289278 | TRIM52-AS1 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289634 | BC012900 | NA | NA | pathogenic process | ulcerative colitis | Digestive System Diseases |
| HSALNT0274011 | UMODL1-AS1 | FLJ33471 | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289454 | ARRDC1-AS1 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289456 | FAM74A3 | OTTHUMG00000067149 | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289834 | FH | NA | NA | pathogenic process | Fumarase deficiency | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289961 | Lnc-HOXC4-3:1 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289994 | Lnc-TEAD4-1:1 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290270 | TCONS_00003876 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290235 | SARCC | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290360 | Ucoo2kmd.1 | NA | ceRNA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289015 | KAZN-AS1 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289722 | CTB-89H12.4 | AC021078.1 | ceRNA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289496 | EPB41L4A-AS2 | FLJ11235 | NA | pathogenic process | lung cancer;breast cancer;kidney cancer | Skin and Connective Tissue Diseases;Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289146 | LINC02567 | ENST00000427806 | NA | pathogenic process | attention deficit hyperactivity disorder | Mental Disorders |
| HSALNT0289833 | FGFR3-AS1 | NA | NA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0289707 | CILinc01 | NA | NA | pathogenic process | osteoarthritis | Musculoskeletal Diseases |
| HSALNT0289708 | CILinc02 | NA | NA | pathogenic process | osteoarthritis | Musculoskeletal Diseases |
| HSALNT0286597 | LINC00629 | LINC00629AB,LINC00629C,LINC00629D,LINC00629 | NA | pathogenic process | choriocarcinoma | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289665 | C2dat1 | NA | NA | pathogenic process | ischemic brain injury | Cardiovascular Diseases |
| HSALNT0289217 | POU6F2-AS2 | FLJ12971 | protein localization | pathogenic process | oesophageal squamous cell cancer | Neoplasms |
| HSALNT0289946 | Lnc13 | NA | NA | pathogenic process | celiac disease | Nutritional and Metabolic Diseases;Digestive System Diseases |
| HSALNT0289729 | CTD903 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290093 | NONHSAT104436 | NA | NA | pathogenic process | esophageal squamous cell cancer | Neoplasms |
| HSALNT0289550 | AC024560.2 | AC024560.1 | NA | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289483 | ENST00000436681 | AP000552.1 | NA | pathogenic process | congenital heart defect | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289536 | AA584040 | NA | NA | pathogenic process | congenital heart defect | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289537 | AA709223 | NA | NA | pathogenic process | congenital heart defect | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289657 | BX478947 | NA | NA | pathogenic process | congenital heart defect | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0247515 | LINC00668 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289719 | CRNDE-h | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0142879 | SMILR | NA | NA | pathogenic process | vascular pathologies | Cardiovascular Diseases |
| HSALNT0290396 | Z38 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0197213 | LINC00507 | NA | NA | developmental process | NA | NA |
| HSALNT0289086 | LINC01082 | TCONSNA00024492 | NA | pathogenic process | alveolar capillary dysplasia with misalignment of pulmonary veins | Cardiovascular Diseases |
| HSALNT0289094 | LINC01185 | FLJ16341 | NA | pathogenic process | NA | NA |
| HSALNT0290160 | PTPRD-AS1 | NA | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290186 | RP11-254I22.1 | MIR583HG | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290204 | RP11-57P19.1 | AC009432.1 | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290211 | RP11-80H5.7 | AL157400.4 | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290215 | RP1-223E5.4 | AL441883.1 | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290224 | RP4-799P18.3 | AL122008.4 | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289126 | LINC01844 | LOC101926975 | NA | pathogenic process | hirschsprung disease | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Digestive System Diseases |
| HSALNT0289947 | Lnc34a | NA | transcriptional regulation | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289150 | LINP1 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289951 | LncARSR | NA | ceRNA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289392 | RBM15-AS1 | AS-RBM15 | translational control | pathogenic process | acute megakaryocytic leukemia | Neoplasms |
| HSALNT0290089 | NONHSAT073641 | NA | NA | pathogenic process | vascular diseases | Cardiovascular Diseases |
| HSALNT0290027 | LOC572558 | NA | NA | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289582 | AK033210 | NA | NA | pathogenic process;developmental process | bronchopulmonary dysplasia | Respiratory Tract Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| HSALNT0289848 | GClnc1 | NA | transcriptional regulation | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289572 | AK021630 | NA | NA | pathogenic process | Parkinson's disease | Nervous System Diseases |
| HSALNT0289603 | AL049437 | NA | NA | pathogenic process | Parkinson's disease | Nervous System Diseases |
| HSALNT0290007 | LOC100507661 | NA | NA | pathogenic process | thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0289084 | LINC01029 | NA | NA | pathogenic process | cognitive functions and neuronal plasticity | Nervous System Diseases |
| HSALNT0290169 | RMEL3 | NA | NA | pathogenic process | melanoma | Neoplasms |
| HSALNT0289959 | Lnc-FRG2C-3 | NA | NA | pathogenic process | ankylosing spondylitis | Musculoskeletal Diseases |
| HSALNT0289966 | Lnc-LIN54-1 | NA | NA | pathogenic process | ankylosing spondylitis | Musculoskeletal Diseases |
| HSALNT0289997 | Lnc-USP50-2 | NA | NA | pathogenic process | ankylosing spondylitis | Musculoskeletal Diseases |
| HSALNT0290000 | Lnc-ZNF354A-1 | NA | NA | pathogenic process | ankylosing spondylitis | Musculoskeletal Diseases |
| HSALNT0288949 | ENST00000455309 | NA | NA | pathogenic process | primary Sjögren's syndrome | Immune System Diseases |
| HSALNT0289920 | LINC02384 | NA | NA | pathogenic process | primary Sjögren's syndrome | Immune System Diseases |
| HSALNT0289998 | Lnc-UTS2D-1:1 | NA | NA | pathogenic process | primary Sjögren's syndrome | Immune System Diseases |
| HSALNT0290067 | N336161 | NA | NA | pathogenic process | primary Sjögren's syndrome | Immune System Diseases |
| HSALNT0290069 | N340599 | NA | NA | pathogenic process | primary Sjögren's syndrome | Immune System Diseases |
| HSALNT0290099 | NR_002712 | NA | NA | pathogenic process | primary Sjögren's syndrome | Immune System Diseases |
| HSALNT0290290 | TCONS_l2_00014794 | NA | NA | pathogenic process | primary Sjögren's syndrome | Immune System Diseases |
| HSALNT0290170 | RMRP | CHH,NME1R,RRP2,RMRP | ceRNA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289900 | LINC00961 | NA | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289077 | LINC00977 | NA | NA | pathogenic process | primary spontaneous pneumothorax | Respiratory Tract Diseases |
| HSALNT0289560 | AF085995 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289566 | AK000053 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289571 | AK021595 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289574 | AK022024 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289595 | AK124307 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289639 | BC020384 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289642 | BC030759 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289715 | CR615992 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289954 | Lnc-CC3 | NA | NA | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289614 | APOC1P1-3 | NA | transcriptional regulation | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290365 | UNMIBC | NA | transcriptional regulation | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290323 | Uc.167 | NA | NA | pathogenic process | ventricular septal defects | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0290212 | RP11-838N2.4 | GAPLINC | ceRNA | pathogenic process | glioblastoma | Neoplasms |
| HSALNT0289109 | LINC01478 | NA | NA | pathogenic process | blood pressure | Cardiovascular Diseases |
| HSALNT0289313 | LINC00342 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289677 | CAR10 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289365 | MAPT-AS1 | NA | transcriptional regulation | pathogenic process | Parkinson's disease | Nervous System Diseases |
| HSALNT0289679 | CAT104 | NA | ceRNA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290260 | STXBP5-AS1 | NA | ceRNA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289861 | HAR1 | NA | NA | pathogenic process | Huntington disease | Mental Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0290359 | UCHL1-AS1 | NA | translational control | pathogenic process | Parkinson's disease | Nervous System Diseases |
| HSALNT0290238 | SCAANT1-AS | NA | NA | pathogenic process | spinocerebellar ataxia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0289648 | BC041488 | NA | transcriptional regulation | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290188 | RP11-359E19.2 | AC022733.1 | transcriptional regulation | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289851 | GIHCG | NA | transcriptional regulation | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289649 | BC087858 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290353 | Uc004cov.4 | NA | NA | pathogenic process | hypertrophic cardiomyopathy | Cardiovascular Diseases |
| HSALNT0290357 | Uc022bqu.1 | NA | NA | pathogenic process | hypertrophic cardiomyopathy | Cardiovascular Diseases |
| HSALNT0127837 | CFTR-AS1 | BGas | transcriptional regulation | pathogenic process | cystic fibrosis | Respiratory Tract Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Digestive System Diseases |
| HSALNT0046367 | MYOSLID | NA | NA | pathogenic process | vascular smooth muscle cell (VSMC) contractile phenotype | Cardiovascular Diseases |
| HSALNT0290331 | Uc.63 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290106 | Numb | NA | NA | pathogenic process | uveal melanoma | Neoplasms |
| HSALNT0289847 | GCASPC | TCONS_00011605,RP1-56L9.7-001,lnc-SOD2-1 | NA | pathogenic process | gallbladder cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289568 | AK001094 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289588 | AK093735 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289631 | BC003519 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290100 | NR_003573 | ANXA2P2 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290119 | P2RX7-V3 | NA | NA | pathogenic process | uveal melanoma | Neoplasms |
| HSALNT0290308 | TMSB4 | NA | ceRNA | pathogenic process | osteoarthritis | Musculoskeletal Diseases |
| HSALNT0288928 | DDX11-AS1 | CONCR | NA | pathogenic process | NA | NA |
| HSALNT0290052 | MELOE | NA | NA | pathogenic process | melanoma | Neoplasms |
| HSALNT0290231 | RSU1P2 | RSU1P2 | ceRNA | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290165 | RBMY2FP | RBMY2FP | NA | NA | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290071 | N375709 | NA | NA | pathogenic process | nasopharyngeal cancer | Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0289748 | DUXAP8 | DUXAP8 | NA | NA | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290030 | LOC729966 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0290143 | POIR | NA | ceRNA | pathogenic process | periodontitis | Stomatognathic Diseases |
| HSALNT0067481 | MELTF-AS1 | MFI2-AS1,AC068302.3 | NA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0290053 | MFI2 | NA | NA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0289922 | Linc-223 | NA | ceRNA | pathogenic process | acute myeloid leukemia | Neoplasms |
| HSALNT0014603 | LINC01138 | LINC00875,FLJ39739 | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290262 | SUZ12P1 | SUZ12P1 | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0290005 | LOC100505976 | NA | NA | pathogenic process | laryngeal squamous cell cancer | Neoplasms |
| HSALNT0290392 | XLOC_l2_010636 | NA | NA | pathogenic process | laryngeal squamous cell cancer | Neoplasms |
| HSALNT0090295 | RASGRF2-AS1 | CTC-459I6.1 | NA | pathogenic process | sepsis-induced endothelial dysfunction | Bacterial Infections and Mycoses |
| HSALNT0289852 | GPC3-AS1 | NA | transcriptional regulation | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0189472 | HOXC-AS1 | NA | transcriptional regulation | pathogenic process | atherosclerosis | Cardiovascular Diseases |
| HSALNT0289157 | LUARIS | lncRNA#32 | transcriptional regulation | NA | NA | NA |
| HSALNT0289371 | MIR3936HG | LOC553103,SLC22A5-AS1 | NA | pathogenic process | gastric cancer;nasopharyngeal cancer | Otorhinolaryngologic Diseases;Stomatognathic Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0290148 | Ppp1r1b | NA | transcriptional regulation | pathogenic process | congenital heart defect | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289038 | LINC00460 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290194 | RP1-13P20.6 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290364 | Unigene56159 | NA | ceRNA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290355 | Uc009yby.1 | NA | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289406 | TFAP2A-AS2 | HIPSTR | NA | developmental process | NA | NA |
| HSALNT0289704 | Chaer | NA | transcriptional regulation | pathogenic process | cardiac hypertrophy | Cardiovascular Diseases |
| HSALNT0211378 | LINC00520 | C14orf34 | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0087374 | MRPS30-DT | BRCAT54 | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289388 | PPP1R12A-AS1 | R12A-AS1 | translational control | NA | NA | NA |
| HSALNT0289013 | ITFG2-AS1 | NA | NA | NA | NA | NA |
| HSALNT0290088 | NONHSAT041499 | NA | NA | pathogenic process | schizophrenia | Mental Disorders |
| HSALNT0290091 | NONHSAT089447 | NA | NA | pathogenic process | schizophrenia | Mental Disorders |
| HSALNT0289970 | Lnc-NKX2-3-1 | NA | transcriptional regulation | pathogenic process | acute lymphoblastic leukemia | Immune System Diseases;Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0289989 | Lnc-RTN4R-1 | NA | transcriptional regulation | pathogenic process | acute lymphoblastic leukemia | Immune System Diseases;Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0289821 | ERL | NA | NA | pathogenic process | Marek's disease | Immune System Diseases;Hemic and Lymphatic Diseases;Virus Diseases |
| HSALNT0192459 | LINC02258 | RP11-248E9.5 | NA | pathogenic process | pneumonia | Respiratory Tract Diseases |
| HSALNT0241871 | SKAP1-AS1 | RP11-456D7.1 | NA | pathogenic process | pneumonia | Respiratory Tract Diseases |
| HSALNT0289439 | DINOL | DINO | NA | NA | NA | NA |
| HSALNT0288901 | CAMTA1-DT | lncCAMTA1 | transcriptional regulation | pathogenic process | liver cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290328 | Uc.345 | NA | transcriptional regulation | pathogenic process | pancreatic cancer | Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0290060 | MSNP1AS | NA | translational control | pathogenic process | autism spectrum disorder | Mental Disorders |
| HSALNT0289376 | NEXN-AS1 | C1orf118,FLJ90637 | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0183194 | LINC02098 | RP11-702B10.1 | NA | pathogenic process | esophageal cancer | Neoplasms |
| HSALNT0198055 | PSPC1-AS2 | RP11-523H24.3 | NA | pathogenic process | esophageal cancer | Neoplasms |
| HSALNT0289155 | LRRC75A-AS1 | C17orf45,NCRNA00188,C17orf76-AS1,FAM211A-AS1,MGC40157 | NA | pathogenic process | rheumatoid arthritis | Immune System Diseases;Musculoskeletal Diseases;Skin and Connective Tissue Diseases |
| HSALNT0289220 | PRKG1-AS1 | RP11-573I11.2 | NA | pathogenic process | rheumatoid arthritis | Immune System Diseases;Musculoskeletal Diseases;Skin and Connective Tissue Diseases |
| HSALNT0289262 | SVIL-AS1 | RP11-534G20.3 | NA | pathogenic process | rheumatoid arthritis | Immune System Diseases;Musculoskeletal Diseases;Skin and Connective Tissue Diseases |
| HSALNT0289281 | VPS33B-DT | NA | NA | pathogenic process | rheumatoid arthritis | Immune System Diseases;Musculoskeletal Diseases;Skin and Connective Tissue Diseases |
| HSALNT0289804 | ENST00000438399 | NA | NA | pathogenic process | rheumatoid arthritis | Immune System Diseases;Musculoskeletal Diseases;Skin and Connective Tissue Diseases |
| HSALNT0290228 | RPKG1-AS1 | NA | NA | pathogenic process | rheumatoid arthritis | Immune System Diseases;Musculoskeletal Diseases;Skin and Connective Tissue Diseases |
| HSALNT0290350 | Uc004afb.1 | NA | NA | pathogenic process | rheumatoid arthritis | Immune System Diseases;Musculoskeletal Diseases;Skin and Connective Tissue Diseases |
| HSALNT0289398 | SLC5A4-AS1 | RP1-90G24.10 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289411 | TNFRSF10A-AS1 | RP11-1149O23.2 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289727 | CTD-2616J11.14 | AC008750.7 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290182 | RP11-150O12.3 | AC124067.4 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289730 | CXCL1P1 | CXCL1P1 | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289803 | ENST00000438347 | CCND3P1 | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289897 | LINC00601 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289503 | KIAA0087 | NA | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289827 | FAM212B-AS1 | NA | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290010 | LOC102723552 | NA | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290181 | RP11-140I24 | LINC01568 | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290201 | RP11-501O2 | LINC02046 | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290206 | RP11-600K151 | NA | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290084 | NONHSAG051968 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0290090 | NONHSAT076747 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0290094 | NONHSAT122730 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0138768 | MIR2052HG | NA | transcriptional regulation | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289096 | LINC01198 | NA | NA | pathogenic process | glioma | Neoplasms |
| HSALNT0289274 | TPT1-AS1 | NA | NA | pathogenic process | glioma | Neoplasms |
| HSALNT0289924 | Linc-cdh4-2 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0144641 | LINC02055 | RP1130-1 | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289737 | DBCCR1 | NA | transcriptional regulation | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289547 | AC012065.7 | NA | NA | pathogenic process | chronic lymphocytic leukemia | Immune System Diseases;Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0289229 | RAMP2-AS1 | NA | NA | pathogenic process | glioblastoma | Neoplasms |
| HSALNT0289591 | AK098081 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289644 | BC037331 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289646 | BC040303 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289717 | CR749831 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289250 | SNHG18 | NA | NA | pathogenic process | glioma | Neoplasms |
| HSALNT0106140 | FOXP4-AS1 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0026202 | RNASEH1-AS1 | LOC100506054 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0288993 | GSEC | ST3GAL4-AS1,DCPS-AS1,FLJ39051 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0060264 | DNAJB8-AS1 | NA | NA | NA | NA | NA |
| HSALNT0248137 | CHMP1B-AS1 | NA | NA | NA | NA | NA |
| HSALNT0021970 | TGFB2-AS1 | NR_046268 | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0078323 | SLC7A11-AS1 | NA | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0134663 | INTS9-AS1 | ENST00000520055 | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0231572 | MMP2-AS1 | NA | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0267869 | SLC12A5-AS1 | RP11-465L10.10 | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0288921 | CSMD2-AS1 | ENST00000434181 | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0288997 | HDAC2-AS2 | ENST00000421891 | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289012 | INO80-AS1 | NA | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289140 | LINC02247 | NA | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289161 | MAGI2-AS3 | NA | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289188 | MNX1-AS2 | NA | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289245 | SMIM10L2B-AS1 | NA | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289407 | TGFB3-AS1 | NA | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289457 | HSD17B3-AS1 | NA | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289919 | LINC02246 | NA | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289288 | ZNF710-AS1 | ENST00000558334 | NA | pathogenic process | early-onset preeclampsia | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289266 | TDRKH-AS1 | RP11-98D18.9 | NA | pathogenic process | NA | NA |
| HSALNT0289128 | LINC01952 | AC004854.4 | NA | pathogenic process | recurrent miscarriage | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0290075 | NCF4-AS1 | CTA-833B7.2 | NA | pathogenic process | recurrent miscarriage | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289360 | LNCSRLR | lncRNA-SRLR | transcriptional regulation | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0288918 | CFLAR-AS1 | ALS2CR10 | NA | pathogenic process | esophageal squamous cell cancer | Neoplasms |
| HSALNT0289710 | COL1A2-AS1 | TCONS_00013888,lncRNA8975-1 | transcriptional regulation | pathogenic process | hypertrophic scar | Skin and Connective Tissue Diseases |
| HSALNT0075075 | LNCPRESS2 | lncPRESS2 | transcriptional regulation | NA | NA | NA |
| HSALNT0011289 | LINC01930 | EU358092 | NA | pathogenic process | schizophrenia | Mental Disorders |
| HSALNT0097120 | HMMR-AS1 | NA | NA | pathogenic process | basal-like breast cancer | Neoplasms |
| HSALNT0184498 | CCND2-AS1 | CCND2-AS2 | NA | pathogenic process | glioma | Neoplasms |
| HSALNT0289045 | LINC00578 | NA | NA | pathogenic process | major depression disorder | Behavior and Behavior Mechanisms |
| HSALNT0288884 | ADAMTS9-AS1 | NA | NA | pathogenic process | epithelial ovarian cancer | Neoplasms |
| HSALNT0080041 | FAM198B-AS1 | NA | NA | pathogenic process | NA | NA |
| HSALNT0103007 | LINC00240 | C6orf41,NCRNA00240,bA373D17.1 | ceRNA | pathogenic process | esophageal squamous cell cancer | Neoplasms |
| HSALNT0289071 | LINC00909 | NA | NA | NA | NA | NA |
| HSALNT0289509 | LINC00680 | NA | NA | NA | NA | NA |
| HSALNT0129070 | LINC00513 | AC016831.7 | NA | NA | NA | NA |
| HSALNT0289129 | LINC02001 | RP11-1094M14.11 | NA | NA | NA | NA |
| HSALNT0289215 | POC1B-AS1 | RP11-734K2.4 | NA | NA | NA | NA |
| HSALNT0289241 | SLC12A9-AS1 | RP11-126L15.4 | NA | NA | NA | NA |
| HSALNT0289275 | TRAM2-AS1 | NA | NA | NA | NA | NA |
| HSALNT0002243 | ENST00000457898.1 | ENSG00000226029 | ceRNA | pathogenic process | oesophageal cancer | Neoplasms |
| HSALNT0288941 | ELF3-AS1 | ENST00000415582 | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0289134 | LINC02158 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289350 | LINC01671 | BC041455 | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289124 | LINC01684 | lnc-JAM2-6 | NA | pathogenic process | nonalcoholic fatty liver disease | Digestive System Diseases |
| HSALNT0289036 | LINC00365 | NA | NA | pathogenic process | esophageal cancer | Neoplasms |
| HSALNT0289111 | LINC01554 | C5orf27,FLJ38821,FIS | NA | pathogenic process | esophageal cancer | Neoplasms |
| HSALNT0289132 | LINC02154 | GS1-600G8.5 | NA | pathogenic process | esophageal cancer | Neoplasms |
| HSALNT0137721 | LINC02155 | RP11-705O24.1 | NA | pathogenic process | esophageal cancer | Neoplasms |
| HSALNT0225363 | LINC02157 | RP11-327J17.1 | NA | pathogenic process | esophageal cancer | Neoplasms |
| HSALNT0289133 | LINC02156 | RP1-90J4.1 | NA | pathogenic process | esophageal cancer | Neoplasms |
| HSALNT0133924 | LINC02153 | NA | NA | pathogenic process | major depression disorder | Behavior and Behavior Mechanisms |
| HSALNT0181656 | LINC02151 | TCONS_00019174 | NA | pathogenic process | major depression disorder | Behavior and Behavior Mechanisms |
| HSALNT0227367 | LINC02152 | NA | NA | pathogenic process | major depression disorder | Behavior and Behavior Mechanisms |
| HSALNT0029246 | BRE-AS1 | NA | NA | NA | NA | NA |
| HSALNT0289251 | SNHG26 | AC005682.5 | NA | pathogenic process | bladder urothelial cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0252719 | LIVAR | lnc18q22.2 | NA | pathogenic process | nonalcoholic steatohepatiti | Digestive System Diseases |
| HSALNT0289074 | LINC00969 | ENST00000453324 | NA | pathogenic process | lung squamous cell cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289138 | LINC02243 | ENST00000441841 | NA | pathogenic process | lung squamous cell cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289399 | SLC9A3-AS1 | UC011CLY.2 | NA | pathogenic process | lung squamous cell cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0288934 | DM1-AS | NA | NA | pathogenic process | myotonic dystrophy type 1 | Musculoskeletal Diseases;Nervous System Diseases |
| HSALNT0009014 | LINC02238 | RP4-788P17.1 | NA | pathogenic process | B cell lymphoma | Immune System Diseases;Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0289163 | MEF2C-AS2 | CTC-467M3.1 | NA | pathogenic process | diffuse large B-cell lymphoma | Hemic and Lymphatic Diseases |
| HSALNT0289181 | MIR4422HG | RP11-101C11.1 | NA | pathogenic process | diffuse large B-cell lymphoma | Hemic and Lymphatic Diseases |
| HSALNT0289403 | SPON1-AS1 | RP11-21,L19.1 | NA | pathogenic process | diffuse large B-cell lymphoma | Hemic and Lymphatic Diseases |
| HSALNT0289461 | CD44-AS1 | RP1-68D18.4 | NA | pathogenic process | diffuse large B-cell lymphoma | Hemic and Lymphatic Diseases |
| HSALNT0262277 | LILRB1-AS1 | AC009892.10 | NA | pathogenic process | NA | NA |
| HSALNT0282241 | LINC01186 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289168 | MHENCR | NA | ceRNA | pathogenic process | melanoma | Neoplasms |
| HSALNT0072994 | LINC02232 | RP11-707A18.1 | NA | pathogenic process | NA | NA |
| HSALNT0080161 | LINC02233 | RP11-6C14.1 | NA | pathogenic process | NA | NA |
| HSALNT0084027 | LINC02236 | RP11-332J15.1 | NA | pathogenic process | NA | NA |
| HSALNT0091870 | LINC02234 | RP11-455B3.1 | NA | pathogenic process | NA | NA |
| HSALNT0139521 | LINC02235 | RP11-354A14.1 | NA | pathogenic process | NA | NA |
| HSALNT0142040 | LINC02237 | RP11-1101K5.1 | NA | pathogenic process | NA | NA |
| HSALNT0289135 | LINC02179 | RP11-189E14.4 | NA | pathogenic process | NA | NA |
| HSALNT0289351 | LINC01689 | AP000469.2 | NA | pathogenic process | NA | NA |
| HSALNT0289137 | LINC02231 | RP11-766N7.4 | NA | pathogenic process | Esophageal squamous cell cancer | Neoplasms |
| HSALNT0220239 | MIR4713HG | RP11-108K3.1 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0288967 | FAM160A1-DT | RP11-610P16.1 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289239 | SATB2-AS1 | NA | translational control | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0289512 | LINC01826 | lnc-MKI67IP-3 | ceRNA | pathogenic process | atherosclerosis | Cardiovascular Diseases |
| HSALNT0289024 | LINC00226 | C14orf97,NCRNA00226 | NA | pathogenic process | pancreatic ductaladenocarcinoma | Neoplasms |
| HSALNT0082192 | F11-AS1 | NA | NA | NA | NA | NA |
| HSALNT0219108 | SPINT1-AS1 | RP11-532F12.5 | NA | pathogenic process | melanoma | Neoplasms |
| HSALNT0289177 | MIR200CHG | U47924.27 | NA | pathogenic process | melanoma | Neoplasms |
| HSALNT0289328 | LINC00888 | NA | NA | pathogenic process | melanoma | Neoplasms |
| HSALNT0289309 | LINC00672 | NA | transcriptional regulation | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289198 | P4HA3-AS1 | NA | NA | pathogenic process | parkinson's disease | Nervous System Diseases |
| HSALNT0197312 | TMEM132D-AS1 | LOC283352 | NA | pathogenic process | human dermal fibroblasts | Cell Physiological Phenomena |
| HSALNT0289472 | ATP2C2-AS1 | RP11-517C16.2-001 | NA | NA | NA | NA |
| HSALNT0233849 | WWOX-AS1 | RP11-190D6.2 | NA | pathogenic process | epithelial ovarian cancer | Neoplasms |
| HSALNT0128829 | FLNC-AS1 | NA | NA | pathogenic process | cervical squamous cancer | Neoplasms |
| HSALNT0289889 | LIF-AS1 | Lnc-LIF-AS | NA | pathogenic process | cervical squamous cancer | Neoplasms |
| HSALNT0011283 | DPYD-AS2 | NA | NA | pathogenic process | cervical squamous cancer | Neoplasms |
| HSALNT0289836 | FLICR | NA | transcriptional regulation | pathogenic process | autoimmune diabete | Immune System Diseases |
| HSALNT0289356 | LINC02402 | ENST00000550337.1 | NA | pathogenic process | diabetes | Endocrine System Diseases |
| HSALNT0137118 | CERNA3 | CTA | ceRNA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0090838 | LINC02488 | CTD-2316B1 | NA | pathogenic process | NA | NA |
| HSALNT0174947 | LINC02489 | CTD-2589M5 | NA | pathogenic process | NA | NA |
| HSALNT0220441 | LINC02490 | RP11-209E8 | NA | pathogenic process | NA | NA |
| HSALNT0289260 | STK32A-AS1 | CTC-255N20 | NA | pathogenic process | NA | NA |
| HSALNT0289143 | LINC02487 | NA | NA | pathogenic process | squamous cell cancer | Neoplasms |
| HSALNT0095585 | SPRY4-AS1 | THCAT68 | NA | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0288927 | DDN-AS1 | CAT1507 | NA | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0012862 | SLC16A1-AS1 | NA | NA | pathogenic process | acute myocardial infarction | Cardiovascular Diseases |
| HSALNT0289412 | TNFRSF14-AS1 | ENST00000416860.2 | NA | pathogenic process | acute myocardial infarction | Cardiovascular Diseases |
| HSALNT0259139 | LINC00665 | NA | NA | NA | NA | NA |
| HSALNT0040268 | DARS-AS1 | NA | NA | pathogenic process | renal disease | NA |
| HSALNT0288913 | CEBPA-AS1 | CEBPA-DT | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289011 | INHBA-AS1 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0288988 | GASAL1 | GASL1 | NA | pathogenic process | liver cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289127 | LINC01857 | AC079767.4 | NA | pathogenic process | tuberculosis | Bacterial Infections and Mycoses |
| HSALNT0289091 | LINC01140 | FLJ41676 | NA | NA | NA | NA |
| HSALNT0281957 | PINCR | NA | transcriptional regulation | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289344 | LINC00890 | NA | NA | pathogenic process | leiomyoma | Neoplasms |
| HSALNT0019828 | LINC00862 | C1orf98,SMIM16 | NA | pathogenic process | cystic fibrosis | Respiratory Tract Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Digestive System Diseases |
| HSALNT0073790 | LINC02562 | RP11-44F21.5 | NA | pathogenic process | cystic fibrosis | Respiratory Tract Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Digestive System Diseases |
| HSALNT0263101 | LINC02560 | CTD-2619J13.13 | NA | pathogenic process | cystic fibrosis | Respiratory Tract Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Digestive System Diseases |
| HSALNT0289144 | LINC02551 | RP11-890B15.2 | NA | pathogenic process | cystic fibrosis | Respiratory Tract Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Digestive System Diseases |
| HSALNT0289458 | DDIT4-AS1 | RP11-442H21.2 | NA | pathogenic process | cystic Fibrosis | Respiratory Tract Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Digestive System Diseases |
| HSALNT0288992 | GPRC5D-AS1 | RP11-392P7.6 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289386 | PCBP1-AS1 | NA | NA | pathogenic process | NA | NA |
| HSALNT0289405 | STARD4-AS1 | NA | NA | pathogenic process | NA | NA |
| HSALNT0201547 | LINC00462 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0207103 | SOX1-OT | LINC00403 | NA | pathogenic process | NA | NA |
| HSALNT0002131 | SLC25A34-AS1 | RP11-169K16.4 | NA | NA | NA | NA |
| HSALNT0289218 | PPP1R26-AS1 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289047 | LINC00589 | C8orf75,TSLNC8 | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289516 | TPM1-AS | TPM1-AS1 | splicing regulation | pathogenic process | esophageal cancer | Neoplasms |
| HSALNT0289314 | LINC01101 | FLJ14816 | NA | pathogenic process | HPV-induced cervical neoplasia | Neoplasms |
| HSALNT0289147 | LINC02572 | AC079776.2 | NA | pathogenic process | epithelial ovarian cancer | Neoplasms |
| HSALNT0096804 | LINC02202 | NA | NA | NA | NA | NA |
| HSALNT0289076 | LINC00973 | CTD-2021J15.2 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0288625 | TTTY10 | NCRNA00133 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289323 | LINC00319 | C21orf125,NCRNA00319,PRED49,FLJ38036 | ceRNA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0015533 | IL6R-AS1 | RP11-350G8.5 | NA | NA | NA | NA |
| HSALNT0090330 | CKMT2-AS1 | NA | NA | NA | NA | NA |
| HSALNT0012995 | HIPK1-AS1 | NA | NA | NA | NA | NA |
| HSALNT0289216 | POLH-AS1 | RP3-337H4.8 | NA | NA | NA | NA |
| HSALNT0289276 | TRDN-AS1 | HRAT13 | NA | NA | NA | NA |
| HSALNT0289159 | LY6E-DT | LOC100133669 | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0288991 | GLIS3-AS1 | C9orf70,MGC16153 | NA | NA | NA | NA |
| HSALNT0288896 | BNC2-AS1 | RP11-62F24.2 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289292 | ZNF503-AS1 | NA | NA | pathogenic process | age-related macular degeneration | Eye Diseases |
| HSALNT0159506 | VIM-AS1 | NA | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0288882 | ACBD3-AS1 | RP11-275I14.4 | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289156 | LRRC8C-DT | FLJ27354 | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289447 | ELN-AS1 | CTB-51J22.1 | NA | pathogenic process | endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0076712 | LINC02264 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0093666 | LINC02201 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0271685 | LINC02573 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289125 | LINC01816 | LOC100133985 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289355 | LINC02381 | LOC400043 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289366 | MBNL1-AS1 | LOC401093 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289513 | MIR4697HG | LINC00947,LOC283174 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289073 | LINC00968 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0114453 | NMBR-AS1 | RP11-137J7.2 | NA | pathogenic process | non-melanoma skin cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289300 | LINC01518 | NA | NA | pathogenic process | non-melanoma skin cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0003783 | LINC02574 | RP11-288L9.1 | transcriptional regulation | pathogenic process | UVB-irradiated KC & non-melanoma skin cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0030828 | LINC02580 | AC093609.1 | NA | pathogenic process | UVB-irradiated KC & non-melanoma skin cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0127022 | LINC02577 | NA | NA | pathogenic process | UVB-irradiated KC & non-melanoma skin cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0154722 | LINC02578 | RP11-127L21.1 | NA | pathogenic process | UVB-irradiated KC & non-melanoma skin cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0288962 | FAM111A-DT | NA | NA | pathogenic process | UVB-irradiated KC & non-melanoma skin cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289148 | LINC02575 | AP001065.15 | transcriptional regulation | pathogenic process | UVB-irradiated KC & non-melanoma skin cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0177212 | RPS6KB2-AS1 | AP003419.16 | NA | pathogenic process | agingâassociated idiopathic pulmonary fibrosis | Physiological Phenomena |
| HSALNT0289072 | LINC00941 | lncRNA-MUF | ceRNA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289338 | LINC00094 | FLJ35348,bA374P20.3 | NA | pathogenic process | lung squamous cell cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0114192 | FILNC1 | NA | translational control | pathogenic process | renal tumor | Neoplasms |
| HSALNT0289199 | PARAL1 | NA | ceRNA | pathogenic process | obesity | Pathological Conditions, Signs and Symptoms;Nutritional and Metabolic Diseases;Physiological Phenomena |
| HSALNT0056667 | LINC02027 | LOC728290 | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289069 | LINC00880 | NA | NA | NA | NA | NA |
| HSALNT0252974 | LINC02582 | CTD-2354A18.1 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289035 | LINC00364 | LncRNA00364 | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0060981 | NCK1-DT | NCK1-AS1,SLC35G2-AS1 | ceRNA | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0288890 | BAALC-AS1 | lncFZD6,FZD6-DT | transcriptional regulation | pathogenic process | liver cancer | Neoplasms;Digestive System Diseases |
| HSALNT0046602 | CPS1-IT1 | CPS1-IT,CPS1IT,CPS1IT1,PRO0132 | NA | pathogenic process | hepatocellular cancer;lung cancer;intrahepatic cholangiocarcinoma | Respiratory Tract Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289445 | DLX6-AS1 | DLX6-A, DLX6A, Evf-2,NCRNA00212,NCRNA00212,FLJ34048 | transcriptional regulation | pathogenic process | split hand/split foot malformation disorder;lung adenocarcinoma | Respiratory Tract Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms |
| HSALNT0289891 | LINC00114 | NA | NA | NA | NA | NA |
| HSALNT0289415 | TSIX | LINC00013,NCRNA00013,XIST-A, XIST-AS1,XISTAS | transcriptional regulation | pathogenic process | systemic sclerosis | Skin and Connective Tissue Diseases |
| HSALNT0217334 | MKRN3-AS1 | ZNF127A, MKRN3A, MKRN3-A,FNZ127,NCRNA00009,ZNF127-AS | NA | pathogenic process | Prader-Willi syndrome | Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0290256 | Lnc-SRA1-1:1 | lnc-SRA1-1:1,SRA1,ENSG00000213523 | transcriptional regulation | pathogenic process | nonalcoholic fatty liver disease;polycystic ovary syndrome;ovarian cancer;dilated cardiomyopathy;cardiomyopathy;breast cancer;laryngeal squamous cell cancer;uterus cancer | Skin and Connective Tissue Diseases;Neoplasms;Cardiovascular Diseases;Female Urogenital Diseases and Pregnancy Complications;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289442 | HCP5 | 6S2650E,D6S2650E,P5-1 | NA | pathogenic process | AIDS | Immune System Diseases;Virus Diseases |
| HSALNT0289284 | Lnc-EIF3M-1:1 | WIT1,WIT-1,WT1A, WT1-AS1 | transcriptional regulation | pathogenic process | gastric cancer;primary myelofibrosis;hepatocellular cancer;Wilms' tumor;acute myeloid leukemia | Neoplasms;Hemic and Lymphatic Diseases;Digestive System Diseases |
| HSALNT0289421 | NONHSAT017524 | KCNQ1-AS2,KCNQ10T1,Kncq1,KvDMR1,KvLQT1-A, LIT1,NCRNA00012 | transcriptional regulation | pathogenic process | prostate cancer;colorectal cancer;hepatocelluar cancer;acute myocardial infarction;kidney cancer;Beckwith-Wiedemann syndrome;breast cancer | Skin and Connective Tissue Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Cardiovascular Diseases;Digestive System Diseases |
| HSALNT0263784 | PCNA-AS1 | PCNAA, PCNA-AS | transcriptional regulation | pathogenic process | gastric cancer;hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289524 | HCG9 | PERB11,HCGIX,HCGIX4,HCGIX-4 | NA | NA | NA | NA |
| HSALNT0289264 | TCL6 | TCL6e1,TNG2,TNG1 | NA | pathogenic process;developmental process | renal cell cancer;leukemia | Male Urogenital Diseases;Neoplasms |
| HSALNT0289203 | ENST00000412654.1 | DD3,NCRNA00019,PCAT3 | transcriptional regulation;ceRNA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289462 | NONHSAT017465 | ASM,ASM1,BW, D11S813E,LINC00008,NCRNA00008,WT2 | transcriptional regulation;ceRNA | developmental process;pathogenic process | prostate cancer;glioma;cancer;breast cancer;ovarian cancer;Marek's disease;gestational trophoblastic diseases;glioblastoma;non-small cell lung cancer;hyperhomocysteinemia;congenital heart defect;congenital hyperinsulinism;pancreatic cancer;Beckwith-Wiedemann syndrome;endometriosis;trophoblastic tumor;adrenocortical cancer;coronary artery disease;Wiedemann-Beckwith syndrome;bladder cancer;melanoma;myeloproliferative polycythaemia vera;hepatocelluar cancer;meningioma;breast adenocarcinoma;neuroblastoma;embryonal cancer;osteosarcoma;esophageal cancer;kidney cancer;malignant digestive cancer;chronic myeloid leukemia;mullerian aplasia;malignant hematopoiesis;gastric cardia adenocarcinoma;cervical cancer;gallbladder cancer;pheochromocytoma;germ cell tumor;colorectal cancer;hydatidiform mole;Pancreatic ductal adenocarcinoma;pre-eclampsia;atherosclerosis;esophageal squamous cell cancer;calcific aortic valve disease;gastric cancer;osteoarthritis;choriocarcinoma;chronic myeloproliferative disorders;neural tube defects;skin cancer;ulcerative colitis;type 2 diabetes;thyroid cancer;pneumoconiosis;infertility;liver cancer;heart failure;medulloblastoma;laryngeal squamous cell cancer;Silver-Russell syndrome;pituitary adenoma;hepatocellular cancer;nasopharyngeal cancer;growth restriction;Prader-Willi syndrome;diabetic cardiomyopathy;obesity;lung cancer;Parkinson's disease;renal cell cancer;Wilms' tumor | Nutritional and Metabolic Diseases;Cell Physiological Phenomena;Virus Diseases;Female Urogenital Diseases and Pregnancy Complications;Cardiovascular Diseases;Physiological Phenomena;Neoplasms;Male Urogenital Diseases;Endocrine System Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Immune System Diseases;Hemic and Lymphatic Diseases;Musculoskeletal Diseases;Nervous System Diseases;Digestive System Diseases;Skin and Connective Tissue Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Occupational Diseases;Otorhinolaryngologic Diseases;Stomatognathic Diseases |
| HSALNT0288932 | NONHSAT033797 | BCM, BCMS1,DLB1,LEU1,LEU2,LINC00021,NCRNA00021,XTP6 | transcriptional regulation;ceRNA | pathogenic process | lymphocytic leukemia;B-cell chronic lymphocytic leukemia;myeloma;multiple myeloma;hematopoietic and solid tumors;chronic lymphocytic leukemia;inherited bone marrow failure disorder;lymphoma;breast cancer;head and neck squamous cell cancer | Skin and Connective Tissue Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Immune System Diseases;Hemic and Lymphatic Diseases;Cardiovascular Diseases |
| HSALNT0289493 | DBH-AS1 | NCRNA00118,BPR | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0088415 | ENST00000506884.1 | DKFZP586D0823,NCRNA00206 | NA | pathogenic process | prostate cancer;glioblastoma | Male Urogenital Diseases;Neoplasms |
| HSALNT0289463 | IGF2-AS | IGF2A,PEG8,IGF2-AS1 | transcriptional regulation | pathogenic process | liver cancer;type 1 diabetes;prostate cancer;Wilms' tumor;hepatocelluar cancer | Neoplasms;Nutritional and Metabolic Diseases;Male Urogenital Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0269786 | Lnc-CTSZ-5:1 | GNASA, GNAS-A,SANG,NESP-A, NESPA, GNAS1A, NCRNA00075 | transcriptional regulation | pathogenic process | non-small cell lung cancer;pseudohypoparathyroidism type Ib | Musculoskeletal Diseases;Respiratory Tract Diseases;Neoplasms |
| HSALNT0289252 | NONHSAT054526 | C6orf160,MGC16362,bA33E24.2,U50HG,NCRNA00044,LINC00044 | NA | pathogenic process | gastric cancer;lymphoma;melanoma | Immune System Diseases;Neoplasms;Hemic and Lymphatic Diseases;Digestive System Diseases |
| HSALNT0023827 | NONHSAT010191 | DISC1-AS1,DISC1O, NCRNA00015 | transcriptional regulation | pathogenic process | bipolar disorder;affective disorder;major depressive affective disorder;schizophrenia;autism spectrum disorder;depression | Bacterial Infections and Mycoses;Mental Disorders;Behavior and Behavior Mechanisms |
| HSALNT0203415 | NONHSAT034251 | SCA8,KLHL1A,NCRNA00003 | transcriptional regulation | pathogenic process | spinocerebellar ataxia;spinocerebellar ataxia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0290312 | TRAF3IP2-AS1 | C6UA, C6orf3,NCRNA00248,TRAF3IP2-AS2 | transcriptional regulation | pathogenic process | schizophrenia;cocaine abuse | Chemically-Induced Disorders;Mental Disorders |
| HSALNT0289008 | HYMAI | NCRNA00020 | NA | pathogenic process | transient neonatal diabetes | Nutritional and Metabolic Diseases |
| HSALNT0288968 | FAM201A | C9orf122 | NA | pathogenic process | leukemia | Neoplasms |
| HSALNT0288969 | FAM222A-AS1 | NA | NA | pathogenic process | NA | NA |
| HSALNT0289484 | FAM226A | CXorf50,NCRNA00246,NCRNA00246A,LINC00246A,MGC34827 | NA | pathogenic process | NA | NA |
| HSALNT0289497 | FAM215A | C17orf88,APR-2,LINC00530 | NA | pathogenic process | ovarian cancer;leukemia | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289230 | NONHSAT089783 | LUST | transcriptional regulation | pathogenic process | tumor | Neoplasms |
| HSALNT0002923 | LINC00339 | NCRNA00339,HSPC157 | NA | pathogenic process;developmental process | Pancreatic ductal adenocarcinoma | Neoplasms |
| HSALNT0144027 | ASAP1-IT1 | ASAP1-IT,ASAP1IT,ASAP1IT1,DDEF1IT1,HSPC054,NCRNA00050 | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289212 | NONHSAT076153 | NCRNA00071,LINC00071,PCAT9 | transcriptional regulation;ceRNA | pathogenic process | osteoarthritis;prostate cancer;glioma | Musculoskeletal Diseases;Male Urogenital Diseases;Neoplasms |
| HSALNT0289016 | KCNQ1DN | BWRT,HSA404617 | NA | pathogenic process | aging;Wilms' tumor | Physiological Phenomena;Neoplasms |
| HSALNT0288933 | NONHSAT033821 | DLB2,BCMSUN,RFP2O,LEU2,TRIM13O, NCRNA00022,LINC00022,MIR15AHG | transcriptional regulation | pathogenic process | lymphocytic leukemia;B-cell chronic lymphocytic leukemia;myeloma;multiple myeloma;chronic lymphocytic leukemia;non-small cell lung cancer | Neoplasms;Respiratory Tract Diseases;Immune System Diseases;Hemic and Lymphatic Diseases;Cardiovascular Diseases |
| HSALNT0217624 | PWAR4 | PAR4,PAR-4 | NA | pathogenic process | Prader-Willi syndrome and Angelman syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0289165 | ENST00000553584.1 | SNHG23,SNHG24,NCRNA00024,Irm,Rian,Bsr,LINC00024,AL132709.8,lnc-MGC | NA | pathogenic process | Prader-Willi syndrome and Angelman syndrome;temple syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0289482 | CECR7 | SAHL1 | NA | pathogenic process | hepatocellular cancer;cat eye syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Digestive System Diseases |
| HSALNT0074223 | ENST00000504263.1 | GDEP,PCAN1,PCA4 | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0061175 | PISRT1 | NCRNA00195 | transcriptional regulation | developmental process;pathogenic process | blepharophimosis syndrome | Eye Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| HSALNT0190912 | ENST00000538665.1 | Tmevpg1,LincR-Ifng-3'A, NEST | transcriptional regulation | pathogenic process | Hashimoto's thyroiditis;primary immune thrombocytopenia;multiple sclerosis;Sjögren syndrome | Immune System Diseases ;Immune System Diseases;Endocrine System Diseases;Nervous System Diseases |
| HSALNT0038178 | FAM138B | F379 | NA | NA | NA | NA |
| HSALNT0145703 | FAM138C | F379 | NA | NA | NA | NA |
| HSALNT0288963 | FAM138A | F379 | NA | NA | NA | NA |
| HSALNT0183947 | FAM138D | F379 | NA | NA | NA | NA |
| HSALNT0226092 | FAM138E | F379 | NA | NA | NA | NA |
| HSALNT0253925 | FAM138F | F379 | NA | NA | NA | NA |
| HSALNT0289326 | NONHSAT087716 | LOH3CR2A,NCRNA00312,NAG7,NAG-7,ERR10,ERR-10,LMCD1DN | transcriptional regulation | pathogenic process | nasopharyngeal cancer;bladder cancer;non-small cell lung cancer | Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Stomatognathic Diseases |
| HSALNT0288886 | ENST00000609176.1 | AIR,NCRNA00088,IGF2RA, IGF2R-AS1 | transcriptional regulation | pathogenic process | NA | NA |
| HSALNT0254857 | MIR7-3HG | C19orf30,NCRNA00306,LINC00306,PGSF1,PGSF1a,PGSF1b,Huh7,uc002mbe.2 | NA | pathogenic process | liver cancer;hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0185751 | LOH12CR2 | LOH2CR12 | NA | pathogenic process | pre-B acute lymphoblastic leukaemia | Hemic and Lymphatic Diseases |
| HSALNT0289479 | DSCR8 | C21orf65,MTAG2,CT25.1a,CT25.1b,MMA-1a,MMA-1b | NA | pathogenic process | Down syndrome;melanoma | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Nervous System Diseases |
| HSALNT0289030 | LINC00313 | C21orf84,NCRNA00313, | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289029 | LINC00310 | C21orf82,NCRNA00310 | NA | pathogenic process | NA | NA |
| HSALNT0272435 | LINC00161 | C21orf100,NCRNA00161 | ceRNA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0289184 | ENST00000602580.1 | C21orf35,FLJ38295,C21orf34,LINC00478,MONC | NA | pathogenic process | myeloid leukemia | Hemic and Lymphatic Diseases |
| HSALNT0289005 | HOXA11-AS | HOXA11A,HOXA11-AS1,HOXA11, HOXA-AS5,NCRNA00076 | ceRNA | pathogenic process | uterine cervix cancer;ovarian cancer;glioma;cervical cancer;gastric cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Digestive System Diseases |
| HSALNT0193654 | RMST | NCRM, NCRNA00054,LINC00054 | transcriptional regulation | developmental process;pathogenic process | breast cancer;rhabdomyosarcoma | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290079 | NONHSAT102247 | NCRUPAR,ENSG00000225407 | transcriptional regulation | developmental process;pathogenic process | gastric cancer;colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289167 | MESTIT1 | MEST-AS1,MEST-IT,MEST-IT1,NCRNA00040,PEG1-AS | NA | pathogenic process | Silver-Russell syndrome | Musculoskeletal Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| HSALNT0273791 | DSCAM-AS1 | M41 | NA | pathogenic process | adolescent idiopathic scoliosis;breast cancer | Musculoskeletal Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289391 | PWARSN | PAR-SN,PARSN | NA | pathogenic process | NA | NA |
| HSALNT0127791 | ST7-AS1 | ST7OT1,ST7AS1 | NA | pathogenic process | glioma;autism | Mental Disorders;Neoplasms |
| HSALNT0206298 | DAOA-AS1 | DAOAA, DAOA-A,G30 | NA | pathogenic process | panic disorder;schizophrenia;bipolar disorder | Mental Disorders |
| HSALNT0167060 | OLMALINC | C10orf75,NCRNA00263,LINC00263,bA34D15.5,FLJ12974,HI-LNC80 | NA | pathogenic process | type 2 diabetes | Nutritional and Metabolic Diseases;Endocrine System Diseases |
| HSALNT0026878 | LINC00299 | C2orf46,NCRNA00299,FLJ45673 | NA | pathogenic process;developmental process | intellectual and developmental disability;neurodevelopmental disabilities | Mental Disorders;Nervous System Diseases |
| HSALNT0289081 | LINC01020 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0101186 | LINC00518 | C6orf218,MGC40222 | NA | pathogenic process | NA | NA |
| HSALNT0083960 | LINC01018 | SRHC | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289361 | LPP-AS2 | MYCLo-5,MYCLo-6 | NA | NA | NA | NA |
| HSALNT0143233 | LINC00964 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289364 | MAPKAPK5-AS1 | C12orf47,FLJ39616 | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289053 | LINC00635 | NA | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289327 | LINC00636 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0262657 | ZNF582-AS1 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289020 | LINC00115 | NCRNA00115,FLJ22639 | ceRNA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289254 | SNHG7 | MGC16037,NCRNA00061 | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289162 | MAP3K20-AS1 | MLK7-AS1 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0145357 | RHPN1-AS1 | C8orf51,MGC3113 | NA | NA | NA | NA |
| HSALNT0289343 | NONHSAT137541 | DXS399E,NCRNA00001,DXS1089,swd66,LINC00001 | transcriptional regulation;ceRNA | pathogenic process | non-small cell lung cancer;B-cell acute lymphoblastic leukemia;bladder cancer;testicular germ cell tumor;colorectal cancer;cancer;ovarian cancer;female cancers;renal collecting duct cancer;membranous nephropathy;Trisomy 21;gastric cancer;hepatocellular cancer;nasopharyngeal cancer;Klinefelter's syndrome;glioblastoma;breast cancer;cystic fibrosis | Skin and Connective Tissue Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Respiratory Tract Diseases;Immune System Diseases;Male Urogenital Diseases;Stomatognathic Diseases;Hemic and Lymphatic Diseases;Female Urogenital Diseases and Pregnancy Complications;Nervous System Diseases;Otorhinolaryngologic Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289389 | PRNT | M8 | NA | pathogenic process | NA | NA |
| HSALNT0288942 | Lnc-PDZD8-3:1 | NCRNA00045,EMX2-AS1 | transcriptional regulation | pathogenic process | NA | NA |
| HSALNT0200443 | LINC00598 | TTL | NA | pathogenic process | NA | NA |
| HSALNT0289517 | TTTY17A | NCRNA00140 | NA | NA | NA | NA |
| HSALNT0027901 | MYCNOS | NCYM,N-CYM,MYCN-AS1 | transcriptional regulation | pathogenic process | neuroblastoma | Neoplasms |
| HSALNT0047175 | DIRC3 | FLJ14199 | NA | pathogenic process | familial renal cell cancer;breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289363 | ENST00000534336.1 | PRO1073,MALAT-1,NCRNA00047,HCN,NEAT2,LINC00047,mascRNA | splicing regulation;;translational control;transcriptional regulation;protein localization;ceRNA | pathogenic process | prostate cancer;glioma;cancer;breast cancer;ovarian cancer;amyotrophic lateral sclerosis;proliferative vitreoretinopathy;glioblastoma;endometrial stromal sarcoma;oral squamous cell cancer;acute myocardial infarction;hemangioma;pancreatic cancer;endometrioid endometrial cancer;melanoma;tongue squamous cell cancer;HIV;hepatocelluar cancer;bladder cancer;neuroblastoma;lung cancer;nasopharyngeal cancer;osteosarcoma;esophageal cancer;kidney cancer;hepatic steatosis;urothelial cancer;diabetes;triple-negative breast cancer;liver fibrosis;cervical cancer;uterus cancer;gallbladder cancer;decreased myogenesis;esophageal squamous cell cancer;fibrosarcoma;colorectal cancer;Pancreatic ductal adenocarcinoma;pre-eclampsia;retinal neurodegeneration;small cell lung cancer;multiple myeloma;gastric cancer;lung adenocarcinoma;uveal melanoma;epithelial ovarian cancer;TDP-43-associated pathological states;thyroid cancer;congenital microtia;liver cancer;renal clear cell cancer;laryngeal squamous cell cancer;pituitary adenoma;hepatocellular cancer;non-small cell lung cancer;pulmonary arterial hypertension;diabetic cardiomyopathy;vulvar squamous cell cancer;hyperglycaemia;papillary thyroid cancer;Parkinson's disease;renal cell cancer;lung cancer brain metastasis | Eye Diseases;Skin and Connective Tissue Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Respiratory Tract Diseases;Nutritional and Metabolic Diseases;Male Urogenital Diseases;Cell Physiological Phenomena;Immune System Diseases;Hemic and Lymphatic Diseases;Virus Diseases;Stomatognathic Diseases;Cardiovascular Diseases;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Endocrine System Diseases;Digestive System Diseases;Nervous System Diseases |
| HSALNT0289744 | DLG2-AS1 | DLG2A, DLG2-A,PSZA11q14,SZ-1 | NA | pathogenic process | schizophrenia;myotonic dystrophy type 1;heart failure | Pathological Conditions, Signs and Symptoms;Musculoskeletal Diseases;Mental Disorders;Cardiovascular Diseases;Nervous System Diseases |
| HSALNT0289164 | NONHSAT039745 | FP504,GTL2,LINC00023,NCRNA00023,PRO0518,PRO2160,onco-lncRNA-83,prebp1 | translational control;transcriptional regulation;ceRNA | pathogenic process | oral squamous cell cancer;phaeochromocytoma;prostate cancer;testicular germ cell tumor;glioma;cancer;osteosarcoma;non-functioning pituitary adenoma;heroin abuse;stroke;non-small cell lung cancer;thrombocytopenic purpura;acute myeloid leukemia;pancreatic cancer;bladder cancer;tongue squamous cell cancer;hepatocelluar cancer;meningioma;drug abuse;liver fibrosis;pancreatic neuroendocrine tumor;esophageal squamous cell cancer;myelodysplastic syndrome;retinoblastoma;chronic myeloid leukemia;type 1 diabetes;breast cancer;cervical cancer;kidney cancer;gallbladder cancer;cholestatic liver injury;colorectal cancer;neuroblastoma;multiple myeloma;gastric cancer;osteoarthritis;lung adenocarcinoma;endometrial cancer;Huntington disease;diabetes;type 2 diabetes;lung cancer;epithelial ovarian cancer;primary myelofibrosis;metabolic syndrome;pituitary adenoma;hepatocellular cancer;nasopharyngeal cancer;vulvar squamous cell cancer;papillary thyroid cancer;renal cell cancer;Wilms' tumor | Skin and Connective Tissue Diseases;Pathological Conditions, Signs and Symptoms;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Respiratory Tract Diseases;Nutritional and Metabolic Diseases;Male Urogenital Diseases;Immune System Diseases;Stomatognathic Diseases;Hemic and Lymphatic Diseases;Chemically-Induced Disorders;Musculoskeletal Diseases;Mental Disorders;Female Urogenital Diseases and Pregnancy Complications;Cardiovascular Diseases;Otorhinolaryngologic Diseases;Endocrine System Diseases;Digestive System Diseases;Nervous System Diseases |
| HSALNT0290298 | TERC | DKCA1,PFBMFT2,SCARNA19,TR,TRC3,hTR | NA | pathogenic process | prostate cancer;dyskeratosis congenita;lung squamous cell cancer | Skin and Connective Tissue Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases |
| HSALNT0288907 | CASC2 | NA | ceRNA | pathogenic process | colorectal cancer;gastric cancer;endometrial cancer;lung cancer;renal cell cancer;glioma | Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases |
| HSALNT0205332 | MIR17HG | C13orf25,MIRHG1,FLJ14178,MIRH1,MIHG1,NCRNA00048,miR-17-92,LINC00048 | NA | pathogenic process | diffuse large B-cell lymphoma;syndromic developmental defect;cancer | Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0288716 | TTTY6 | TTY6,TTTY6A,LINC00127 | NA | NA | NA | NA |
| HSALNT0288731 | TTTY4 | TTY4,TTTY4A,LINC00123 | NA | NA | NA | NA |
| HSALNT0288815 | TTTY3 | TTY3,TTTY3A,LINC00121 | NA | NA | NA | NA |
| HSALNT0288703 | TTTY5 | TTY5,LINC00126 | NA | NA | NA | NA |
| HSALNT0289255 | SNHG8 | NCRNA00060,LINC00060 | NA | pathogenic process | gastric cancer;malignant pleural mesothelioma | Neoplasms;Digestive System Diseases |
| HSALNT0289486 | Lnc-EPCAM-1:2 | BC200,BC200a,NCRNA00004,LINC00004 | splicing regulation;translational control | pathogenic process | aging;lung cancer;glioma;ovarian cancer;esophageal squamous cell cancer;non-small cell lung cancer;esophageal cancer;Alzheimer's disease;tongue cancer;parotid cancer;breast cancer;cervical cancer | Skin and Connective Tissue Diseases;Neoplasms;Respiratory Tract Diseases;Stomatognathic Diseases;Mental Disorders;Female Urogenital Diseases and Pregnancy Complications;Physiological Phenomena;Endocrine System Diseases;Nervous System Diseases |
| HSALNT0144426 | ZFAT-AS1 | ZFATAS,ZFAT-AS,SAS-ZFAT,NCRNA00070 | NA | pathogenic process | autoimmune disease | Immune System Diseases |
| HSALNT0289285 | ZEB1-AS1 | NA | NA | pathogenic process | esophageal squamous cell cancer;autoimmune thyroid disease;hepatocelluar cancer | Immune System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289185 | MIRLET7BHG | linc-Ppara | NA | developmental process | NA | NA |
| HSALNT0289374 | NBR2 | NCRNA00192 | transcriptional regulation | pathogenic process | gastric cancer;breast cancer;cancer | Skin and Connective Tissue Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289417 | NONHSAT084827 | FLJ20618,NCRNA00080,LINC00080 | transcriptional regulation;ceRNA | pathogenic process | osteosarcoma;prostate cancer;glioma;ovarian cancer;glioblastoma;non-small cell lung cancer;B-cell neoplasms;chronic kidney disease;melanoma;bladder cancer;urothelial cancer of the bladder;esophageal squamous cell cancer;multiple sclerosis;breast cancer;hepatoblastoma;colorectal cancer;multiple myeloma;gastric cancer;Huntington disease;hepatocellular cancer;oesophageal squamous cell cancer;renal cell cancer | Skin and Connective Tissue Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Respiratory Tract Diseases;Immune System Diseases;Male Urogenital Diseases;Hemic and Lymphatic Diseases;Cardiovascular Diseases;Female Urogenital Diseases and Pregnancy Complications;Mental Disorders;Endocrine System Diseases;Digestive System Diseases;Nervous System Diseases |
| HSALNT0288973 | FAS-AS1 | FASA, FAS-A,SAF | transcriptional regulation | pathogenic process | ataxia telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Immune System Diseases;Nutritional and Metabolic Diseases;Cardiovascular Diseases;Nervous System Diseases |
| HSALNT0288996 | HAS2-AS1 | HAS2A, HAS2-A,HASNT,NCRNA00077 | transcriptional regulation | NA | NA | NA |
| HSALNT0289390 | PSORS1C3 | NCRNA00196 | NA | pathogenic process | rheumatoid arthritis;psoriasis | Immune System Diseases;Musculoskeletal Diseases;Skin and Connective Tissue Diseases |
| HSALNT0289868 | HLA-AS1 | NA | NA | pathogenic process | psoriasis;liver injury;multiple sclerosis;AIDS | Skin and Connective Tissue Diseases;Immune System Diseases;Virus Diseases;Digestive System Diseases;Nervous System Diseases |
| HSALNT0290154 | NONHSAT011777 | NCRNA00074 | transcriptional regulation | pathogenic process | psoriasis;prostate cancer | Skin and Connective Tissue Diseases;Male Urogenital Diseases;Neoplasms |
| HSALNT0262809 | PEG3-AS1 | PEG3AS,PEG3-AS,APEG3,NCRNA00155 | NA | NA | NA | NA |
| HSALNT0289533 | Lnc-LRR1-1:1 | 7S RNA,SRP RNA,4.5S SRP RNA,4.5S RNA,RN7SL1 RNA,ENSG00000258486,lnc-LRR1-1:1 | protein localization | pathogenic process | AIDS;Leishmaniasis;dermatomyositis;polymyositis | Skin and Connective Tissue Diseases;Immune System Diseases;Virus Diseases;Musculoskeletal Diseases;Parasitic Diseases;Nervous System Diseases |
| HSALNT0290081 | Lnc-C11orf16-1:1 | 29A,lnc-C11orf16-1:1 | NA | pathogenic process | neuroblastoma | Neoplasms |
| HSALNT0289382 | NONHSAT134764 | NCRNA00194 | NA | pathogenic process | AIDS;Down syndrome;HIV | Immune System Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases;Virus Diseases |
| HSALNT0289253 | Lnc-TCF24-2:3 | U87HG,HBII-276HG,NCRNA00058 | translational control;ceRNA | pathogenic process | hepatocellular cancer;hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289653 | NONHSAT017676 | AY195961.1,NONHSAT017674,AY034469.1,NONHSAT017675,AY034470.1 | NA | NA | NA | NA |
| HSALNT0290398 | ENST00000554403.1 | Zfh-5AS,ENSG00000157306,ENST00000554403.1 | NA | NA | NA | NA |
| HSALNT0011306 | MIR137HG | NA | NA | pathogenic process | schizophrenia;lung cancer;malignant lymphoma | Respiratory Tract Diseases;Mental Disorders;Neoplasms |
| HSALNT0289449 | Lnc-EVX1-9:1 | HOXA6as | NA | pathogenic process | glioma | Neoplasms |
| HSALNT0289451 | CCDC26 | MGC27434,RAM | transcriptional regulation | pathogenic process | hematological malignancies;glioma;acute myeloid leukemia;leukemia;pancreatic cancer;breast cancer | Skin and Connective Tissue Diseases;Neoplasms;Hemic and Lymphatic Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289893 | LINC00271 | C6orf217,NCRNA00271 | NA | pathogenic process | type 2 diabetes;schizophrenia | Nutritional and Metabolic Diseases;Mental Disorders;Endocrine System Diseases |
| HSALNT0288892 | BCAR4 | NA | transcriptional regulation | pathogenic process | osteosarcoma;breast cancer;colorectal cancer | Skin and Connective Tissue Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289890 | LINC00032 | C9orf14,NCRNA00032 | NA | pathogenic process | narcolepsy;melanoma | Mental Disorders;Neoplasms;Nervous System Diseases |
| HSALNT0274572 | PICSAR | C21orf113,LINC00162,NCRNA00162,NLC1-C,NLC1C,PRED74 | transcriptional regulation | pathogenic process | testicular embryonal cancer;narcolepsy;cutaneous squamous cell cancer | Male Urogenital Diseases;Mental Disorders;Neoplasms;Nervous System Diseases |
| HSALNT0256354 | Lnc-OR10H5-1:1 | CUDR,LINC00178,NCRNA00178,UCAT1,onco-lncRNA-36 | transcriptional regulation;ceRNA | developmental process;pathogenic process | oral squamous cell cancer;osteosarcoma;prostate cancer;ovarian cancer;non-small cell lung cancer;acute myocardial infarction;pancreaticobiliary maljunction;pancreatic cancer;melanoma;tongue squamous cell cancer;hepatocelluar cancer;bladder cancer;acute myeloid leukemia;esophageal squamous cell cancer;esophageal cancer;liver cancer;colorectal cancer;Pancreatic ductal adenocarcinoma;urinary bladder;gastric cancer;endometrial cancer;breast cancer;hepatocellular cancer;squamous cell cancer;lung cancer;renal cell cancer | Skin and Connective Tissue Diseases;Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Cardiovascular Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289475 | Lnc-BIRC7-2:1 | HAR1F,NCRNA00064,LINC00064 | transcriptional regulation | pathogenic process | Huntington disease;Alzheimer's disease | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Mental Disorders;Nervous System Diseases |
| HSALNT0288995 | ENST00000447910.2 | HAR1R,NCRNA00065,LINC00065 | transcriptional regulation | pathogenic process | Huntington disease;hereditary haemorrhagic telangiectasia;Alzheimer's disease | Mental Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Nervous System Diseases |
| HSALNT0288958 | EPB41L4A-AS1 | C5orf26,NCRNA00219,TIGA1 | NA | pathogenic process | lung cancer;cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289170 | Lnc-CRYBA4-2:1 | C22orf35,FLJ25967,Rncr2,gomafu,NCRNA00066,LINC00066,lncRNA-MIAT | splicing regulation;ceRNA | pathogenic process | prostate cancer;chronic lymphocytic leukemia;cancer;drug abuse;diabetes-induced microvascular dysfunction;schizophrenia;acute myocardial infarction;dilated cardiomyopathy;lung adenocarcinoma;diabetic retinopathy;myocardial infarction;Alzheimer's disease | Neoplasms;Respiratory Tract Diseases;Immune System Diseases;Male Urogenital Diseases;Chemically-Induced Disorders;Hemic and Lymphatic Diseases;Cardiovascular Diseases;Mental Disorders;Endocrine System Diseases;Nervous System Diseases |
| HSALNT0289007 | NONHSAT107640 | NCRNA00078,LINC00078,HCCAT1 | transcriptional regulation;ceRNA | pathogenic process | prostate cancer;glioma;hepatocelluar cancer;osteosarcoma;atherosclerosis;gastric cancer;hepatocellular cancer;esophageal cancer;liver cirrhosis;diffuse large B-cell lymphoma;pancreatic cancer;papillary thyroid cancer;liver cancer;cervical cancer;colorectal cancer | Neoplasms;Male Urogenital Diseases;Hemic and Lymphatic Diseases;Cardiovascular Diseases;Female Urogenital Diseases and Pregnancy Complications;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0288940 | NONHSAT087635 | EGO,NCRNA00190 | NA | pathogenic process;developmental process | prostate cancer;breast cancer | Skin and Connective Tissue Diseases;Male Urogenital Diseases;Neoplasms |
| HSALNT0289387 | PINK1-AS | PINK1-AS1,FLJ00387,PINK1A, naPINK1 | transcriptional regulation | pathogenic process | glucose metabolism disorder;Parkinson's disease;diabetes | Nutritional and Metabolic Diseases;Endocrine System Diseases;Nervous System Diseases |
| HSALNT0289225 | ENST00000513868.2 | NCRNA00079,LINC00079,onco-lncRNA-100,MIR1204HG,PVT | transcriptional regulation;translational control | pathogenic process | murine plasmacytomas;prostate cancer;cancer;ovarian cancer;renal cancer;B-cell lymphoma;non-small cell lung cancer;pancreatic cancer;Hodgkin's lymphoma;asthma;hepatocelluar cancer;bladder cancer;plasmacytoma;cleft lip;acute promyelocytic leukemia;diabetic nephropathy;esophageal cancer;kidney cancer;type 1 diabetes;breast cancer;cervical cancer;diabetic kidney disease;hematological malignancies;colorectal cancer;neuroblastoma;cardiac hypertrophy;multiple myeloma;gastric cancer;lymphoma;type 2 diabetes;thyroid cancer;pleural mesothelioma;lung squamous cell cancer;Burkitt lymphoma;hepatocellular cancer;renal cell cancer | Skin and Connective Tissue Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Respiratory Tract Diseases;Nutritional and Metabolic Diseases;Male Urogenital Diseases;Immune System Diseases;Stomatognathic Diseases;Hemic and Lymphatic Diseases;Virus Diseases;Female Urogenital Diseases and Pregnancy Complications;Cardiovascular Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289189 | ENST00000604258.1 | NA | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0246525 | NARF-AS1 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0147433 | NONHSAT130421 | CDKN2BA,ANRIL,RP11-145E5.4,NCRNA00089,p15A, CDKN2B-A, PCAT12 | siRNA;transcriptional regulation;ceRNA | pathogenic process | glaucoma;prostate cancer;glioma;cancer;osteosarcoma;neurofibromatosis;ischemic heart failure;stroke;non-small cell lung cancer;hypertension;intracranial aneurysm;aortic aneurysm;periodontitis;acute lymphoblastic leukemia;Alzheimer's disease;coronary artery disease;melanoma;bladder cancer;abdominal aortic aneurysm;ovarian cancer;esophageal cancer;basal cell cancer;breast cancer;cervical cancer;coronary heart disease;gallbladder cancer;acute myocardial infarction;colorectal cancer;neuroblastoma;peripheral artery disease;esophageal squamous cell cancer;atherosclerosis;leukemia;hereditary cutaneous malignant melanoma;gastric cancer;cardiovascular disease;coronary disease;frailty;diabetes;type 2 diabetes;thyroid cancer;primary open-angle glaucoma;ischemic stroke;plexiform neurofibroma;laryngeal squamous cell cancer;hepatocellular cancer;nasopharyngeal cancer;myocardial infarction;lung cancer;endometriosis;primary myelofibrosis | Eye Diseases;Skin and Connective Tissue Diseases;Pathological Conditions, Signs and Symptoms;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Respiratory Tract Diseases;Nutritional and Metabolic Diseases;Male Urogenital Diseases;Stomatognathic Diseases;Immune System Diseases;Hemic and Lymphatic Diseases;Female Urogenital Diseases and Pregnancy Complications;Cardiovascular Diseases;Mental Disorders;Nervous System Diseases;Otorhinolaryngologic Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0050854 | NONHSAT087920 | NCRNA00068,GHRL-AS1 | transcriptional regulation | NA | NA | NA |
| HSALNT0288959 | ENST00000583516.1 | HESRG | NA | pathogenic process | embryonal cancer | Neoplasms |
| HSALNT0287173 | FMR1-AS1 | FMR1A, FMR1-A,ASFMR1,FMR4 | transcriptional regulation | pathogenic process | fragile X syndrome;neurological disorder | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0289499 | HCG4 | HCGIV-10,HCGIV.9 | NA | pathogenic process | NA | NA |
| HSALNT0288994 | HAND2-AS1 | DEIN,NBLA00301,FLJ11539 | NA | pathogenic process | neuroblastoma | Neoplasms |
| HSALNT0289286 | NONHSAT074775 | ZEB2A, ZEB2-A,ZEB2NAT | splicing regulation | pathogenic process | bladder cancer;hepatocellular cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Digestive System Diseases |
| HSALNT0017702 | NONHSAT007663 | SNHG2,NCRNA00030 | transcriptional regulation;ceRNA | pathogenic process | varicose great saphenous veins;prostate cancer;glioma;cancer;ovarian cancer;non-small cell lung cancer;hypertension;pancreatic cancer;B-cell neoplasms;melanoma;head and neck cancer;hepatocelluar cancer;bladder cancer;autoimmune disease;liver fibrosis;kidney cancer;breast cancer;cervical cancer;colorectal cancer;multiple myeloma;gastric cancer;osteoarthritis;endometrial cancer;lymphoma;type 2 diabetes;pleural mesothelioma;hepatocellular cancer;lung adenocarcinoma;lung cancer;renal cell cancer | Skin and Connective Tissue Diseases;Neoplasms;Respiratory Tract Diseases;Immune System Diseases;Male Urogenital Diseases;Nutritional and Metabolic Diseases;Hemic and Lymphatic Diseases;Musculoskeletal Diseases;Cardiovascular Diseases;Female Urogenital Diseases and Pregnancy Complications;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0288891 | NONHSAT024403 | BACE1A,FJ573250,NCRNA00177,BACE1-AS1 | translational control;transcriptional regulation | pathogenic process | ovarian cancer;colorectal cancer;Alzheimer's disease | Neoplasms;Female Urogenital Diseases and Pregnancy Complications;Mental Disorders;Nervous System Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289414 | TRPM2-AS | TRPM2-AS1 | NA | pathogenic process | melanoma;prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0288935 | DNM3OS | DNM3-AS1,MIR199A2HG | NA | pathogenic process | epithelial ovarian cancer | Neoplasms |
| HSALNT0288930 | DGCR5 | NCRNA00037,LINC00037 | transcriptional regulation | pathogenic process | Huntington disease;DiGeorge syndrome;velocardiofacial syndrome;clear cell renal cell cancer | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Male Urogenital Diseases;Hemic and Lymphatic Diseases;Musculoskeletal Diseases;Cardiovascular Diseases;Female Urogenital Diseases and Pregnancy Complications;Mental Disorders;Endocrine System Diseases;Nervous System Diseases |
| HSALNT0288893 | ENST00000499008.3 | BDNFO,BT2A,BT2B,BT2C,BT2D,NCRNA00049,BDNF-AS1,BDNFAS | siRNA;transcriptional regulation | developmental process;pathogenic process | Huntington disease;schizophrenia;psychiatric disease;obesity | Pathological Conditions, Signs and Symptoms;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nutritional and Metabolic Diseases;Mental Disorders;Physiological Phenomena;Nervous System Diseases |
| HSALNT0120317 | Lnc-EVX1-12:1 | HOXA-AS1,NCRNA00179,HOXA1-AS1 | transcriptional regulation | pathogenic process;developmental process | colorectal cancer;Pancreatic ductal adenocarcinoma;promyelocytic leukemia;acute myeloid leukemia;infiltrating ductal cancers ;acute promyelocytic leukemia;leukemia;glioma | Neoplasms;Hemic and Lymphatic Diseases;Digestive System Diseases |
| HSALNT0290158 | NONHSAT129210 | PTCSC,AK023948,NCRNA00197 | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0289004 | NONHSAT028508 | HOXC-AS4,HOXC11-AS1,NCRNA00072 | siRNA;transcriptional regulation;ceRNA | pathogenic process | oral squamous cell cancer;prostate cancer;glioma;cancer;breast cancer;osteosarcoma;renal cancer;glioblastoma;non-small cell lung cancer;sarcoma;pancreatic cancer;large B-Cell lymphoma;bladder transitional cell cancer;B-cell neoplasms;melanoma;asthenozoospermia;hepatocelluar cancer;bladder cancer;acute myeloid leukemia;aortic valve calcification;infiltrating ductal cancers ;ovarian cancer;diffuse large B-cell lymphoma;gastrointestinal stromal tumor;atypical teratoid rhabdoid tumor;urothelial cancer;triple-negative breast cancer;gastric cardia adenocarcinoma;cervical cancer;temporomandibular joint osteoarthritis;gallbladder cancer;esophageal squamous cell cancer;colorectal cancer;Pancreatic ductal adenocarcinoma;rheumatoid arthritis;gastric cancer ;pre-eclampsia;acute leukemia;small cell lung cancer;multiple myeloma;gastric cancer;osteoarthritis;LPS-induced sepsis;endometrial cancer;head and neck squamous cell cancer;gastric adenocarcinoma;lung cancer;liver cancer;ischemic stroke;ischemic heart failure;laryngeal squamous cell cancer;pituitary adenoma;hepatocellular cancer;nasopharyngeal cancer;lung adenocarcinoma;papillary thyroid cancer;Parkinson's disease;renal cell cancer;gastrointestinal cancer | Skin and Connective Tissue Diseases;Neoplasms;Respiratory Tract Diseases;Immune System Diseases;Male Urogenital Diseases;Stomatognathic Diseases;Hemic and Lymphatic Diseases;Virus Diseases;Musculoskeletal Diseases;Female Urogenital Diseases and Pregnancy Complications;Cardiovascular Diseases;Otorhinolaryngologic Diseases;Endocrine System Diseases;Digestive System Diseases;Nervous System Diseases |
| HSALNT0289192 | ENST00000501122.2 | NCRNA00084,TncRNA,MENepsilon/beta,LINC00084,VINC | transcriptional regulation;ceRNA | pathogenic process | oral squamous cell cancer;glioma;ovarian cancer;amyotrophic lateral sclerosis;paraspeckle disintegration;nasopharyngeal cancer;AIDS;frontotemporal lobar degeneration;prostate cancer;systemic lupus erythematosus;renal syndrome;TDP-43-associated pathological states;HIV;Huntington disease;chronic lymphocytic leukemia;acute promyelocytic leukemia;esophageal squamous cell cancer;multiple sclerosis;breast cancer;intrauterine growth restriction;colorectal cancer;leukemia;gastric cancer;malignant pleural mesothelioma;endometrial cancer;gastric adenocarcinoma;papillary thyroid cancer;infertility;bladder cancer;hepatocellular cancer;non-small cell lung cancer;obesity;lung cancer;Parkinson's disease;laryngeal squamous cell cancer | Skin and Connective Tissue Diseases;Pathological Conditions, Signs and Symptoms;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Respiratory Tract Diseases;Immune System Diseases;Male Urogenital Diseases;Nutritional and Metabolic Diseases;Stomatognathic Diseases;Hemic and Lymphatic Diseases;Virus Diseases;Female Urogenital Diseases and Pregnancy Complications;Mental Disorders;Physiological Phenomena;Nervous System Diseases;Otorhinolaryngologic Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0095094 | NONHSAT104072 | U19H,NCRNA00059 | NA | pathogenic process | myelodysplastic syndrome | Hemic and Lymphatic Diseases |
| HSALNT0245443 | NONHSAT056039 | ncRAN,Nbla12061,Nbla10727 | NA | pathogenic process | bladder cancer;bladder cancer;colorectal cancer;neuroblastoma | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Digestive System Diseases |
| HSALNT0288897 | BOK-AS1 | BOKA,NCRNA00151,NAToB | NA | pathogenic process | esophageal squamous cell cancer;testicular cancer;cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289532 | NONHSAT113149 | 7-3 RNA,K-RNA,7SK-RNA,7SK snRNA,RN7SK,ENSG00000202198,NONHSAT113149 | transcriptional regulation | developmental process;pathogenic process | cancer;cardiac hypertrophy;gastric cancer;AIDS;multiple sclerosis;colorectal adenocarcinoma | Neoplasms;Immune System Diseases;Virus Diseases;Cardiovascular Diseases;Digestive System Diseases;Nervous System Diseases |
| HSALNT0289182 | MIR4435-2HG | MIR4435-1HG,LINC00978,AGD2,AK001796,lncRNA-AWPPH,MORRBID | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289200 | PARTICL | PARTICLE | transcriptional regulation | pathogenic process | low-dose irradiation | Disorders of Environmental Origin |
| HSALNT0289172 | ENST00000517411.1 | LINC01604,TCONS_00015189 | transcriptional regulation;ceRNA | pathogenic process | gallbladder cancer;Burkitt lymphoma | Neoplasms;Immune System Diseases;Hemic and Lymphatic Diseases;Virus Diseases;Digestive System Diseases |
| HSALNT0001792 | NPPA-AS1 | NPPAA, NPPA-AS | splicing regulation | pathogenic process | cardiovascular disease | Cardiovascular Diseases |
| HSALNT0290230 | RRP1B | NA | transcriptional regulation | pathogenic process | spinocerebellar ataxia;laryngeal squamous cell cancer;cancer | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Nervous System Diseases |
| HSALNT0289467 | CLLU1 | NA | NA | NA | NA | NA |
| HSALNT0289173 | ENST00000531381.1 | AGD1,lncRNA-N2,linc-NeD125 | NA | developmental process;pathogenic process | myeloid leukemia;myopia;cervical cancer;neuroblastoma | Eye Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0059175 | NONHSAT091315 | LINC00902,LSAMP-AS1,LSAMP-AS3,LSAMPAS3,NCRNA00295 | transcriptional regulation;ceRNA | pathogenic process | glioma;Pancreatic ductal adenocarcinoma;osteosarcoma;esophageal squamous cell cancer;ischemic heart failure;gastric cancer;hepatocellular cancer;non-small cell lung cancer;acute myeloid leukemia;colorectal cancer | Respiratory Tract Diseases;Cardiovascular Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289647 | BC040587 | NA | NA | pathogenic process | osteosarcoma;breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0059186 | LINC00901 | LSAMP-AS4,TCONS_00005428,BC040587 | NA | pathogenic process | osteosarcoma;gastric cancer;breast cancer | Skin and Connective Tissue Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0233366 | HCCAT5 | HTA,FJ222407 | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290040 | LSINCT5 | NA | NA | pathogenic process | chronic heart failure;colorectal cancer;ovarian cancer;gastric cancer;lung cancer;breast cancer | Skin and Connective Tissue Diseases;Neoplasms;Respiratory Tract Diseases;Cardiovascular Diseases;Female Urogenital Diseases and Pregnancy Complications;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0179611 | DISC1FP1 | Boymaw | transcriptional regulation | pathogenic process | schizophrenia | Mental Disorders |
| HSALNT0217643 | SNHG14 | 115HG,IC-SNURF-SNRPN,LNCAT,NCRNA00214,U-UBE3A-AT, UBE3A-A, UBE3A-AS1,UBE3AATS | ceRNA | pathogenic process | Angelman syndrome;cerebral infarction;Prader-Willi syndrome | Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Nervous System Diseases |
| HSALNT0289273 | TP73-AS1 | KIAA0495,PDAM | NA | pathogenic process | esophageal squamous cell cancer;oligodendroglial tumors;non-small cell lung cancer;glioblastoma;multiple myeloma | Neoplasms;Respiratory Tract Diseases;Immune System Diseases;Hemic and Lymphatic Diseases;Cardiovascular Diseases |
| HSALNT0290311 | TP53COR1 | Trp53cor1 | transcriptional regulation | pathogenic process | prostate cancer;colorectal cancer;hepatocelluar cancer;atherosclerosis;Burkitt lymphoma;chronic lymphocytic leukemia;B cell lymphoma;lung cancer;cervical cancer | Neoplasms;Respiratory Tract Diseases;Immune System Diseases;Male Urogenital Diseases;Hemic and Lymphatic Diseases;Virus Diseases;Cardiovascular Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases |
| HSALNT0289221 | NONHSAT129019 | CARLo-3,PCAT8 | transcriptional regulation | pathogenic process | gastric cancer;prostate cancer;glioma;colorectal cancer | Male Urogenital Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0020131 | PCAT6 | KDM5B-AS1,ncRNA-a2,PCAN-R1,KDM5BAS1,onco-lncRNA-96 | transcriptional regulation | pathogenic process | prostate cancer;triple-negative breast cancer;lung cancer | Respiratory Tract Diseases;Skin and Connective Tissue Diseases;Male Urogenital Diseases;Neoplasms |
| HSALNT0289277 | TRERNA1 | LINC00651,ncRNA-a7,treRNA | transcriptional regulation | NA | NA | NA |
| HSALNT0014972 | ENST00000416894.1 | LINC00568,ncRNA-a1,FAL1 | transcriptional regulation | pathogenic process | ovarian cancer;thyroid cancer | Female Urogenital Diseases and Pregnancy Complications;Endocrine System Diseases;Neoplasms |
| HSALNT0290008 | Lnc-SNAI1-1:1 | Noncoding RNA activating7: ncRNA-a7,ENST00000431460.1,ENSG00000231265,TRERNA1 | transcriptional regulation | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290248 | Lnc-BSPH1-1:1 | EU035784.1,lnc-BSPH1-1:1 | transcriptional regulation | NA | NA | NA |
| HSALNT0289342 | Lnc-ZCCHC13-1:1 | NCRNA00183,ENOX,LINC00183,DCBALD06 | transcriptional regulation | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289280 | VLDLR-AS1 | lincRNA-VLDLR | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0288982 | ENST00000602812.1 | NCRNA00182,MIR374AHG,LINC00182,FLJ33139 | transcriptional regulation | pathogenic process | hepatocellular cancer;breast cancer;colorectal cancer;hepatocelluar cancer | Skin and Connective Tissue Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0091079 | MEF2C-AS1 | NA | NA | pathogenic process | gastric cancer;Prader-Willi syndrome and Angelman syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Digestive System Diseases;Nervous System Diseases |
| HSALNT0189341 | PCBP2-OT1 | TUC338 | NA | pathogenic process | hepatocellular cancer;tongue squamous cell cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290373 | WRAP53 | NA | NA | pathogenic process | hepatocellular cancer;cancer;dyskeratosis congenita | Skin and Connective Tissue Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Digestive System Diseases |
| HSALNT0289265 | NONHSAT112472 | LINC00532,lincRNA-NRNA024015 | NA | pathogenic process | esophageal squamous cell cancer;gastric cancer;testicular cancer;aplastic anemia | Male Urogenital Diseases;Neoplasms;Hemic and Lymphatic Diseases;Digestive System Diseases |
| HSALNT0289175 | NONHSAT081499 | MIRHG2,BIC,NCRNA00172 | NA | pathogenic process | B-cell chronic lymphocytic leukemia;chronic lymphocytic leukemia;breast cancer;glioma | Immune System Diseases;Skin and Connective Tissue Diseases;Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0289051 | LINC00620 | NA | NA | pathogenic process | cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0120390 | NONHSAT119717 | NCRNA00213,HOXA-AS6,RP1-170O19.3,HOXA13-AS1 | transcriptional regulation | pathogenic process | hirschsprung disease;colorectal cancer;prostate cancer;tongue squamous cell cancer;Pancreatic ductal adenocarcinoma;osteosarcoma;hepatocelluar cancer;gastric cancer;hepatocellular cancer;non-small cell lung cancer;pancreatic cancer;lung cancer;glioma | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289287 | NONHSAT080206 | C20orf199,NCRNA00275,ZNFX1-AS1,HSUP1,HSUP2 | transcriptional regulation;ceRNA | pathogenic process | gastric cancer;hepatocellular cancer;ductal cancer;colorectal cancer;breast cancer | Skin and Connective Tissue Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289259 | Lnc-NDFIP1-3:1 | SPRIGHTLY | transcriptional regulation | pathogenic process | prostate cancer;melanoma;glioma;esophageal squamous cell cancer;pre-eclampsia;bladder cancer;renal clear cell cancer;gastric cancer;hepatocellular cancer;non-small cell lung cancer;lung cancer;breast cancer;cervical cancer;colorectal cancer | Skin and Connective Tissue Diseases;Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases |
| HSALNT0105595 | Lnc-CDKN1A-1:1 | PANDA | transcriptional regulation | pathogenic process | colorectal cancer;cancer;bladder cancer;gastric cancer;hepatocellular cancer;non-small cell lung cancer;p53-associated pathological states;breast cancer;renal cell cancer | Skin and Connective Tissue Diseases;Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases |
| HSALNT0068185 | HTT-AS | HTT-AS1,HTTAS | NA | pathogenic process | Huntington disease | Mental Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0099036 | HEIH | LINC-HEIH,lncRNA-HEIH,LINC00848,HCCAT2 | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0222533 | NPTN-IT1 | lncRNA-LET | NA | pathogenic process | gallbladder cancer;colorectal cancer;hepatocelluar cancer;esophageal squamous cell cancer;lung squamous cell cancer;nasopharyngeal cancer;gastric cancer;hypoxia;squamous cell lung cancer;cervical cancer | Pathological Conditions, Signs and Symptoms;Neoplasms;Respiratory Tract Diseases;Stomatognathic Diseases;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Digestive System Diseases |
| HSALNT0289747 | DQ786243 | NA | transcriptional regulation | pathogenic process | crohn's disease;colorectal cancer;hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289204 | ENST00000561978.1 | PCAT-1,PCA1 | transcriptional regulation;ceRNA | pathogenic process | prostate cancer;colorectal cancer;esophageal squamous cell cancer;bladder cancer;hepatocellular cancer;lung cancer | Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases |
| HSALNT0275894 | PCAT14 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0211999 | HIF1A-AS2 | 3'aHIF-1A,aHIF | translational control | pathogenic process | bladder cancer;osteosarcoma;renal cancer;glioblastoma;gastric cancer;acute myocardial infarction;kidney cancer;breast cancer | Skin and Connective Tissue Diseases;Neoplasms;Male Urogenital Diseases;Cardiovascular Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases |
| HSALNT0288999 | HIF1A-AS1 | 5'aHIF-1A,5'aHIF1alpha | NA | pathogenic process | acute myocardial infarction;non-small cell lung cancer;cardiovascular disease;aortic aneurysm;thoracoabdominal aorta aneurysm;kidney cancer | Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Cardiovascular Diseases;Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0289258 | SOX2-OT | SOX2OT,DKFZp761J1324,NCRNA00043 | transcriptional regulation | pathogenic process | colorectal cancer;esophageal squamous cell cancer;lung squamous cell cancer;retinal neurodegeneration;neurodevelopmental syndromes associated with the SOX2 locus;hepatocellular cancer;lung cancer;breast cancer;Alzheimer's disease | Eye Diseases;Skin and Connective Tissue Diseases;Neoplasms;Respiratory Tract Diseases;Mental Disorders;Digestive System Diseases;Nervous System Diseases |
| HSALNT0289700 | CDR1-AS | CDR1NAT,ciRS-7,CDR1as | ceRNA | NA | NA | NA |
| HSALNT0289149 | LINCMD1 | MIR133BHG,LINC-MD1 | ceRNA | developmental process;pathogenic process | Duchenne muscular dystrophy | Musculoskeletal Diseases |
| HSALNT0288894 | BGLT3 | LINC01083,BGL3,lncRNA-BGL3 | ceRNA | pathogenic process | chronic myeloid leukemia | Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0289042 | LINC00473 | C6orf176,bA142J11.1 | transcriptional regulation | pathogenic process | non-small cell lung cancer;renal cell cancer | Respiratory Tract Diseases;Male Urogenital Diseases;Neoplasms |
| HSALNT0101681 | LINC01108 | LncRNA-ES1 | NA | developmental process | NA | NA |
| HSALNT0289418 | TUNAR | LINC00617,TUNA,HI-LNC78 | transcriptional regulation | developmental process;pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289197 | ENST00000500949.2 | cyrano,linc-OIP5 | NA | developmental process | NA | NA |
| HSALNT0289046 | Lnc-PRL-6:2 | NA | NA | pathogenic process | West Syndrome;West syndrome | Nervous System Diseases |
| HSALNT0289656 | BX118339 | NA | NA | pathogenic process | West syndrome | Nervous System Diseases |
| HSALNT0021726 | LINC00538 | Yiya,PROX1UT | NA | pathogenic process | colorectal cancer;cancer | Neoplasms;Digestive System Diseases |
| HSALNT0273249 | CBR3-AS1 | PlncRNA-1,PlncRNA1 | ceRNA | pathogenic process | esophageal squamous cell cancer;hepatocellular cancer;prostate cancer | Male Urogenital Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289179 | NONHSAT130385 | LOC554202,hsa-lnc-31,LncHIFCAR | ceRNA | pathogenic process | bladder cancer;gastric cancer;breast cancer;colorectal cancer;Pancreatic ductal adenocarcinoma | Skin and Connective Tissue Diseases;Neoplasms;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases |
| HSALNT0288925 | NONHSAT096369 | KIAA0114,SNHG13,ANCR,AGU2,lncRNA-ANCR | transcriptional regulation | developmental process;pathogenic process | prostate cancer;colorectal cancer;osteosarcoma;bone diseases;postmenopausal osteoporosis;hepatocellular cancer;breast cancer | Skin and Connective Tissue Diseases;Neoplasms;Male Urogenital Diseases;Musculoskeletal Diseases;Digestive System Diseases |
| HSALNT0290329 | Uc.388 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289842 | FR0348383 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289279 | TTTY15 | DKFZP434I143,NCRNA00138 | NA | pathogenic process | NA | NA |
| HSALNT0289718 | Lnc-IRX3-4:2 | LOC643911,LINC00180,CRNDEP | transcriptional regulation;ceRNA | pathogenic process | gallbladder cancer;colorectal cancer;ovarian cancer;medulloblastoma;chronic lymphocytic leukemia;renal cell cancer;glioma | Neoplasms;Immune System Diseases;Male Urogenital Diseases;Hemic and Lymphatic Diseases;Female Urogenital Diseases and Pregnancy Complications;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289685 | CCND1 | NA | NA | pathogenic process | tumor;cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289935 | LincRNA-p21 | NA | transcriptional regulation | pathogenic process | lung cancer;cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290134 | PCNCR1 | NA | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289492 | NONHSAT099821 | DBE-T,DUX4L30 | transcriptional regulation | developmental process;pathogenic process | facioscapulohumeral muscular dystrophy | Musculoskeletal Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0289455 | BANCR | LINC00586 | transcriptional regulation | pathogenic process | osteosarcoma ;lung cancer;melanoma;colorectal cancer;osteosarcoma;esophageal squamous cell cancer;bladder cancer;eosinophilic esophagitis;gastric cancer;hepatocellular cancer;non-small cell lung cancer;retinoblastoma;papillary thyroid cancer | Neoplasms;Respiratory Tract Diseases;Immune System Diseases;Male Urogenital Diseases;Hemic and Lymphatic Diseases;Female Urogenital Diseases and Pregnancy Complications;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0209589 | ENST00000556013.2 | NA | ceRNA | pathogenic process | papillary thyroid cancer;thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0289103 | LINC01268 | LOC285758 | NA | pathogenic process | NA | NA |
| HSALNT0289070 | LINC00887 | linc-ATP13A4-8,HEIRCC | transcriptional regulation | pathogenic process | hypoxic and inflammatory renal epithelial injury;renal clear cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0288931 | NONHSAT035954 | C14orf167,PRO1488,AS1DHRS4 | transcriptional regulation | NA | NA | NA |
| HSALNT0288974 | FENDRR | FOXF1-AS1,TCONS_00024240,lincFOXF1,onco-lncRNA-21 | transcriptional regulation | developmental process;pathogenic process | osteosarcoma;gastric cancer;non-small cell lung cancer;lung cancer | Respiratory Tract Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0106473 | LINC01512 | LOC100132354,TCONS_00011120,HI-LNC77 | NA | pathogenic process | lung adenocarcinoma;type 2 diabetes | Respiratory Tract Diseases;Nutritional and Metabolic Diseases;Endocrine System Diseases;Neoplasms |
| HSALNT0289059 | LINC00673 | HI-LNC75,HILNC75,LUCAIR1,SLNCR,SLNCR1 | transcriptional regulation | pathogenic process | pancreatic cancer;type 2 diabetes;non-small cell lung cancer;melanoma;Pancreatic ductal adenocarcinoma | Neoplasms;Respiratory Tract Diseases;Nutritional and Metabolic Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289107 | LINC01433 | LOC728228 | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0143571 | NONHSAT129017 | CARLo-5,onco-lncRNA-40 | ceRNA | pathogenic process | gallbladder cancer;glioma;hepatocelluar cancer;ovarian cancer;acute myeloid leukemia;gastric cancer;hepatocellular cancer;non-small cell lung cancer;lung adenocarcinoma;endometrial cancer;lung cancer;breast cancer;colorectal cancer | Skin and Connective Tissue Diseases;Neoplasms;Respiratory Tract Diseases;Female Urogenital Diseases and Pregnancy Complications;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289408 | ENST00000448587.1 | ENST00000448587.1,FLJ90734,NCRNA00036,LINC00036,onco-lncRNA-16 | translational control | pathogenic process;developmental process | bladder cancer;colorectal cancer;esophageal squamous cell cancer;gastric cancer;skin desease;squamous cell cancer | Skin and Connective Tissue Diseases;Neoplasms;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases |
| HSALNT0289152 | LNCPRESS1 | lncPRESS1 | translational control | NA | NA | NA |
| HSALNT0289145 | LINC02561 | RP11-445P17.8 | NA | pathogenic process | cystic fibrosis | Respiratory Tract Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Digestive System Diseases |
| HSALNT0289065 | LINC00850 | KUCG1 | NA | pathogenic process | Duchenne muscular dystrophy | Musculoskeletal Diseases |
| HSALNT0289431 | AFAP1-AS1 | AFAP1A, AFAP1-A,MGC10981 | NA | pathogenic process | non-small cell lung cancer;colorectal cancer;Pancreatic ductal adenocarcinoma;esophageal squamous cell cancer;hepatocellular cancer;nasopharyngeal cancer;lung adenocarcinoma;pancreatic cancer;Barrett's Esophagus;lung cancer | Neoplasms;Respiratory Tract Diseases;Stomatognathic Diseases;Otorhinolaryngologic Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289519 | XACT | NA | NA | NA | NA | NA |
| HSALNT0248684 | GATA6-AS1 | locus5689,BM742401 | NA | pathogenic process | gastric cancer;chronic lymphocytic leukemia | Immune System Diseases;Neoplasms;Hemic and Lymphatic Diseases;Digestive System Diseases |
| HSALNT0289222 | ENST00000430058.1 | NA | transcriptional regulation | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0289655 | BTG3-AS1 | ASBEL | translational control | pathogenic process | ovarian cancer;colorectal cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Digestive System Diseases |
| HSALNT0289224 | NONHSAT130775 | NONHSAT130775,PTENpg1,PTEN2,ENSG00000237984 | transcriptional regulation;ceRNA | pathogenic process | gastric cancer;prostate cancer;renal cell cancer;cancer;hepatocelluar cancer | Male Urogenital Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0290129 | PAN | NA | transcriptional regulation | pathogenic process | Kaposi's sarcoma | Neoplasms;Virus Diseases |
| HSALNT0289939 | LINC-ROR | lincRNA-RoR,lincRNA-ST8SIA3,ROR | transcriptional regulation;ceRNA | pathogenic process | gallbladder cancer;liver cancer;glioma;malignant melanoma;unveal melanoma;breast cancer;gastric cancer;hepatocellular cancer;nasopharyngeal cancer;pancreatic cancer;endometrial cancer;triple-negative breast cancer;colorectal cancer | Skin and Connective Tissue Diseases;Neoplasms;Stomatognathic Diseases;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0290322 | UBE3A-ATS | NA | NA | pathogenic process | Angelman syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0091004 | LINC00461 | EyeLinc1,Visc-1a,Visc-1b,Visc-2,LOC645323 | NA | pathogenic process;developmental process | retinal and visual function | Eye Diseases |
| HSALNT0289491 | CTBP1-AS | PCAT10 | transcriptional regulation | pathogenic process | chronic hepatitis C;prostate cancer;polycystic ovary syndrome | Neoplasms;Male Urogenital Diseases;Virus Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases |
| HSALNT0037401 | ENST00000441383.1 | LINC00876,AC096655.1-002 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0120344 | NONHSAT119676 | HOXA3as | transcriptional regulation | pathogenic process | promyelocytic leukemia;gastric cancer | Neoplasms;Hemic and Lymphatic Diseases;Digestive System Diseases |
| HSALNT0091313 | ENST00000511918.1 | SCAL1 | transcriptional regulation | pathogenic process | non-small cell lung cancer;lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289425 | BLACAT1 | linc-UBC1,LINC00912,onco-lncRNA-30 | transcriptional regulation | pathogenic process | bladder cancer;gastric cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Digestive System Diseases |
| HSALNT0149012 | GLIDR | LINC01172,MGC21881,TCONS_00015562 | NA | pathogenic process | glioblastoma | Neoplasms |
| HSALNT0217561 | PWAR5 | PAR5,PAR-5 | NA | pathogenic process | glioblastoma;Prader-Willi syndrome and Angelman syndrome;Prader-Willi syndrome | Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Nervous System Diseases |
| HSALNT0289272 | TP53TG1 | TP53AP1,H_RG012D21.9,LINC00096 | NA | pathogenic process | non-small cell lung cancer;ataxia telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Respiratory Tract Diseases;Immune System Diseases;Nutritional and Metabolic Diseases;Cardiovascular Diseases;Nervous System Diseases |
| HSALNT0289598 | AK126698 | NA | NA | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0217598 | NONHSAT041063 | NCRNA00002 | transcriptional regulation | pathogenic process | Prader-Willi syndrome | Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0143633 | CCAT2 | NCCP1,LINC00873 | transcriptional regulation | pathogenic process | non-small cell lung cancer;oral squamous cell cancer;colorectal cancer;ovarian cancer;esophageal squamous cell cancer;bladder cancer;small cell lung cancer;gastric cancer;hepatocellular cancer;prostate cancer;cervical squamous cell cancer;lung cancer;breast cancer;cervical cancer | Skin and Connective Tissue Diseases;Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289026 | LINC00261 | C20orf56,NCRNA00261,bA216C10.1,HCCDR1,TCONS_00027846,ALIEN,DEANR1,onco-lncRNA-17 | NA | pathogenic process | pancreatic cancer;non-small cell lung cancer;gastric cancer | Respiratory Tract Diseases;Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289078 | LINC00982 | FLJ42875 | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290082 | NEAT1_2 | NEAT1_2 | protein localization | pathogenic process | amyotrophic lateral sclerosis | Nutritional and Metabolic Diseases;Nervous System Diseases |
| HSALNT0288989 | GATA3-AS1 | NA | transcriptional regulation | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289427 | GNG12-AS1 | NA | transcriptional regulation | NA | NA | NA |
| HSALNT0290395 | YAM1 | Yam-1 | transcriptional regulation | pathogenic process;developmental process | skeletal myogenesis | Musculoskeletal Diseases |
| HSALNT0289202 | PAX8-AS1 | NA | NA | pathogenic process | malignant pleural mesothelioma;cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0054469 | RASSF1-AS1 | ANRASSF1 | transcriptional regulation | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0290261 | SUMO1P3 | SUMO1P3 | NA | pathogenic process | bladder cancer;gastric cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Digestive System Diseases |
| HSALNT0289002 | HNF1A-AS1 | C12orf27,NCRNA00262,FLJ38690,HAS1 | ceRNA | pathogenic process | esophageal adenocarcinoma;osteosarcoma;esophageal squamous cell cancer;gastric cancer;hepatocellular cancer;nasopharyngeal cancer;adenocarcinoma;lung adenocarcinoma;pancreatic cancer | Neoplasms;Respiratory Tract Diseases;Otorhinolaryngologic Diseases;Endocrine System Diseases;Digestive System Diseases;Stomatognathic Diseases |
| HSALNT0289377 | NIPBL-AS1 | NIPBL-DT,NIPBL-AS | NA | pathogenic process | autism spectrum disorder | Mental Disorders |
| HSALNT0289249 | SNHG15 | C7orf40,FLJ38860,MYO1GUT,Linc-Myo1g | NA | pathogenic process | gastric cancer;hepatocellular cancer;hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0235898 | ENST00000574306.1 | C17orf91,MGC14376,DKFZp686O06159 | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0235898 | ENST00000574306.1 | C17orf91,MGC14376,DKFZp686O06159 | NA | NA | NA | NA |
| HSALNT0288984 | ENST00000579368.1 | MTCL1-AS1,HMlincRNA717 | NA | pathogenic process | pancreatic cancer;non-small cell lung cancer;gastric cancer | Respiratory Tract Diseases;Endocrine System Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289369 | MIF-AS1 | LOC284889,MIF-AS | transcriptional regulation | pathogenic process | malaria;nephrolithiasis | Skin and Connective Tissue Diseases;Male Urogenital Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Parasitic Diseases |
| HSALNT0129086 | NONHSAT123382 | MKLN1-AS1,FLJ43663,PINT,LincRNA-Pint | transcriptional regulation | pathogenic process | colorectal cancer;heart failure | Pathological Conditions, Signs and Symptoms;Cardiovascular Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289240 | NONHSAT075852 | LINC00913,SChLAP1,PCAT11 | transcriptional regulation | pathogenic process | bladder cancer;prostate cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0193241 | SOCS2-AS1 | NA | transcriptional regulation | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0138824 | CASC9 | ESCCAL-1,ESSCAL1,LINC00981 | NA | pathogenic process | esophageal squamous cell cancer;esophageal cancer | Neoplasms |
| HSALNT0267627 | HNF4A-AS1 | uc002xlx | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289194 | NKILA | NA | NA | pathogenic process | nasopharyngeal cancer;breast cancer;tongue squamous cell cancer | Skin and Connective Tissue Diseases;Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0289304 | LINC00942 | NA | NA | pathogenic process | ovarian cancer;autism spectrum disorder | Female Urogenital Diseases and Pregnancy Complications;Endocrine System Diseases;Mental Disorders;Neoplasms |
| HSALNT0289187 | MNX1-AS1 | CCAT5,LOC645249 | NA | pathogenic process | ovarian cancer;colorectal cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Digestive System Diseases |
| HSALNT0289518 | VPS9D1-AS1 | MYU | NA | pathogenic process | ovarian cancer;colorectal cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Digestive System Diseases |
| HSALNT0290266 | TC0101441 | NA | NA | pathogenic process | epithelial ovarian cancer | Neoplasms |
| HSALNT0289426 | ERLNC1 | TC0101441,ElncRNA1 | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290050 | ENST00000416928.2 | NA | NA | NA | NA | NA |
| HSALNT0043560 | ENST00000416928.2 | HOXD-AS1,Mdgt | NA | pathogenic process | bladder cancer;neuroblastoma | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289092 | LINC01158 | PANTR1,linc-Brn1a,linc-POU3F3 | transcriptional regulation | pathogenic process;developmental process | esophageal squamous cell cancer;gastric cancer;glioma | Neoplasms;Digestive System Diseases |
| HSALNT0289448 | GHET1 | lncRNA-GHET1 | NA | pathogenic process | bladder cancer;gastric cancer;colorectal cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Digestive System Diseases |
| HSALNT0289514 | PEG13 | NA | transcriptional regulation | pathogenic process | intellectual disabilities | Behavior and Behavior Mechanisms;Pathological Conditions, Signs and Symptoms;Mental Disorders;Nervous System Diseases |
| HSALNT0289183 | ENST00000414769.1 | MGC16121,H19X | NA | pathogenic process | choriocarcinoma | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289201 | NONHSAT018635 | NA | transcriptional regulation | pathogenic process;developmental process | uveal melanoma | Neoplasms |
| HSALNT0288956 | LINC01234 | LCAL84,onco-lncRNA-32 | ceRNA | pathogenic process | oesophageal squamous cell cancer;breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289021 | CYTOR | C2orf59,NCRNA00152,MGC4677 | transcriptional regulation;ceRNA | pathogenic process | colorectal cancer;gastric cancer;hepatocellular cancer;pancreatic cancer;breast cancer;renal cell cancer | Skin and Connective Tissue Diseases;Neoplasms;Male Urogenital Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289706 | CHRF | NA | ceRNA | pathogenic process | cardiac hypertrophy;silicosis | Respiratory Tract Diseases;Occupational Diseases;Cardiovascular Diseases |
| HSALNT0143635 | ENST00000502056.1 | LINC00860,CARLo-1 | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0143672 | CASC11 | TCONS_00014535,LINC00990,CARLo-7,ENST00000518376 | transcriptional regulation | pathogenic process | hepatocellular cancer;colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289032 | LINC00323 | PRED42,FLJ37173 | NA | pathogenic process | breast cancer;hereditary haemorrhagic telangiectasia | Skin and Connective Tissue Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Neoplasms |
| HSALNT0024655 | LINC01139 | LINK-A,TCONS_00000027 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0289018 | LEF1-AS1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia;colorectal cancer | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0247326 | LINC00667 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases |
| HSALNT0290145 | POU3F3 | NA | transcriptional regulation | pathogenic process | esophageal squamous cell cancer;glioma | Neoplasms |
| HSALNT0199349 | LINC00426 | NA | NA | pathogenic process | primary Sjögren's syndrome | Immune System Diseases |
| HSALNT0155974 | LINC00963 | MetaLnc9 | NA | pathogenic process | prostate cancer;renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289211 | PCF11-AS1 | NA | NA | pathogenic process | hepatocellular cancer;adolescent idiopathic scoliosis | Musculoskeletal Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289534 | 91H | NA | transcriptional regulation | pathogenic process | osteosarcoma;esophageal squamous cell cancer;breast cancer;colorectal cancer | Skin and Connective Tissue Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289446 | ELFN1-AS1 | MYCLo-2 | transcriptional regulation | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0288883 | ACTA2-AS1 | uc001kfo.1,ZXF1 | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289443 | NONHSAT121673 | RSBN1L-AS1 | transcriptional regulation | pathogenic process | liver fibrosis;glioblastoma | Neoplasms;Digestive System Diseases |
| HSALNT0289986 | LncRNA-MVIH | NA | NA | pathogenic process | hepatocellular cancer;non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289977 | LncRNA-ATB | NA | ceRNA | pathogenic process | colorectal cancer;hepatocelluar cancer;gastric cancer;pancreatic cancer;renal cell cancer;pneumoconiosis | Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Occupational Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289622 | ATB | NA | ceRNA | pathogenic process | prostate cancer;glioma;keloid;gastric cancer;hepatocellular cancer;pancreatic cancer;breast cancer;colorectal cancer | Pathological Conditions, Signs and Symptoms;Skin and Connective Tissue Diseases;Neoplasms;Tissues;Male Urogenital Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0289586 | AK057054 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0278370 | LINC01315 | lnc-C22orf32-1,C22orf32-1 | NA | pathogenic process | nasopharyngeal cancer | Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0055601 | ADAMTS9-AS2 | NA | NA | pathogenic process | non-small cell lung cancer;glioma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289383 | ENST00000608917.1 | PACER,PTGS2-AS1 | transcriptional regulation | pathogenic process | osteosarcoma;osteoarthritis;inflammation and cancer | Musculoskeletal Diseases;Neoplasms |
| HSALNT0289268 | TGFB2-OT1 | FLJ11812 | ceRNA | NA | NA | NA |
| HSALNT0288938 | DUBR | LINC00883 | ceRNA | pathogenic process | asthma and chronic obstructive pulmonary disease | Respiratory Tract Diseases |
| HSALNT0289440 | Lnc-FOXC1-1:1 | LINC01379,TCONS_00011636 | transcriptional regulation | pathogenic process | esophageal squamous cell cancer;basal-like breast cancer;oral squamous cell cancer | Neoplasms |
| HSALNT0288924 | CYP51A1-AS1 | ENST00000453068,LRRD1-AS1 | NA | pathogenic process | renal cell cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289395 | RPL34-AS1 | FLJ37673,RP11-462C24.1 | NA | pathogenic process | gastric cancer;colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289435 | C5orf66-AS1 | CTC-276P9.1,Epist | NA | pathogenic process | esophageal squamous cell cancer;bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289052 | LINC00623 | NA | NA | pathogenic process | nasopharyngeal cancer | Otorhinolaryngologic Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0289831 | FER1L4 | FER1L4 | ceRNA | pathogenic process | gastric cancer;endometrial cancer;colorectal cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Digestive System Diseases |
| HSALNT0288985 | ENST00000426539.1 | LINC01458,lncRNA-AC130710 | NA | pathogenic process | ovarian cancer;gastric cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Digestive System Diseases |
| HSALNT0288881 | ABHD11-AS1 | WBSCR26,LINC00035,NCRNA00035 | NA | pathogenic process | gastric cancer;mutant huntingtin | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Digestive System Diseases |
| HSALNT0282263 | ZNF674-AS1 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289207 | PCAT29 | NA | NA | pathogenic process | prostate cancer;glioma;bladder cancer;renal clear cell cancer;skin melanoma;hepatocellular cancer;lung adenocarcinoma;stomach adenocarcinoma | Neoplasms;Respiratory Tract Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases |
| HSALNT0289672 | CADM1 | NA | NA | NA | NA | NA |
| HSALNT0289297 | LINC01527 | lnc-SPRR2D-1,RP1-13P20.6 | NA | pathogenic process | squamous cell cancer | Neoplasms |
| HSALNT0289158 | LUNAR1 | NA | transcriptional regulation | pathogenic process | diffuse large B-cell lymphoma;T cell acute lymphoblastic leukemia | Hemic and Lymphatic Diseases |
| HSALNT0289830 | FAR2P-1 | NA | NA | pathogenic process | lung adenocarcinoma;non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289263 | ENST00000607033.1 | EYA4-AS1 | transcriptional regulation | pathogenic process | kidney clear cell sarcoma | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0145373 | MAFA-AS1 | RP11-909N17.3,TCONS_00014882 | NA | pathogenic process | lung adenocarcinoma;non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290229 | RPLP0P2 | RPLP0P2 | NA | pathogenic process | lung adenocarcinoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289291 | ZNF295-AS1 | C21orf121,NCRNA00318,PRED87 | NA | pathogenic process | lung adenocarcinoma;epithelial ovarian cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0084473 | LINC01513 | RP11-1C1.7,TCONS_00009352 | NA | pathogenic process | NA | NA |
| HSALNT0289471 | IRAIN | IGF1R-AS | transcriptional regulation | pathogenic process | pancreatic cancer;acute myeloid leukemia;non-small cell lung cancer;breast cancer | Skin and Connective Tissue Diseases;Neoplasms;Respiratory Tract Diseases;Endocrine System Diseases;Digestive System Diseases |
| HSALNT0290402 | ZNRD1-AS1 | NA | NA | pathogenic process | hepatocellular cancer;lung cancer;cervical cancer | Respiratory Tract Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Digestive System Diseases |
| HSALNT0289504 | LCAL1 | onco-lncRNA-27 | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289169 | MHRT | Myheart | transcriptional regulation | pathogenic process | heart hypertrophy;acute myocardial infarction | Pathological Conditions, Signs and Symptoms;Cardiovascular Diseases |
| HSALNT0289859 | HA117 | NA | NA | pathogenic process | hirschsprung disease | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Digestive System Diseases |
| HSALNT0026673 | ENST00000414795.1 | lncRNA-CMPK2 | transcriptional regulation | pathogenic process | chronic hepatitis C;HCV | Digestive System Diseases;Virus Diseases |
| HSALNT0289887 | LET | NA | NA | pathogenic process | gallbladder cancer;esophageal squamous cell cancer;gastric cancer;nasopharyngeal cancer;renal cell cancer;cervical cancer | Neoplasms;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Digestive System Diseases;Stomatognathic Diseases |
| HSALNT0007921 | NFIA-AS1 | RP5-833A20.1 | transcriptional regulation | pathogenic process | atherosclerosis;glioma | Cardiovascular Diseases;Neoplasms |
| HSALNT0247156 | GAPLINC | LINC01540,TCONS_00026238,lncRNA-uc002kmd.1 | siRNA | pathogenic process | gastric cancer;colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0288917 | CERNA2 | HOST2,lncRNA-HOST2 | ceRNA | pathogenic process | hepatocellular cancer;epithelial ovarian cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289113 | LINC01564 | TCONS_00011314 | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0289088 | LINC01105 | FLJ30594,LOC150622 | NA | pathogenic process | gastric cancer;leukemia and neuroblastoma | Neoplasms;Digestive System Diseases |
| HSALNT0289464 | AGAP2-AS1 | LOC100130776,PUNISHER | transcriptional regulation | pathogenic process | non-small cell lung cancer;glioma;leukemia and neuroblastoma | Respiratory Tract Diseases;Neoplasms |
| HSALNT0288960 | EWSAT1 | TMEM84,NCRNA00277,LINC00277,FLJ33768 | transcriptional regulation | pathogenic process | Ewing sarcoma | Neoplasms |
| HSALNT0289242 | SLC25A25-AS1 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289317 | KCNK15-AS1 | RP11-445H22.4 | NA | pathogenic process | osteoarthritis;breast cancer | Musculoskeletal Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289864 | HIF2PUT | NA | NA | pathogenic process | osteosarcoma;colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289267 | TEX41 | DKFZp686O1327,LINC00953 | transcriptional regulation | NA | NA | NA |
| HSALNT0290361 | UFC1 | NA | transcriptional regulation;ceRNA | pathogenic process | osteoarthritis;hepatocellular cancer | Musculoskeletal Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289886 | LEIGC | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289367 | MDC1-AS1 | MDC1-AS | NA | pathogenic process | bladder cancer;glioma | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289190 | NBAT1 | CASC14,NBAT-1 | transcriptional regulation | pathogenic process | breast cancer;renal clear cell cancer;neuroblastoma | Skin and Connective Tissue Diseases;Male Urogenital Diseases;Neoplasms |
| HSALNT0234826 | LINC00917 | NA | NA | pathogenic process | intervertebral disc degeneration;breast cancer | Musculoskeletal Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289419 | LINC00173 | NCRNA00173,FLJ42957 | NA | pathogenic process | HIV-1-infected;hepatocelluar cancer | Virus Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0290138 | PEG10 | NA | NA | pathogenic process | diffuse large B-cell lymphoma;esophageal cancer | Neoplasms;Hemic and Lymphatic Diseases |
| HSALNT0289136 | LINC02224 | BRCAT107,ENST00000505706 | NA | pathogenic process | active tuberculosis | Bacterial Infections and Mycoses |
| HSALNT0289866 | HIT | NA | transcriptional regulation | pathogenic process | non-small cell lung cancer;breast cancer | Respiratory Tract Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0003927 | SNHG12 | ASLNC04080,C1orf79,LINC00100,NCRNA00100,PNAS-123 | NA | pathogenic process | osteosarcoma;endometrial cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289099 | LINC01225 | NA | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0290047 | MALAT2 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0176345 | NONHSAT021826 | LINC00057,NCRNA00057,U22HG,UHG,lncRNA16 | NA | pathogenic process | astrocytoma;hepatocellular cancer;non-small cell lung cancer;Parkinson's disease;neuroblastoma | Respiratory Tract Diseases;Neoplasms;Digestive System Diseases;Nervous System Diseases |
| HSALNT0094592 | WSPAR | TCONS_00009511-XLOC_004555,lncTCF7 | transcriptional regulation | pathogenic process | hepatocellular cancer;liver cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289308 | LINC00511 | onco-lncRNA-12 | NA | pathogenic process | lung adenocarcinoma;breast cancer | Respiratory Tract Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0289452 | FAM83H-AS1 | onco-lncRNA-3 | NA | pathogenic process | NA | NA |
| HSALNT0289041 | LINC00472 | C6orf155,dJ288M22.3,FLJ13189 | NA | pathogenic process | ovarian cancer;breast cancer | Skin and Connective Tissue Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Endocrine System Diseases |
| HSALNT0289925 | Linc-ITGB1 | NA | NA | pathogenic process | gallbladder cancer;breast cancer | Skin and Connective Tissue Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0016239 | LINC01133 | lncRNA-PAGBC | transcriptional regulation | pathogenic process | non-small cell lung cancer;colorectal cancer;lung squamous cell cancer | Respiratory Tract Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289489 | CCEPR | CCHE1,lncRNA-CCHE1 | transcriptional regulation | pathogenic process | hepatocellular cancer;cervical cancer | Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Digestive System Diseases |
| HSALNT0289402 | SOX21-AS1 | NA | NA | pathogenic process | lung adenocarcinoma;oral squamous cell cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0288905 | CASC15 | LINC00340,lnc-SOX4-1 | NA | pathogenic process | basal cell cancer;melanoma;neuroblastoma | Neoplasms |
| HSALNT0289555 | AC104699.1 | NA | NA | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0096322 | CLMAT3 | SPARC-AS1 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289233 | RGMB-AS1 | NA | NA | pathogenic process | lung adenocarcinoma;non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0289908 | LINC01419 | LVCAT7,TCONS_00014497 | NA | pathogenic process | hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289541 | AB209630 | NA | NA | pathogenic process | hypopharyngeal squamous cell cancer | Neoplasms |
| HSALNT0289608 | AOC4P | AOC4P | NA | pathogenic process | colorectal cancer;hepatocelluar cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289082 | LINC01021 | LINC01021,LOC643401,RP11-46C20.1 | NA | pathogenic process | NA | NA |
| HSALNT0196121 | LINC01089 | LIMT | NA | pathogenic process | breast cancer;astrocytoma | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0123080 | EGFR-AS1 | NA | NA | pathogenic process | hepatocellular cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289539 | AB073614 | NA | NA | pathogenic process | ovarian cancer;glioma | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0242418 | CACNA1G-AS1 | NA | NA | pathogenic process | keloid | Pathological Conditions, Signs and Symptoms;Skin and Connective Tissue Diseases;Tissues |
| HSALNT0170814 | MIR210HG | NA | transcriptional regulation | pathogenic process | hypoxic and inflammatory stress | NA |
| HSALNT0288979 | FOXC2-AS1 | ODRUL | NA | pathogenic process | osteosarcoma | Neoplasms |
| HSALNT0289022 | LINC00160 | C21orf52,NCRNA00160 | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0105274 | LINC01016 | NA | NA | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0288904 | CARMN | MIR143HG,CARMEN | transcriptional regulation | pathogenic process | cardiac differentiation | Cardiovascular Diseases |
| HSALNT0289123 | LINC01630 | LOC100287225 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0288971 | FAM30A | C14orf110,KIAA0125,HSPC053 | NA | pathogenic process | gallbladder cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289506 | LINC00346 | C13orf29,NCRNA00346 | NA | pathogenic process | hepatocellular cancer;breast cancer | Skin and Connective Tissue Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289643 | BC032469 | NA | ceRNA | pathogenic process | esophageal squamous cell cancer;gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289580 | AK024171 | NA | NA | pathogenic process | intervertebral disc degeneration;gastric cancer | Musculoskeletal Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0290187 | RP11-284N8.3.1 | NA | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289839 | FMR6 | NA | NA | pathogenic process | fragile X syndrome;fragile X-associated premature ovarian insufficiency | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Female Urogenital Diseases and Pregnancy Complications;Nervous System Diseases |
| HSALNT0290152 | PRAL | lncRNA-PRAL | NA | pathogenic process | hepatocellular cancer;lung cancer | Respiratory Tract Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289380 | NORAD | LINC00657 | transcriptional regulation;translational control | pathogenic process | breast cancer | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0086803 | LIFR-AS1 | NA | NA | pathogenic process | preterm | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0076183 | PANCR | NA | NA | pathogenic process | atrial fibrillation | Pathological Conditions, Signs and Symptoms;Cardiovascular Diseases |
| HSALNT0288975 | FEZF1-AS1 | NA | transcriptional regulation | pathogenic process | gastric cancer;colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0238475 | CCDC144NL-AS1 | NA | ceRNA | pathogenic process | ovarian cancer;cardiac hypertrophy | Female Urogenital Diseases and Pregnancy Complications;Endocrine System Diseases;Cardiovascular Diseases;Neoplasms |
| HSALNT0290102 | NR_026689 | NA | NA | pathogenic process | ovarian cancer;lung cancer | Respiratory Tract Diseases;Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289522 | ADARB2-AS1 | C10orf109,NCRNA00168,bA466B20.1 | NA | pathogenic process | breast cancer;pancreatic ductal adenocarcinoma | Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0288936 | DPP10-AS1 | BC032913 | NA | pathogenic process | breast cancer;colorectal cancer | Skin and Connective Tissue Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0289474 | GAS8-AS1 | C16orf3 | NA | pathogenic process | papillary thyroid cancer;breast cancer | Skin and Connective Tissue Diseases;Endocrine System Diseases;Neoplasms |
| HSALNT0289063 | LINC00704 | LINC00704 | NA | pathogenic process | NA | NA |
| HSALNT0289238 | SAMMSON | LINC01212 | NA | pathogenic process | melanoma | Neoplasms |
| HSALNT0289027 | LINC00302 | C1orf46,NCRNA00302,XP33 | NA | developmental process | NA | NA |
| HSALNT0245543 | SNHG20 | C17orf86,NCRNA00338,LINC00338,PRO0872,FLJ25582,DKFZp686L05235,SCARNA16HG | transcriptional regulation | pathogenic process | hepatocellular cancer;colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0015631 | DCST1-AS1 | RP11-307C12.11 | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0149810 | PGM5-AS1 | FAM233A,LOC572558 | NA | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0290236 | SBF2-AS1 | NA | transcriptional regulation | pathogenic process | non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0290325 | Uc.338 | NA | transcriptional regulation | pathogenic process | hepatocellular cancer;lung cancer | Respiratory Tract Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0290002 | LOC100130476 | NA | NA | pathogenic process | esophageal squamous cell cancer;gastric cardia adenocarcinoma | Neoplasms |
| HSALNT0289049 | Lnc-TNKS-1:1 | Rncr3 | NA | pathogenic process | diabetes | Endocrine System Diseases |
| HSALNT0020406 | LINC00628 | NA | transcriptional regulation | pathogenic process | gastric cancer | Neoplasms;Digestive System Diseases |
| HSALNT0289478 | DSCR4 | DCRB | NA | pathogenic process | Down syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0017675 | GAS5-AS1 | NA | NA | pathogenic process | oral submucous fibrosis;non-small cell lung cancer | Respiratory Tract Diseases;Neoplasms;Stomatognathic Diseases |
| HSALNT0289523 | HCG11 | bK14H9.3,FLJ14049,FLJ30357 | NA | pathogenic process | prostate cancer | Male Urogenital Diseases;Neoplasms |
| HSALNT0134828 | LINC02099 | AC145110.1 | NA | pathogenic process | rheumatoid arthritis;breast cancer | Immune System Diseases;Musculoskeletal Diseases;Skin and Connective Tissue Diseases;Neoplasms |
| HSALNT0209098 | G2E3-AS1 | CAT1647 | NA | pathogenic process | bladder cancer | Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0289139 | LINC02245 | lnc-SERTAD2-3,AC007386.2 | NA | pathogenic process | ovarian cancer | Endocrine System Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms |
| HSALNT0008167 | FOXD3-AS1 | pasFOXD3 | transcriptional regulation | pathogenic process | glioma | Neoplasms |
| HSALNT0289335 | LINC00998 | NA | NA | pathogenic process | major depression disorder | Behavior and Behavior Mechanisms |
| HSALNT0289379 | NNT-AS1 | NA | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0055497 | PSMD6-AS1 | ENST00000462717,lnc00462717 | NA | pathogenic process | papillary thyroid cancer;glioma | Endocrine System Diseases;Neoplasms |
| HSALNT0289130 | LINC02081 | CTD-2357A8.3,XLOC_012582 | NA | pathogenic process | esophageal cancer | Neoplasms |
| HSALNT0289306 | LINC00052 | TMEM83,NCRNA00052,FLJ31461 | ceRNA | pathogenic process | hepatocellular cancer;breast cancer | Skin and Connective Tissue Diseases;Neoplasms;Digestive System Diseases |
| HSALNT0199070 | PLUT | PDX1-AS1,PLUTO,HI-LNC71 | transcriptional regulation | pathogenic process | type 2 diabetes | Nutritional and Metabolic Diseases;Endocrine System Diseases |
| HSALNT0289341 | LINC01505 | RP11-308N19.1 | NA | pathogenic process | NA | NA |
| HSALNT0289315 | LINC01116 | TALNEC2 | transcriptional regulation | pathogenic process | prostate cancer;glioblastoma | Male Urogenital Diseases;Neoplasms |
| HSALNT0006439 | FOXD2-AS1 | MGC12982 | NA | pathogenic process | lung cancer | Respiratory Tract Diseases;Neoplasms |
| HSALNT0252387 | LINC00305 | C18orf20,NCRNA00305,MGC39571,HsT1235 | NA | NA | NA | NA |
| HSALNT0289473 | FBXL19-AS1 | NCRNA00095,MGC125469,MGC125470,MGC125472 | NA | pathogenic process | colorectal cancer | Neoplasms;Digestive System Diseases |
| HSALNT0187807 | LINC02555 | AC079630.2 | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0251493 | LINC01929 | CTD-2171N6.1 | NA | pathogenic process | papillary thyroid cancer | Endocrine System Diseases;Neoplasms |
| HSALNT0244776 | LINC01152 | TCONS_00025128,CMPD | NA | pathogenic process | NA | NA |
| HSALNT0284591 | DIAPH2-AS1 | NA | NA | pathogenic process | Hodgkin's disease | Neoplasms |
| HSALNT0289226 | PWAR1 | PAR1,PAR-1 | NA | pathogenic process | Prader-Willi syndrome and Angelman syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nervous System Diseases |
| HSALNT0289339 | LINC00950 | FP588 | NA | NA | NA | NA |
| HSALNT0289740 | DGCR12 | DGS-E | NA | pathogenic process;developmental process | DiGeorge syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hemic and Lymphatic Diseases;Musculoskeletal Diseases;Cardiovascular Diseases;Endocrine System Diseases |
| HSALNT0275220 | DGCR9 | DGS-A,POM121L5P | NA | pathogenic process | DiGeorge syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hemic and Lymphatic Diseases;Musculoskeletal Diseases;Cardiovascular Diseases;Endocrine System Diseases |
| HSALNT0288929 | DGCR10 | DGS-B | NA | pathogenic process | NA | NA |
| HSALNT0289494 | DGCR11 | DGS-D | NA | pathogenic process | NA | NA |
| HSALNT0267755 | LINC02597 | Long intergenic non-protein coding RNA 2597, LOC101929866 | Transcriptional regulation | Pathogenic process | Postmenopausal osteoporosis (PMOP) | Musculoskeletal Diseases |
| HSALNT0178412 | UVRAG-DT | UVRAG divergent transcript, LOC100506113 | Transcriptional regulation | Pathogenic process | Postmenopausal osteoporosis (PMOP) | Musculoskeletal Diseases |
| HSALNT0185540 | LINC02598 | Long intergenic non-protein coding RNA 2598, RP11-277P12.9 | _ | Pathogenic process | Lung squamous cell carcinoma (LUSC) | Neoplasms; Respiratory Tract Diseases |
| HSALNT0278274 | SREBF2-AS1 | SREBF2 antisense RNA 1, RP5-821D11.7 | _ | Pathogenic process | Lung squamous cell carcinoma (LUSC) | Neoplasms; Respiratory Tract Diseases |
| HSALNT0021177 | LINC02602 | Long intergenic non-protein coding RNA 2602, TCONS_00001798 | _ | Pathogenic process | Non-small cell lung cancer (NSCLC) | Neoplasms; Respiratory Tract Diseases |
| HSALNT0021052 | MIR205HG | MIR205 host gene, LINC00510 | CeRNA | Pathogenic process | Head & neck squamous cell carcinoma (HNSCC) | Neoplasms |
| HSALNT0107588 | ZNF451-AS1 | ZNF451 regulatory antisense RNA 1, BC032020 | Transcriptional regulation | Pathogenic process | Pancreatic ductal adenocarcinoma (PDAC) | Neoplasms |
| HSALNT0189537 | SCAT2 | S-phase cancer associated transcript 2, CBX5-AS1 | _ | Pathogenic process | Kidney clear cell carcinoma (KIRC) | Neoplasm |
| HSALNT0107867 | SCAT8 | S-phase cancer associated transcript 8, EYS-AS1 | _ | Pathogenic process | Kidney clear cell carcinoma (KIRC) | Neoplasm |
| HSALNT0158500 | LINC00707 | long intergenic non-protein coding RNA 707 | Transcriptional regulation | Pathogenic process | Lung cancer (LC) | Neoplasms; Respiratory Tract Diseases |
| HSALNT0185476 | LINC02470 | long intergenic non-protein coding RNA 2470, AC091814.2 | _ | Pathogenic process | Non-small cell lung cancer (NSCLC) and overian cancer | Neoplasm |
| HSALNT0068302 | LINC02600 | long intergenic non-protein coding RNA 2600, AC141928.1 | _ | Pathogenic process | Non-small cell lung cancer (NSCLC) and overian cancer | Neoplasm |
| HSALNT0123915 | LINC02604 | long intergenic non-protein coding RNA 2604, lncHERG | CeRNA | Pathogenic process | Glioblastoma | Neoplasms |
| HSALNT0160932 | MACORIS | macrophage enriched lincRNA repressor of IFN-gamma signaling, MacORIS | Transcriptional regulation | _ | Cardiometabolic Diseases | Cardiovascular Diseases |
| HSALNT0171022 | KRTAP5-AS1 | KRTAP5-1/KRTAP5-2 antisense RNA 1 | CeRNA | Pathogenic process | Gastric Cancer | Neoplasms; Digestive System Diseases |
| HSALNT0215076 | GSC-DT | GSC divergent transcript, DIGIT | _ | Developmental process | _ | _ |
| HSALNT0072605 | CHAER1 | Cardiac hypertrophy associated epigenetic regulator 1, Chaer | Translational control | Pathogenic process | Cardiac hypertrophy | Cardiovascular Diseases |
| HSALNT0027291 | ODC1-DT | ODC1 divergent transcript, lncRNA-MIF | CeRNA | Pathogenic process | Head and neck carcinoma | Neoplasm |
| HSALNT0039409 | MAP3K2-DT | MAP3K2 divergent transcript, ENST00000433673 | _ | Pathogenic process | Polycystic ovary syndrome (PCOS) | Female Urogenital Diseases and Pregnancy Complications |
| HSALNT0208284 | ZFHX2-AS1 | ZFHX2 antisense RNA 1 | Transcriptional regulation | Developmental process | _ | _ |
| HSALNT0152349 | LINC02603 | long intergenic non-protein coding RNA 2603, MIRLET7DHG | _ | _ | _ | _ |
| HSALNT0081596 | TENM3-AS1 | TENM3 antisense RNA 1 | _ | _ | _ | _ |
| HSALNT0165522 | LINC00858 | long intergenic non-protein coding RNA 858, LOC170425, CRCAL-2 | _ | _ | non-small cell lung cancer | Respiratory Tract Diseases |
| HSALNT0281930 | SCAT1 | S-phase cancer associated transcript 1 LINC02081, CTD-2357A8.3, XLOC_012582 | _ | _ | esophagal cancer | Digestive system Diseases |
| HSALNT0191750 | LNCOG | lncRNA osteogenesis associated, LINC02407, RP11-54A9.1, lncRNA-OG | _ | _ | osteogenic differenciation | Musculoskeletal Diseases |
| HSALNT0246388 | DCXR-DT | DCXR divergent transcript RP13-650J16.1 | _ | _ | prostate cancer | Male Urogenital Diseases |
| HSALNT0209659 | NKX2-1-AS1 | NKX2-1 antisense RNA 1 | _ | _ | lung cancer | Respiratory Tract Diseases |
| HSALNT0038250 | ACTR3-AS1 | ACTR3 antisense RNA 1, AC104653.1 | _ | _ | glioblastoma | Nervous system diseases |
| HSALNT0043145 | ITGA6-AS1 | ITGA6 antisense RNA 1, AC078883.3 | _ | _ | glioblastoma | Nervous system diseases |
| HSALNT0281822 | LINC02601 | long intergenic non-protein coding RNA 2601, RP5-1172N10.2 | _ | _ | glioblastoma | Nervous system diseases |
| NA | ZKSCAN7-AS1 | ZKSCAN7 ZNF cluster antisense RNA 1, RP11-944L7.4, FLJ12738, ZFP, ZNF167, ZNF448, ZNF64, ZSCAN39 | _ | _ | glioblastoma | Nervous system diseases |
| HSALNT0120721 | GARS-DT | GARS divergent transcript, AC005154.6, AC005154.1 | _ | _ | heroine addiction | Nervous system diseases |
| NA | GPRACR | GPR107 adjacent cis regulating lncRNA, LncGPR107 | _ | _ | liver cancer | Digestive system Diseases |
| HSALNT0082561 | LINC01060 | long intergenic non-protein coding RNA 1060 | _ | _ | pancreatic cancer | Digestive system Diseases |
| HSALNT0058704 | TBILA | TGF-beta induced lncRNA, RP11-757F18.5 | _ | _ | non-small cell lung cancer | Respiratory Tract Diseases |
| NA | UGDH-AS1 | UGDH antisense RNA 1 | _ | _ | invertebral disc degeneration | Musculoskeletal Diseases |
| HSALNT0245777 | TNRC6C-AS1 | NA | _ | _ | Thyroid cancer | Endocrine system Disease |
| HSALNT0225753 | LINC02244 | long intergenic non-protein coding RNA 2244, RP11-20G13.3 | _ | _ | obesity | Digestive system Diseases |
| NA | NKAIN3-IT1 | NKAIN3 intronic transcript, LOC643763 | _ | _ | glioblastoma | Nervous system diseases |
| HSALNT0013113 | NGF-AS1 | NA | _ | _ | dysmenorhea | Female Urogenital Diseases |
| HSALNT0031057 | LINC01121 | long intergenic non-protein coding RNA 1121, UNQ6975 | _ | _ | pancreatic cancer | Digestive system Diseases |
| HSALNT0234176 | ARLNC1 | androgen receptor regulated long noncoding RNA 1, LINC02170, PRCAT47 | _ | _ | prostate cancer | Male Urogenital Diseases |
| NA | MPPED2-AS1 | MPPED2 antisense RNA 1, RP5-1024C24.1 | _ | _ | thyroid neoplasias | Endocrine system Disease |
| NA | LINC01703 | NA | _ | _ | Hepatocellular carcinoma | Digestive system Diseases |
| HSALNT0144162 | HPYR1 | Helicobacter pylori responsive 1, LINC00027 | _ | pathogenic process | H. pylori infection | _ |
| HSALNT0172266 | LINC00958 | long intergenic non-protein coding RNA 958, | protein localization,transcriptional regulation | pathogenic process | bladder cancer, glioma | _ |
| HSALNT0167574 | SH3PXD2A-AS1 | SH3PXD2A antisense RNA 1 | transcriptional regulation | pathogenic process | colorectal cancer | _ |
| NA | SSTR5-AS1 | SSTR5 antisense RNA 1 | transcriptional regulation | pathogenic process | neuroendocrine prostate cancer | _ |
| NA | TSPOAP1-AS1 | TSPOAP1, SUPT4H1 and RNF43 antisense RNA 1 | _ | pathogenic process | breast cancer | _ |
| NA | LINC00174 | long intergenic non-protein coding RNA 174 | ceRNA | pathogenic process | colorectal carcinoma | _ |
| HSALNT0169064 | LINC01561 | long intergenic non-protein coding RNA 1561 | ceRNA | pathogenic process | breast cancer | _ |
| NA | LINC00514 | long intergenic non-protein coding RNA 514 | transcriptional regulation | pathogenic process | neuroendocrine prostate cancer | _ |
| HSALNT0282164 | LINC02595 | long intergenic non-protein coding RNA 2595, AK098783 | _ | pathogenic process | colorectal cancer | _ |
| HSALNT0197396 | FZD10-AS1 | FZD10 antisense divergent transcript | _ | _ | _ | _ |
| NA | LINC01567 | long intergenic non-protein coding RNA 1567, LOCCS | transcriptional regulation | pathogenic process | colon cancer | _ |
| NA | ADPGK-AS1 | ADPGK antisense RNA 1 | transcriptional regulation | pathogenic process | pancreatic cancer | _ |
| HSALNT0255381 | RAB11B-AS1 | RAB11B antisense RNA 1 | transcriptional regulation | pathogenic process | osteosarcoma | _ |
| HSALNT0237805 | SNHG29 | Small nucleolar RNA host gene 29, LRRC75A-AS1, C17orf76-AS1 | transcriptional regulation | pathogenic process | acute myeloid leukemia, rheumatoid arthritis | _ |
| NA | SNHG17 | small nucleolar RNA host gene 17 | transcriptional regulation | pathogenic process | colorectal cancer | _ |
| HSALNT0215138 | DICER1-AS1 | DICER1 antisense RNA 1 | transcriptional regulation | pathogenic process | osteosarcoma | _ |
| HSALNT0043929 | TTN-AS1 | TTN antisense RNA 1 | transcriptional regulation | pathogenic process | esophageal squamous cell carcinoma | _ |
| HSALNT0152594 | LINC00092 | long intergenic non-protein coding RNA 92 | transcriptional regulation | pathogenic process | ovarian cancer | _ |
| HSALNT0050704 | THUMPD3-AS1 | THUMPD3 antisense RNA 1, SETD5-AS1 | transcriptional regulation | pathogenic process | Neuron death in stroke | _ |
| HSALNT0205980 | LINC00554 | long intergenic non-protein coding RNA 554, lncZic2 | transcriptional regulation | pathogenic process | liver cancer | _ |
| HSALNT0141703 | ZFPM2-AS1 | ZFPM2 antisense RNA 1, SCAT3 | transcriptional regulation | pathogenic process | multiple cancers, gastric carcinogenesis | _ |
| NA | HOXB-AS1 | HOXB cluster antisense RNA 1 | transcriptional regulation | pathogenic process | autosomal dominant polycistic kidney disease | _ |
| HSALNT0167650 | CFAP58-DT | CFAP58 divergent transcript, ITPRIP-1 | transcriptional regulation | pathogenic process | innate immune response to viral infection | _ |
| NA | FAM230A | family with sequence similarity 230 member A | _ | _ | _ | _ |
| NA | CPNE8-AS1 | CPNE8 antisense RNA 1, RP11-396F22.1 | transcriptional regulation | pathogenic process | cervical cancer | _ |
| NA | THORLNC | testis associated oncogenic lncRNA | transcriptional regulation | pathogenic process | melanoma, skin squamous cell carcinoma,osteosarcoma, renal cell carcinoma | _ |
| NA | IATPR | ITGB1 adjacent tumor promoting lncRNA | transcriptional regulation | pathogenic process | breast cancer, gallbladder cancer | _ |
| HSALNT0242280 | PICART1 | p53 inducible cancer associated RNA transcript 1, AC009720.1, NR_038230, LOC84080 | transcriptional regulation | pathogenic process | breast cancer, colorectal cancer, lung cancer | _ |
| NA | LINC02599 | long intergenic non-protein coding RNA 2599, AC026904.1 | transcriptional regulation | pathogenic process | breast cancer | _ |
| HSALNT0183231 | ETS1-AS1 | ETS1 antisense RNA 1, pancEts-1, Ets-1 promoter-associated noncoding RNA | transcriptional regulation | pathogenic process | gastric cancer, neuroblastoma | _ |
| NA | MAPK6-DT | MAPK6 divergent transcript, lncMAPK6 | transcriptional regulation | pathogenic process | liver cancer | _ |
| HSALNT0036655 | IL1R1-AS1 | IL1R1 antisense RNA 1, AC007271.3 | transcriptional regulation | pathogenic process | Oral squamous cell carcinoma, breast cancer | _ |
| HSALNT0001134 | LINC01672 | long intergenic non-protein coding RNA 1672, long intergenic non-protein coding RNA 1672 | transcriptional regulation | pathogenic process | Esophageal squamous cell carcinoma | _ |
| HSALNT0135857 | SIRLNT | SIRT1 regulating lncRNA tumor promoter, SIRT1 regulating lncRNA tumor promoter, | ceRNA | pathogenic process | Breast cancer | _ |
| HSALNT0135484 | LINC01605 | long intergenic non-protein coding RNA 1605, TCONS_00014973, LincDUSP | transcriptional regulation | pathogenic process | Colon Cancer, Bladder cancer | _ |
| HSALNT0184552 | GAU1 | GALNT8 antisense upstream 1, GALNT8 divergent transcript | transcriptional regulation | pathogenic process | Neuroblastoma and retinoblastoma | _ |
| HSALNT0287294 | LINC00894 | long intergenic non-protein coding RNA 894 | transcriptional regulation | pathogenic process | Lung adenocarcinoma | _ |
| HSALNT0000250 | LINC02593 | long intergenic non-protein coding RNA 2593, AL645608.1 | _ | pathogenic process | breast cancer, hepatocellular carcinoma | _ |
| HSALNT0241060 | LINC02594 | long intergenic non-protein coding RNA 2594, CTC‐501O10.1 | _ | _ | gastric cancer | _ |
| HSALNT0022481 | LINC01705 | long intergenic non-protein coding RNA 1705, RP11-400N13.3 | transcriptional regulation | pathogenic process | gastric cancer | _ |
| HSALNT0022477 | LINC02474 | long intergenic non-protein coding RNA 2474, RP11-400N13.2 | transcriptional regulation | pathogenic process | gastric cancer | _ |
| HSALNT0030809 | LINC02590 | long intergenic non-protein coding RNA 2590, AC016735.2 | transcriptional regulation | pathogenic process | gastric cancer | _ |
| HSALNT0170966 | MUC5B-AS1 | MUC5B antisense RNA 1 | transcriptional regulation | pathogenic process | lung adenocarcinoma | _ |
| HSALNT0275151 | FAM230D | family with sequence similarity 230 member D, LINC02592: long intergenic non-protein coding RNA 2592, AC008079.1 | _ | _ | _ | _ |
| HSALNT0275163 | FAM230E | family with sequence similarity 230 member E, LINC01662: long intergenic non-protein coding RNA 1662 | _ | _ | _ | _ |
| HSALNT0275179 | FAM230F | family with sequence similarity 230 member F, LINC01663: long intergenic non-protein coding RNA 1663 | _ | _ | _ | _ |
| NA | FAM230G | family with sequence similarity 230 member G, AC007731.1 | _ | _ | _ | _ |
| NA | FAM230H | family with sequence similarity 230 member H, AP000552.1 | _ | _ | Papillary thyroid carcinoma | _ |
| NA | FAM230I | family with sequence similarity 230 member I, LINC01658: long intergenic non-protein coding RNA 1658 | _ | _ | _ | _ |
| HSALNT0275150 | FAM230J | family with sequence similarity 230 member J, LINC01660: long intergenic non-protein coding RNA 1660 | _ | _ | _ | _ |
| HSALNT0103387 | HCG14 | HLA complex group 14, dJ111M5.4 | transcriptional regulation | pathogenic process | Celiac disease, Nutritional and Metabolic Diseases | _ |
| NA | LINC01510 | long intergenic non-protein coding RNA 1510 | transcriptional regulation, ceRNA | pathogenic process | Colorectal cancer, Non-small cell lung cancer | _ |
| NA | LNCOC1 | lncRNA associated with ovarian cancer 1, Lnc-OC1 | transcriptional regulation | pathogenic process | Ovarian cancer | _ |
| NA | LGALSL-DT | LGALSL divergent transcript, LOC105374771 | transcriptional regulation | pathogenic process | Postmenopausal osteoporosis (PMOP) | _ |
| HSALNT0002862 | LINC02596 | long intergenic non-protein coding RNA 2596, LOC105376834 | transcriptional regulation | pathogenic process | Postmenopausal osteoporosis (PMOP) | _ |
| NA | DEC1 | deleted in esophageal cancer 1, CTS9, Candidate Tumor Suppressor CTS9 | NA | pathogenic process | esophageal squamous cell carcinoma | Neoplasms |
| NA | MYOPARR | myogenin promoter-associated myogenic regulatory antisense long non-coding RNA | transcriptional regulation | NA | NA | NA |
| NA | PCED1B-AS1 | PCED1B antisense RNA 1 | ceRNA | pathogenic process | Tuberculosis | Bacterial Infections and Mycoses |
| NA | UMLILO | upstream master lncRNA of the inflammatory chemokine locus | transcriptional regulation | NA | NA | NA |
| NA | LINC02631 | long intergenic non-protein coding RNA 2631, AC092620.3 | NA | NA | NA | NA |
| NA | BMNCR | bone marrow associated non-coding RNA | transcriptional regulation | NA | NA | NA |
| NA | ZEBTR | ZEB1 transcriptional regulator RNA, LncRNA-BX111 | NA | pathogenic process | Pancreatic cancer | Neoplasms |
| NA | SNHG31 | small nucleolar RNA host gene 31 | NA | NA | NA | NA |
| NA | LINC00574 | long intergenic non-protein coding RNA 574, C6orf208, FLJ13162, dJ182D15.1, CRALA | NA | pathogenic process | Primary breast cance | Neoplasms |
| NA | RCC2-AS1 | RCC2 antisense RNA 1 | NA | pathogenic process | non-small cell lung cancer | Neoplasms |
| NA | PRDM16-DT | lnc-dPrdm16 | NA | NA | NA | NA |
| NA | BCL6-AS1 | BCL6 antisense RNA 1, lnc-RP11-211G3.3.1-1 | NA | pathogenic process | diffuse large B-cell lymphoma | Neoplasms; Immune System Diseases |
| NA | C1orf220 | chromosome 1 open reading frame 220, FLJ35530 | NA | NA | NA | NA |
| NA | MIR122HG | lnc-pri-miR-122 | NA | NA | NA | NA |
| NA | PANTR1 | linc-POU3F3, linc-Brn1a, LINC01158 | NA | developmental process | NA | NA |
| NA | C11orf72 | FLJ90834, chromosome 11 open reading frame 72 | NA | NA | NA | NA |
| NA | CT66 | cancer/testis antigen 66, cancer/testis associated transcript 66 | NA | NA | NA | NA |
| NA | CT75 | cancer/testis antigen 75 | NA | NA | NA | NA |
| NA | MIR9-3HG | MIR9-3 host gene, LINC00925, long intergenic non-protein coding RNA 925 | NA | NA | NA | NA |
| NA | RN7SL2 | RNA component of signal recognition particle 7SL2, RNA7SL, cytoplasmic 2, 7SL1c, 7L30.1, RNSRP2 | NA | NA | NA | NA |
| NA | RN7SL3 | RNA component of signal recognition particle 7SL3, RN7SL631P, (RNA,7SL, cytoplasmic 631, pseudogene), (RNA, 7SL, cytoplasmic 3) | NA | NA | NA | NA |
| NA | CT70 | cancer/testis associated transcript 70, cancer/testis antigen 70, LeXis | ceRNA, transcriptional regulation | pathogenic process | osteosarcoma, colon adenocarcinoma | Neoplasms |
| NA | CT69 | cancer/testis associated transcript 69, cancer/testis associated transcript 69 | NA | NA | NA | NA |
| NA | C10orf91 | chromosome 10 open reading frame 91 (putative), chromosome 10 open reading frame 91, bA432J24.4 | NA | NA | NA | NA |
| NA | CTBP1-DT | CTBP1 divergent transcript, C4orf42, CTBP1-AS1, CTBP1-AS2, chromosome 4 open reading frame 42, CTBP1 antisense RNA 1 (head to head), CTBP1 antisense RNA 2 (head to head) | NA | NA | NA | NA |
| NA | FAM201B | family with sequence similarity 201 member B, | NA | NA | NA | NA |
| NA | MAFG-DT | MAFG divergent transcript, MAFG antisense RNA 1 (non-protein coding), MAFG antisense RNA 1, MAFG antisense RNA 1 (head to head) | NA | NA | NA | NA |
| NA | RPP38-DT | RPP38 divergent transcript, C10orf111, chromosome 10 open reading frame 111, MGC35468, bA455B2.4 | NA | NA | NA | NA |
| NA | CDRT3 | CMT1A duplicated region transcript 3 | NA | NA | NA | NA |
| NA | DLEU2L | deleted in lymphocytic leukemia 2 like, BCMS upstream neighbor-like, BCMSUNL | NA | NA | NA | NA |
| NA | ARHGAP42-AS1 | AK124326 | NA | NA | NA | NA |
| HSALNG0116707 | ASB16-AS1 | DKFZp762C2414,C17orf65
CeRNA |
NA
Osteosarcoma |
NA | ||
| NA | BAIAP2-DT | lnc-BAIAP2,BAIAP2-AS1 | NA | NA | NA | NA |
| HSALNT0289434 | BASP1-AS1 | LOC285696 | NA | NA | NA | NA |
| NA | BCAN-AS1 | RP11-284F21.9 | NA | NA | NA | NA |
| NA | C2ORF27A | C2orf27 | NA | NA | NA | NA |
| NA | CALHM6-AS1 | RP1-93H18.6 | NA | NA | NA | NA |
| NA | CAVIN2-AS1 | LOC105373813 | NA | NA | NA | NA |
| HSALNG0108275 | CHASERR | LINC01578 | NA | NA | NA | NA |
| NA | CHROMR | CHROME,PRKRA-AS1 | NA | NA | NA | NA |
| HSALNG0119714 | DLGAP1-AS1 | HsT914,FLJ35776 | NA | NA | NA | NA |
| HSALNG0119716 | DLGAP1-AS2 | MGC11082 | NA | NA | NA | NA |
| NA | EGILA | Lnc-EGFR | NA | NA | NA | NA |
| NA | ELDR | Fabl,LINC01156 | NA | NA | NA | NA |
| NA | EMSLR | EMS | NA | NA | NA | NA |
| NA | EPCART | TPCAT-2-180961,PRCAT122,PCAT-2-180961 | NA | NA | NA | NA |
| NA | EVA1A-AS | EVA1A-AS1 | NA | NA | NA | NA |
| HSALNG0082135 | FAM99A | FLJ42833 | NA | NA | NA | NA |
| HSALNG0082137 | FAM99B | DKFZp781M09150 | NA | NA | NA | NA |
| NA | FAM218A | FLJ31659,TRIM61-AS1,C4orf39 | NA | NA | NA | NA |
| HSALNG0099631 | GAS6-DT | FLJ44054,GAS6-AS2 | NA | NA | NA | NA |
| HSALNT0048545 | GCSIR | Lnc-ITM2C-1 | NA | NA | NA | NA |
| HSALNG0047439 | GMDS-DT | GMDS-AS1 | NA | NA | NA | NA |
| HSALNT0026700 | GRASLND | RNF144A-AS1 | NA | NA | NA | NA |
| NA | HOXC13-AS | HOXC-AS5 | NA | NA | NA | NA |
| NA | IGFL2-AS1 | AC006262.5 | NA | NA | NA | NA |
| HSALNG0082653 | IRAG1-AS1 | MRVI1-AS1 | NA | NA | NA | NA |
| HSALNT0129814 | KDM7A-DT | JHDM1D-AS1 | NA | NA | NA | NA |
| HSALNT0025249 | KIF26B-AS1 | RP11-62I21.1 | NA | NA | NA | NA |
| NA | KLRK1-AS1 | LOC101928100 | NA | NA | NA | NA |
| NA | LASTR | LINC02657 | NA | NA | NA | NA |
| HSALNG0069631 | LDLR-AS1 | BM450697 | NA | NA | NA | NA |
| HSALNG0131739 | LINC00266-1 | bA476I15.3,RBRP,C20orf69,NCRNA00266,NCRNA00266-1 | NA | NA | NA | NA |
| HSALNG0097328 | LINC00458 | LncRNA-ES3,ES3 | NA | NA | NA | NA |
| NA | LINC00515 | PRED21,C21orf71 | NA | NA | NA | NA |
| HSALNG0104041 | LINC00637 | HITT | NA | NA | NA | NA |
| HSALNG0122571 | LINC00908 | ASRPS | NA | NA | NA | NA |
| HSALNG0112089 | LINC00920 | CALIC | NA | NA | NA | NA |
| HSALNG0035402 | LINC01094 | CTEPHA1 | NA | NA | NA | NA |
| HSALNT0131038 | LINC01287 | TCONS_l2_00027522 | NA | NA | NA | NA |
| NA | LINC01551 | C14orf23 | NA | NA | NA | NA |
| HSALNG0004816 | LINC01555 | FLJ35487,C1orf180 | NA | NA | NA | NA |
| NA | LINC02145 | FLJ33360 | NA | NA | NA | NA |
| NA | LINC02250 | TCONS_00023273 | NA | NA | NA | NA |
| NA | LINC02303 | TRMP | NA | NA | NA | NA |
| NA | LINC02476 | LVCAT5,lnc-TSPAN12 | NA | NA | NA | NA |
| HSALNT0006451 | LINC02605 | RP11-79H23.3,IL-7,AS | NA | NA | NA | NA |
| NA | LINC02620 | BCRT1 | NA | NA | NA | NA |
| NA | LINC02682 | TCONS_00019584,lnc-SOX6-1 | NA | NA | NA | NA |
| NA | LINC02835 | lncMER52A | NA | NA | NA | NA |
| NA | LINC02859 | LncRNA-LOC101928316 | NA | NA | NA | NA |
| NA | LINC02861 | RP11-462G12.2 | NA | NA | NA | NA |
| NA | LINC02862 | AC073284.4 | NA | NA | NA | NA |
| NA | LINC02864 | RP11-169F17.1 | NA | NA | NA | NA |
| NA | LINC02867 | LA16c-313D11.9 | NA | NA | NA | NA |
| NA | LINC02882 | RP11-81H3.2 | NA | NA | NA | NA |
| NA | LINC02883 | KMU15 | NA | NA | NA | NA |
| NA | LINC02886 | RP11-697M17.1 | NA | NA | NA | NA |
| NA | LINC02891 | lnc-RTN4R-1 | NA | NA | NA | NA |
| NA | LINCADL | linc-ADAL | NA | NA | NA | NA |
| NA | LNC-LBCS | LBCS | NA | NA | NA | NA |
| NA | LNCDAT | YYLNCT | NA | NA | NA | NA |
| NA | LNCNEF | lncRNA-NEF,LINC01384 | NA | NA | NA | NA |
| NA | LNCTAM34A | GUARDIN,LINC01759 | NA | NA | NA | NA |
| HSALNG0047822 | LY86-AS1 | FLJ33708,LY86AS,LY86-AS | NA | NA | NA | NA |
| HSALNG0067477 | MAILR | MAIL1,AZIN1-AS1 | NA | NA | NA | NA |
| NA | MIR9-1HG | CROC4,C1orf61 | NA | NA | NA | NA |
| NA | MIR23AHG | LOC284454 | NA | NA | NA | NA |
| HSALNT0159828 | MIR1915HG | bA418C1.3,C10orf114,CASC10 | NA | NA | NA | NA |
| NA | NR4A1AS | NR4A1-AS1 | NA | NA | NA | NA |
| NA | NRAD1 | NCRNA00284,LINC00284 | NA | NA | NA | NA |
| HSALNT0140217 | OTUD6B-AS1 | GS1-251I9.4 | NA | NA | NA | NA |
| HSALNG0041428 | OXCT1-AS1 | SARRAH | NA | NA | NA | NA |
| NA | PCSEAT | PRCAT38 | NA | NA | NA | NA |
| HSALNT0268592 | PELATON | GCRL1,LINC01272,SMIM25 | NA | NA | NA | NA |
| HSALNG0069519 | PGM5P3-AS1 | FAM233B | NA | NA | NA | NA |
| HSALNT0180290 | PGR-AS1 | AT1,AT2,AT3 | NA | NA | NA | NA |
| HSALNT0114603 | PHACTR2-AS1 | NR027113,lncIHS | NA | NA | NA | NA |
| HSALNG0092289 | PRANCR | LINC01481,CNOT2-DT | NA | NA | NA | NA |
| NA | PSLNR | LA16c-83F12.6 | NA | NA | NA | NA |
| HSALNG0049455 | PSMB8-AS1 | XXbac-BPG246D15.8,TAP1-AS1,TAPSAR1 | NA | NA | NA | NA |
| HSALNG0055664 | PSMG3-AS1 | KIAA1908 | NA | NA | NA | NA |
| HSALNG0094500 | PXN-AS1 | EyeLinc4 | NA | NA | NA | NA |
| HSALNT0289231 | RCAN3AS | TCONS_00001428 | NA | NA | NA | NA |
| HSALNT0289236 | ROCR | LINC02095 | NA | NA | NA | NA |
| NA | SAP30-DT | ENST00000608794 | NA | NA | NA | NA |
| NA | SCP2D1-AS1 | dJ1068E13.1,C20orf78 | NA | NA | NA | NA |
| NA | SFTA1P | SFTPF | NA | NA | NA | NA |
| HSALNG0108960 | SNHG9 | DKFZp686N06141,NCRNA00062 | NA | NA | NA | NA |
| HSALNT0104616 | SNHG32 | D6S57,G8,C6orf48 | NA | NA | NA | NA |
| HSALNG0118528 | SOX9-AS1 | FLJ37644 | NA | NA | NA | NA |
| NA | SPATA8 | MGC44294,SRG8 | NA | NA | NA | NA |
| NA | THY1-AS1 | RP11-334E6.12 | NA | NA | NA | NA |
| NA | TMEM18-DT | AC092159.2 | NA | NA | NA | NA |
| NA | TNRC17 | CAGL234 | NA | NA | NA | NA |
| NA | TP73-AS2 | RP5-1092A11.2 | NA | NA | NA | NA |
| HSALNT0289424 | TTTY22 | NCRNA00147 | NA | NA | NA | NA |
| NA | UICLM | CROCC2-AS1 | NA | NA | NA | NA |
| HSALNG0078695 | UNC5B-AS1 | UASR1 | NA | NA | NA | NA |
| NA | VPS13B-DT | OLC8 | NA | NA | NA | NA |
| NA | WAKMAR2 | Lnc-TNFAIP3 | NA | NA | NA | NA |
| NA | ZKSCAN2-DT | CTD-2547G23.4 | NA | NA | NA | NA |
